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Background: Wounds such as Diabetic foot ulcers (DFU) and leg ulcers (LU) are burdensome, 
reduce a patient’s quality of life (QoL) and require a lot of time, money, and resources to heal. 
Patients have access to many types of dressing, but no guidance exists identifying a preferred 
dressing regimen, in part due to lack of data supporting clinical and cost-effectiveness. This 
research investigates treatment of DFU and LU with protease-modulating matrix interventions 
with the intent of creating treatment guidelines. 
Methods: A multi-method research protocol was designed to include; systematic literature 
reviews; Delphi methodology expert panel; patient reported outcomes study; retrospective 
real-world data analysis; and a collection of economic modelling. Economic models include 
budget impact modelling, cost-consequence analysis, cost-utility and cost-effectiveness 
analysis, supported by data collected in the four previous studies. Statistical and sensitivity 
analysis have been performed where necessary and external guidelines and best practice 
followed to assure high-quality research.  
Results: The studies showed the variance in care; the efficacy of the sucrose-octasulfate 
dressing and the burden of DFU and LU. Economic modelling found that the sucrose-
octasulfate dressing was both a clinically and cost-effective option; improving time to healing 
and reducing the cost of care; whilst the incidence of adverse events such as infection or 
amputation was less. The results of this research have been included in guidance published by 
the National Institute for Health and Care Excellence (NICE).  
Discussion: The most cost-effective dressing is not the one with the lowest acquisition cost. 
Scenario analysis showed the sucrose-octasulfate dressing as cost-saving when a comparator 
was zero cost; demonstrating the impact of improved healing time on reducing overall costs. 
Patients, healthcare professionals and payers should be aware of the newly published NICE 
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Chapter 1 Introduction and background 
1.1 Introduction 
Diabetic Foot Ulcers (DFU) and Leg Ulcers (LU) are examples of chronic wounds which fail to 
follow a normal healing pattern and are caused by an underlying aetiology such as diabetes or 
venous/arterial disease (Frykberg and Banks, 2015). Chronic wounds have been shown to have 
high levels of Matrix Metalloproteinases (MMPs) enzymes expressed during the inflammatory 
phase of healing that play a role in cell proliferation, and it has been shown that persistent 
elevated MMPs in a wound are linked to slow healing (Olzyck et al., 2014). MMPs are expressed 
at higher levels in the wounds of patients with diabetes or venous insufficiency and are thought 
to contribute to impaired wound healing (Lazaro et al., 2016). High levels of MMPs in the 
wound, can be changed by using protease-modulating matrix (PMM) interventions to create 
an environment more amenable to healing.   
Wounds that do not heal, consume substantial healtchcare resources and are a significant 
burden for the patient, for the healthcare system, and to society as a whole. In the United 
Kingdom (UK) a study in 2012-3 found that DFUs and venous LUs accounted for 8% and 13% 
of all wounds; this study also recorded unspecified LUs which accounted for a further 19% of 
wounds seen in the National Health Service (NHS) (Guest et al., 2015). Guest et al., (et al., 
(2015) did not solely focus on chronic wounds, also including surgical wounds, burns, trauma 
and abscesses. Nonetheless, it is evident that chronic wounds create a large burden on the 
health system; considering that a wound will need regular monitoring and the dressing will 
need changing by a health care provider (HCP), so a patient is in frequent contact with HCPs 
for a potentially long period of time.  
Clarity on optimal treatment strategies for chronic wounds, both in terms of clinical and cost-
effectiveness, is sought by the studies within this PhD thesis given that current UK guidelines 
do not provide specific advice to HCPs with regards to dressings.  
The primary aim of this thesis is to evaluate the clinical and economic impact of PMM 
interventions in DFU and LU to inform the development of treatment guidelines in the UK. The 




1.2.1 Diabetic foot ulcers (DFU) 
Patients with diabetes are at an increased risk of foot ulcers (Kerr, 2017). The risk is partly due 
to diabetic neuropathy that affects over 50% of type 1 and type 2 diabetic patients (Tesfaye et 
al., 2013). Diabetic neuropathy is the degeneration of the nervous system caused by high blood 
glucose levels and up to 75% of diabetic neuropathy is categorized as distal polyneuropathy; 
presenting as sensory or motor, affecting the feet, legs, hands, and arms (Bansa et al., 2006). 
Another presentation of diabetic neuropathy, autonomic neuropathy, affects internal 
processes in the body connected with ulceration, causing reduced sweating, leading to dry skin 
at risk of abrasion (Pendsey, 2010). Patients suffer weakness and a loss of sensation, frequently 
starting in the lower legs, so a small cut or scrape can be exacerbated by usual day-to-day 
activities and go unnoticed by the patient until it has fully ulcerated. To mitigate these 
processes, patients are advised to maintain good blood glucose control; however, this will not 
reverse any existing damage (Inzucchi et al., 2012). 
Diabetes is also a risk factor for peripheral vascular disease which occurs earlier and in greater 
severity than a non-diabetic population (Huysman & Mathieu, 2009). Metabolic changes 
caused by diabetes impacts the vascular system, including the structure and functionality of 
the arteries; initially presenting as fatigue in the lower extremities (American Diabetes 
Association, 2003). Further developments of vascular disease can include pain, tissue loss, and 
gangrene. Ischaemia (defined as inadequate blood supply) is a consequence of peripheral 
vascular disease and impairs wound healing and tissue reformation. As with diabetic 
neuropathy, patients are advised to maintain control of their blood glucose levels to mitigate 
the negative impact of peripheral vascular disease, but again this will not reverse any damage 
or heal any DFUs present (Diabetes.co.uk, 2019). Higher than expected levels of MMPs, linked 
to slow healing, are found from the very first emergence of a DFU (Lazaro et al., 2016). As a 
result steps to prevent ulcers should be observed in the first instance and if a patient does 
become ulcerated then controlling MMP expression using interventions such as a PMM 
dressing may improve healing.  
The growth of the diabetic population in the UK (NHS Digital, 2017) indicates that the incidence 
of DFU is set to rise. In the 20-year period between 1998 and 2018 the number of people 
diagnosed with type 1 or type 2 diabetes in the UK has more than doubled, from 1.8 million to 
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3.7 million, with nearly another 1 million people thought to be undiagnosed (Diabetes UK, 
2018). DFUs often precede amputation; a last resort after unsuccessful prior treatment of an 
ulcer impacted by diabetic neuropathy, peripheral arterial disease, or critical ischaemia. 
Given these dramatic consequences, it is unsurprising that DFU is associated with a high cost 
to the healthcare system. A Diabetes UK report states that in 2014-15 the NHS spent 
approximately £1 billion, or £1 in every £140, on foot ulcers or amputations (Kerr, 2017). In 
addition to the economic consequences associated with DFUs and amputations, the clinical 
burden is high to the patient; with mortality at 5 years post amputation reported at 62.2% 
(Stern et al., 2017). Typically, DFUs are located on the foot or lower leg and can prevent 
patients from walking, driving, and getting about independently; leading to an increased 
reliance on others. Further to this, patients are often pre-retirement age and a persistent ulcer 
may prevent them from working, causing a burden to families and the state due to productivity 
costs and social care requirements (Coffey et al., 2019).  
1.2.2 Leg ulcers (LU) 
Leg ulcers are a sore or break in the skin that takes more than 2 weeks to heal; they can be 
triggered by underlying aetiologies such as venous and arterial disease both of which cause an 
increased likelihood of ulceration. LUs are more common in older individuals, with the annual 
prevalence for individuals aged 65- 95 reported at 1.69% (Alavi et al., 2016).  LUs are the most 
frequently reported wound (Guest et al., 2015) and are a significant contributor to the 7 billion 
USD per year spent on chronic wounds worldwide (Alavi et al., 2016). 
LUs can be a complication of venous disease where valves inside the veins in the leg do not 
adequately prevent backwards flow when returning blood to the heart. Backwards flow results 
in venous stasis, high pressure, swelling in the legs and consequently, blood vessels can 
become damaged (British Association of Dermatologists, 2017). Structural changes in the veins 
and valves controlling blood flow is often a result of aging, presenting with deteriorated 
function in the lower legs and wounds forming from broken blood vessels (Kelechi et al., 2015). 
Venous leg ulcers usually develop on the lower leg above the ankle and can cause pain, itching, 
swelling, changes in the skin, and produce an odorous exudate (NHS, 2019).  
In addition to vascular disease, arterial disease can also cause ulcers. Atherosclerosis, caused 
by smoking, obesity, hypertension or diabetes, is the leading cause of arterial LU when the 
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arteries fail to provide adequate oxygen and nutrients resulting in tissue breakdown (Moffatt, 
2001). Arterial ulcers can occur anywhere on the lower leg and compared with venous LU are 
often deeper wounds that are more rounded with clear borders, and the limb appears pale in 
colour and there is often a reduction in hair (Newton, 2011).  
The diagnosis of LU and the corresponding causal aetiology can be helped by a doppler 
ultrasound to measure ankle brachial pressure index (ABPI), the ratio of blood pressure in the 
ankle compared with the arm (Al-Qaisi et al., 2009). The ‘unspecified’ ulcers reported by Guest 
et al., (et al., (2015) are potentially patients who did not have an ABPI measurement thus 
preventing a more specific diagnosis. ‘Unspecified’ ulcers account for 19% of the wounds 
presenting to the NHS and is an important subgroup to consider.  
LUs are often slow to heal due to the inevitable poor blood supply resulting from venous or 
arterial disease; these wounds are also debilitating for a patient, causing pain or discomfort. 
Quality of life (QoL) outcomes are reduced in patients with LUs due to the ulcer, the dressing, 
or the resulting self-isolation because of pain, odour or exudate; patients also report 
depression, anxiety and low mood (Green et al., 2014).  
The aetiology of LUs is not always established by a clinician in a treatment setting and therefore 
the data and literature relating to LUs can include ulcers of either, mixed, or unknown origin. 
For the purposes of this PhD thesis all references are made to LUs of any aetiology. This is 
because of similar treatment patterns and the large number of wounds (around 19%), that 
would have to be excluded by following a narrower definition including only wounds that have 
had further diagnostic tests to establish aetiology.  
1.2.3 Treatment guidelines regarding dressings for DFU and LU 
The National Institute for Health and Care Excellence (NICE) DFU guidelines state that dressings 
should be offered to patients with a DFU (NICE, 2016). Section 1.5.10 addressed wound 
dressings directly; instructing HCPs to consider the clinical assessment and patient preference, 
but to use appropriate devices with the lowest acquisition cost (NICE, 2016).  A NICE Evidence 
Summary published in 2016 identified little high-quality evidence to support the use of 
advanced dressings for chronic wounds (NICE, 2016).   
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The Scottish Intercollegiate Guidelines Network (SIGN) has published a national guideline for 
the management of chronic venous LU in 2010. SIGN identified compression as the mainstay 
of treatment and found no evidence to support a single type of dressing above the others, 
recommending that a simple non-adherent dressing be used (SIGN, 2010). 
1.3 Evidence gap and rationale for research 
Analysis of the literature for wound care has highlighted a gap within the current body of 
evidence in reaction to new clinical trials of wound care dressings. The data gap provides the 
rationale for this PhD and informs the design of this research study.  
In December 2017, Urgo Medical Ltd reported the first double-blind randomised controlled 
trial (RCT) of patients with neuro-ischaemic DFU; the Explorer study (Edmonds et al., 2018). 
This RCT tested two dressing types: a sucrose octasulfate dressing which is a PMM dressing, 
and a neutral dressing which was identical but without the active ingredient (Edmonds et al., 
2018). The Explorer study offered valuable high-quality evidence in the field of wound care, as 
both this, and a previous trial in LU, managed to achieve double blinding due to Urgo Medical 
Ltd being the manufacturer of both the study and comparator dressings (Meaume et al., 2012). 
With the efficacy of this intervention being demonstrated in clinical trials it now important to 
examine the evidence for the clinical and cost-effectiveness specific to the UK, using a broad 
evidence base, including real world evidence and economic modelling.   
With the publication of Meaume et al., (2012) and Edmonds et al., (2018) there is now evidence 
to counter the claims of low-quality evidence in the field of dressings for wound care. A review 
by the Cochrane Collaboration in 2016 explored the use of PMM dressings for venous LU, with 
no single dressing shown as superior, thus no specific dressing protocol has been adopted into 
any subsequent published guidance. The Cochrane review did not include DFUs and the 
publication of newer studies of these interventions (Westby et al., 2016). A further review to 
incorporate new evidence is thus required to include observational studies of clinical outcomes 
across the two aetiologies of interest, DFU and LU. The economic burden of having and 
managing a chronic wound is also a topic that has not previously been subject to a systematic 
review and will be investigated.  
Validation by clinical and health economic experts of the methods used, and results produced 
by the research in this thesis is also required, given that recommendations for treatment 
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guidelines would seek to change clinical practice. A change of clinical practice is an ambitious 
goal, but this could be achieved if this research compels NICE to produce new guidance.  
NICE recommended guidelines are amongst the most respected source of clinical guidance, in 
the UK and worldwide, due to the robust process and methodology followed, which includes 
consultation with experts (NICE, 2016). This thesis hopes to produce guidance that could be 
recommended according to this world-class method, so this process must be emulated. As a 
result, this thesis will include repeated consultation with a multidisciplinary group of experts 
to anticipate any potential issues regarding adoption of a new technology. 
Existing data on patient QoL has broadly been collected using qualitative methods, including 
interviews and focus groups. A few RCTs have collecting data using Patient Reported Outcome 
(PRO) tools were also identified (Green et al., 2014). Utility scores for patients with DFUs have 
been reported using the SF Health Surveys (SF-12) and EuroQol 3-dimension (EQ-5D-3L) 
instruments; these studies took place in the Netherlands and Sweden (Ragnarson-Tennvall and 
Apelqvist, 2000; Redekop et al., 2004). QoL scores can differ across geographies, health care 
systems and treatment practices. In addition, a difference in society and culture has been 
shown to cause divergence in how QoL dimensions are scored by patients from different 
countries (Feng et al., 2017).  
Considering these factors, it is asserted that QoL studies require updating with patients from 
the UK to provide data most reflective of the UK population. Utility scores for DFU and LU have 
not been reported since early in the century, for DFU never in the UK, and never in an 
observational setting using validated tools. There is also the possibility that reported utility 
scores will change over time. For example, the recent focus on mental health by many charities 
and public health bodies may mean patients are more comfortable to reveal the burden of 
anxiety/depression, whereas in the past this may have gone unsaid.  
Health Technology Assessment (HTA) bodies such as NICE prefer data from patients within 
their countries to ensure generalisability of the outcomes to their locale; and given the 
ambition of this thesis to meet the standard set by NICE this preference will be observed. 
Therefore, an observational real-world study to collect QoL data from UK patients using 
validated PRO tools would add to the body of knowledge on the burden of DFU and LU, 
generalisable to the wider UK population.  
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Further supporting the rationale for the need for up to date QoL research is that since the 
publication of the previous studies, the EuroQol questionnaire has advanced, from the EQ-5D-
3L to the EQ-5D-5L, there are now five levels of answer in each of the five dimensions where 
previously there were only three. By using the new five level version, the utility scores collected 
are more sensitive to changes in QoL (Janssen et al., 2018).  
Real-world data is available in the form of pooled observational studies and database studies 
using electronic records such as the THIN database. A large pooled observational analysis 
published in 2017 showed improved healing outcomes were associated with use of the sucrose 
octasulfate dressing in 10,220 patients and identified various risk factors for impaired healing 
(Munter et al., 2017). Further analysis in a multidisciplinary setting, to better reflect UK 
treatment practice, would aim to establish treatment patterns and behaviours, healing 
outcomes and resource use. Previous analysis of the cost of DFU and LU to the UK NHS when 
treated in primary care, showed that they cost £7800 and £7600, respectively, to treat for 12 
months, as per data from The Health Improvement Network (THIN) database (Guest et al., 
2018a; Guest et al., 2018b). 
The collection of the data regarding DFU and LU provides an opportunity to inform accurate 
health care modelling using concurrent contemporary data. Models could then compare the 
outcomes reported in clinical trials with real-world practice and use these comparisons to help 
determine quality standards for treating chronic wounds. 
 
1.4 Aims  
The primary aim of this thesis is: 
To evaluate the clinical and economic impact of PMM interventions in DFU and LU to 
inform the development of treatment guidelines in the United Kingdom. 
To achieve the primary aim, this thesis has the following objectives served by the individual 
studies: 
A. To evaluate current treatment guidelines.  
➢ Addressed by studies 1, 3, 4, and 5. 
B. To gain consensus on guidelines, and treatment strategies for chronic wounds.  
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➢ Addressed by study 2. 
C. To quantify QoL for DFU and LU patients 
➢ Addressed by study 3. 
D. To assess clinical and economic impact of PMM interventions in wound management.  
➢ Addressed by studies 1, 2, 4, 5 
E. To assess the clinical and economic impact of the proposed recommendations.  
➢ Addressed by study 5. 
The findings of this PhD thesis will create a new body of evidence to provide answers not found 
in current literature, thereby improving current knowledge and providing an evidence base for 
guidance recommendations. It is hoped that this research will result in a change in treatment 
practice, with the goal of improving outcomes for patients. An optimal guideline would enable 
the delivery of maximum benefit to patients using the resources available.  
To address the gaps in the current research, this thesis has undertaken a series of studies to 
address the primary aim and objectives. Desk research consisting of two systematic reviews 
performed on interlinking topics within the management of DFU and LU have been performed. 
The reviews adhere to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines, which provide a framework for SLRs relating to health care 
interventions.  
Qualitative methods have been used to illicit individual opinions in the expert consensus study. 
The statements developed using thematic analysis of existing literature were tested using a 
Delphi methodology (Braun, 2006). Patient views regarding their wound and QoL were 
collected using a questionnaire pack consisting of validated PRO tools and a demographic 
information sheet developed by the researcher (AB). Current treatment pathways have been 
examined using quantitative methods and the economic evaluation has modelled the data to 
investigate the budget-impact and cost-utility associated with the proposed 
recommendations.  
A multi methods approach to data collection and analysis in this thesis allows for a greater 
understanding of the complexities and nuances of wound care. By understanding experiences 
and opinions of an individual and relating this to measured variables and outcomes the results 






1.5 Thesis structure  
There are five studies in total that constitute this thesis, each using a different method to 
examine the impact of DFU and LU on clinical, economic and QoL outcomes. The PhD 
researcher (AB) has driven the conception, design and execution of all studies that make up 
this programme. AB carried out and led all elements of studies 1 and 2, and informed data 
collection and performed all data analysis and economic modelling for studies 3-5.  
Chapter 1 of this study is the introduction to this body of knowledge and has presented 
information on DFU and LU, the rationale for the research and the thesis primary aim and 
objectives. Chapter 2 presents two systematic literature reviews (SLR) that constitute study 1, 
the first a clinical SLR that investigates the efficacy of PMM dressings and the second an 
economic SLR of topical chronic wound care interventions more broadly. Chapter 3 will present 
the Delphi methodology expert consensus panel, study 2, highlighting areas of uncertainty 
upon which a consensus will be sought from a multidisciplinary panel of experts.  
Chapter 4 presents two studies, study 3 and study 4, both examples of real-world evidence 
studies. Collecting data from patients in practice; study 3 seeks to evaluate patient QoL using 
standardized tools whilst study 4 investigates the real-world incidence and causes of treatment 
switching for patients with a DFU or LU. Chapter 5 presents the economic evaluation of the 
PMM intervention for patients with a DFU and LU using multiple methods of cost-modelling. 
Chapter 6 presents the overall discussion of the body of knowledge presented here whilst 
Chapter 7 puts forth the recommendations and conclusions drawn.  
The studies are not performed in isolation, rather they each will inform the design and 
development of the final economic modelling and subsequent recommendations. Figure 1.1 
shows the relationships and interdependencies of the studies. This figure is shown repeatedly 
throughout the thesis, with the relevant sections highlighted in colour to illustrate the multi-




Figure 1.1. Overall PhD framework 
All five studies focus on DFU and LU patients when considering chronic wounds. Pressure ulcers 
and acute wounds were deemed out of scope for this thesis, due to different treatment 
strategies, and the fact they occur in diverse patient populations. Pressure ulcers are often 
found in patients who are immobile for long periods of time whilst acute wounds can happen 
to anyone with little predisposition.  
The overarching design of the thesis is a multi-method study; with projects that can either be 
interpreted on their own; or be viewed together as part of this overall PhD thesis. Whilst some 
researchers make no distinction between multi-method and mixed methods studies (Stange, 
2006) this thesis is aligned with the definition provided by Pat Bazeley where multi-method 
research consists of different approaches or methods that are used in parallel or sequence but 
are not integrated until inferences are made (Johnson et al., 2007). Multi-methods in this 
instance refers to the different ways of collecting data demonstrated in this thesis; but also to 
the different approaches of each study; looking at varied perspectives (the patient, a care 
provider or health care budget holder). The intent of this approach is to provide a holistic 
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overview of all issues regarding wound care in order to develop optimal recommendations for 
treatment guidance. 
The Delphi panel was the first study performed. The broad systematic search of literature used 
to develop the evidence-based statements for the Delphi panel informs the development of 
the subsequent SLRs that comprise study 1. The clinical SLR in study 1 informed the economic 
modelling with regards to which PMM intervention was of most interest and had the strongest 
evidence from RCTs and observational studies, and the outcomes associated with the use of 
this dressing in patients with DFU and LU.  
The economic SLR informed the data analysis of the chart extraction, study 4. The economic 
SLR highlighted variance in the application of standard care in the literature and this then 
became a research priority for the chart extraction; to understand treatment switching, in 
addition to reporting on healing outcomes. Patient utility scores collected using EQ-5D-5L in 
study 3 were used directly in the economic modelling as a core component of the cost-utility 
analysis. Study 4 confirmed the suspicion that standard care incorporated a large variance 
when considering DFU and LU. By not using a variable standard care protocol and instead 
relying on the RCTs identified in study 1, the modelling can be asserted to show the difference 
powered only by the sucrose octasulfate dressing. Should another standard care protocol be 
substituted into the model; the results should remain consistent as the only difference 
between the treatment arms was the sucrose octasulfate dressing as a replacement for a 




1.6 Organisational setting 
The partnership between Manchester Metropolitan University (Manchester Met) and Urgo 
Medical Ltd, a wound care medical device manufacturer, has facilitated this PhD. Urgo Medical 
Ltd commissioned Manchester Met to manage data generation and the subsequent 
submission of evidence to NICE. NICE produces guidance, briefings and knowledge summaries 
to guide HCPs in England where NICE guidance is mandatory. Medical device manufacturers 
such as Urgo Medical Ltd can participate in the Medical Technologies Evaluation Process 
(MTEP) with NICE, to obtain guidance for their products. Upon the completion of a successful 
clinical trial, Urgo Medical Ltd wished to submit their product to NICE for MTEP review 
(Edmonds et al., 2018). A project was commissioned to develop a robust evidence portfolio of 
clinical, economic, and patient related outcomes. This PhD thesis has been developed 
concurrently, to complement this project with aims that were broader than the MTEP sought 
to address.  
 
1.7 Chapter summary 
This chapter contextualises the PhD thesis; by providing an overview of the conception and 
context of the research, an introduction to the disease areas, LU and DFU, and current 
guidelines that dictate the treatment of these wounds with dressings. The chapter also 
provides a critical review of current research in this area and highlights evidence gaps that have 
shaped the development of this thesis. The PhD structure has been discussed, giving an insight 
into the five constituent studies and their methodologies, whilst exploring the linkages 
between the studies and how together they address the primary aim and thesis objectives.  
The next chapter in this thesis discusses the SLRs, first the clinical review of PMM interventions 
and then the SLR focused on economic outcomes associated with topical interventions for 
wounds. The SLRs highlight the current research in existence on this subject and inform the 




Chapter 2 Clinical and economic systematic literature reviews 
2.1 Introduction 
This chapter presents two systematic literature reviews (SLRs), that have been carried out to 
understand the current body of work that surrounds the economic analyses of topical wound 
care interventions and the clinical efficacy of protease-modulating matrix (PMM) 
interventions. A literature review becomes systematic when it is based on a clear question and 
performed according to an explicit methodology that includes pre-defined inclusion and 
exclusion criteria, an appraisal of evidence quality and a summary of the evidence. The 
Cochrane Handbook for Systematic Reviews highlights that SLRs are conducted with a view to 
minimize bias, to provide reliable and generalizable findings that can inform evidence-based 
conclusions and guide decision making (The Cochrane Collaboration, 2011).  
These reviews were carried out independently of each other, to address separate aims. The 
aims were informed by the SLR that was carried out in advance of the Delphi Methodology 
expert panel (study 2) presented in chapter 3, as shown in Figure 2.1. The first SLR is a focussed 
SLR on PMM interventions and their clinical effectiveness. This is followed by a review 
pertaining to economic outcomes of a broader range of topical interventions for chronic 
wounds.  
This chapter presents each SLR in turn, exploring the background relating to each topic, setting 
out the methodology used, presenting the results and a discussion of the findings. A critical 
review of both SLRs follows to explore the synergies between the two reviews and illustrate 





Figure 2.1. SLRs within the PhD framework 
 
2.2 A systematic review of clinical efficacy of PMM interventions for treating DFU or LU 
2.2.1 Introduction 
Diabetic foot ulcers (DFUs) or Leg Ulcers (LUs) can cause a considerable burden to a patient 
and health care provider (HCP), taking a long time to heal and requiring frequent interventions. 
Dressings are a mainstay of treatment with countless options for an HCP. PMM interventions 
are an alternative to basic or other advanced dressings. A systematic review was undertaken 
to assess the clinical effectiveness of PMM interventions for DFUs and LUs. 
2.2.2 Background 
DFU and LU are examples of wounds that fail to follow a normal healing pattern (Russell et al., 
2018). These wounds frequently present as a symptom of an underlying chronic comorbidity 
such as diabetes, venous or arterial disease (Frykberg & Banks, 2015). They may last for many 
months or even years, causing a burden felt by patients, the healthcare system and the wider 
economy. DFU and LU caused by venous or arterial disease can, without appropriate 
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treatment, become long lasting wounds. Treatment pathways for these patients are 
complicated, with a wide variation in practice found in recent retrospective studies (Guest et 
al., 2018a; Guest et al., 2018b). Variance in treatment is explored in this thesis in the following 
economic SLR (see section 2.3), and in study 4 presented in chapter 4.  
Wound dressings are a mainstay treatment applied as part of a wider treatment strategy, 
which may also include compression, debridement, offloading and infection control to achieve 
full wound closure (SIGN, 2010; NICE, 2016). PMM dressings or interventions act on the matrix-
metalloproteases (MMPs) present in DFU and LU. These interventions are intended to 
rebalance MMPs, enzymes that play a role in cell proliferation expressed during the 
inflammatory state of healing (Olzyck et al., 2014). Studies show higher levels of MMPs in DFU 
and LU from onset in comparison with acute wounds (Lazaro et al., 2016). 
Given traditional low levels of evidence associated with wound care studies due to the difficulty 
in blinding there is often uncertainty concerning the validity of wound care studies. The 
National Institute for Health and Care Excellence (NICE) provides only limited guidance on the 
use of dressings, with a focus on the “least costly dressing” that meets the needs of the patient 
(NICE, 2019). The vast array of dressings available poses a challenge to clinicians and decision 
makers regarding dressing selection (BNF, 2015). 
An earlier systematic review of PMM dressings looking solely at venous LUs did not find 
conclusive evidence for the use of PMM dressings (Westby et al., 2016).  In recent years, new 
high-quality evidence has become available for the use of PMM dressings. A pooled analysis of 
observational trials (Munter et al., 2017) and a double-blinded randomised controlled trial 
(RCT) (Edmonds et al., 2018) highlights the need to review the evidence. No review has 
included these new high-quality studies.  
The new high-quality evidence in this field and the fact that these interventions are offered in 
multiple indications, including DFU and LU of all aetiologies, drives the need to perform a 
systematic review to provide evidence on which PMM interventions which could offer 




2.2.3 Study aims 
The aim of study 1a was: 
− To establish the clinical effectiveness of PMM interventions in the treatment of DFU 
and LU. 
The objectives of study 1a were:  
− To document all studies of PMM interventions in the treatment of DFU. 
− To analyse and critically appraise the included studies. 
2.2.4 Methods 
A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines was undertaken (Moher et al., 2009). An electronic database 
search, and consultation with experts and manufacturers identified the literature. Two 
researchers (AB and PhD supervisor, IO) independently performed data extraction with a third 
(PhD supervisor, FF) consulted in case of any discrepancies. A narrative synthesis of results and 
critical appraisal of included studies was performed. Further detail about the search strategy 
is described in this section.  
Search strategy 
The following electronic databases were searched: Centre Reviews and Dissemination (CRD) 
York Database; Cochrane Library (all databases); Medline (PubMed); NICE Evidence; Science 
Direct/Scopus. The databases were searched in April 2018 with no date stipulation, given that 
the search criteria of protease-modulating matrix interventions itself would restrict the results. 
Relevant ongoing research was accessed using the World Health Organisation International 
Trial Registry and ClinicalTrials.gov. Other sources included citation searches of included 
studies, contact with relevant manufacturers and experts. The search string used can be found 
in Appendix A. 
Eligibility criteria 
The inclusion and exclusion criteria for this review are shown in Table 2.1. There were no 
restrictions with respect to the date of publication due to PMM interventions being a relatively 
recent innovation. Methods to diagnose a venous, arterial or diabetic ulcer may vary and this 
review accepted any as described by the included studies. 
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Table 2.1. Clinical SLR inclusion and exclusion criteria 
Inclusion criteria 
Population Diabetic foot ulcer, leg ulcer, or a study of chronic wounds  
Interventions Protease modulating matrix interventions  
Outcomes Wound area reduction, wound closure.  
Study design Randomised controlled trials, observational studies 
Language  English language 
Exclusion criteria 
Population Paediatrics (<18), acute wounds  
Interventions N/A 
Outcomes N/A 
Study design In vitro studies, review or discussion articles, treatment 
pathway/guidelines, systematic/lliterature reviews or meta 
analyses, epidemiology studies, Modelling, case studies, economic 
studies, database studies 
Language  Non-English language  
 
Data extraction (selection and coding) 
Two researchers (AB and PhD supervisor, IO) independently assessed titles and abstracts 
retrieved by the searches for relevance (.ris files were extracted to EndNote using Excel 
database for review). Access to the full text files was obtained for titles appearing relevant at 
initial screening.  
The researchers then independently assessed the eligibility of the text against this study’s 
inclusion and exclusion criteria shown in Table 2.1. The researchers applied the pre-defined 
criteria independently to produce a final list of included studies. Data was extracted into tables 
with different information extracted for RCTs and observational studies.  
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Risk of bias (quality) assessment 
A critical appraisal of studies was carried out on the studies as per the NICE submission 
templates for Medical Technologies Evaluation Programme (MTEP); which is derived from York 
University CRD (NICE, 2017). The templates are different for RCT and observational studies. 
Strategy for data synthesis 
A structured narrative synthesis of the data was constructed using the completed data tables; 
stratified according to wound type, and then by intervention. As the included studies were not 
homogenous with regards to population, comparator or outcome measurements; a meta-
analysis was not able to be performed (Sedgwick, 2015).  
2.2.5 Results 
From searching the databases, 272 results were returned. Discussion with experts and 
manufacturers provided 11 further titles. After initial screening of the 283 titles and abstracts, 
68 were excluded due to lack of relevance to the research question. The remaining 215 texts 
were judged against the inclusion and exclusion criteria in Table 2.1. Two hundred and eight 





Figure 2.2. Clinical SLR PRISMA reporting diagram 
The list of included studies can be found in Table 2.2. Data extraction tables for study 
methodology were completed; the two DFU RCTs are detailed in Table 2.3 and the three LU 
RCTs in Table 2.4; and observational studies for both indications are shown in Table 2.5.  
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Vin et al., 2002 The healing properties of Promogran in LU LU ORC 
Silicone 
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Schmutz et al., 
2008 
Evaluation of the TLC-NOSF matrix in the local 
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2012 
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Munter et al., 
2017 
The reality of routine practice: a pooled data 
analysis on chronic wounds treated with TLC-





Edmonds et al., 
2018 
Sucrose octasulfate dressing versus control 
dressing in patients with neuroischaemic DFU 
(Explorer): an international, multicentre, 






Abbreviations: DFU: diabetic foot ulcer, LU: leg ulcer, ORC: oxidized regenerated cellulose. 
SO: sucrose octasulfate. TLC-NOSF: lipido-colloid technology nano-oligosaccharide factor.  
37 
 
Table 2.3. Clinical SLR summary of methodology of DFU RCTs 
Study  Veves et al., 2002 Edmonds et al., 2018 
Objectives 
To evaluate healing rates of DFU 
treated with ORC compared with 
saline-moistened gauze 
To demonstrate superiority of SO 
compared with control for the 
treatment of neuro-ischemic DFU 
Location United States UK, Spain, Germany, France, Italy 
Design 
Multi-centre randomised, 
prospective, controlled trial 
Multicentre, randomised, 
prospective, double blind 
controlled trial 
Duration 12 weeks 20 weeks 
Sample  276 240 
Inclusion criteria 
− > 18 years 
− DFU present for > 30 days. 
− Area >1cm2. 
− Wagner grade 1 to 2. 
− Adequate circulation 
− No necrotic tissue 
 
− > 18 years 
− HbA1c level ≤ 10%. 
− Neuro-ischemic DFU 
− Area 1-30 cm2 
− Confirmed neuropathy 
− No local clinical infection 
Exclusion  
− Allergy to study dressing. 
− Infection. 
− Ulcer extending to bone. 
− Severe comorbidity, poor health, 
immunosuppressant or 
corticosteroid use. 
− Unwillingness to comply with 
offloading. 
− Multiple ulcers on one foot. 
− Surgery/revascularization 
(1month). 
− Acute ischemic event (3 months) 
− Dialysis for renal failure. 
− >20% necrotic tissue or 
extending to bone. 
− Neoplastic condition. 
− Severe comorbidity, poor health, 
immunosuppressant or 
corticosteroid use. 
− Inter-digital, heel or posterior. 
Randomisation Stratified by wound size Stratified by wound size 
Blinding Unclear in publication 




Study  Veves et al., 2002 Edmonds et al., 2018 
Intervention/ 
comparator  
ORC (n = 138)  
Moistened Gauze (n = 138) 
SO (n=126) 
Neutral dressing (n=114) 
Baseline 
differences 
No significant difference at 
baseline. Verified using 
appropriate tests 
No significant difference at 
baseline. Verified using 
appropriate tests 
Follow-up 
12 weeks. No information 
available regarding patients lost to 
follow up 
20 weeks. 37 patients did not 
complete. (SO n=18, comparator 
n=19) 
Statistical tests 
Random-effects mixed model. 
Linear logistic regression. Odds 
ratio. 
ITT. Regression logistic analysis. 4 
sensitivity analyses on ITT, and 1 
on PP  
Primary 
outcomes 
Complete healing. 100% 
reepithelialisation, no draining 
confirmed by blinded assessor 
Wound closure at 20 weeks. 100% 
reepithelialisation, no draining 




Time to complete ulcer healing 
Time to complete wound closure 
Relative and absolute WAR 
Adverse events/Quality of Life 
Abbreviations: DFU: diabetic foot ulcer, ITT: intention to treat, ORC: oxidized regenerated 
cellulose, PP: per protocol, SO: sucrose octasulfate, WAR: wound area reduction.  
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Table 2.4. Clinical SLR summary of methodology of LU RCTs 
Study  Meaume et al., 2012 
 
Schmutz et al., 2008 
 
Vin et al., 2002 
Objectives 
To assess efficacy of 
the SO in LU 
To assess SO relative 
to ORC in LU 
To evaluate LU healing 
rate using ORC 








open label, controlled  
Multi-centre, 
randomised, two-arm 
open label, controlled  
Duration  8 weeks 12 weeks 12 weeks 
Sample  187 117 73 
Inclusion criteria 
− > 18 years 
− ABPI of ≥0.8 – 1.3 
− Using compression 
− 5-50 cm2 & 6-36 
months 
− 50% granulation 
− > 18 years 
− ABPI of ≥0.8 
− Using compression 
− 5-25cm2 & 3–24 
months. 
− LU with ABPI of ≥0.8 
− Free from infection 
− Wound at least 30 
days. 
− Wound ≥2cm2 
.≤10cm2 
Exclusion criteria 
− Suspicion of 
infection 
− Malignant wound 
− Severe comorbidity, 
poor health, 
immunosuppressant 
or corticosteroid use 
− CMC contact 
dermatitis. 
− Recent surgery/DVT 
− Suspicion of 
infection 
− Malignant wound 
− Severe comorbidity, 
poor health, 
immunosuppressant 
or corticosteroid use 
− Necrotic/devitalised. 
− Recent surgery/DVT 
− No compression 
− Immobile patients 
and/or unable to 
care for themselves 
− Severe comorbidity, 
poor health, 
immunosuppressant 
or corticosteroid use 
 
Randomisation Blocks of 2 by centre Unclear Unclear 
Method of 
blinding 
Dressings identical.  
Blinded clinicians. 
N/A Open label N/A Open label 
40 
 
Study  Meaume et al., 2012 
 
Schmutz et al., 2008 
 
Vin et al., 2002 
Intervention/ 
comparator  
SO (n = 93) 
Standard care (n = 94) 
SO (n = 57) 



















8 weeks. Withdrawals: 
SO (n = 4) Control (n = 
6) 
12 weeks. One lost to 
follow-up 

















Relative WAR of last 
available planimetry 















Tolerability: Pain and 
ease of removal. 
Abbreviations: ABPI: Ankle-brachial pressure index, DVT: Deep vein thrombosis, LU: leg ulcer, 
ORC: Oxidized regenerated cellulose, SO: Sucrose octasulfate, WAR: Wound area reduction 
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Table 2.5. Clinical SLR summary of methodology of observational studies 
Study  Munter et al., 2017 Richard et al., 2012 
Objective Study real-world efficacy of SO  Estimate efficacy, tolerability and 
acceptability of SO in DFUs 
Location France and Germany France 
Design Pooled observational studies Open-label single arm pilot study 
Duration 4-20 weeks 12 weeks 
Population Chronic wounds  DFU  
Sample size 10,220 (1306 DFU, 7903 LU)  34  
Inclusion  − Use of the sucrose octasulfate 
dressing  
− >18 years 
− Neuropathic, non-ischaemic DFU.  
− 1–15cm2,  
− Located on the forefoot or midfoot.  
− Texas University classification 1A  
− > 50% granulation tissue.  
Exclusion  − N/A − Clinical signs or symptoms of infection 
Follow-up Date of inclusion, latest visit and 
calculation of follow-up duration. 
 Analysis of the last evaluation. One 
patient excluded due to missing data. 
Statistical 
tests 
Binary logistic regression analysis. 
OR calculated for covariates with 
95 % CI. Mean estimate of time to 
closure calculated using Kaplan-
Meier method.  
The statistical analysis, purely 
descriptive, without any test, was 
performed on an ITT basis for both the 




Wound closure.  
 
Relative WAR (%)  
Secondary 
outcomes  
Time to 50 % reduction of the 
PUSH score. 
Healing rate and mean healing time,  
Tolerability and acceptability. 
Abbreviations: CI: confidence interval, DFU: diabetic foot ulcer, ITT: intention to treat, LU: 
leg ulcer, OR: odds ratio, PUSH: pressure ulcer scale for healing, SO: sucrose octasulfate, 




The two PMM interventions used in the included studies, were the sucrose octasulfate dressing 
(marketed in the United Kingdom (UK) under the brand name UrgoStart and manufactured by 
Laboratoires Urgo) and the oxidized regenerated cellulose (ORC) dressing (marketed in the UK 
under the brand name Promogran and manufactured by Acelity). These dressings both claim 
to inhibit MMPs in a wound and have this as part of a registered mode of action. In the sucrose 
octasulfate dressing, the potassium salt of sucrose octasulfate acts at the tissue level and has 
been shown to inhibit excess MMPs and interacts with growth factors restoring their biological 
functions contributing to tissue formation (White et al., 2015).  Oxidized regenerated cellulose 
(ORC) has been shown to bind and inactivate damaging MMPs present within the wound, also 
binding with naturally occurring growth factors preventing them from being broken down by 
damaging proteases (Cullen & Ivins, 2010). 
Study demographic data 
The seven studies included 9859 patients in total; 1822 of these with a DFU and 8037 with a 
LU, Munter et al., (2017) did not include sex data for all included patients, and also included 
pressure ulcers but these have been excluded from this analysis. DFUs were more common in 
males, with only 32% of the recorded population being female. Conversely the LU population 
was predominantly female (62.1%). Patients with LU were on average approximately 10 years 
older than patients with DFU. Of 9859 patients included in this systematic review, 9.1% (n = 
893) were from RCTs and the remaining 90.9% (n =8966) were from the observational studies. 
The three LU RCTs included 377 patients, and the two DFU RCTs included 516 patients. 
Table 2.6. Clinical SLR pooled study demographic data 
Patient characteristics Total population DFU LU 
Included patients 9859 1822 8037 
Male 4286 (43.5%) 1239 (68.0%) 3047 (37.9%) 
Female 5573 (56.5%) 583 (32.0%) 4990 (62.1%) 
Mean age 65.4 years* 61.2 years* 71.6 years* 




The DFU RCTs included in this review tended to have a longer follow up than the studies for 
LU; with Veves et al., (2002) being 12 weeks, and Edmonds et al., (2018), 20 weeks. The 
inclusion and exclusion criteria appear similar between the two studies, despite not being well 
described in Veves et al., (2002), resulting in patients with similar baseline characteristics. 
Veves et al., (2002), mandated that the ulcer be larger than 1cm2 and Edmonds et al., (2018), 
stipulated a size range, from 1cm2 - 30cm2. DFUs tend not to be as large as LUs, with their size 
less considered as a marker of severity.  
Edmonds et al., (2018), required the DFUs to be confirmed as neuro-ischaemic, a category of 
ulcers that are considered more difficult to heal than ulcers without neuropathy or ischaemia 
(Yotsu et al., 2014). These RCTs have exclusion criteria affecting patients with a weakened 
immune response, or with comorbidities or concomitant medication that could influence 
healing. This may not be reflective of a real-world treatment population; however, allows for 
greater control of confounding within the RCTs. Both DFU studies have a primary outcome 
measure that addressed full wound healing, or closure.  
LU RCTs 
The inclusion and exclusion criteria for all LU studies were comparable, all excluding patients 
with concomitant illnesses or medications that may impair healing. Vin et al., (2002), was most 
restrictive in terms of ulcer size, stipulating that it must be between 2cm2 and 10cm2, whilst 
Schmutz et al., (2008), had a broader range of 5-25cm2. Meaume et al., (2012), had no 
restriction on ulcer size or age. All the studies included compression as part of standard care 
for both treatment arms.  
Wound care trials are usually difficult to achieve blinding however, Meaume et al., (2012), was 
a double blinded study with the others being open label. Double blinding was achieved as 
Laboratoires Urgo manufactured both study dressings used in the trial; one impregnated with 
the sucrose octasulfate matrix and one without. This is the same methodology as in the DFU 
RCT carried out on the sucrose octasulfate dressing.  
The primary outcome was wound area reduction (WAR) in 2 out of 3 LU studies, with only Vin 
et al., (2002), capturing full wound healing. Full wound healing is a more relevant endpoint for 
patients and caregivers as this reflects the goal of treatment, whereas WAR is a surrogate 
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measure that does not guarantee full closure; and does not account for wound depth. It is 
likely that these surrogate endpoints were used instead of complete wound closure as the 
study follow up periods of 8 weeks (Meaume et al., 2012) and 12 weeks (Vin et al., 2002: 
Schmutz et al., 2008) would not be long enough to record wound closure. 
Observational studies 
The two observational studies include data from 10,254 patients, with Munter et al., (2017), 
being a pooled analysis of 10,220 patients, including patients with both LU (n = 7903) and DFU 
(n = 1785), amongst other wounds. Munter et al., (2017) intended to understand real-world 
treatment patterns with the sucrose octasulfate dressing, using a large patient cohort pooled 
from 8 other observational studies. The included studies have not been assessed for risk of bias 
and appear all to be manufacturer driven and led. Length of follow up ranges from 4 weeks to 
20 weeks and the outcome measure reported by Munter et al., (2017) was wound closure or 
proportion of patients with a 50% reduction in the PUSH score; reaching this in 29.8% and 
37.4% of LU and DFU patients respectively. Richard et al., (2012) was a prospective pilot study 
on 34 DFU patients, with primary objective assessing relative WAR of the wounds within 12 
weeks. 
Primary outcomes 
The results of the primary outcomes are shown in Table 2.7, structured to show the LU, DFU 
RCTs and observational studies separately, with the results of Munter et al., (2017) stratified 
by wound type, LU or DFU. Of the total 7 studies included, 3 had a primary outcome of relative 
WAR and 4 assessed healing or closure outcomes. The studies provide evidence that not all 
PMM dressings offer the same clinical benefit to patients, with only the sucrose octasulfate 
dressing recording statistically significant outcomes, Edmonds et al., (2018) demonstrated an 
odds ratio of 2.6 (p = 0.002) of healing at 20 weeks when using the sucrose octasulfate dressing 
on DFUs. Looking at the total population Munter et al., (2017) show a 30.8% benefit when a 
treatment regime included the sucrose octasulfate dressing, broken down as a 29.8% (CI: 
28.8%-30.9%) benefit for LU patients and 37.4% (CI: 34.8%-40.1%) for DFUs. For ORC, Veves et 
al., (2002) did not reach statistical significance improving wound healing versus control for 
DFU, nor did Vin et al., (2002) when studying LU; an improvement was noted but this result 
failed to reach significance (p = 0.184). Overall, there is a stronger evidence base for the clinical 
benefit of the sucrose octasulfate dressing compared to ORC. 
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Table 2.7. Clinical SLR results of included studies 
  
LU RCT DFU RCT OBSERVATIONAL STUDIES 
















Munter et al., 2017  
DFU LU 
(n=) Active 93 57 36 126 138 34 1273 7660 
Control 94 60 37 114 138 N/A N/A N/A 
Duration Weeks 8 12 12 20 12 12 4-20 4-20 
Analysis 
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P = 0.12 n/a n/a n/a 
Risk of bias (quality) assessment 
The NICE submission template (as relevant to each design) for MTEP were used to assess 
quality and risk of bias (NICE, 2017) as presented in Tables 2.8 and 2.9. The assessment of RCTs 
had 7 questions to report from the studies in the following categories: randomisation, 
concealment, baseline similarity, blinding, withdrawal imbalances, unreported outcomes, ITT 
analysis. A scoring method was applied, giving a point for each dimension the study could 
satisfy- giving a maximum of 7 points. One study scored 7 points (Edmonds et al., 2018) one 
study scored 6 points (Meaume et al., 2012), and one each scored 5, 4, 3, and 2 points, giving 
an average score of 5.4. There are no defined criteria for interpreting the scoring; however it 
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is to be assumed that the more points scored; the more robust the study can be considered. 
The critical review of the observational studies also had 7 questions, asking about recruitment, 
exposure, outcome measurement, confounding factors, follow up and precision of results. A 
scoring method of assigning a point per category satisfied was applied, and both studies scored 
only 1 point, showing that these studies did not report enough data to be considered high 
quality. The methodological assessment of the studies is in Table 2.8 for the RCTs and Table 
2.9 for the observational studies.  
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Not clear No No 
Outcomes all 
reported? 
No No No Not clear No 
ITT analysis? 
Missing data? 
Yes Yes Not clear Not clear Yes 






Table 2.9. Clinical SLR risk of bias assessment of observational studies (NICE 2017) 
  Richard et al., 2012. Munter et al., 2017 
Acceptable recruitment? Yes, consecutive patients Not clear, pooled studies 
Exposure measured? Not clear Not clear 
Outcome measured? Not clear, relative WAR Not clear, wound closure 
Confounders Identified? Not clear Not clear 
Confounders mitigated? Not clear Not clear 
Follow-up of complete? No, 1 missing & 8 withdrawn Yes, at least 1 follow up 
Results precise? No, CI of ± 49.9%. Yes, p=<0.001 
Score 1 2 
 
2.2.6 Discussion 
A systematic search of the literature was undertaken to investigate whether PMM 
interventions are clinically effective treatment for DFUs and/or LUs. This review has found 
evidence that some PMM interventions were clinically effective in the management of DFU 
and LU, compared to control.  
For patients with a DFU, Edmonds et al., (2018) measured wound closure and achieved this 
endpoint in 48% of patients using the sucrose octasulfate dressing versus 30% of patients using 
control, with an odds ratio of 2.6 in favour of the intervention; subgroup analysis also showed 
that the earlier that treatment is initiated, the better the outcomes. For ORC, Veves et al., 
(2002) also achieved a positive result for the PMM intervention, however this study did not 
reach the threshold for statistical significance. The result suggests that the sucrose octasulfate 
dressing is more likely to result in better healing outcomes for these patients.  
For patients with a LU, the most measured endpoint in the RCTs was WAR; perhaps because 
LUs can take a very long time to heal and clinical studies that measured full healing would need 
to be long in duration: and thus very expensive. Instead, studies rely on the proven statistical 
link between the rate of initial wound area reduction and eventual closure (Cardinal et al., 
2008). All studies included showed the superiority of the PMM intervention, however the ORC 
study as reported by Vin et al., (2002), did not reach statistical significance. Meaume et al., 
(2012) found a statistically significant benefit for the sucrose octasulfate dressing with 26.7% 
48 
 
difference between the groups, in favour of the study dressing; repeated in Schmutz et al., 
(2008); where patients using this dressing had a WAR of 54.4% versus only 12.9% of those using 
control, a statistically significant result. The LU RCTs may suggest that the sucrose octasulfate 
dressing is not only better than control but is also superior to the ORC matrix in treating these 
wounds. 
There is also some evidence of benefit for patients in a real-world setting, with Munter et al., 
(2017) aiming to understand if the efficacy demonstrated in clinical studies is effectively 
translated to a real-life patient; with 37.4% and 29.8% of DFU and LU patients reaching the 
endpoint of either wound closure or 50% reduction in PUSH score. However, there is difficulty 
in observing real-world trends; this pooled analysis of observational studies is without a critical 
appraisal of included studies and scored low in the critical assessment.  
Both Meaume et al., (2012) and Edmonds et al., (2018) compared two wound care products 
by the same manufacturer. The studies achieved double blinding by producing both the 
intervention and control dressing with the same material, packaging and colours as one 
another; with the sole difference of the sucrose octasulfate dressing having the active healing 
matrix to inhibit excess metalloproteases and restore local angiogenesis. By performing double 
blinded RCTs, high-quality evidence has now been produced in the field of wound care; setting 
a new standard for manufactures.  
The risk of bias (quality) assessment of the evidence scored the RCTs as being of an overall 
moderate quality when considered as a collective, however Meaume et al., (2012) and 
Edmonds et al., (2018) both individually scored highly, reflecting the robust double-blinded 
nature of these studies. The observational studies both were of low quality when evaluated by 
the critical review. Uncertainty of evidence undermines the data produced; and in an external 
environment of manufacturer led studies, the open-label studies score poorly on risk-of-bias 
scoring methodologies due to the practicalities of wound care products. Due to the high-
quality of the studies by Meaume et al., (2012) and Edmonds et al., (2018) there is limited 
uncertainty when assessing the positive results in these RCTs. To balance RCTs with real-world 
practice, expert opinion and real-world data could be sought inform best treatment practice.  
This systematic review highlights the need for further research into the efficacy of PMM 
treatments; given the use of the proxy endpoint WAR in many RCTs. Future studies could follow 
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the example of Meaume et al., (2012) and Edmonds et al., (2018) which demonstrate the 
feasibility of double blinding when examining wound care devices.  More research into the 
patient perspective of ulceration and living with treatment would help to understand quality 
of life (QoL) factors. Secondary outcomes of tolerance and adverse events reported in the 
studies here give insight into patient issues, however using validated tools such as EQ-5D-5L 
and SF-36 allows for greater transferability of results. A review of patient level data to examine 
the treatment practices used by HCPs would be useful to establish treatment pathways; or to 
highlight how RCTs differ from ‘real-life’ in terms of patient characteristics, treatment plans 
and outcomes. A dressing, by its nature is frequently changed, and a treatment switch at 
dressing change is speculated by this author to be more likely in a real-life setting opposed to 
a protocolised clinical study setting. All the studies stipulate using the study dressing for the 
duration of follow-up (from 8 to 20 weeks) and treatment patterns applied by HCPs in a clinic 
may deviate from this; perhaps having an impact on efficacy.  
2.2.7 Conclusions 
This review provides some evidence that PMM interventions have a clinical benefit on wound 
healing outcomes; however, there were several methodological issues with the studies 
included. New evidence shows promising results for the treatment of DFUs involving inhibition 
of excess metalloproteases and restoration of local angiogenesis by sucrose octasulfate 
dressings. 
The findings of this systematic review can inform clinical decision making concerning the use 
PMM interventions. The evidence collected shows the superiority of the sucrose octasulfate 
dressing over the ORC matrix, highlighting that not all PMM interventions are the same. The 
evidence suggests that the sooner a patient is treated with the sucrose octasulfate dressing, 
the better the healing outcomes. Early intervention combined with reducing healing time in 





2.3 A systematic review of economic outcomes associated with use of topical interventions 
for treatment of chronic wounds 
2.3.1 Introduction 
Chronic wounds such as DFU and LU are burdensome for patients, their caregivers, the 
healthcare system, and wider society. They can last a long time, often for more than a year. 
Chronic wounds are more prevalent in older people, due to the impact aging has on the wound 
repair processes and the increased incidence of diabetes and cardiovascular disease (Gould et 
al., 2018). Patients diagnosed with a chronic comorbidity such as diabetes or venous 
insufficiency are at a higher risk of developing a chronic wound (Frykberg & Banks, 2015; Kerr, 
2017). The prevalence and incidence of diabetes is rising in the United Kingdom (UK), as too is 
the size of the elderly population (Zghebi et al., 2017; Office for National Statistics, 2018). The 
growth of these populations suggests that there will also be a growth in the financial and 
economic cost of their co-morbidities; including chronic wounds. A retrospective database 
study suggests that 2.2 million people, or 4.5% of the adult population presented with a chronic 
wound in the study year (Guest et al., 2015). Chronic wounds also contribute to a significant 
portion of healthcare spending in the UK, with an estimated 5.5% of National Health Service 
(NHS) expenditure on chronic wound care (Phillips et al., 2016). 
2.3.2 Background 
Treating chronic wounds involves a range of standard care interventions, including 
debridement, infection control, offloading, surgery, compression, and use of dressings (Jones 
et al., 2018). A combination of these strategies may be appropriate for a patient presenting 
with a chronic wound. The optimal treatment pathway is still uncertain; with many products 
offering a variety of evidence as to their clinical and cost-effectiveness. Wound dressings and 
topical interventions are a key component of treatment strategies to achieve wound closure 
for a range of wounds. Dressings have been categorised by the British National Formulary (BNF) 
as being either basic, advanced, antimicrobial, or specialised; spending on wound-care dressing 
prescriptions in England was almost £106 million in the year ending August 2017 (NICE, 2019).  
The uncertainty surrounding the clinical and cost-effectiveness of interventions impacts the 
benefits felt by patients and the wider economy. In terms of dressings, the National Institute 
for Health and Care Excellence (NICE) states that HCPs should “routinely choose the least costly 
dressing” (emphasis added) unless a specific dressing can be justified on clinical grounds (NICE, 
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2016). This instruction demonstrates a preference for cost-containment; rather than assessing 
the cost-effectiveness or cost-dominance of a dressing; contrary to standard NICE technology 
appraisal processes (NICE, 2016). The choice of dressing is thus left to an individual HCP; 
theorised to cause a variance in treatment practices, given the lack of standardised guidance 
on specific products and the abundance of products available.  
A series of SLRs on different types of wound dressings performed by the Cochrane 
Collaboration found no superior intervention when looking at clinical outcomes of wound care 
dressings, largely because of a high risk of bias and low-quality clinical studies (Dumville et al., 
2011; Dumville et al., 2012; Westby et al., 2016). Meta-analysis is often impossible in wound 
care studies due to the heterogeneity of studies and an unclear and often varied standard care 
protocol. Standard care can vary by wound aetiology, geographical location and clinician 
discipline. To the knowledge of the present researcher no SLR looking at economic outcomes 
associated with dressings was identified in current literature. To address this current gap, a 
systematic review was undertaken to examine the economic impact of topical interventions 
for chronic wounds and the variance associated with standard care.  
2.3.3 Study aims 
The aim of study 1b was: 
− To explore the economic impact of interventions for chronic wounds and estimate the 
cost of standard care in the UK. 
The objectives of study 1b were:  
− To establish a definition of standard care. 
− To document economic evaluations of topical interventions for chronic wounds. 
− To establish if more expensive wound care products are cost-effective. 
2.3.4 Methods 
A systematic review was carried out following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). This review searched 
several databases and included discussion with experts and manufacturers to identify the 
literature. Two researchers (AB and a research associate) performed data extraction, with a 
third (PhD supervisor, IO) consulted where there were disagreements. Economic endpoints 
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were extracted, including incremental cost-effectiveness ratio (ICER), cost-per Quality 
Adjusted Life Year (QALY) and disease related resource use. A narrative synthesis of results and 
critical appraisal using the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) statement were performed (Husereau et al., 2013).  
Search strategy 
In line with recommendations by the Cochrane Collaboration, search terms were identified 
according to the Population, Intervention, Comparator and Outcome (PICO) framework to 
retrieve literature pertinent to the search topic (The Cochrane Collaboration, 2019). The search 
terms were used to obtain literature relating to chronic wounds, specifically DFU and LU and 
their management, treatment or care using a dressing, compression, or standard care. These 
wound aetiologies were selected as they have been shown to be the most common chronic 
wounds in a recent study of UK real-world data (Guest et al., 2015). Further terms were used 
to identify economic outcomes. Table 2.10 shows a full list of search terms. No comparator 
was determined as the interventions included were deemed broad enough to capture a range 
of studies.  
Table 2.10. Economic SLR search terms used 
Search terms Item 
(Wound (*) and chronic) or (ulcer and (or diabetic foot or leg)) Population 
Management or treatment or care Intervention 
Dressing (*) Intervention 
Resource and (use or utilisation) or cost Outcome 
Quality of life or patient outcomes or burden or impact Outcome 
Effectiveness or efficacy Outcome 
 
Data sources 
Electronic databases (Science Direct, NICE Evidence database, Medline (PubMed), Centre of 
Reviews and Dissemination/NHS Economic Evaluation Database (University of York), and the 
Cochrane Database) were searched using these terms and a citation search of included articles 
was performed. Further relevant titles were identified through discussions with manufacturers 
and experts.  
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Table 2.11. Economic SLR inclusion and exclusion criteria 
Inclusion criteria 
Population Chronic wounds- DFU or LU 
Interventions Topical dressings or applications 
Outcomes Economic outcomes 
Study design Randomised controlled trials with economic evaluation, economic 
modelling 
Language  English Language 
Search dates After 1987 
Exclusion criteria 
Population Paediatrics (<18), acute wounds (including Burns, Trauma, Surgery) 
pressure Ulcers.  
Interventions Surgical, novel non-surgical, infection control measures, debridement, 
bioengineered skin substitutes, offloading 
Outcomes Not meeting inclusion criteria  
Study design In vitro studies, review or discussion articles 
Language  Non-English language  
Search dates Before 1987 
 
Types of study included 
This study reviewed economic analyses of randomised controlled trials (RCTs), and other 
examples of economic modelling. All other study designs, review articles, expert opinion and 
guidance documents were excluded. Searches were limited to 30 years, from 1987-2017, to 
ensure that included articles were not outdated.  
Interventions 
Topical applications and standard care were the interventions of interest, to understand the 
variance in standard care methods and costs. Standard care did not need to fit any pre-
specified criteria, as this review would accept any definition as provided by a study. Surgery 
was excluded, as were novel non-surgical interventions such as vacuum assisted closure, 
hyperbaric oxygen therapy and electric stimulation as these were deemed to be procedures 




This review included studies of patients with chronic wounds. Chronicity is defined as a wound 
caused by an underlying aetiology, such as diabetes or vascular insufficiency; or as a wound 
with a duration of over 4 weeks (Russell et al., 2018). Non-healing surgical wounds, burns, and 
acute trauma wounds were excluded due to their lack of underlying aetiology. Pressure ulcers 
were excluded as these occur in a different population; predominantly in immobile or 
hospitalised patients and have different treatment methods. Methods to diagnose a venous, 
arterial or diabetic wound may vary and this review accepted any as described by the included 
the studies. 
Data extraction (selection and coding) 
The first reviewer (AB) undertook initial screening of titles and available abstracts exported to 
EndNote. The initial screening removed duplicate articles, irrelevant titles, foreign language, 
and letters, editorials or other discussion texts. The database stored bibliographic information, 
abstracts, and the link to the full text. If the full text was unavailable, then an effort was made 
to retrieve it, if the abstract indicated that the article met the inclusion and exclusion criteria.  
The titles exported to the Excel database were then reviewed against the pre-determined 
inclusion and exclusion criteria, shown in Table 2.11. Two researchers (AB and a research 
associate) undertook the review, applying the inclusion and exclusion criteria independently of 
each other.  
Risk of bias (quality) assessment 
Studies were judged using the CHEERS statement, which includes parameters for methods, 
assumptions, results, and discussion as per the standards set by the International Society of 
Pharmacoeconomic and Outcomes Research (ISPOR) (Husereau et al., 2013). Two researchers 
(AB and a research associate) completed an independent review of the quality assessment.  
Strategy for data synthesis 
A structured narrative synthesis of the data was constructed using data tables, stratified 
according to wound type, and then by intervention. A meta-analysis using standard statistical 
methods was considered, however the studies were not sufficiently homogenous to perform 




From searching the databases, 3417 results were returned (Table 2.12). Discussion with 
experts and manufacturers provided 5 further titles. After initial screening of the 3422 titles 
and abstracts, 2585 were excluded for being not relevant to the research questions. The 
remaining 817 texts were judged against the inclusion and exclusion criteria in Table 2.2. Of 
these, 805 titles were excluded, with 12 being included as per the PRISMA flow chart in Figure 
2.3.  
 
Table 2.12. Economic SLR article sources 
Search tool Count 
Science Direct 2479 
NICE Evidence search 805 
Medline (PubMed) 78 
CRD (University of York) 47 
Cochrane 8 
Discussion with experts and manufacturers 5 
Total exported to EndNote:  3422 
 
The design of the included studies can be found in Table 2.13 and the endpoints, documented 
resource use and results are shown in Table 2.14, with a record of ‘n/a’ if the study did not 












Table 2.13. Economic SLR design of included studies 
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Abbreviations: CCA: cost-consequence analysis, CEA: cost-effectiveness analysis, CMA: cost-
minimisation analysis, CUA: cost-utility analysis, DFU: diabetic foot ulcer, LU: leg ulcer, UK: 








Table 2.14. Economic SLR endpoints, resource use and results of included studies 
Study Time 
horizon 
Health states Efficacy 
source 
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The studies predominantly examined LU, with nine studies focusing on these patients 
(Schonfeld et al., 2000; O'Brien et al., 2003; Guest et al., 2005; Guest et al., 2009; Guest et al., 
2012; Ashby et al., 2014; Jemec et al., 2014;  Augustin et al., 2016; Nherera et al., 2016). The 
dominance of the LU studies in this review is reflective of these wounds being the most 
common of the chronic wounds. Only three of the studies looked at DFU, including the two 
oldest included studies (Apelqvist & Ragnarson-Tennvall, 1996; Persson et al., 2000; Craig et 
al., 2013).  In the 12 studies, 14 interventions were used. Standard (or good) care was used 8 
times.  
Settings and perspectives 
Five studies were carried out in the UK (Guest et al., 2009; Guest et al., 2012; Craig et al., 2013; 
Ashby et al., 2014; Jemec et al., 2014), four in the US (Schonfeld et al., 2000; Guest et al., 2005; 
Nherera et al., 2016), two in Germany (Guest et al., 2005; Augustin et al., 2016), two in Sweden 
(Apelqvist & Ragnarson-Tennvall, 1996; Persson et al., 2000) and one in Ireland (O'Brien et al., 
2003). One study covered both the US and Germany (Guest et al., 2005). All studies were from 
the Healthcare provider or payer perspective; except for Apelqvist & Ragnarson-Tennvall 
(1996) which took a societal perspective. 
Study types 
Included were seven cost-effectiveness analyses (Persson et al., 2000; Schonfeld et al., 2000; 
O'Brien et al., 2003; Guest et al., 2005; Guest et al., 2012; Ashby et al., 2014; Jemec et al., 
2014), three cost-utility analyses (Guest et al., 2009; Augustin et al., 2016; Nherera et al., 2016), 
one cost-consequence analysis (Craig et al., 2013) and one cost-minimisation analysis 
(Apelqvist & Ragnarson-Tennvall, 1996). 
Results of included studies 
The results of economic analyses are presented in Table 2.14, with standard care being used 
as a comparator or combination therapy treatment in eight instances. Positive economic 
outcomes in favour of the study intervention were recorded in all studies. All the interventions 
measured by the included economic analyses were either dominant, cost saving, cost-
effective, or resulted in savings to the healthcare system when measured against their 




higher rate of healing was the driver behind the cost savings on most of the studies; this is 
because the less time a patient has an ulcer, the less time they are consuming costly healthcare 
resources.  
Standard care 
Due to the nature of treating chronic wounds, standard care such as offloading, compression, 
debridement, dressings and infection control are used, alongside treatment by 
multidisciplinary teams including practice nurses, podiatrists, vascular surgeons, tissue viability 
nurses, and health care assistants. A range of methods of achieve offloading, compression, 
debridement, dressing and infection control were used in the studies, depending on the 
stipulation of the study design. Use of the different techniques to achieve wound healing was 
as clinically required; determined by clinician judgement upon inspection of the wound.  
Of the five studies set in the UK, standard care was used in 3 cases (Guest et al., 2012; Craig et 
al., 2013; Jemec et al., 2014). Guest et al., (2012) reported that the 6-monthly National Health 
Service (NHS) cost of managing a LU was approximately £2200 in all three groups, with little 
difference between the interventions. Craig et al., (2013) reported an annual cost for DFU 
outpatient and inpatients at £3330 and £4488 respectively. Jemec et al., (2014) measured the 
cost of a LU being £1468.14 for a period of 16.7 weeks until healing.  
Resource use 
Many of the studies measured the direct costs and excluded indirect costs; with only one taking 
a societal perspective, this model was published in 1996, before the conception of NICE and 
other Health Technology Assessment (HTA) bodies; so, the exclusion of perceived non-relevant 
costs may not have seemed appropriate (Apelqvist & Ragnarson-Tennvall, 1996). Persson et 
al., (2000) found that 83% of costs are accounted for by topical treatments and inpatient care 
and practice nurse visits accounted for up to 58% of costs reported by Guest et al., (2012). Staff 
costs such as nursing time, affected by number of dressing changes, was found to be an 
important parameter (Guest et al., 2005; O’Brien et al., 2013). 
Data sources 
Four studies were economic analyses carried out concurrent to a clinical trial, (Apelqvist & 




further three were subsequent analyses based on prior clinical trials (Schonfeld et al., 2000; 
Guest et al., 2009; Augustin et al., 2016). Three studies were based on published pooled studies 
or meta-analyses (Persson et al., 2000; Ashby et al., 2014; Nherera et al., 2016). The studies 
that used meta-anyses or a synthesis of peer-reviewed and published data are arguably more 
generalisable as the effectiveness data is based on more than one source. Further to this, one 
study synthesised eight studies to obtain effectiveness data, but this was not published (Guest 
et al., 2005) and a further study used real-world data to power the model; which can also be 
viewed as more generalisable as due to the heterogeneity of real-world data and the fact that 
is has been taken from routine practice (Guest et al., 2012).  
Clinical endpoints 
Wound healing or closure was the endpoint in most of the studies; measured in time to healing, 
probability of healing or healing rate. Those that did not use full healing looked at wound area 
reduction (Apelqvist & Ragnarson-Tennvall, 1996; Guest et al., 2009; Jemec et al., 2014; 
Augustin et al., 2016). In one study, recurrence had a probability of 0.10 regardless of 
intervention (Guest et al., 2005) and in another, (Schonfeld et al., 2000) recurrence varied by 
treatment arm, with Graftskin having an increase of 2.85 months ulcer-free in a 12-month 
follow-up than use of Unna’s boot alone.  
Health states 
Studies used varied and different health states. All models included unhealed ulcers and healed 
ulcers, with different studies specifying sub-categories of these. Infected and complicated 
ulcers were included in two studies (Persson et al., 2000; Nherera et al., 2016). One study also 
differentiated between improved, unchanged and worsened ulcers (Guest et al., 2009), and 
two had a separate health state for recurrent ulcers (Schonfeld et al., 2000; Guest et al., 2009). 
When included, amputation was treated as a health state (Persson et al., 2000).  
Critical appraisal- CHEERS checklist 
The methodological quality of the studies that were included in this review was assessed by 
use of the widely endorsed CHEERS statement (Husereau et al., 2013). The CHEERS statement 
measures the transparency and completeness of the reporting of methods and findings in 
economic evaluations using modelling. Table 2.15 shows the review of the included studies 




2000), whilst Ashby et al., (2014) reported on the least items. No study reported on all items 
in the CHEERS checklist, demonstrating that there is further information that could guide 
conclusions or any subsequent decision making based on these studies.  
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This review synthesises evidence suggesting that topical interventions can offer cost-effective 
solutions for treating chronic wounds compared with standard care alone. The objectives of 
study 1b were:  
− To establish a definition of standard care 
− To document economic evaluations of topical interventions for chronic wounds 
− To establish if more expensive wound care products be cost-effective 
The economic impact of new topical interventions for chronic wounds has been shown to be 
negligible when the new intervention is coupled with an improvement in healing outcomes. 
The key drivers of cost are the resource-intensive approach to treating wounds that require a 
multidisciplinary team and often multiple clinician appointments per week. Improving time to 
healing is important to redistribute these resources elsewhere; patients with a healed wound 
no longer require intensive treatment. This review has shown that, according to the included 
studies, more expensive wound care products can be cost-effective as long as they improve 
healing outcomes. This review has failed to provide a definition of standard care, given the 
multiple different treatment protocols prescribed across the different studies.  
This review shows that more expensive interventions in all instances are cost-effective when 
compared to standard care; likely a result of decreased healing times, faster onset of healing 
and reduced healthcare system costs for a patient with a long-lasting wound. Costs relevant to 
the NHS are of the most interest to this research, as it is UK treatment guidelines that are of 
interest. In the UK, for DFU patients, an annual cost of £3909 was measured in one study when 
finding the mean of inpatient and outpatient costs (Craig et al., 2013). For LU, annual costs of 
£4400-£4571.45 can be extrapolated from the included studies (Guest et al., 2012; Jemec et 
al., 2014). These results indicate that wounds are expensive to treat, approximately £4000 per 
year per patient.   
The strengths of this review are that it uses recognized reporting guidelines, PRISMA and the 
CHEERS statement for reporting economic studies, and the broad inclusion criteria allowed for 
a range of interventions to be included, providing greater information regarding the disease 
area. The broad inclusion criteria may also be considered a limitation, as the studies were not 




wound care studies are not often homogenous even when investigating the same intervention; 
as shown in the clinical SLR presented earlier in this chapter. Another limitation of this study 
was the inclusion criteria spanned a long time; which means that costs between the studies 
are difficult to compare like for like. However, to mitigate this, this SLR did not aim to make 
explicit comparisons between the results of the included analyses but was looking for patterns 
and trends with regards to topical wound care interventions for DFU and LU. This review only 
included studies in the English language due to the capabilities of the research team; so, it is 
possible that relevant literature in other languages may have been excluded. Further research 
into chronic wounds by a multi-lingual study team would be necessary to confirm these results 
outside of English-language only publications.  
In an external environment of budget cuts and financial pressure on the healthcare systems, 
cost-effective solutions to health care problems are desirable. This study has shown that cost-
effective interventions are not necessarily those with the lowest acquisition cost, the use of 
which may not lead to the best possible healing outcomes for patients. Longer term costs 
should also be factored in, regarding the ongoing costs of treating a chronic wound and the 
risk of recurrence.  
Current NICE guidance does not prescribe a specific dressing or intervention nor indicate 
clearly when different dressings or interventions are required (NICE, 2018). The lack of 
direction coupled with an abundance of products available leads to a vast number of 
interventions being used for treating chronic wounds. The variance of treatment methods is 
evidenced in this study, presenting eight instances of standard care, which included a vast array 
of different protocols. Without a specific definition of standard care, a meta-analysis will likely 
continue to be impossible to perform for wound care. 
2.3.7 Conclusions 
Currently, a clinician is directed to use “the least costly” dressing, an instruction demonstrated 
by this review that is unlikely to result in cost-effective treatment pathways. With a mandated 
treatment pathway, it is likely that there could be improvements in improving patient 
outcomes. Improving outcomes for patients is ultimately the most effective way to alleviate 
strain on the healthcare system; if the uncertainty surrounding evidence supporting new 




the economic impact of full wound closure, recurrence and treatment of complicated wounds 
would aid in achieving efficient resource allocation. To ensure that economic analyses are 
reliable, they need to be based on high-quality clinical evidence.  
2.4 Critical review and lessons learned 
The two SLRs presented in this chapter had different study aims and objectives that were 
intended to serve the needs of the PhD thesis. The clinical SLR had a focussed approach, only 
examining the PMM interventions that are of interest to this thesis. The economic SLR had 
broader search terms due to the fact that PMM interventions only account for a small share of 
the market and there is only one published economic evaluation that would have been 
available to analyse (Augustin et al., 2016). This broad approach required numerous titles and 
abstracts to be screened against the inclusion and exclusion criteria; assessing over 3000 titles 
was a time consuming activity.  
The focus of the clinical SLR was on the sucrose octasulfate dressing and ORC matrix 
intervention; which were the only two registered PMM interventions on the BNF website prior 
to applying the inclusion and exclusion criteria. Since this time, the BNF list of PMM dressings 
has been updated, to include more interventions; however 2 of these are not currently on 
formulary in the UK (BNF, 2019). A targeted search of online databases for the 2 additional 
products, Cadesorb ointment (Marketed in the UK by Smith & Nephew Healthcare Ltd) and 
Catrix dressing sachets (Marketed in the UK by Cranage Healthcare Ltd) did not reveal any new 
RCT, observational trial, or economic model on patients with DFU or LU to include in this 
review.  
The economic SLR sought to understand if interventions that have higher acquisition costs can 
be cost-effective, and also to understand and define standard care with regards to DFU and 
LU. The study was able to determine that cost-effectiveness is not driven by the acquisition 
cost of a device, but rather its efficacy with regards to improving healing outcomes for a 
patient. The more certain a decision maker can be with regards to the clinical evidence 
supporting an intervention, the more likely they are to realise the economic benefits that can 
be offered through faster healing and fewer adverse events.  
A strength of these systematic reviews is that they been performed according to guidelines 




generalisable as the methods used to carry out the research meet recognised international 
standards. In addition to this, multiple researchers were involved in the data selection and 
extraction process; a further strength as it helps to limit unconscious bias that an individual 
could bring if working in isolation.  
A limitation of both reviews is that due to the included studies being heterogeneous, meta-
analysis of the results was not undertaken. These systematic reviews also have limitations 
given the inclusion of only English language studies, so relevant literature in other languages 
may have not been captured by the search. Chronic wounds are not only an issue in English-
speaking countries and follow-up research focussing on the rest of the world would help to 
confirm these results.  
2.4.1 Implications 
This chapter has presented two SLRs on different topics, both relating to chronic wounds as 
per the primary aim, to investigate both clinical and cost-effectiveness. The two reviews 
together provide more insights than would have been found should only one have been 
performed. In this case, coverage was given not only to the intervention of interest but also to 
the wider economic impact of wound care and related management strategies.  
The economic SLR presented in this chapter is the first SLR that explicitly explores the 
divergence in standard care for patients with chronic wounds. The lack of standardized 
standard-care has been an issue in earlier research; Cochrane SLRs of wound dressings have 
found in depth meta-analysis difficult to perform (Dumville et al., 2013; Dumville et al., 2013; 
Wu et al., 2015; Westby et al., 2016) due to heterogeneity. The economic SLR presented in this 
thesis, looks further at the standard care arm and identified multiple protocols that made a 
meta-analysis impossible. Further to this, a review of the economic outcomes provides 
evidence that interventions with a higher acquisition cost can be cost-effective, and even cost 
dominant in some circumstances. When comparing the evidence produced here with NICE 
Guideline 19 (NICE, 2016) instructing clinicians to use the dressing with the lowest acquisition 
cost; there is an obvious disconnect. Because of this research, policy makers should be aware 
of the findings that the lowest cost dressings are not necessarily the best; and consider this 




The clinical SLR presented in this chapter is the first to investigate PMM interventions in both 
DFU and LU patients. Addressing the wound aetiologies separately, but together, is important 
as DFU and LU are distinct types of wound but can be treated similarly by HCPs. Finding a 
dressing that improves outcomes for patients with both DFU and LU would simplify treatment; 
clinicians would be able to treat DFU and LU patients with the same dressing and not be 
disadvantaging one group. Using the same dressing for both patient groups would also 
streamline NHS procurement processes; as one dressing could be used in place of many others.  
The clinical SLR is the first to include the large scale real-world observational study of patients 
using the sucrose octasulfate dressing; and the double blinded RCT of the same dressing in 
patients with DFU (Edmonds et al., 2018; Munter et al., 2018). The clinical SLR, included a head 
to head study of two different PMM interventions, the sucrose octasulfate and ORC which 
showed the sucrose octasulfate to be superior when considering WAR. The clinical SLR also 
included studies comparing sucrose octasulfate and ORC to a neutral dressing, and whilst the 
sucrose octasulfate dressing found a significant benefit, the ORC failed to reach significance. 
Therefore, this research can assert with confidence that PMM dressings offer benefits to 
patients, and particularly the sucrose octasulfate dressing.  
2.5 Chapter summary 
The two SLRs presented in this study complement one another as part of the wider portfolio 
of work on PMM dressings. They have shown that list price is not an indicator of cost-
effectiveness and should not be used as the only parameter to judge wound care dressings. 
They have also shown a divergence in treatment practice; standard care was not standard 
enough to enable a meta-analysis in either SLR. Finally, they have shown that PMM dressings 
can offer improved healing outcomes for patients; and thus are a good candidate for further 
study into cost and QoL outcomes.  
The reviews indicate that more thorough investigation into standard care for patients with a 
DFU or LU is required, and that modelling, and utility scores need to be updated to be relevant 
to the UK. The next chapter in this thesis is a Delphi method expert panel, which seeks input 




2.6 Dissemination  
The results of these studies have been presented at The International Society of 
Pharmacoeconomics and Outcomes Research (ISPOR) conference in the United States, 





Chapter 3 Delphi methodology expert panel to gain consensus on the use of 
dressings in the management of chronic wounds 
 
3.1 Introduction 
Expert opinion can both explain and inform best practice by providing enhanced understanding 
of current treatments and factors affecting outcomes that may not be evident in desk or clinical 
research. Opinion is unfortunately often subject to low levels of evidence; yet there are 
methodologies to counter this; one being the Delphi methodology, with core principles of 
anonymity and iteration. This study uses a Delphi methodology to achieve the objective of 
consensus on best practice and ideal treatments or treatment pathways. The methodology is 
modified to accommodate the use of electronic review, and to include a literature review of 
studies found using a systematic search as the first part of the study (see Figure 3.1) of the 
study. Issues pertaining to patient experience and resource use considerations are also 
addressed by the panel.  
 




This chapter presents study 2 of the thesis, which is a Delphi study investigating areas of 
uncertainty present in literature surrounding dressings for chronic wounds; determined by the 
literature review undertaken as the first part of the study and the second part of the study 
sought to seek consensus from a range of experts on these issues to gain clarity and a direction 
for study.   
3.2 Background 
With large patient populations presenting with chronic wounds there are many treatments 
available including a variety of dressing types. There are varying levels of evidence to support 
these interventions, but the quality of the trials is often dubious, and SLRs from organisations 
such as Cochrane struggled to find strong evidence towards certain treatments versus others 
(Westby et al., 2016).  
Therefore, there is a large amount of uncertainty with regards to dressings in wound 
management. Uncertainty can present in many ways, including: 
1. An inconclusive SLR(s),  
2. A subject being deemed as not having enough robust evidence judged against risk of 
bias and level of evidence tools.  
3. Opposing results published on the same subject, often by competitor products. 
National Institute for Health and Care Excellence (NICE) guidance for treating diabetic foot 
ulcers (DFU) is not specific on the type of dressing (NICE, 2016). The vague instruction to use 
the dressing with the lowest acquisition cost can be attributed to the large number of available 
dressings, and the current lack of robust evidence to support a single type above all others in 
improving wound outcomes. Uncertainty is present not only in the NICE guidelines for 
treatment of DFU but also in the Scottish Intercollegiate Guidelines Network (SIGN) guidance 
for treating leg ulcers (LU), endorsed by NICE (SIGN, 2010). The lack of specific guidance on 
which dressings to use on which patients leads to inconsistencies across formularies and 
regions in the United Kingdom (UK). It is this prevailing climate of uncertainty which 
demonstrated the need to seek expert advice. 
According to the Grades of Recommendation Assessment, Development and Evaluation 




randomised controlled trials (RCTs), or database studies (Guyatt et al., 2008). Expert opinion 
sought via a regular expert panel can be subject to uncontrolled bias; from intentional bias of 
malicious intent to unintentional biases or dominance of any individual. The risk of bias, left 
unchecked without an apparent method of control, leads to low levels of evidence 
classifications. It is speculated by the author of this thesis that a low level of evidence ranking 
can lead to the undervaluation of the breadth and depth of knowledge available through 
consultation with experts and thus a rich source of knowledge is underutilised. Enhancements 
to the methods of eliciting and reporting expert opinions with a focus on improving levels of 
scrutiny and transparency, would enable meaningful and robust consensus outcomes that 
could be subject to more favourable levels of evidence rankings than unstructured expert 
panels.  
The Delphi methodology aims to arrive at an expert consensus using an iterative process. The 
method consists of a group of experts anonymously replying to questions; then receiving the 
group feedback, after which this process repeats itself (RAND Corporation, 2019). The Delphi 
methodology was developed in the 1950s with the goal of obtaining the most reliable 
consensus from a group of experts. The methodology involved the repeated individual 
questioning of the experts, avoiding direct confrontation of the experts with one another as 
introduced by Dalkey & Helmer in 1963. This practice encourages individuals to reflect on their 
own opinions and knowledge in the context of the feedback from others outside of their usual 
sphere of activity, leading to final consensus statements truly representative of a wide range 
of individuals and disciplines. 
Despite the limitation of the Delphi methodology having a low ranking according to the GRADE 
system; The International Society of Pharmacoeconomic and Outcomes Research (ISPOR), a 
leading organisation in the field of Health Economic research, has recognised the Delphi 
methodology as the preferred approach in a guidance document (Mullins et al., 2014). It is 
hoped that this endorsement should lead to a greater uptake of the Delphi methodology as a 
process to obtain expert advice; and is the rationale for using the methodology in this research. 
Having a structured, methodological approach to a meeting with an expert panel provides a 





When compiling evidence to support a new intervention or practice, the Delphi methodology 
is a useful tool to test assumptions, validate data and understand drivers, without the expense 
associated with a clinical trial. Innovations are seldom developed in isolation, and the input of 
a variety of clinical, economic, and policy experts are vital. Bodies such as NICE seek expert 
opinion for Health Technology Appraisals (HTA) by submission of an evidence dossier, and it is 
critical to shaping the understanding of a technology.  
Pharmaceutical and medical device companies often hold advisory boards, a popular method 
of eliciting expert opinion, regulated by the Code of Conduct for the Pharmaceutical Industry 
as enforced by the Prescriptions Medicines Code of Practice Authority (PMCPA) (PMCPA, 
2019). Advisory boards are useful for guiding strategy or asking medical questions, which 
cannot be answered through a literature search. Advisory boards are under intense scrutiny 
due to several trespasses of the PMCPA code of conduct by companies in the recent past 
(PMCPA, 2015; 2015; 2018; 2018)   
The Delphi methodology can provide more transparency and scientific rigour than a traditional 
Advisory Board when there is a need to seek guidance from experts to validate assumptions 
and compare results of published literature with clinical expertise. Table 3.1 shows a 
comparison of advisory boards (expert panel) and the Delphi methodology.  





3.3 Study aims 
The aim of study 2 was: 
− To identify uncertainty regarding the use of dressings in the management of DFU and 
LU and gain consensus 
The objectives of study 2 were: 
− To perform a literature review on a broad topic to create evidence-based statements 
− To test the evidence-based statements with a multidisciplinary group using the Delphi 
methodology to generate a consensus.  
3.4 Methods 
This section discusses the methodology that was used in this study. First the design is 
presented, and the six stages of the study are discussed in turn. The stages are literature 
review, statement generation, anonymous voting and feedback, the face-to-face meeting and 
the consensus development. This study was conceived in April 2017, with the expert panel 
meeting held in early June 2017. Prior to the consensus meeting, a systematic literature search 
was carried out to source articles for thematic analysis and the generation of evidence-based 
statements to put to the panel. This review was the first to be carried out for this PhD thesis, 
acted as an exploratory review to inform the SLRs carried out on the topics of clinical and cost-
effectiveness in study one, presented in chapter 2. 
3.4.1 Study design 
The study was designed in two parts; first, a literature review to generate evidence-based 
statements followed by the expert consensus process carried out in accordance to the Delphi 
methodology. The literature search presented in this chapter was carried out in line with 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting 
guidelines (Moher et al., 2009). Quotations were extracted from the included titles that 
highlighted areas of uncertainty identified using the criteria set out in section 3.2. This review 
generated a set of statements included in a workbook sent to participants. The workbook also 
contained details of the methodology and search strategy with bibliographic details of all titles 




Following the literature search and statement generation, the Delphi methodology was used 
to validate the statements. The Delphi methodology was modified to include electronic review 
and voting, followed by a face-to-face meeting. Experts received the electronic workbooks to 
record agreement or dissent with the list of statements. After each round of voting, all 
responses were compiled, and anonymised responses were circulated to the group.  
The face-to-face meeting agenda was to review the statements already confirmed or rejected, 
and to discuss and try reach consensus on any outstanding statements. The process is 
demonstrated in the schematic in Figure 3.2. 
 
Figure 3.2. Process flow of Delphi study methodology 
 
3.4.2 Stage 1: Literature review using systematic search methods 
A set of search terms were identified in line with the Population, Intervention, Comparator, 
Outcome (PICO) framework to identify areas of uncertainty in wound management. The PICO 
framework is recommended by the Cochrane Handbook of Systematic Reviews (Higgins & 
Green, 2011). The search terms were used to obtain literature relating to DFU, and LU and 
their management, treatment, or care using a dressing.  Further terms were used to identify 
economic outcomes, efficacy outcomes, and quality of life (QoL) outcomes, see Appendix B for 
a full list of search terms. There were no specific comparators searched for, because ‘dressings’ 
is a large category that would include a variety of different interventions.  
Five electronic databases were searched using these search terms. Databases were chosen 
because of their broad coverage; Centre for Reviews and Dissemination (CRD) from University 




review articles returned by ScienceDirect. The NICE Evidence search was used as well as the 
Cochrane database of systematic reviews. 
Abstracts were exported to EndNote and AB undertook initial screening of titles and abstracts 
to discard duplicate articles, irrelevant titles, foreign language, and any letters, editorials or 
other discourse pieces. An Excel database was created to store bibliographic information and 
links to the full text of titles not discarded at initial screening stage. The titles exported to the 
Excel database were reviewed against the inclusion and exclusion criteria shown in Table 3.2. 
Table 3.2. Delphi literature review inclusion and exclusion criteria 
Inclusion criteria 
Population Diabetic foot ulcer, leg ulcer, or a study of mixed wounds  
Interventions Dressings 
Outcomes Wound healing, wound area reduction, healing rate, quality of life 
outcomes, economic outcomes 
Study design Randomised controlled trials 









Language  English language 
Search dates After 1987 
Exclusion criteria 
Population Paediatrics (<18), acute wounds  
Interventions Surgical, novel non-surgical, infection control measures, debridement, 
bioengineered skin substitutes or offloading 
Outcomes Not meeting inclusion criteria  
Study design In vitro studies, review or discussion articles 
Language  Non-English language  





An adult population was selected as chronic wounds in children are considered unlikely and 
potentially treated using different protocols. Acute wounds such as burns, trauma or surgery 
were excluded due to the different presentations of these wounds. Dressings were the 
intervention of interest, given the lack of robust guidance relating to this significant part of 
treatment. Non-English language articles were excluded due to the language ability of the 
review team. The time parameter was only to include the last 30 years to limit articles to 
practices and interventions that are still in use, and not to consider outdated advice. 
Articles were judged as having ‘met’, ‘maybe met’, or ‘not met’ the inclusion and exclusion 
criteria. The included texts were critically appraised by ranking against the GRADE evidence 
classification system (Guyatt et al., 2008). Due to time restrictions involved with this project a 
more in-depth critical review was not possible. The results of this first systematic search were 
used to inform the development of more specific SLR protocols executed in chapter 2 of this 
thesis to look at clinical and economic outcomes for patients with chronic wounds. The SLRs 
presented in chapter 2 were appraised using more in-depth methods as prescribed by 
guidelines from ISPOR and NICE (Drummond & Jefferson, 1996; Husereau et al., 2013). 
3.4.3 Stage 2: Statement generation using thematic analysis 
Thematic analysis is the process of identifying patterns or themes within data (Maguire & 
Delahunt, 2017). This study has used the six steps set out by Braun and Clarke (2006).   
The first step required becoming familiar with the data by reading included study articles and 
extracting quotations regarding uncertainty, as defined in section 3.2. After this, initial codes 
were assigned deductively using 4 pre-defined categories (clinical effectiveness, economics 
and cost, QoL, and epidemiology). Within these categories themes were developed using open 
coding, meaning that the categories were not pre-determined and were refined throughout 
the process.  
Themes were reviewed to ensure they were separate and distinct and source documentation 
consulted to ensure that references still supported the theme. The statements were then 
written by AB using the themes from each category.  The source materials were then re-
checked to ensure the data supported the statement. Some semantic refinement was made to 
a few statements and for each statement and the source documents and quotations were 




reviewed by the Manchester Met supervisory team and the workbook was produced and sent 
to participants (Appendix B.3)   
3.4.4 Stage 3 and 4: Delphi methodology  
To inform the Delphi approach that this study has used earlier examples were sought; however, 
despite being noted as a useful and flexible approach by Hasson et al., (2008) very limited 
examples were found in the field of wound care research. In a previous example of a Delphi 
panel in wound care, the statements tested are the researchers own hypotheses, or ideas that 
are to be tested among an expert population (Mokkink et al., 2010). This study wanted to 
improve credibility by developing a set of evidence-based statements generated from a 
systematic search of the literature to submit to the panel. This was carried out prior to the 
statement generation, and full search details were made available to participants. 
Participants were asked “Do you agree with this statement?” with yes or no being the only 
response options. It was considered to mandate the ranking of a statement on a scale on 0-9, 
ranging from “do not agree at all” to “totally agree”, which arguably provides a more in-depth 
view of the opinions of the panel. However, after discussion with the supervisory team, this 
study opted for a binary approach due to the ambitious objective of creating a unanimous 
consensus document endorsed by all participants. A wider range of answers could lead to an 
increased sense of uncertainty about a statement but would be beneficial in highlighting the 
perceived importance of the statements in relation to one another.  
The methodology followed consisted of two iterations of expert review and voting, using the 
workbook provided by Manchester Met. The rating column had a drop-down option restricting 
to yes or no only and a message encouraging participants to offer useful feedback that would 
be conducive to finding a consensus. In offering the participants the option to rephrase the 
statement, this method allows for modification due to semantics.  
This study used a methodology that allowed the amendment of statements until a unanimous 
consensus, or a consensus above an 80% threshold, was reached attempts to prevent the 
inclusion of any weakly supported statements. Using previous wound care Delphi methodology 
studies as a guide, 80% consensus is considered a relatively high threshold (Mokkink et al., 
2010). Any statement that fell in between 80% ‘yes’ and 80% ‘no’ was amended using the 




of this process, each reference for every statement was given a Level of Evidence (LoE) ranking 
using an adapted version of the SIGN classification (Harbour et al., 2011). 
A face-to-face meeting was carried out to discuss the consensus, implications for clinical 
practice and area of future research.  
Panel members 
The study was designed with the aim of arriving at consensus on a range of pre-defined 
statements using a multidisciplinary panel, representative of experts with diverse areas of 
expertise. McKenna (1994) stated that ‘experts’ referred to a ‘panel of informed individuals, 
and so this formed the basis of panel selection. The selection criteria of the panel members 
stated that they had to be actively involved in patient care for chronic wounds of any aetiology. 
Individuals were identified by Urgo Medical Ltd and their credentials checked by the lead 
researcher (AB). It has been argued that to define one group as representative of all expert 
opinion is problematic; given that an individual’s willingness to participate will be driven by 
their interest in the research question (Strauss & Zeigler 1975). To mitigate this issue, this study 
sought to include participants with varied backgrounds, to be as representative of the whole 
wound care community as possible.  
The panel members were deliberately chosen to not be homogenous, in the hope that 
encouraging consensus amongst a varied group would generate important insights. The value 
of this heterogeneity is fully exploited by the Delphi principle of anonymity; which serves to 
empower members of the group who may otherwise feel unable to voice their opinion face-
to-face with their peers and superiors. 
The clinical practitioners on the panel represented Nursing, (Vascular Nurse Specialist, Nurse 
Consultant Tissue Viability, Lead Tissue Viability Nurse, Senior Lecturer in Nursing), Tissue 
viability speciality (Clinical lead, Tissue Viability, Head of Tissue Viability Services), Podiatry 
(Clinical Lead Podiatrist, Hospital Podiatrist, Advanced Podiatrist), Surgery (Consultant Vascular 
Surgeon), and Diabetology (Consultant Diabetologist). 
DFUs and LUs are most often seen by Nurses, including Tissue Viability Specialists who make 
decisions regarding treatment strategies, including dressings and topical treatments during 




treatment plan to a patient. Their front-line exposure to chronic wounds gives knowledge and 
insight into the patient experience and the practical application of the treatment. 
Podiatrists are health care professionals who have been trained to prevent, diagnose, treat and 
rehabilitate abnormal conditions of the feet and lower limbs. They also prevent and correct 
deformity, keep people mobile and active, relieve pain and treat infections. They can give 
advice to patients on how to look after their feet and what type of shoes to wear (NHS, 2018). 
Vascular Surgeons can be involved in the treatment pathway for wounds requiring surgery, 
especially in surgery to treat and prevent the underlying cause of LUs, the venous insufficiency.  
Diabetologists are experts in the treatment of diabetes, and subsequently are exposed to 
patients suffering from DFUs.  Due to the nature of a consultant’s position, these health care 
providers may only see patients periodically and although they advise on optimal treatment 
plans, they are not routinely involved with the practical day-to-day implementation of this plan.  
Optimising treatment pathways for patients and improving wound outcomes are the 
responsibility of a diverse team of healthcare professionals. This methodology offers the 
opportunity for these disciplines to take advantage of their individual unique insights and 
collectively use their knowledge to offer advice on best practice.  
The geographical spread of the panel covered the North, South, East and West of England, 
representing 9 National Health Service (NHS) Trusts. Many of the clinicians on the panel were 
working at teaching or university hospitals.  
The panel members included professionals at varied stages of their careers and at different 
levels of seniority. Panel representation is available in Appendix B. The diversity of roles held 
along the treatment pathway by the participants was hoped to enable a robust discussion 
which offered a platform to a multitude of opinions. 
In addition to the wound care clinicians on the panel, there was also a range of technical 
specialists invited to review the evidence presented to support the statements generated from 
the SLR. Three Professors in Health Economic and Outcomes research or Health Policy and 
academic representation were consulted in order provide an academic standpoint on the 




running of the day, as directed by the Panel Chairperson, who sought to ensure a fair but 
flexible application of the methodology. The author of this thesis (AB) led the sessions on the 
methodology used to produce the statements, workbook and amendment of the statements 
throughout the process.  
3.4.5 Stage 5: Face-to-face meeting 
A face-to-face meeting was arranged for the panel members to come together to discuss the 
process, results and their knowledge and experience. Hosting a face-to-face meeting did not 
undermine the principle of anonymity for the Delphi process; given that the workbooks had 
already been completed individually by each participant; and they had already seen the 
comments made on earlier revisions. The agenda consisted of a thorough review of the 
statements and comments made (including on statements that had reached consensus) and a 
session to discuss the final consensus document; its presentation and any supporting 
documentation. The clinical experts were also asked to discuss:  
1. Platforms for dissemination. 
2. How a consensus document could lead to awareness, and a change in clinical practice. 
3. How to determine the impact of this consensus statement. 
4. Areas of future research interest. 
3.4.6 Stage 6: Consensus generation 
Using the Statements that reached consensus, a consensus statement was constructed; 
grouping the statements into categories and where necessary providing additional contextual 
and supporting information. After the face-to-face meeting, the terminology used was agreed 
and defined and these definitions accompany the consensus statement. The statement was 
submitted to the entire panel for their review and final approval and was then published in the 
Journal of Wound Care (Russell et al., 2018). 
3.4.7 Ethics considerations 
In this study, Urgo UK Ltd sponsored the funding of the panel, providing travel, subsistence and 
payment for a day’s work for the members of the panel. The transfer of value creates an 
inevitable risk of bias towards the favouring of Urgo products due to their involvement. As a 




final themes of this study, however the systematic, iterative, and independent qualities of the 
methodology, work to protect from the risk of bias.  
The PhD researcher (AB) and the Manchester Met study team handled the methodology and 
execution of both the SLR and statement generation, independently of Urgo input. The ‘arms-
length’ agreement extends across all studies to protect the academic rigour of the study and 
was respected by both parties. The study was granted ethics approval by the Manchester 
Metropolitan Faculty Ethics committee (Ethics Reference: 1486). 
The development of the methodology was undertaken by the Manchester Met study team. All 
communications regarding the structure, content and format of the meeting was the 
responsibility of Manchester Met. Urgo contact with the participants was limited to logistical 
arrangements for the final face-to-face meeting, held at a modest location convenient for 
many of the delegates.  
The workbook used in the study was designed to present a broad evidence base. The agenda 
for the final face-to-face meeting consisted of an overview of responses so far and a further 
discussion with representation from the faculty of Health, Psychology and Social Care.  
 
3.5 Results 
This section discusses the results of this study with each of the six stages addressed in turn. 
The stages are: SLR, statement generation, anonymous voting and feedback, the face-to-face 
meeting and the final consensus development.  
3.5.1 Stage 1: Systematic literature review 
The search of the electronic databases retrieved 3417 titles as shown in Table 3.3. Titles were 
screened; leaving 817 abstracts to be reviewed against the inclusion and exclusion criteria.  
Table 3.3. Delphi literature review search results from each database 
Search tool Count 
Science Direct 2479 
NICE Evidence search 805 





After application of the inclusion and exclusion criteria by two researchers, 295 texts remained, 
of which 240 were available in English (Figure 3.3). These articles were read by AB and where 
relevant, quotations extracted in the four stipulated categories to inform the development of 
the statements.  
  
Figure 3.3. Delphi literature review PRISMA flow diagram 
CRD (University of York) 47 
Cochrane 8 




3.5.2 Stage 2: Statement generation 
From the texts included in the literature review, 311 quotations were extracted from 145 
texts. These statements were given sub-categories and were placed into logical groups 
shown in Table 3.4. An initial list of 48 statements was developed, addressing the topics 
shown in Table 3.5.  
Table 3.4. Thematic analysis of statements 








− Early intervention 
− Failed Healing 
− Guidelines 
− Healing indicator 
− Protease 
− Ultrasound 
− Broad impact 
− Caregivers 









− Treatment focus 















− Cost of illness 
− Early 
treatment 
− Healing time 
− Resource Use 
 
Table 3.5. Statements and categories 
Clinical effectiveness 
(n=10) 
Quality of life (n=11) Epidemiology (n=16) 
Economics and cost 
(n=11) 
− Compression (n=3) 
− Guidelines (n=2) 
− Protease (n=2) 
− Dressings (n=1) 
− Early intervention 
(n=1) 
− Dressings (n=2) 
− Healing (n=2) 
− Broad impact (n=1) 
− Caregivers (n=1) 
− Chronicity (n=1) 
− Compression (n=1) 
− Protease (n=6) 
− Wound 
environment (n=6) 





− Cost of illness (n=3) 
− Resource use (n=3) 





− Failed healing 
(n=1) 
 
− Pain (n=1) 
− Psychological (n=1) 
− Treatment focus 
(n=1) 
− Chronicity (n=1) 
− Diagnosis (n=1) 
− Follow up (n=1) 
− Prevalence (n=1) 
 
 
The final list of statements was included in the workbook that was sent to participants for their 
review and assessment of the evidence in the first iteration of voting. The final workbook 
consisted of 6 sheets and can be found in Appendix B:  
1. Cover sheet: For participants to record their name, affiliation and job title.  
2. Introduction: An overview of the workbook and the process 
3. Instructions: An overview of the tasks needed to be completed by the participant.  
4. Voting sheet: For the participants to record their responses.  
5. References: Full listing of quotations, with bibliographic information and level of 
evidence rankings.  
6. Search methodology: An overview of the search strategy and results of the SLR.  
The workbook was developed by the researcher (AB). Critical discussions then took place with 
the study team at Manchester Met to pilot and refine the workbook. Once finalised the 
workbook was sent to Urgo Medical Ltd for user acceptance testing. The hyperlinks to the full 
texts were all checked by a second reviewer and after final sign off by all parties, was emailed 
to participants.  
3.5.3 Stage 3: Delphi panel iteration 1: Anonymous voting 
The modified process that was used for this study included two rounds of anonymous email 
voting followed by a face-to-face meeting. The threshold for consensus was 80%, and 
participants had the option of voting yes or no against the statements, thereby confirming or 
rejecting the statements respectively.  
The initial feedback from the participants was good, regarding the functionality of the 
workbook and their understanding of their role. Ten participants returned the workbook within 
the stipulated period to allow for feedback to be compiled. The comments received on each of 




Iteration 1 of the workbook resulted in 38 statements confirmed according to the 
methodology, and 9 statements amended and resubmitted to the next round. Zero statements 
were rejected. There was zero incidence of a participant voting no on a question and not 
leaving a comment.  
3.5.4 Stage 4: Delphi panel iteration 2: Anonymous voting 
Results were sent to participants along with the second workbook with amended statements. 
The 9 statements that did not reach the consensus threshold were amended considering the 
comments received, either omitting words, adding clarification or by deferring to the wording 
suggested by the experts. The 9 amended statements were the basis of workbook 2 used in 
iteration 2. Participants could see comments that were made on the statements by their peers, 
and the consensus levels reached per statement. By providing feedback in this way, it was 
hoped that participants would understand the amendments made to the statements.  
Iteration 2 followed the same process as iteration 1; with participants receiving the workbook 
via email. Due to the number of statements confirmed and removed, workbook 2 was much 
smaller and far quicker to complete. The amended statements were in the voting sheet of 
workbook 2, as shown in Appendix B.  
The same 10 participants returned the workbook before the deadline, and their responses 
were included in the work that was carried forward to the meeting. The contents of the 
workbooks were used to develop and inform the agenda for the face-to-face meeting, where 
all 10 participants, plus one late entry, would be present. Statements and their comments can 
be seen in Appendix B.  
Iteration 2 resulted in the confirmation of 5 statements, leaving 4 statements to be amended 
and discussed at the face-to-face meeting; along with an overview of all the confirmed 
statements. Zero statements were rejected and wherever a participant replied no, a comment 
was always made.  
3.4.5 Stage 5: Face-to-face meeting 
A final face-to-face meeting was the culmination of this Delphi process, 19 people attended 
the final meeting. These consisted of:  




− 4 representatives from Manchester Met (IO, FF, GY, AB) 
− 1 Chairperson; Professor of Health Economics (ND) 
− 1 facilitator (RS) 
− 2 Urgo representatives (RN, LG) 
The representatives of the study from Urgo did not participate in the discussions and were only 
in the room to observe, with RN leaving after the morning session. There were no 
presentations from Urgo team members at any point in the meeting.  
The day was split into two parts, with the morning session to provide an opportunity to discuss 
the confirmed statements from both voting iterations. Using the Delphi methodology, a total 
of 31 comments were ignored because the statement had reached 80% consensus. Many of 
the comments made resonated with the panel and there was lively debate over semantics, 
with vocabulary, grammar and definitions being discussed by the panel.  With the inclusion of 
a definitions section relating to certain terminologies, the panel managed to reach a 
unanimous consensus for all statements making up the consensus statement; to be 
constructed from the statements in the second half of the day.  
Following earlier preparatory work grouping the statements, AB updated the statements and 
created an outline to share with the group after lunch. The four groups used to categorise the 
statements were:  
1. The role of matrix metalloproteinases (MMPs) 
2. QoL for patients with LU/DFU/PU 
3. Time to healing and NHS burden 
4. Early intervention and economic impact 
Forty-one statements were arranged in 9 paragraphs to the participants, with 4 regarding the 
role of MMPS (18 statements used), 3 regarding QoL for patients (11 statements used), 1 for 
time to healing and NHS burden (8 statements used), and 1 for early intervention and 
economic impact (4 statements used). 
The last session of the day was to discuss the purpose of making the consensus statement and 
dissemination opportunities. The panel produced listings of potential platforms for 




produced a list of measures to understand the impact of the consensus and areas of future 
research interest. These responses can all be seen in Appendix B.  
The members of the panel all signed off on the output of the day and deemed it a truly 
representative consensus.  
3.5.6 Stage 6: Consensus development  
The consensus statement was developed using the statements confirmed at the face-to-face 
meeting. The statements were left exactly as they had been agreed, no changes to the text 
were allowed. Building the consensus statement required adding some additional explanatory 
text, which was often based on the definitions also provided at the end of the statement.  
The thorough semantic appraisal at the meeting allowed for the statement to be 
representative of many views. The consensus statement was drafted and circulated to the 
panel for review, which was overwhelmingly positive and after minor amendments produced 
the final consensus statement appearing below. 
3.6 Consensus statement 
There is a need for consensus in areas of uncertainty. Uncertainty can be identified by 
contradictory information in the literature, a lack of robust evidence or systematic reviews that 
prove inconclusive. Recent reports and guidelines on wound management are not specific and 
do not make recommendations on treatment options. The Cochrane Review “Protease-
modulating matrix treatments for healing venous leg ulcers” identifies the need for further 
research into these dressings.  
Contents of this consensus statement:  
1. The role of matrix metalloproteinases (MMPs) 
2. Quality of life for patients with DFU, LU and PU 
3. Time to healing and NHS burden 
4. Early intervention and economic impact 





The statements that were voted on are identified below with bold text (sections 3.6.1 – 3.6.4). 
Underlined words or phrases must be interpreted according to their definition, listed in Table 
3.6 at the end of the consensus statement (section 3.6.6). 
3.6.1 The role of MMPs in chronic wounds: 
Wounds are deemed chronic when they do not follow a normal healing pattern and can be 
perpetuated by having an underlying aetiology (Levine, 1995; Schuren et al., 2005; Demidova-
Rice et al., 2012; Flegg et al., 2015; Frykberg and Banks, 2015; Kelichi et al., 2015). A normal 
healing pattern contains four phases of healing categorised according to the activity of their 
cellular components: haemostasis phase, inflammatory phase, proliferative phase, and 
maturation (or remodelling) phase. Wounds with underlying aetiologies include diabetic foot 
ulcers (DFUs), leg ulcers, (LUs) and pressure ulcers (PUs). 
Matrix metalloproteinases (MMPs) are a part of healthy healing, expressed at the 
inflammatory phase of early wound healing (Crovetti et al., 2004; Brougton et al., 2006; Moffat 
et al., 2014; Olczyk et al., 2014; Heublein et al., 2015). MMPs are enzymes that are responsible 
for degradation of the extracellular matrix and play a pivotal role in regulation of cell 
proliferation, migration, differentiation, and death. When a wound moves to the proliferative 
phase of healing, the level of MMPs fall (Trengove et al., 1999). If the wound does not advance 
to the proliferative phase of healing in an expected time, it can be considered chronic. These 
chronic wounds have been shown to have up to 30 times the level of MMPs than an acute 
wound (Trengrove et al., 1999; Eming et al., 2007; Medical Advisory Secretariat, 2009; Zelen 
et al., 2015; Ahmad, 2016; Westby et al., 2016)  
Wounds such as DFU, LU and PU are shown to have raised levels of MMPs from first 
presentation to a wound care specialist (Beidler et al., 2008; Rayment et al., 2008; Menghini 
et al., 2013; Heublein et al., 2015; Lazaro et al., 2016). With raised levels of MMPs, the wound 
is stuck in the inflammation phase, leading to the destruction of new tissues (Wysocki et al., 
1993; Snyder, 2005; Schmutz et al., 2008; Ravari et al., 2011) thus preventing progression to 
the next stage of healing (Ravari et al., 2011; Heublein et al., 2015; PrescQIPP, 2015).  
Persistently elevated levels of MMP are predictive of non-healing (Wysocki et al., 1993; 
Schuren et al., 2005; Snyder, 2005; NICE, 2016; Westby et al., 2016) and specifically, of the 24 




(Trengrove et al., 1999; Campbell and Parish, 2010; Moffat et al., 2014; Heublein et al., 2015; 
Kelechi et al., 2015). Interventions that modulate the wound environment may enhance 
healing (Trengrove et al., 1999; Schuren et al., 2005; Meaume et al., 2012; Humbert et al., 
2014; Moffat et al., 2014; Heublein et al., 2015; Alavi et al., 2016), because evidence suggests 
removing excess MMPs from wounds improves healing (Meaume et al., 2012; Grier et al., 
2013; Humbert et al., 2014; PrescQIPP, 2015; Westby et al., 2016).  A specific MMP-9 inhibitor 
is potentially more effective in stimulating healing (Rayment et al., 2008; Campbell and Parish, 
2010; Heublein et al., 2015). In addition to modulating the wound environment, the ideal 
dressing should be cost-effective, acceptable to the patient, easy to change, effectively 
manage exudate, and also be effective on older and larger wounds (Phillips et al., 1994; Ouahes 
and Phillips, 1995; O’Donnell and Lau, 2006; Medical Advisory Secretariat, 2009; Australian 
Wound Management Associated Inc. and the New Zealand Wound Care Society Inc, 2011; 
O’Donnell and Balk, 2011; Kim and Steinberg, 2012; CADTH Rapid Response Reports, 2013; 
Kruger et al., 2013; NICE, 2014; Kelechi et al., 2015; PrescQIPP, 2015; Widener, 2015; Wu et 
al., 2015; Alavi et al., 2016; NICE, 2016). 
The lipido-colloid nano-oligosaccharide factor (TLC-NOSF) technology inhibits MMPs and 
accelerates healing (Schmutz et al., 2008; Meaume et al., 2012; British National Formulary, 
2015; Augustin et al., 2016), it has been shown as superior to basic foam dressings in reducing 
healing time (Meaume et al., 2012; Augustin et al., 2016) and as superior to oxidized 
regenerated cellulose and collagen, especially in non-responsive, older wounds (Schmutz et 
al., 2008). Further to this, TLC-NOSF has been shown to reduce levels of MMP-9 in vitro 
(Bernerd et al., 2008; Coulomb et al., 2008) 
3.6.2 Quality of life for patients with DFU, LU and PU 
Wounds such as DFU, LU and PU are associated with increased morbidity and mortality 
(Frykberg, 1998; Nelson et al., 2006; Medical Advisory Secretariat, 2009; Diabetes UK, 2013; 
Zelen et al., 2015; Mousa et al., 2016). In addition to this increased risk of death and high 
likelihood of comorbidities, patients with these conditions suffer significantly reduced health 
related quality of life across dimensions such as pain, physical limitation, social isolation, and 
anxiety/depression (Krasner, 1998; Purwins et al., 2010; Gorecki et al., 2012; Hogg et al., 2012; 
Green et al., 2014). The psychological impact of these wounds can be severe, with patients 




future (Phillips et al., 1994; Kinmond et al., 2003; Herber et al., 2007; Gorecki et al., 2012; 
Green et al., 2014).  These wounds can take a long time to heal and have a high likelihood of 
recurrence, which again detracts from quality of life (Korn et al., 2002; Etufugh and Phillips, 
2007; Jones, 2009; Hogg et al., 2012; Green et al., 2014; Wu et al., 2016; NICE 2017). Clinician 
focus tends to be on the treatment of the wound, which fails to account for the large 
psychological and social burden experienced by some patients (Dealey, 2001; Green et al., 
2014; NICE, 2017; NIHR, 2016).  
The pain caused by chronic wounds impacts quality of life (Phillips et al., 1994; Krasner 1998; 
Herber et al., 2007; Tabolli et al., 2007; Ciliberti et al., 2014, Alavi et al., 2016; Domingues et 
al., 2016: Mousa et al., 2016). Dressing changes can be a cause of pain: products and 
techniques to minimise this are recommended (Phillips et al., 1994; Krasner, 1998; Tabolli et 
al., 2007; Ciliberti et al., 2014; Alavi et al., 2016) Dressing changes and local management of 
the wound site is considered easy in most cases with the TLC-NOSF dressing (Stevens and 
Chaloner, 2005; Schmutz et al., 2008), which has also been shown to significantly reduce 
pain/discomfort and anxiety/depression for a patient (Schmutz et al., 2008; Meaume et al., 
2012).  
In addition to the health-related quality of life burden, the patient also faces financial costs 
such as time away from work, early retirement, medications, dressings, and transport costs 
(Ouahes and Phillips, 1995; Reichardt, 1999; Etufugh and Phillips, 2007; Kelechi et al., 2015). 
Chronic wounds are a burden to both the patient and to the carer (Tabolli et al., 2007) and this 
cost is often excluded or underestimated in cost-effectiveness models (Phillips et al., 1994; 
Ouahes and Phillips, 1995; O’Brien et al., 2003; Tabolli et al., 2007; Jeffcoate et al., 2009; 
Souliotis et al., 2016).  
3.6.3 Time to healing and NHS burden 
As well as a quality of life burden to patients, DFU, LU and PU are a significant workload burden 
for healthcare providers (Ghatnekar et al., 2001; Ohura et al., 2004; Martinez-Sanches et al., 
2005; Vikatmaa et al., 2008; Guillen-Sola et al., 2013; Hopkins and Worboys, 2014; Moffat et 
al., 2014; Ahmad, 2016; Alavi et al., 2016; NHS Rightcare, 2017; NICE, 2017). Home visits are a 
key driver of the cost to treat chronic wounds (Rudolph, 2001; Short and Bull, 2009; Foglia et 




therefore fewer visits are more likely to reduce costs, especially when the dressing also reduces 
healing time (Rudolph, 2001; Short and Bull, 2009; Foglia et al., 2012; Guest et al., 2012; Alavi 
et al., 2016). Protease inhibitors have been shown to be a cost-effective option (Nisi et al., 
2005; Moffat et al., 2014; Augustin et al., 2016). Management plans associated with shorter 
treatment periods and fewer adverse events are more cost-effective (Franks and Bosanquet, 
2004; Ohura et al., 2004; Augustin et al., 2016; Zelen et al., 2015; Souliotis et al., 2016). Ulcers 
can be slow to heal, with wound size and duration affecting healing (O’Brien et al., 2003; 
Margolis et al., 2004; O’Meara et al., 2009; Watson et al., 2011; Alavi et al., 2016). The initial 
wound area reduction at 4 weeks is predictive of healing by 24 weeks (Margolis et al., 2003; 
Meaume et al., 2012; PrescQIPP, 2015).  
3.6.4 Early intervention and economic impact 
Early diagnosis and treatment of a DFU, LU or PU can improve quality of life for a patient 
(Meissner et al., 2007; Kelechi et al., 2015). This early investment in treatment provides a 
reduction in long-term costs; prolonged futile treatment is more costly (Augustin and 
Vanscheidt, 2012; Kelechi et al., 2012; Augustin et al., 2016; Raju et al., 2016). There is a need 
for a long-term view from decision makers, for example, the purchase price of a dressing is not 
indicative of cost-effectiveness (Schmutz et al., 2008).  
Some ulcers are more expensive to manage, these include: chronic wounds, recurrent wounds, 
and older wounds (Currie et al., 1998; Smith and Ingram, 2010; Dealey et al., 2012; Guidelines 
and Audit Implementation Network, 2013; Demarre et al., 2015). Older wounds are harder and 
more expensive to heal so early intervention will reduce the healing time and cost (Smith and 
Ingram, 2010; Augustin and Vanscheidt, 2012; Hopkins and Worboys, 2014; Augustin et al., 
2016; Raju et al., 2016). LU is more prevalent in older populations who may benefit from less 
invasive treatment options (Ouahes and Phillips, 1995; Rudolph, 2001; Pang et al., 2010; 
Australian Wound Management Association Inc. and the New Zealand Wound Care Society 
Inc., 2011). An adjunctive therapy such as a dressing that modulates the microenvironment 
can promote faster healing in complicated wounds (Reichardt, 1999; Snyder, 2005; Meissner 
et al., 2007; Meaume et al., 2012; Carter et al., 2014; Ghatneker at al., 2015; Alavi et al., 2016). 
An adjunctive therapy to standard wound care should be considered in cases where you 
anticipate wound healing may be compromised (Reichardt, 1999; Snyder, 2005; Meissner et 




3.6.5 Consensus summary 
This consensus process sought to address areas of uncertainty in the management of chronic 
wounds. The expert consensus panel has agreed that 
− Chronic wounds including DFU, LU and PU significantly impair a patient’s health and quality 
of life and this needs to be taken into consideration in patient care with the aim of reducing 
healing time. 
− Inhibiting MMPs plays an important role in wound healing and raised levels of these 
enzymes have been shown to be present in DFU, LU and PU.  
− Early interventions are a more cost-effective option, both in terms of health and quality of 






Table 3.6. Consensus statement definitions 
Term  Definition 
Normal healing 
pattern 
A normal healing pattern contains four phases of healing categorised 
according to the activity of their cellular components. The phases are 
haemostasis phase, inflammatory phase, proliferative phase, and 
maturation (or remodelling) phase. Normal healing will move 
through these phases at a predictable rate.  




By regulating the integrity and composition of the extracellular 
matrix, these enzymes play a pivotal role in the control of signals 
elicited by matrix molecules that regulate cell proliferation, 
differentiation, and death.  
Acute wound An injury to the skin that occurs suddenly rather than over time. It 
heals at a predictable and expected rate according to the normal 
wound healing process 
Basic dressings A foam dressing with no active agents. 
Morbidity  A diseased condition or state. 
Mortality Likelihood of death, or death rate. 
Significantly Having reached statistical significance. 
Carer An unpaid carer; a relative, friend or neighbour. 
Healthcare Provider Any individual, institution, or agency that provides health services. 
Advanced dressings Dressings that regulate wound healing by simple physicochemical 
means, typically by controlling moisture levels. 
Adjunctive therapy Another treatment used together with the primary treatment. Its 
purpose is to assist the primary treatment. 
Standard wound 
care 
Standard care used to promote wound healing, which can be 
achieved through off-loading in DFU, compression in LU and/ or 





This section discusses the strengths and limitations of this study, the impact of the core 
principle of anonymity and the systematic search and literature review that preceded the 
expert panel. This modified Delphi methodology expert consensus panel was carried out in a 
short time frame, between April and June 2017. The aims of this study were to identify areas 
of uncertainty present in literature surrounding dressings for chronic wounds and seek 
consensus from a broad range of wound care practitioners, academics and policy experts on 
topics of uncertainty in using wound dressings. This study achieved these aims, the literature 
search had a broad scope and resulted in the generation of evidence-based statements using 
thematic analysis to understand the uncertainty present in the literature. The participation of 
both the clinical and technical experts is invaluable, with decades of experience culminating in 
a 1200-word document detailing agreed best practices and observations based on clinical 
practice.  
The strengths of this process include the systematic literature search performed to generate 
the statements, and the transparency of the workbook that allowed participants to access all 
the quotations from literature that the statements were based on. The iterative approach that 
is inherent when using the Delphi methodology is another key strength, in this study, two 
rounds of individual voting was followed by a face-to-face meeting. The iterative nature of the 
Delphi methodology allows participants to review their own answers in the context of 
comments from other members of the panel. Iteration is conducive to arriving at a consensus, 
as the same questions are deliberated multiple times, with new information. This study also 
made commenting mandatory in case of an answer that disagreed with the statement. This 
obligation was insisted upon for the process to provide the response that was needed to 
develop a statement that reflected the thinking of the panel. The mandatory commenting 
allowed for flexibility; the ability to edit statements in line with comments was useful when 
crafting the wording of the statements in line with the panel’s opinions. The evidence was 
repeatedly consulted, to check if evidence was available to support a new suggested wording.  
The limitations of this process included the protocol consensus threshold, if strictly applied, 
would have led to 31 comments from experts being overlooked because the statement 
reached a threshold of 80%. The intricate semantic discussions that took place during the face-




a limitation, the choice to not rank the statements was deliberate to facilitate consensus, 
however in hindsight could have proven advantageous when structuring the statement. The 
assumption that a consensus would not easily be achieved was incorrect. As with all research 
of individual opinion, there needs to be understanding of any personal bias that could impact 
the results.  
It is asserted that the low level of evidence limitations of a Delphi panel are best addressed by 
conducting one as a part of a rage of evidence generation activities, such as SLRs, database 
studies, clinical trials, and modelling activities. A Delphi panel is an important part of a wider 
portfolio of work required to assess any new intervention. In terms of qualitative data, the 
expert panel is only half of the picture, given that the clinicians and health care providers are 
only one group of stakeholders involved with wound management. The patient experience also 
needs to be understood to make robust recommendations about treatment. 
To ensure that all participants were on an even footing, and to avoid a situation where the 
majority fall in line with the most senior in the room, the first two rounds of voting were carried 
out remotely, via the electronic workbook that was sent to the participants. When consulting 
a varied group of participants from a range of disciplines including nurses, podiatrists, 
clinicians, surgeons, academics, and health policy experts, there is a risk that the group can 
become overwhelmed by a particularly senior or vocal member. To minimise this risk and to 
give all participants an equal voice, the voting was carried out individually and where a 
statement was disagreed with, a reason explaining why, or a suggestion for how it could be 
better worded or phrased was mandatory. All participants complied with this rule; which 
meant that wherever there was dissent, there was explanation.  
As part of the process all comments were shared with the group, with the identity of the author 
redacted. Anonymity allows the opinions of every group member to be considered as equal, 
with no weighting for seniority or discipline. It also allows the participant to consider their own 
opinion in the context of others, and at the face-to-face meeting it became apparent that these 
were really considered, resulting in numerous semantic changes in line with the comments, 
resulting in statements that represented the views of the entire group. The anonymity 
contributes significantly to this, because it empowers the participants to be actively involved 




The modification of the traditional Delphi methodology to include a literature review as the 
first stage of the study further increased the robustness of this study. The search strategy for 
the systematic search was made available to all participants throughout the process, as was 
the full bibliographic details of all quotations and references used to inform the statements. 
Being transparent with the methods and sources used to develop the workbook was intended 
to encourage the participants to familiarise themselves with the evidence base and access the 
raw data when making conclusions and decisions about the validity of a statement.  
Consulting the literature is vital to understand the current published evidence base on a topic, 
however the reality of a situation can often differ from the clinical trial setting of a paper, or 
from the guidelines recommended by a governing body. To then test the validity of statements 
generated from the literature review using a panel of experts allows for a synthesis of both 
quantitative and qualitative evidence. This synthesis is useful in informing understanding about 
real-world practice, clinical opinion and expert guidance in areas of uncertainty.  
3.8 Chapter summary 
This chapter has explored the use of expert advice to gain knowledge and understanding 
regarding clinical use, treatment pathways and current standards of care. Expert opinion is 
often subject to low levels of evidence classifications, due to its typically uncontrolled nature, 
however this can be counterbalanced using a Delphi methodology. The Delphi methodology, 
and its anonymous, iterative approach protects from many of the risks of a traditional expert 
panel. A multidisciplinary panel was chosen, and a Delphi methodology expert consensus panel 
was carried out; resulting in the creation of a consensus document which can claim to be both 
evidence-based and expert endorsed, with a transparent methodology and results to support 
those claims.  
The next chapter of this thesis explores the patient perspective of chronic wounds, through 
two real-world evidence studies, one looking at patient reported outcomes and one 
performing a chart review of patient records.  
3.9 Dissemination 
This study has been presented as a conference abstract, poster presentation and published 




Chapter 4 A study of real-world health-related quality of life and treatment 
switching in people with Diabetic Foot Ulcers and Leg Ulcers 
 
4.1 Introduction 
The previous chapter elicited expert opinions from a range of professionals in the field of 
wound care using the iterative Delphi methodology. Expert opinion can be considered as a 
lower level evidence compared with clinical trials due to its subjective nature and risk of bias 
as explored in chapter 3. Despite this, expert opinion helps to shape the treatment landscape 
for people with chronic wounds. To provide a fuller picture of the narrative surrounding wound 
management, it is necessary to gather real-world data through medical records and 
consultation with patients. This chapter therefore presents a real-world assessment of health-
related quality of life and treatment switching in patients with diabetic foot ulcers (DFU) and 
leg ulcers (LU), both from patients directly and from electronic medical records.  
Real-world data (RWD) can come in many formats and can be broadly defined as data that is 
not collected in a clinical trial setting, such as electronic health records or product and disease 
registries (Makady et al., 2017). Real-world evidence (RWE) is the product of real-world data, 
once analysis has taken place and insights generated (U.S. Food & Drug Administration, 2019).  
For this thesis two sources of real-world data were sought; meaning that no intervention was 
delivered to patients and the studies only collected enough data to satisfy the needs of the 
studies. The two studies presented in this chapter are study 3, patient reported outcomes and 
study 4, chart extraction. These studies, and how they are linked to the overall thesis is shown 
in Figure 4.1.  
The patient reported outcomes (PRO) study focussed entirely on patients and the burden of 
living with and managing a chronic wound. Understanding the impact and burden of chronic 
wounds, such as DFU and LU, is almost impossible without incorporating the patient voice into 
data collection. Historically, treatment decisions have been made by health care providers in 
isolation, or under the directive of clinical guidelines, however patient empowerment is a 
movement that is growing in the twenty-first century. The European Patients’ Forum defines 
patient empowerment as the patients’ ability to express their needs, present their concerns 




patients helps to highlight what is important when it comes to management and care; from 
the perspective of the people who are the ultimate customer and consumer of the product. 
 
 
Figure 4.1. Real world studies within the PhD framework 
The chart extraction study is a retrospective review of electronic patient records collected from 
treatment settings in England. This study sought to examine of real-world treatment practices 
that exist within care pathways, to compare this with treatment practices recommended by 
clinicians or in clinical guidelines.  
4.2 Background  
4.2.1 Quality of life and chronic wounds 
There is a body of existing literature examining quality of life (QoL) for patients with chronic 
wounds. A thorough two-part systematic literature review (SLR) analysed both qualitative and 
quantitative studies of the patient experience for those with a LU (Green and Jester, 2009; 




studies and advocated a holistic treatment approach, highlighting the need to understand that 
the practitioner is treating the patient, and not just the wound. The quantitative review by 
Green and Jester (2010) looked at PRO measures (PROMs) from 11 studies and found that 
patients with wounds suffered deficits in QoL and demonstrated that pain, mobility, and mood 
were the most significantly impaired when compared to the general population.   
The reviews by Green and Jester (2009 and 2010), although thorough, only focussed on 
patients with LU. Whilst these patients make up a significant portion of all chronic wounds 
(Guest et al., 2015), other wounds, including DFU are also of interest to the National Institute 
of Health and Care Excellence (NICE); when scoping a technology for wound care NICE gathers 
evidence to ensure the inclusion of all patient groups that could possibly benefit from the 
review of an intervention. The protease-modulating matrix (PMM) technology that is the focus 
of this research has also been shown to be of benefit to DFU patients (Edmonds et al., 2018) 
thus findings from this population also need to be investigated to fully understand the benefits 
offered by this intervention.  
Therefore, to address literature relating to DFU patients and the QoL burden they face; this 
chapter includes a review of the literature in relation to QoL outcomes for all chronic wound 
patients. Like Green & Jester (2009 and 2010), both qualitative studies assessing patient 
experiences with chronic wounds and quantitative randomised controlled trials (RCTs) with a 
health-related QoL PROM as a secondary endpoint were included.  
A review of the literature identified 11 qualitative studies and 6 RCTs with endpoints relating 
to patient QoL. Of the 11 qualitative studies, 5 assessed LU 2 looked at pressure ulcers (PUs), 
1 at DFU, and 3 looking at chronic wounds more broadly. Of the 8 RCTs included for data 
extraction, 4 of the studies assessed LUs and 2 assessed DFUs.  
The 11 qualitative articles returned by this search strategy were varied in their design, including 
using semi-structured interviews of small groups (Kinmond et al., 2003; Van Hecke et al., 2011; 
Gorecki et al., 2012) and larger online surveys to reach over 1000 people (Gethin et al., 2014). 
Many of the studies focused on LU, with only one addressing DFU directly (Kinmond et al., 
2003) which found that having a DFU led to patients living a restricted life, existing in social 
isolation, and an idea of ‘loss of self’ and becoming a burden. These psychosocial factors have 




study performed using unstructured interviews of 13 patients with LU in the United Kingdom 
(UK) also found that patients were concerned by the restrictions they faced; struggled to cope 
with ulceration and the perceptions of others towards them (Walshe, 1995). This study also 
highlighted the fact that the significant restrictions on patients’ activities such as going out, 
washing, or walking around were not sufficiently addressed by treatment.  
Six quantitative studies of QoL were carried out in an RCT setting (Jeffcoate et al., 2009; 
Michaels et al., 2009; Watson et al., 2011; Moffatt et al., 2014; Meaume et al., 2017; Edmonds 
et al., 2018). These trials used a range of PROMs, but predominantly generic tools to assess 
QoL including EQ-5D/VAS (Jeffcoate et al., 2009; Michaels et al., 2009; Watson et al., 2009; 
Moffatt et al., 2014; Meaume et al., 2017; Edmonds et al., 2017). Only one of the studies 
(Jeffcoate et al., 2009) used a disease-specific PROM, the Cardiff Wound Impact Schedule 
(CWIS), in addition to the generic SF-36 measure. The scoring of the measures demonstrated 
reduced QoL and utility scores for patients, driven by mobility and psychological scores relating 
to anxiety and depression. 
The review of the current literature demonstrates that whilst there have been studies carried 
out on patients with DFU and LU to assess their QoL, the PROM data has been collected 
exclusively in an RCT setting. Arguably the patient’s included in these studies are not 
generalisable to the wider population given the often-strict inclusion and exclusion criteria 
enforced by clinical study protocols. They are also impacted by the fact that the patient is 
participating in a clinical trial and is not experiencing standard care that they would experience 
in the real-world. Another limitation of the more informal studies, such as those carried out in 
an observational setting is that they often have small numbers of patients and do not use 
PROMs to collect data, relying on more qualitative methods such as interviews and focus 
groups. These are extremely important methods that enable a researcher to delve into patient 
insights, but not the focus for the present study.  
4.2.2 Real-world evidence and chronic wounds 
In addition to patient insights and understanding the burden of disease; real-world data 
collection can be useful in determining current treatment patterns, resource use, and patient 
outcomes (Huang et al., 2018). Data collected in a real-world setting can be compared to data 




environment and the strict inclusion and exclusion criteria. Real-world data relating to clinical 
outcomes and resource use can be derived in several ways, from electronic medical records, 
product and disease registries, clinical audits, data from mobile devices, and, where relevant, 
insurance and claims data. In the UK there are several large datasets generated from electronic 
medical records of patients within the National Health Service (NHS), owned by the 
government Department of Health, managed by NHS Digital (CPRD, 2019; NHS Digital, 2019). 
There are also privately-owned datasets, including The Health Improvement Network (THIN) 
database (UCL Institute of Epidemiology and Health Care, 2018).  
The THIN database was the data source for a pair of studies published in 2018 on DFU and LU 
management in the UK (Guest et al., 2018a; Guest et al., 2018b). This database contains data 
from 11.1 million patients, of which about 3.7 million patient records are active, with a 
coverage of 6.2% of the UK. However, it is worth bearing in mind that the THIN database is 
based on the Vision software, which is developed for patient management and not clinical 
research; meaning that data endpoints sought by researchers may not be available. GP 
practices are also only one care setting that patients interact with health care professionals 
and as such, the THIN database only provides a partial view of the patient journey. The study 
designed for this research sought to understand the full patient journey by including multiple 
care providers.  
The studies by Guest et al., (2018a and 2018b) reported the cost of wound care over 12 months 
for a DFU and a LU as being £7800 and £7600 respectively. The study on DFU noted that 48% 
of patients received at least one prescription for a compression system, despite compression 
being not recommended for use in patients with DFU, and patients who did not receive 
compression were significantly (P < 0·001) more likely to heal (Guest et al., 2018b). Conversely, 
the gold standard of treatment for LU should always include a compression system, whereas 
their study found that 13% of patients did not receive one. However, these patients did not 
have a reduced chance of healing but did incur significantly (P<0.001) longer time to healing 
(Guest et al., 2018a). This deviation in standard treatment practice highlights the importance 
of identifying a clinical and cost-effective treatment strategy that can be clearly communicated 
to health care providers (HCPs) via continuous medical education to ensure adherence to 




4.3 Study aims 
The aim of study 3 was:  
− To document and quantify QoL for DFU and LU patients.  
The objectives of study 3 were: 
− To use PROMs in an observational treatment setting.  
− To inform utility scoring for economic modelling.  
The aim of study 4 was: 
− To establish treatment pathways, incidence of treatment switching, outcomes and 
resource use across multiple care settings.  
The objectives of study 4 were: 
− To collect data from patients using retrospective real-world data 
− To use thematic analysis to develop a model to interpret the incidence and cause of 
treatment switching. 
4.4 Methods 
This section describes the methods used for both the PRO and the chart extraction studies. 
First, the design of the studies is described, followed by an overview of the included 
participants; and an explanation of the tools used in each study. Following this, the analysis 
plans and data collection methodology for each study is set out and finally ethics 
considerations addressed. Both studies are examples of real-world evidence generation, the 
PRO study had a focus on patient QoL, and the chart extraction examined electronic patient 
records. 
4.4.1 Study designs 
Study 3, the PRO study, was a prospective, non-comparative, cross-sectional study of validated 
tools to investigate QoL in patients with DFU and LU.  
Study 4, the chart extraction study, was a retrospective, non-comparative review of electronic 
patient records carried out in multiple treatment settings to investigate incidence of treatment 





The patients that were included in the PRO study and the chart extraction, were of similar 
demographic characteristics, subject to very broad inclusion criteria.  
For Study 3, the PRO study, the patients were included if they had either a DFU or LU. There 
was no requirement for the size of the wound, nor for wound duration. No exclusion criteria 
were set regarding comorbidities or any requirements for overall health status. Patients with 
a closed wound were eligible to partake in the study if they were still attending the DFU/LU 
clinic; to understand the ongoing burden of ulceration, given the chronicity of the disease.  
For study 4, the chart extraction study, patients were included if they had a DFU or LU and a 
record in the selected centres, with a minimum of two appointments to facilitate the analysis 
of treatment patterns. Again, there were no exclusion criteria relating to comorbidities or 
requirements for health status.  
The stipulations for patients were intentionally kept broad for these two studies, to align with 
the ethos of real-world evidence; to provide a contrast with RCTs. RCTs operate using a strict 
protocol and all deviations are carefully managed to minimise any bias or confounding factors 
that could influence the results. RCTs are devised to ensure that the effect measured is related 
to the investigative product and not due to any other factor and they sit atop the hierarchy of 
evidence classifications due to their methodological robustness (Guyatt et al., 2008). Trials can 
be designed to isolate treatment effect and can perhaps use endpoints not routinely measured 
in practice, or surrogate or proxy endpoints that do not have much meaning to patients. In 
contrast to this, these studies investigate a sample of patients that exist outside of the trial 
setting. These patients not only have the disease of interest, in this case DFU or LU, but also 
have a range of comorbidities, and are likely to be of worse health than a population in a clinical 
trial.  
The patients recruited into the two real-world evidence studies described in this chapter are 
intended to be a representative sample of the patients found in routine clinical practice. For 
the PRO study (study 3), patients were recruited consecutively at clinics, after providing written 
consent to participate. The patient sample in the chart extraction was selected by the nurse 




Patients in the chart extraction study provided written consent prior to data collection. Patients 
who were recruited into the PRO had to complete the study questionnaire pack, which was 
designed with patient accessibility in mind, the pages were printed single side with a minimum 
font size of 16 point. Patients could be helped by a carer, relative, or health care professional 
if they struggled to read or understand the questions.  
The target level of recruitment for each study was set at 100 patients, with a desired ratio of 
DFU and LU patients at 1:1. This figure was reached based on calculations using a sample size 
calculator, which indicated that a sample of 96 patients would be able to give a confidence 
level of 95% with a confidence interval of ±10 (Creative Research Systems, 2018).  
4.4.3 Study tools 
Study 3: Demographic sheet 
Study 3, the PRO study, made use of validated PROMS as tools to collect data on patients’ QoL 
and wellbeing. These tools are often used as companion measures in a clinical trial, to provide 
secondary outcomes on patient QoL. With multiple measures from individual patients, clinical 
trial statisticians are then able to present a longitudinal dataset for each patient, allowing for 
analysis of QoL over time, and to measure the impact of the investigative product. In this cross-
sectional study, there was only one interaction with any recruited patient and no follow up 
period. With just one measure from each patient, there is no way to follow patients and their 
progress over time.  
To counter this, a demographic questionnaire was developed. This demographic sheet was 
designed to collect data about patients to contextualise their answers to the validated PROMs. 
The demographic sheet was 3 pages in length, at font size 16, designed to not burden patients 
with excessive forms. The questionnaire contained questions regarding: sex, age, wound type, 
size and duration, single/multiple wounds, wound recurrence and the number of visits to 
different health care practitioners (HCPs).  
Patients were asked about the size of their wound at two time-points; at the beginning of 
treatment and on the day of completing the questionnaires. They were asked to compare the 
size of their wound to the 8cm2 image in the pack and answer if their wound was smaller, or 
the same size or bigger at the start of treatment. For the present day, they were also given an 




The demographic sheet asked for details regarding visits to different HCPs and use of different 
wound care dressings; compression with the aspiration of understanding patient resource use. 
There was also a question regarding the use of companion diagnostics such as a doppler 
ultrasonography which is used in patients with a LU to map and understand venous 
insufficiency in the lower limbs (Galeandro et al., 2012). These details were collected with the 
intent of creating a matrix of patient demographics versus QoL.  
The demographic sheet sought to identify and provide evidence for some theorised factors 
that can negatively impact QoL for patients with a DFU and LU. Vice versa, it was hoped that 
some level of understanding could be sought about the demographics and resource use of 
patients with very poor QoL scores; to see if patients with severely suppressed QoL consumed 
the most healthcare resources and reported multiple wounds and many different treatment 
options.  
The demographic sheet was piloted on a sample of 10 patients and was well received by 
patients. However, details of treatment plans including visits to HCPs and use of companion 
diagnostics was not always reliably recorded. After discussion with the supervisory team at 
Manchester Met it was decided to retain these fields but due to missing and inconsistent data 
recording, it was acknowledged that a quantitative analysis of these fields would be unlikely.  
Study 3: Validated PROMs 
Validated PROMs are instruments that are integral to comparative research to understand 
patient experience and insights. The International Society for Quality of Life Research (ISOQOL) 
have recommended minimum standards for PROMs used in research and include the following 
requirements for the PROM to be acceptable: documentation of the conceptual and 
measurement model; evidence for reliability, validity; interpretability of scores; quality 
translation, and acceptable patient and investigator burden (Reeve et al., 2013).  
There are both generic PROMs and disease-specific PROMs; which are among the hundreds of 
validated tools available for research. Disease specific measures can measure dimensions of 
interest to patients suffering with a certain disease, in this case DFU and LU. Examples of 
disease specific questionnaires that have been validated for measuring QoL for patients with 
chronic wounds include the Charing Cross Venous Ulcer Questionnaire (CXVUQ), Diabetic Foot 




in patients with DFU found that there was no ‘gold-standard’ PROM that was superior to all 
others for assessing QoL (Hogg et al., 2012).  
The study described in this thesis included patients with both DFU and LU; different to other 
QoL studies of patients with chronic wounds. Despite Jull et al., (2010) showing the CXVUQ as 
more sensitive, this measure is only intended for use in patients with LU, and not DFU. As a 
result, this PROM was excluded from this study and CWIS was chosen for this study as it could 
be used for both aetiologies of interest.  
CWIS is a disease specific tool that was developed over three stages, informed by patients at 
each step; a focus group, a pilot group and a 3 month follow up process all determined the 
final form (Price and Harding, 2004). Analysis during development showed no significant 
differences between responses across the wound types; which makes CWIS suitable for this 
study, which includes both DFU and LU. CWIS is a longer tool, at 7 pages when included in the 
final study pack. The tool asks patients about various issues, on the domains of well-being, 
physical symptoms and daily living, and social life. It also has a slight repetitive guise that could 
be misleading. In Sweden, during the translation and validation process for CWIS, patients 
commented that the tool was too extensive, with too many questions (Fagerdahl et al., 2014).  
In addition to including the disease specific CWIS, this study was also intended to capture utility 
scores for the economic modelling performed in chapter 5. Utility scores are a numerical 
valuation of a given health state. Usually, values are given between 0 and 1; where a value of 
1 represents perfect health and 0 indicates death. Some value sets include values below 0; 
which indicate that the health state is considered worse than death (York Health Economics 
Consortium, 2016).  
Using generic PROMs provide results that can be used to calculate quality adjusted life years 
(QALYs) for patients in designated health states. EuroQol 5-dimension (EQ-5D) is the most 
commonly used utility instrument, and therefore comparisons to other diseases using a like-
for-like scale can be achieved, which is likely why the EQ-5D is preferred and recommended by 
NICE (NICE, 2013). It is possible to map other generic tools to EQ-5D using statistical methods, 
however as with all data manipulation there is the risk of loss of meaning as the data is 
transformed. As this study was designed to be mindful of the requirements and preferences of 




EQ-5D is measured across 5 domains: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. These can either be measured using a 3-point or 5-point scale using the 
EQ-5D-3L and EQ-5D-5L, respectively. The EQ-5D-5L system was first made available in 2011 
and has now been translated into upwards of 150 languages (Herdman et al., 2011). A study 
comparing the use of EQ-5D-3L and EQ-5D-5L concluded that the 5L had increased sensitivity 
and precision; and that past use of EQ-5D-3L may have led to an overestimation of quality 
adjusted life years in economic evaluations (Janssen et al., 2018).  
NICE has issued a position statement on the use of EQ-5D-3L and the adoption of EQ-5D-5L 
(NICE, 2018). The position statement states that NICE does not currently recommend the use 
of the 5L value set due to the lack of data, and some concerns raised by a quality assurance 
group (Hernández-Alava et al., 2018). The advice is not to cease using the EQ-5D-5L tool, which 
has been shown to have greater precision; but in the manner of reporting. The preferred 
method is to use a methodology that maps the EQ-5D-5L responses to the valuation set for the 
EQ-5D-3L, a nonparametric model that was more simple than other proposed methodologies 
(van Hout et al., 2012). 
In addition to EQ-5D, which reports a utility score, this study explored the use of the Self-
Assessment of Treatment, version 2 (SAT-II). This PROM measures the patients experience with 
pain and focuses on the treatment impact upon their pain (van Nooten et al., 2017). This 
measure was considered of interest after a review of literature found that pain was a 
dimension repeatedly reported by patients as important to them and had a high prevalence 
across the studies included. Pain is assessed by EQ-5D, but after consideration it was decided 
to use SAT-II in the pilot testing, to interrogate important issues that impact QoL for patients. 
The patient burden was considered low as SAT-II consisted of only 3 questions spread over 2 
pages.  
The final PRO study pack consisted of a participant information sheet and written consent 
form, the demographic information sheet, and the three validated PROMs, SAT-II, EQ-5D-5L 
and CWIS. The pack was 19 pages long and only available in hard copy, which was deemed 
appropriate as the use of pen and paper tools has been proven to be equivalent to electronic 




Study 4: iPad tool 
Study 4, the chart extraction study did not use any pre-existing validated measures and the 
data capture tool was custom created especially for this study. The tool was designed by a joint 
project between Manchester Met and Urgo Medical Ltd as part of a pilot before 
commencement of this PhD. The development of the software and user interface as an iPad 
application was carried out by a data analyst at Urgo Medical Ltd. The iPads were loaned to 
each centre for the period of data capture, and once this was complete the iPads were then 
returned to Urgo Medical Ltd where the data analyst uploaded the data into a specially made 
database in Microsoft Excel.  
The development of the application was designed in collaboration with Nurse practitioners 
who were familiar with the databases used by health care professionals in clinics. The iPad 
application was designed to mimic the layout and information collected by these systems, used 
every day by clinicians, to reduce the workload burden of the individual performing the data 
capture.  
The iPad tool created a record for each visit by a patient; with no identifying information 
included. Patients were assigned a wound number which increased consecutively with each 
visit; creating a longitudinal data set for each patient. The data headings shown in Table 4.1 
are those that were included as fields on the iPad application for data extraction. These fields 
were used to extrapolate further inferences, which were calculated by the database and are 
listed in the data analysis plan (see section 4.4.5). 
Table 4.1. Data fields included in iPad extraction tool 
CR-WoundNo RecordID Sex Wound number 
Date of final 
visit 
Initial visit date 
Date wound 
closed 
Wound type Wound Severity Visit Date 





















The iPad application was piloted and initially used on just one centre for 10 patients to receive 
feedback and to understand how the tool could be improved for use in other centres. The 
feedback received was entirely to do with the user interface, such as the positioning of fields 
and links on the screen, and there were no comments regarding the data sought. These issues 
were fixed and refined by the data analyst at Urgo Medical Ltd and the tool was rolled out for 
use in the study.  
It is important to note that the iPad tool did not make fields mandatory to complete a record. 
This decision was made due to practitioner advice during development; nurses advised that 
many records in electronic medical records were incomplete and this would make data 
collection more difficult if a cohort of complete records needed to be found. The risk of 
receiving partial data was offset with the need to be pragmatic when collecting the data.  
4.4.4 Data collection 
The data collection for study 3, the PRO study, and study 4, the chart extraction differed in 
their approach, but both were rigorous methods of data collection. The PRO study was 
prospectively administered at centres across the UK. For the chart extraction study, data 
collection was managed through Urgo Medical Ltd using nurses at each centre to extract data 
into the iPad tool provided, discussed earlier in this chapter. In addition, the local governance 
and approval flows for each of the centres was followed to ensure compliance with the highest 
ethics standards (see section 4.4.6 ethics). 
Study 3: PRO study  
This study was carried out in person, at clinics, there were no electronic records completed 
and the packs were presented only in paper format. Due to this, there was no way for the 
researchers to mandate that fields be completed consistently across patients, and no way to 
ensure that fields were completed at all. The risk of missing data was considered when 
developing the questionnaire pack, but the use of electronic devices would have been 
impractical; multiple patients would often be completing the study packs concurrently, and the 
number of devices that would be necessary would have been more than allowed by budgetary 
constraints.  
For the PRO study, centres were not paid for their participation, and nor were patients 




understand their own results relevant to their clinical setting and were able to access this data 
free of charge. The patients would have no access to their data after it had been submitted; 
due to the logistical difficulties that this would entail; needing to identify records and return 
them was out of the scope of this study and not required under the Data Protection Act 1998.  
To drive patient recruitment, given the short time window for data collection in this study; the 
PRO study questionnaire pack was also included in materials used as part of patient education 
days left with centres for patients to complete when a member of the Urgo Medical Ltd team 
interacted with a centre. Some patients required assistance when filling in the PRO study pack, 
and this was provided by either a carer who accompanied them, or the health care professional 
supervising the completion; or, rarely, a member of the Urgo Medical Ltd team who was 
trained by the Manchester Met researcher (AB) in how to assist with queries. AB was not 
present during data collection due to the restraints of the ethics approval granted by the 
university not authorising direct access to patients. Having members of the Urgo Medical team 
collecting data was potentially a cause for concern, however after study team discussions it 
was decided to not be an issue as this was not a product specific exercise, and there was no 
risk of promotion to patients. In addition to this; the code of practice that is enforced upon the 
pharmaceutical industry is not mandated for medical device companies; due to the additional 
educational programmes they run given that a lot of products, including dressings, are used by 
patients or carers without health care professional input.  
Study 4: Chart extraction study 
The patient data was recorded either for the study period, until wound closure, or the patient 
left treatment for another reason; whichever was the soonest. Data regarding which 
treatments were given, products used, patient and wound status, and all free-text notes were 
captured by this study. For the chart extraction study, centres were paid the equivalent of the 
salary of a band 5 nurse, for 2 weeks per 20 records extracted to recompense the centre for 
the time cost of having the nurse complete the data extraction and was not an incentive 
payment. All payments were approved and paid by Urgo Medical Ltd as part of their role in this 
partnership. The data that was extracted was then sent to Urgo Medical Ltd for upload into a 
database, but all analysis was completed by the primary researcher (AB) as part of the agreed 




patients to fill in any details; which is why a nurse at the centre was given the role of data 
extraction. 
Due to the nature of the study; there were additional local governance procedures to follow in 
each of the centres after initial ethics approval had been granted by the Manchester Met. The 
fact that there was a transfer of value between Urgo Medical Ltd and the centres involved 
posed a risk of bias, but after careful consideration; it was decided that this was balanced by 
the thorough and rigorous data analysis plan. 
4.4.5 Data analysis  
Descriptive analysis of the data is presented for both studies, with subgroup analysis 
performed for the PRO study and thematic analysis of the reasons for treatment switching 
included in the chart extraction. No inferential analyses were carried out for either study due 
to the cross-sectional nature of the data and small sample size, especially when considering 
subgroup analysis.  
Study 3: PRO study 
Study 3, the PRO study was designed to give insight into the patient experience of living with 
and managing a chronic wound to address the objectives set out in section 4.3. Together, the 
demographic sheet and the validated PROMs can be used to paint a picture of different patient 
archetypes. One of the key pieces of information that were collected by the demographic 
questionnaire was the duration of the wound, which fell into one of the following categories: 
0-6 months, 7-12 months or 13 months and longer. Wound duration is important to patients, 
because of the understandable long-term impact of having a chronic wound; but is also 
important to clinicians because of the known correlation between wound duration and a 
lowered likelihood of healing (Bosanquet and Harding, 2014).  
In addition to wound duration, the size of the wound is deemed important when considering 
treatment; many clinical trials have a wound size stipulation, which implies a preference for a 
certain size of wound to facilitate healing. Larger wounds, by their nature, have more skin to 
recover and thus, even at the same healing rate, would take longer until fully closed. As time 
to healing is often a primary endpoint in clinical trials, it is potentially important to 
manufacturers and study sponsors to exclude wounds that could reduce the impact of their 




Using a matrix of duration vs size, a severity matrix was developed to classify wounds as either 
mild, moderate or severe. The matrix can be seen in Table 4.2. DFU and LU patients would each 
be stratified in accordance with their severity rating as per the matrix to perform subgroup 
analysis on the outcomes of the PROMs to explore the differences between patients with 
wounds of varying duration and size.  
Table 4.2. Wound severity matrix 
13 months + Severe Severe 
7-12 months Moderate Severe 
0-6 months Mild Moderate 
 Smaller than 8cm2 Larger than 8cm2 
 
Using a matrix of duration vs size was decided upon because of these characteristics being 
prevalent in the literature (Frykberg and Banks, 2015). Not only have these factors been 
analysed as determinants of healing, but they are also often included in the patient baseline 
attributes in clinical trial reports. Due to the cross-sectional nature of the PRO study, it was 
deemed appropriate to attempt to generalise results in a context familiar to clinicians and 
researchers by including an overt reference to size and duration of wounds. The additional 
benefit of these two measurements is that they are easy to ascertain and are non-invasive for 
a patient.  
The validated PROMs have been scored according to their own methodologies; with CWIS 
being represented as a score out of 100, over three domains; well-being, physical functioning 
and social life, with the lower the number, the worse the score. The instructions for scoring 
CWIS are not publicly available, but as part of the licence for CWIS the scoring tool was sent to 
the researcher to interpret the results.  
EQ-5D-5L results have been interpreted using the so called ‘crosswalk methodology’ which 




scores are reported as an index value; which can be termed a utility score. The EQ-5D tool also 
asks patients to score their own health on a visual analogue scale (VAS) of 0-100; which give 
an insight into a patient’s own opinion of their quality of life; compared to the utility score that 
is transformed using a value set produced by a broader population. 
SAT-II has only been reported in literature as a longitudinal tool, and as such the clinically 
meaningful differences identified in the scoring tool are for comparing one patient’s own 
records over time (van Nooten et al., 2017). This PROM presented a challenge to interpret, and 
it was decided to apply the clinically meaningful differences between patient groups of 
interest. Patient subgroups of interest included patients with wounds that were 
mild/moderate or severe, stratified by wound aetiology. EQ-5D index scores are also reported 
for subgroups relating to patient demographics such as age, sex, wound recurrence and, in the 
case of DFU, amputation history.  
Study 4: Chart extraction study 
The chart extraction study, study 4, collected many data points, as shown in Table 4.1. From 
these data fields, other data points could be calculated in the database, to aid analysis. A list 
of fields that were generated by the database from the data that was collected using the iPad 
tool is shown in Table 4.3.   
For the chart extraction study, the research aims presented in section 4.3 were to investigate 
incidence of treatment switching and the rationale behind these switches. The incidence of 
treatment switching, was the primary endpoint. Every appointment was coded in accordance 
with whether a switch had occurred or not. Table 4.4 shows the codes used.  
A treatment switch was defined as only a change of primary dressing; a change of the 
secondary dressing and bandage/compression system was not considered to be a treatment 
switch for the purposes of this study. After discussion with wound care experts, a secondary 
dressing was deemed to not be influential in wound healing and thus not of interest to this 
study. Secondary dressings are intended to mainly provide extra cushioning for a patient, or to 
hold the primary dressing in place when a non-adhesive product is used.  
Reasons for treatment switching, if provided, were also recorded. Thematic analysis was used 




and sub-categories were assigned where appropriate; and the categories were not pre-
defined, as per the thematic analysis methodology.  
Table 4.3. Database fields for chart extraction 
Data field Description  
Count How many appointments the patient had attended 
Wound closed at end Was the wound closed at the last recorded visit 
Infection ended When the last infection had ended 
Changes to infection cure Number of dressing changes before infection resolved. 
Cured infection Date that infection was cured 
Infection occurrences How many times a single patient had had an infection 
Infection day 1 When the infection was first reported 
Infection duration How long the infection lasted 
Treatment number Was the treatment first line, second line, third line etc. 
RunTot_Treatment Number Running total of treatments received by a patient 
DaysToClose How many days did the wound take to close 
Days Dressing Used How many days a dressing was used for 
No weeks on treatment How many weeks the patient had been on all treatments. 
 
Table 4.4. Coding of treatment switching 
Code Meaning 
0 No potential for switch- either a first assessment or a final visit due to wound closure 
1 No switch; the same primary dressing used as at previous visit 
2 Treatment switch; primary dressing different to previous visit 
  
Secondary endpoints include descriptive analysis of patient treatments and outcomes, 
including the number of visits made by patients to each healthcare provider, split by aetiology. 
Further to this, a healing outcome of the proportion of DFUs and LUs healed at 20 weeks is 




randomised clinical trials to highlight if there is a discrepancy in real-world healing rates. 
Subgroup analysis comparing the centres’ switching rates and healing outcomes has also been 
performed using non-inferential descriptive statistics.  
4.4.6 Ethics considerations 
Both studies presented in this chapter; study 3, the PRO study, and study 4, the chart 
extraction; were granted ethics approval by the Manchester Metropolitan Faculty Ethics 
committee (Reference: 1486). This ethics approval process was rigorous and included needing 
to submit all patient facing documentation through the process. The PRO study pack, and chart 
extraction letter to patients requesting consent for inclusion were both included in the 
approval; which was sought for all studies in this thesis.  
The Data Protection Act 1998 (DPA), was adhered to when carrying out this study, as it 
preceded the implementation of General Data Protection Regulation (GDPR) implemented on 
the 25th May 2018. Despite this; the research presented here had adhered to the 7 principles 
of GDPR, which are: lawfulness, fairness and transparency; purpose limitation; data 
minimisation; accuracy; storage limitation; integrity and confidentiality (security) and 
accountability. 
NHS approval was not required for either of these studies as their designs; questionnaire and 
retrospective medical chart studies fall under the category of unnecessary consent, as defined 
by Manchester Met (Manchester Metropolitan University, 2019). Despite this; consent was 
sought from patients for the PRO study; and all centres that participated in the chart extraction 
completed their own local governance and approval processes for research.  
Patients could ask any questions before they provided consent and were able to withdraw this 
consent at any time. To withdraw consent, a patient would have to be identified before their 
data was destroyed. Patients could only be identified by using their consent form, which was 
signed by them and coded with their patient reference number. All data uploads into databases 
only included this patient reference number, made up of a centre code and a sequential 
number, to track numbers of patients from each centre. The consent forms were separated 
from the rest of the study questionnaire packs and have been kept stored in separate locked 




Due to the nature of the PRO study being administered via a questionnaire; this study has gone 
over and above the usual standard by gaining signed written consent. For a questionnaire 
study; this is not usually required due to the implied consent granted by the patient filling out 
the questionnaire. This study also wanted to gain explicit consent, as the patients included 
could be considered vulnerable due to their age and impaired health status.  
Anonymity was central to the chart extraction study, with the data being extracted from 
medical records being anonymous, and the lead researcher (AB) having no way of identifying 
patients. Should consent be withdrawn, the study centres hold the key to identifying the 
patients; however, they do not have a copy of the data as this was stored on the iPad tool, 
which was returned to Urgo Medical Ltd, who also cannot identify the patients.  
Due to the nature of the data including medical details, and this considered as sensitive private 
data, considerations are made when using disaggregated data, or subgroups, to ensure that 
no groups of less than 5 patients are analysed. Small number suppression was applied not only 
for sample size considerations, but also in case any person can be identified by their wound 
characteristics or other data provided (Office for National Statistics , 2006).  
The scientific principles of transparency, data integrity and ethical behaviour are upheld in 
these studies; through attitude and integrity of the research team, both at Manchester Met, 
and at Urgo Medical Ltd, who understood the importance of the arms-length agreement in 
protecting patients and the results of the study.  
 
4.5 Results 
This section first describes the results of study 3, the PRO study, then followed by the results 
of study 4, the chart extraction study. First the characteristics of the patients included in each 
study is presented, followed by insights into QoL, using the validated PROMs for the PRO study, 
and a descriptive analysis of incidence of treatment switching and thematic analysis of the 
reasons for switching for the chart extraction study. Attention is paid to the subgroups of 
interest; across wound aetiologies, wound severity and health states including open, closed 




4.5.1 PRO study 
A total of 94 patients were included in the PRO study; of these, 42 had a DFU and 51 had a LU; 
1 patient did not complete this field and was excluded from the analysis as it was impossible 
to determine their wound aetiology, which was the basis for stratifying the cohort.  
DFU participants 
For the DFU patients (n = 42), the mean age was 64.05 years (±11.24) with a range of 45-85 
years. The group was predominantly male, with 29 individuals (69%) versus only 13 females 
(31%). In this cohort, the mean number of previous wounds was 2.15 (±2.54). Of the 42 
patients, 36 answered regarding a prior amputation, and of those that answered, it was an 
even split (50%/50%) between patients with a prior amputation and those without. The 
question specified that the amputation had to be because of their wound, and not for an 
unrelated incident.  
When using the wound severity matrix of size versus duration this could be calculated for 41 
patients, only 1 with missing data. Of these; 17 patients (41.5%) had a severity of mild of 
moderate, and another 17 (41.5%) reported wounds that fit the severe category. Of the 41 
patients, 7 (17.1%) reported on closed wounds.  
There was also a near even spit between new and recurrent wounds in this patient subgroup, 
with 21 (51.2%) new wounds and 20 (48.8%) recurrent wounds. Again, one patient was missing 
from this analysis. When analysing data regarding single or multiple wounds, the group was 
not so evenly divided, with 27 (67.5%) single wounds and 13 (32.5%) multiple wounds; two 
patients did not answer this question on the demographic sheet. Table 4.5 shows the 
breakdown of patient characteristics for those in the DFU group.  
LU participants 
For the LU patients (n = 51), the mean age of patients was 71.12 years (±11.83) with a range 
of 48-93 years. The group was nearly evenly split with regards to gender, with 25 (49%) males 
and 26 (51%) females. In this cohort, the mean number of previous wounds was 4.4 (±14.54). 
For this question, one patient had answered that they had 100’s of previous wounds; which 
was inputted at 100 despite this perhaps being an exaggeration. This may have contributed to 
the large standard deviation on this item. Patients with LU were not expected to answer the 




that they had a DFU, however 6 LU patients did answer this question, but all responded that 
they had not had an amputation because of their wound. 
When using the wound severity matrix of size versus duration this could be calculated for 50 
patients, only 1 with missing data. Of these; 16 patients (32%) had a severity of mild/moderate, 
and 19 (38%) reported wounds that fit the severe category. Of the 50 patients, 15 (30%) 
reported that they had a closed wound on the day they filled in the PRO questionnaire pack.  
Patients with a new wound made up 54% of the sample, with 27 people reporting that the 
wound in question was on a new wound site; and a recurrence made up the other 46% of the 
group, with 23 people nothing that the study wound was one that had previously been closed 
and had reopened. Again, one patient was missing from this analysis. When asking about single 
or multiple wounds, the group was not at all evenly divided, with only 15 (29.4%) single wounds 
and 36 (70.6%) multiple wounds; all patients answered this question on the demographic 






Table 4.5. DFU participant characteristics 
  Mean (n =) Standard Deviation 
Patient age 64.05 11.24 
Previous wounds 2.15 2.54 
Sex (n =)  % 
Male 29 69.0 
Female 13 31.0 
Total 42 100.0 
Prior amputation (n =) % 
Yes 18 42.9 
No 18 42.9 
Missing 6 14.3 
Total 42 100.0 
Wound severity (n =) % 
Mild 9 21.4 
Moderate 8 19.0 
Severe 17 40.5 
Closed 7 16.7 
Missing 1 2.4 
Total 42 100.0 
Wound type (n =) % 
New wound 21 50.0 
Recurrent wound 20 47.6 
Missing 1 2.4 
Total 42 100.0 
Number of wounds (n =) % 
Single 27 64.3 
Multiple 13 31.0 
Missing 2 4.8 





Table 4.6. LU participant characteristics 
 Mean (n =) Standard Deviation 
Patient age 71.12 11.83 
Previous wounds 4.40 14.54 
Sex (n =)  % 
Male 25 49.0 
Female 26 51.0 
Total 51 100.0 
Wound severity (n =)  % 
Mild 11 21.6 
Moderate 5 9.8 
Severe 19 37.3 
Closed 15 29.4 
Missing 1 2.0 
Total 51 100.0 
Wound type (n =)  % 
New wound 27 52.9 
Recurrent wound 23 45.1 
Missing 1 2.0 
Total 51 100.0 
Number of wounds (n =)  % 
Single 15 29.4 
Multiple 36 70.6 
Total 51 100.0 
 
PROM results 
After including the SAT-II in the pilot study of the first 10 patients, it was decided not to include 
this outcome measure in the main study, since both EQ-5D-5L and CWIS had questions 
regarding pain, and further research into the scoring methodology of SAT-II highlighted 
difficulties. The patient group size here was not large enough to power a study reliant on the 




had only been reported longitudinally and it was deemed out of the scope of this thesis to 
validate its use in a cross-sectional study prior to reporting the results. Due to this, the 
following section only reports on the EQ-5D-5L and CWIS validated tools; this is not thought to 
undermine the robustness of this study, given that both a generic and a disease specific tool 
were still used to report QoL.  
The research undertaken and presented in the background and methods section of this 
chapter asserts that EQ-5D is the most relevant for economic modelling and reports that CWIS 
can accurately represent QoL for patients with both DFU and LU. Even though the study 
included both DFU and LU patients, and was designed to accommodate both in the design, the 
reporting of results presents the wound aetiologies separately. This is because ultimately, they 
are different diseases, driven by different underlying causes and if they were combined in an 
aggregated analysis then some key issues important to each patient group may be less clear, 
or lost entirely.  
EQ-5D 
Table 4.7 shows the results of the analysis using EQ-5D for both DFU and LU patients. For both 
patient groups, the index score calculated using the crosswalk methodology to map to the EQ-
5D-3L value set is shown and the result of the VAS is also presented (van Hout et al., 2012). 
The VAS asks the participant to record their self-rated health on a 20-cm vertical, visual 
analogue scale with one end labelled ‘the best health you can imagine’ and the other labelled 
as ‘the worst health you can imagine’ (van Reenen & Janssen, 2015). 
Table 4.7. EQ-5D index scores and VAS results for DFU and LU patients 
EQ-5D-5L scores DFU (n =) Mean Std. Deviation 
       40 0.55 0.28 
Visual analogue scale 41 59.88 20.39 
EQ-5D-5L scores LU (n =) Mean Std. Deviation 
Index score 51 0.64 0.30 





For the DFU group, two patients’ responses did not enable the calculation to an index score, 
and one patient did not mark a response on the VAS. In the LU group, all patients completed 
the PROM and were included in the analysis.  
In the DFU group, the mean index score (SD) was 0.55 (±0.28), with some respondents 
obtaining the maximum score of 1.00, the lowest reported index score was 0.04. For LU 
patients, the index score was higher, with a mean score of 0.64 (±0.30). Patients also reported 
index scores of 1.00, the maximum score. However, the lowest result in this group was -0.20; 
a score of less than 0 indicates a health state that is deemed worse than death.  
The mean VAS score for DFU patients was 59.88 (±20.39), with a range of 17-95. The LU 
patients again scored marginally better on this measure, with a mean VAS score of 63.63 
(±21.34) and range of 15-99.  
CWIS  
CWIS is scored on a 0-100 scale, with a higher score representing better QoL outcomes. The 
tool produces a score in three categories: well-being, physical functioning and everyday living, 
and social life. Table 4.8 presents the results for the CWIS tool as reported by the DFU and LU 
patients in this study.  
Table 4.8. CWIS results for DFU and LU patients 
CWIS Scores DFU (n =) Mean Std. Deviation 
Well-being  34 51.15 22.93 
Physical symptoms & daily 
living  
36 71.16 25.73 
Social life  40 81.57 21.28 
CWIS Scores LU (n =) Mean Std. Deviation 
Well-being  49 49.71 25.02 
Physical symptoms & daily 
living  
44 75.07 21.98 





More patients did not complete all the fields of the CWIS tool when compared to EQ-5D. For 
DFU patients, out of total possible 42 patients, 34 patients were included in the analysis for 
well-being, 36 for physical symptoms and daily living and 40 for social life. When considering 
LU patients, the full cohort was 51 patients and 49 completed the well-being section and were 
included in the analysis, 44 for the physical symptoms and daily living section and 47 for social 
life.  
For DFU patients, the mean scores (SD) for well-being, physical activities and daily living, and 
social life were 51.15 (±22.93), 71.16 (±25.73) and 81.57 (±21.28) respectively. Each category 
saw patients that scored the maximum available 100 points, indicating a fully positive score, 
and the minimum social life score was 17, wellbeing score was 7 and for physical symptoms 
and daily living there was a patient who scored 0 points.  
For LU patients, the mean scores for well-being, physical activities and daily living, and social 
life were 49.71 (±25.02), 75.07 (±21.98) and 83.34 (±20.95) respectively. Each category saw 
patients that scored the maximum available 100 points, indicating a fully positive score, and 
the minimum social life score was 8, wellbeing score was 4 and for physical symptoms and daily 
living 13; for the LU subgroup, no patients scored 0 points.  
Subgroup analysis 
When using the severity matrix of duration versus size, the proportion of wounds that fit each 
category in each of the two groups is shown in Figure 4.2. 32% of LUs were classified as 
mild/moderate vs 38% severe and 41.5% of DFUs mild/moderate and 41.5% severe. More LUs 
were reported as closed compared to DFUs, 30% and 17% respectively, potentially due to the 
ongoing maintenance and compression needed by LU patients to prevent a recurrence. The 
number of reported closed wounds was more than was expected, and the results for closed 
wounds have not been presented here; as they were deemed unlikely to be generalisable, 






Figure 4.2. Wounds stratified according to severity  
 
EQ-5D subgroup analysis 
Table 4.9 presents the DFU results for the subgroups of mild, moderate, and severe wounds 
for the EQ-5D index score and the VAS result. The mean with 95% confidence interval, and 
standard deviation are presented for each group.  
For the index scores, the mean results for mild, moderate and severe wounds were 0.80, 0.55 
and 0.47, respectively; following the expected pattern that QoL decreases as a wound becomes 
more severe.  The VAS for these subgroups follows a different pattern, with mean results for 
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Table 4.9. EQ-5D results for DFU severity subgroups 
 DFU Subgroups EQ-5D 
Index score 
Mild 
Mean 0.80 (CI: 0.69 - 0.91) 
Std. Deviation 0.14 
Moderate 
Mean 0.55 (CI: 0.33 - 0.78) 
Std. Deviation 0.22 
Severe 
Mean 0.47 (CI: 0.32 - 0.62) 




Mean 61.11 (CI: 48.25 - 73.97) 
Std. Deviation 16.73 
Moderate 
Mean 65.50 (CI: 47.16 - 83.84) 
Std. Deviation 17.48 
Severe 
Mean 61.15 (CI: 48.09 - 74.22) 
Std. Deviation 21.62 
 
Table 4.10 presents the LU results for the subgroups of mild, moderate, severe, and closed 
wound for the EQ-5D index score and the VAS result. The mean with 95% confidence interval, 
and standard deviation are presented for each group. 
For the index scores, the mean results for mild, moderate and severe wounds were 0.83, 0.73 
and 0.56, respectively. As seen in the DFU subgroups, the scores follow the expected pattern 
that QoL decreases as a wound becomes more severe. The VAS for the subgroup of LU is again 
non-concordant with the index score results, with mean results for mild, moderate and severe 





Table 4.10. EQ-5D results for LU severity subgroups 
LU Subgroups EQ-5D 
Index score 
Mild 
Mean 0.83 (CI: 0.72 - 0.94) 
Std. Deviation 0.16 
Moderate 
Mean 0.73 (CI: 0.38 - 1.07) 
Std. Deviation 0.14 
Severe 
Mean 0.56 (CI: 0.41 - 0.72) 




Mean 62.50 (CI: 49.97 - 75.03) 
Std. Deviation 17.52 
Moderate 
Mean 65.00 (CI: 20.22 - 109.78) 
Std. Deviation 18.03 
Severe 
Mean 61.06 (CI: 48.90 - 73.22) 
Std. Deviation 23.64 
 
The mean EQ-5D index and VAS scores and 95% confidence intervals for DFU and LU when 





Table 4.11. EQ-5D results for DFU and LU demographic subgroups 
  DFU LU 




















































































(46.85, 68.45) Amputation history not 







The mean EQ-5D index scores for all patients representing each wound aetiology from this 
study is shown in context with EQ-5D scores reported in the literature for other chronic 
diseases in Figure 4.3 (Peters et al., 2014). This comparison is not a statistical meta-analysis; 
however it is one of the advantages of using EQ-5D; as comparisons can be made between 
disease areas; and the trend highlighted here shows that DFU and LU score poorly when 






Figure 4.3. EQ-5D utility scores of DFU and LU compared with other long-term conditions 
 
CWIS 
Table 4.12 below presents the DFU results for the subgroups of mild, moderate and severe 
wounds for the three endpoints reported by the CWIS tool. The mean with 95% confidence 
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Table 4.12. CWIS results for DFU severity subgroups 
DFU Subgroups CWIS 
Well-being 
Mild 
Mean 54.34 (CI: 43.55 - 65.13) 
Std. Deviation 14.037 
Moderate 
Mean 60.12 (CI: 32.65 - 87.59) 
Std. Deviation 26.177 
Severe 
Mean 43.41 (CI 29.27 - 57.54) 





Mean 85.89 (CI 78.99 - 92.79) 
Std. Deviation 8.981 
Moderate 
Mean 74.13 (CI: 48.11 - 100.16) 
Std. Deviation 24.802 
Severe 
Mean 63.38 (CI: 47.42 - 79.35) 
Std. Deviation 26.424 
Social life 
Mild 
Mean 93.97 (CI: 88.64 - 99.29) 
Std. Deviation 6.931 
Moderate 
Mean 79.85 (CI:61.57 - 98.13) 
Std. Deviation 17.419 
Severe 
Mean 79.18 (CI: 65.82 - 92.54) 
Std. Deviation 22.106 
 
For CWIS well-being scores; mild, moderate and severe DFUs had mean scores of 54.34, 60.12, 
and 43.41 respectively. For the physical symptoms and daily living; mild, moderate, and severe 
wounds had mean scores of 85.89, 74.13, and 63.38 respectively. Finally, for the social life 
domain, mild, moderate, and severe wounds had mean scores of 93.97, 79.85, and 79.18, 
respectively.  
Table 4.13 presents the LU results for the subgroups of mild, moderate and severe wounds for 
the three endpoints reported by the CWIS tool. The mean, median, standard deviation and 





Table 4.13. CWIS results for LU subgroups 
LU subgroups CWIS 
Well-being 
Mild 
Mean 64.28 (CI: 44.64 - 83.92) 
Std. Deviation 27.454 
Moderate 
Mean 47.60 (CI: 42.44 - 52.76) 
Std. Deviation 2.078 
Severe 
Mean 40.54 (CI: 26.23 - 54.85) 





Mean 85.41 (CI: 78.75 - 92.07) 
Std. Deviation 9.309 
Moderate 
Mean 73.27 (CI: 38.11 - 108.43) 
Std. Deviation 14.154 
Severe 
Mean 68.75 (CI: 56.46 - 81.03) 
Std. Deviation 23.892 
Social life 
Mild 
Mean 95.21 (CI: 90.56 - 99.86) 
Std. Deviation 6.504 
Moderate 
Mean 87.50 (CI: 61.66 - 113.34) 
Std. Deviation 10.400 
Severe 
Mean 83.82 (CI: 75.59 - 92.06) 
Std. Deviation 16.012 
 
For CWIS well-being scores; mild, moderate and severe LUs had mean scores of 64.28, 47.60, 
and 40.54 respectively. For the physical symptoms and daily living; mild, moderate and severe 
wounds had mean scores of 85.41, 73.27, and 68.75 respectively. For the social life domain 






4.5.2 Chart extraction 
Patient characteristics  
The chart extraction included 107 patients; of these patients, 36 patients had a DFU and 71 
had a LU. In total, 1050 visits were recorded, with a mean of 9.81 visits per patient, for DFU 
patients the mean number of visits was 7.14 and for LU the patients saw their care provider on 
average 11.16 times.  
From the 1050 visits, there were 208 recorded infections across both wound aetiologies, with 
50 occurrences of infection across 257 DFU visits resulting in an incidence rate of 19.46%. From 
the 793 LU visits there were 158 infections recorded; an incidence rate of 18.37%.  
Healing outcomes  
Healing outcomes could be measured for the patients in the chart extraction. To compare the 
outcomes of patients in the real-world with clinical trial endpoints, it was important to measure 
similar endpoints. An endpoint of the proportion of wounds that had healed at 20 weeks was 
considered in line with a recent RCT of DFUs (Edmonds et al., 2018). For DFU wounds, 9 wounds 
out of 36 (25%) had healed by 20 weeks with a mean time to healing of 69 days. For LU wounds, 
20 out of 71 (28%) wounds had healed at 20 weeks, with a mean time to healing of 70 days.  
Patient distribution  
The distribution of patient across the healthcare providers included in this study is shown in 
Figure 4.4. Most patients in this sample were seen by Practice Nurses (n =42); followed by 
Podiatrists (n =18) and Tissue Viability Nurses (n =17). Of these practitioners, Tissue Viability 
Nurses are overwhelmingly intended to support patients with LU; however, Podiatrists; who 
reported a similar number of patients in this sample, are included on the treatment pathway 





Figure 4.4. Distribution of patients across care settings 
Treatment switching  
To analyse the incidence of treatment switches, it was first necessary to identify visits that 
were eligible for having a treatment change. Wounds that were seen for a first assessment 
(n=27) or were recorded as healed (n=42) at the visit were excluded from the treatment 
switching analysis as these visits could not feasibly result in a switch as they represented either 
the commencement or cessation of treatment. After excluding these visits from the full 
number of 1050, this leaves 981 visits (93.43%) which could have had a potential switch.  
Of the visits eligible for a treatment switch, there was no change to the primary dressing at 199 
(21%) appointments; meaning that most visits resulted in a treatment switch, with 782 (79%) 
incidences of a switch. Thematic analysis was used to categorise the reasons given for 
treatment switching, with four major categories emerging. These were clinical reasons for 
switching, reasons arising from patient preferences, reasons that were external to both the 
clinician and patient, and incidences where no reason was given for the switch.  
Secondary to these categories, sub-categories were assigned to further understand the 
reasons that drove changes to treatment. For clinical reasons, sub-categories included a 
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becoming very sloughy or requiring debridement. Other clinical reasons were the presentation 
of an infection, deterioration or impaired wound healing, improvement of the wound, dressing 
related adverse events, or other miscellaneous reasons that were too disparate to categorise.  
External reasons fitted into two categories; the advice of other health care professionals was 
being heeded, or issues related to continuity of stock where a treatment switch was necessary 
as the health care provider could not find the same dressing to replace the one being removed. 
Patient preference reasons were divided into the following categories, intolerance to the 
current prescribed dressing, pain from their wound or current dressing, finding it difficult to 
self-care with the wound prescribed, or lifestyle reasons- for example wanting a waterproof 
dressing to allow them go swimming on holiday. Where no reason was provided, this was split 
into two categories, where there were notes provided but these did not explain the treatment 
switch, or where the notes section was left blank. Figure 4.5 shows the flow of patients through 
the treatment switching pathway, please note that due to rounding some columns may not 
equal exactly 100%. 
 




Table 4.14 lists the sub-categories generated through thematic analysis, also showing the 
number and proportion of patients that these constitute.  









(n = 211) 
Wound environment 74 35% 9.46% 
Infection 40 19% 5.12% 
Deterioration/impaired healing 37 18% 4.73% 
Wound improvement 35 17% 4.48% 
Dressing related 12 6% 1.53% 
Other 13 6% 1.66% 
Patient 
(n = 42) 
Lifestyle 15 36% 1.92% 
Pain 10 24% 1.28% 
Self-care 4 10% 0.51% 
Tolerance 13 31% 1.66% 
External 
(n = 41) 
Other HCPs  27 66% 3.45% 
Stock availability 14 34% 1.79% 
None 
(n = 488) 
Notes, but no reason 94 19% 12.02% 
Notes left blank 394 81% 50.38% 
 
Just over half of all visits did not have a treatment note in the record; these cannot be judged 
to truly be switches made with no reason. If these records are excluded from analysis, then the 
switches with no reason are the largest cohort, representing 24.23% of all switches with notes 
available. The smallest category of those with notes available is patient self-care (1.03%), 
where the patient had opted to treat themselves outside of the healthcare system. The full 
division of the subcategories, for records that had reasons listed are shown in Figure 4.6, please 





Figure 4.6. Proportion of patients in each sub-category of switching.  
Subgroup analysis 
Further subgroup analysis was focussed on the individual treatment centres that participated 
in the study. The rationale behind this stratification was that each centre may have an 
individual approach to switching, and recording switches, and to understand the divergence in 
care provided for DFU and LU. The centres are anonymised in this analysis as the purpose is 
not to reprimand any centre for their recording habits. The number of visits and wounds at 
each centre is shown in Table 4.15.  
Clinical  - Wound environment
Clinical - Infection
Clinical - Wound deterioration/impaired healing
Clinical - Wound improvement






External - Information/direction from other HCPs
External - Stock availability
None - Notes, but no reason
0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00%




Table 4.15. Wound records at each treatment centre 
Centre Wounds (n) Records (n) Mean visits per wound 
A 14 91 6.5 
B 42 427 10.2 
C 10 82 8.2 
D 25 312 12.5 
E 16 138 8.6 
 
Comparisons between the healing rates, measured as the proportion of wounds healed at 20 
weeks, at the centres and the incidence of treatment switches are shown in Figure 4.7. Centre 
A had a low switch rate and high healing rates for DFU and LU; Centre B conversely had a high 
switching with a low unexplained rate; and achieved average LU healing compared with the 
group. Centre C had a high switch rate with very high unexplained rate and a very low healing 
rate for DFU. Centre D had a moderate switch rate and showed high DFU healing and average 
LU healing rate; and Centre E had a moderate switch rate with low numbers of unexplained 
switches and recorded a medium-high healing rate for LU.
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This section discusses the results presented by each study, compare the different wound 
aetiologies and subgroups and look for areas of interest in the results where a level of 
significance has been reached, or not, and discuss reasons for this. This section also looks at 
the results of each study in context of the wider body of work presented in this thesis and look 
to external sources to compare these results with contemporary data. Each study is discussed 
in turn, given the fact that they have been carried out independently.   
4.6.1 PRO study 
The PRO study included results from 94 patients in total; however, one record was unavailable 
for analysis given that the patient had not answered if they had a DFU or LU and this was 
essential for stratifying and analysing the data. In terms of patient characteristics, there were 
some key differences between the DFU and LU groups. The DFU patients were younger, with 
a mean age of 64.05 vs the LU patients’ mean age of 71.12. This was an expected result, as 
often LU patients can be older, given the fact that these ulcers are frequently related to 
vascular inefficiency, a consequence of aging, compared to DFU patients, who have ulcers 
caused by their diabetes; which is not necessarily a disease caused by age. This result also aligns 
with the outcome of clinical SLR presented in chapter 2; which found that DFU patients were 
younger, and that LU patients were more likely to be female.  
The ratio of males to females in the cohorts was different across the groups with the LU 
patients having a near even split of the sexes, whereas the DFU group included more males. 
Typically, when comparing to clinical studies LU wounds are perhaps more common in females, 
which is not represented here. When considering DFU patients, it is interesting to note that, of 
those who answered, 50% of the group had been through a previous amputation relating to 
their DFU.  
Contrary to expectation, given the high likelihood of recurrence for patients with a LU (Clarke-
Moloney et al., 2014), there were higher numbers of new wound sites reported by LU patients, 
with 27 new wounds vs 23 recurrences. Contrary to this, the DFU group had a more even split 
with 21 new wounds vs 20 recurrences. When also considering the numbers of single versus 
multiple wounds, the two wound aetiologies differ majorly; the majority of DFU patients, 




reported having more than one wound concurrently at the time of completing the 
demographic questionnaire. This difference could be attributed to the different wound 
processes; with a DFU forming often as the result of irritation or abrasion from outside, and a 
LU being formed by a breakdown of the vascular system inside the legs.  
Using the EQ-5D tool, DFU patients had a lower mean index score when compared to patients 
with a LU, 0.55 vs 0.64 respectively; implying that patients with a DFU have a worse QoL than 
patients with a LU. When considering the VAS, the DFU patients also rated their health as 
worse, with a mean of 59.88 versus a mean of 63.63 for LU patients. The results presented 
here indicate a worse QoL than found in the sucrose octasulfate RCT; that reported utility 
scores of 0.63-0.69. This may be influenced by the RCT setting; where patients may have 
renewed optimism and hope for their wound healing (Edmonds et al., 2018). Additionally, 
patients who are recruited into clinical trials are subject to rigorous entry criteria; which often 
exclude patients with comorbidities. The cross-sectional real-world data presented here is 
arguably more representative of the general population; as patients were recruited 
sequentially, with no specific conditions other than having a DFU or LU.  
When analysing the CWIS results, it is apparent that less of the respondents completed all 
pages of the tool. This could be because this tool is much longer than the generic EQ-5D, 
however this is often the case for disease specific tools, as they have more areas related to the 
disease of interest. The CWIS uses a methodology where it asks patients to first state if they 
had experienced a certain phenomenon, and then how stressful this experience was. Where a 
patient did not read the explanatory text at the top of the page, they often left the second 
page blank as it appeared to be a duplicate of the previous page. Confusion could be mitigated 
in future with clearer explanation, or clinician guidance when administering the tool.  
Both patient groups, DFU and LU responded similarly to the CWIS tool; with the well-being 
element the lowest scored, followed by the physical symptoms and daily living, and then social 
life being the least impacted. The well-being element was also scored the lowest when CWIS 
was used in an earlier RCT (Jeffcoate et al., 2009). It is heartening that despite the suppressed 
well-being of the patients, they still reported generally good social lives; and, the fact that 




When analysing the subgroups of mild, moderate, severe and closed wounds it has been noted 
that a pattern emerges from the EQ-5D index scores. The severe wounds score the lowest, 
indicating worse QoL, followed by moderate wounds and then mild wounds. For LU, the same 
is true, with severe wounds shown to be worse than mild wounds. These results imply that 
there is a patient benefit associated with healing a wound before it can be deemed severe, 
according to a matrix of duration versus size.  
The VAS scores from EQ-5D do not follow this same pattern; which can be construed that 
patients do not consider their QoL as impaired compared to the general population sample 
used to create the value set. Mild and severe DFUs scored nearly the same (61.11 and 61.15 
respectively) and moderate LUs scored the best using this ranking.  
When considering CWIS, the severe wounds scored worse across well-being, physical 
symptoms and daily living, and social-life for both DFU and LU. For the well-being score, which 
was the most affected of all the domains when considering the whole sample, severe DFUs 
scored 43.41/100 and severe LUs 40.54/100. 
The anomaly in this study comes when considering the closed wounds subgroups, which in 
addition to being reported in higher numbers than expected, also reported much poorer QoL 
outcomes than expected. When using EQ-5D, closed wounds scored index scores of only 0.01 
higher than a severe wound for both DFU and LU wounds. This implies that a closed wound is 
worse than having either a mild or moderate wound and is only fractionally better than a 
severe wound.  
It was considered that the ongoing treatment for LU patients might explain both the larger 
sample size and the suppressed QoL scores. A theory could be that a patient is focussed on 
their wound closing and being ‘healed’ that when they realise, they must continue to wear 
compression systems, and even potentially attend clinics, they are disheartened and report 
lower QoL scores; however further research would be needed to validate this speculation. 
Given that all responses were collected from treatment centres, the patients with a closed 
wound are logically still attending appointments, which implies the wound is only just closed 
or they have a further complication. These scores provide an interesting insight into the patient 
experience and could be the basis for further research into long term QoL outcomes for 




4.6.2 Chart extraction 
In total, there were 107 wounds included in the chart extraction; of these, many more were 
LU, (n=71) but enough DFUs were included to allow for analysis (n=36). When considering 
patient characteristics, this study has separated the wound aetiologies, but for analysing the 
incidence of treatment switching all results have been aggregated. This was decided due to the 
drive to understand the incidence and reasons for switching across centres- as there is no 
specific guidance or directive for either DFU or LU which could be examined here.  
Patients with a LU had more appointments recorded on average, with a mean number of visits 
at 11.16, 56% higher than the number of visits recorded for DFU patients. This could be due to 
the need to maintain compression and higher levels of exudate present in these wounds 
compared to DFUs which tend to be smaller. 
The LU sample measured here was predominantly collected from practice nurses, a non-
specialist care provider often based at a local GP. This is most likely representative of the 
treatment received by most LU patients, with some having community nurse visits at home, 
and some being seen by a specialist tissue viability nurse if their wound continues to be 
problematic. The DFU patients in the sample collected for this study were mainly treated by a 
podiatrist; which is a specialist service. Further research, using a larger sample, could test if 
this is representative of all DFU patients, given the small numbers of DFU patients (n=36) 
included here.  
When considering healing outcomes, this study recorded the proportion of wounds that had 
healed by 20 weeks of treatment. This endpoint was selected to compare with an RCT of DFU 
wounds; which has the same endpoint (Edmonds et al., 2018). Using endpoints from real-world 
data is also important as it is widely recognized that the performance of medical interventions 
in real life does not exactly mirror the performance measured in RCT.  
For LU patients included in this sample, 20/71 (28%) of wounds had healed at 20 weeks; which 
can be compared unfavourably to results in prospective trials reporting healing rates of 
between 84%-93.3% (Turner and Ovens, 2017; Towler et al., 2018). This demonstrates the vast 
difference in healing rates observed in a trial setting versus the real-world, known as the 
evidence-efficacy gap (Nordon et al., 2016). Similar, but not as divergent is the comparison for 




is comparable to the control arm in an RCT which used a neutral dressing and standard care 
and achieved 30% healing by 20 weeks (Edmonds et al., 2018). However, when looking at the 
active arm in the RCT, 48% of patients using the sucrose octasulfate dressing had healed within 
20 weeks. However, no guidance currently exists mandating use, so treatment switching 
remains prevalent in standard care.  
The incidence of treatment switching was measured at 79% of eligible visits. This means nearly 
4 in 5 visits by a patient result in a new dressing. Most manufacturers recommend that their 
dressing be used for a period of weeks before it is changed, given that dressings can be 
impregnated with an active ingredient which may take time to work. It is also interesting to 
note that the 20-week healing rate is demonstrably lower in the chart extraction than in the 
RCTs included in the clinical SLR presented in chapter 2. An implication here is that using the 
same dressing, any dressing, for the time stipulated in the study protocol may improve wound 
healing rates, but this needs to be explored further.  
The relationship between treatment switching and healing outcomes has been explored across 
the centres included in this study. The centre with the lowest incidence of treatment switching, 
Centre A, recorded the highest proportion of patients healed at 20 weeks in this sample; and 
had the fewest number of visits per wound. Conversely; the centre that reported the highest 
number of treatment switches, Centre C, with nearly 40% unexplained switches, also reported 
the lowest healing rate at 20 weeks. This implies a relationship between unexplained, and 
potentially unnecessary, switches and healing outcomes, however a limitation of this study was 
that this is not an inferential statistical analysis and is only indicative of a trend. It is 
recommended that future research investigates this correlation further; however it may 
present ethical difficulties to investigate in a prospective RCT and so a larger-scale real-world 
study of a retrospective dataset might be better suited.  
When carrying out the thematic analysis, it became apparent that many of the notes had been 
left blank; with no reason given to explain the treatment switch. After discussion with the 
supervisory team about how to categorise these records, it was agreed that they could not be 
assumed to be switches with no reason; as they may have had a valid reason, but this was not 
captured for one of many reasons (no time, lack of staff training, under resourcing, and so on). 




still the largest sub-category included with nearly ¼ of all records not providing a reason for 
the treatment switch.  
Given that so many records were left blank, and thus excluded from analysis; further research 
could explore this topic using more in-depth qualitative methods to understand if the 
treatment notes are a full record; or if the absence of a switching rationale may be a due to 
other external factors. 
It is important for clinicians and decision makers to be aware of real-world evidence that is 
collected from patients, as this can be used to give additional insights into factors that are 
important that could have previously been overlooked. An example of this is the suppressed 
QoL reported by patients with closed wounds. This could be due to a variety of reasons but 
given that this study did not anticipate this result, no additional data can be provided. This 
result should highlight that when treating a patient with a LU, as important as it is to heal a 
wound, it is also important to treat a patient holistically to ensure their overall health status is 
not impacted.  
The large uncertainty present in the management of chronic wounds is not to be 
underestimated; this chart extraction shows that patient outcomes do not match those seen 
in clinical trials, and in the case of LU- are wildly different in the number of healed wounds. 
This issue requires addressing to improve the QoL of patients and drive down costs for the 
healthcare system. Clear and mandated guidance delivered via robust medical education 
campaigns could help to empower health care professionals into choosing interventions that 
could reduce healing time for patients; which is key to reducing the burden of DFU and LU.  
 
4.7 Chapter summary 
This chapter has provided an insight into the patient experience in a real-world setting. The 
PRO study has highlighted the substantial burden on QoL for patients with DFU and LU whilst 
the chart extraction has shown how real-world healing rates compare with those collected in 
a clinical trial setting.  
The objectives of study 3 were to establish QoL issues and utility scoring for patients with DFU 




than their physical functioning or social life as measured by the wound specific PROM CWIS. 
The use of a generic PROM, EQ-5D has enabled a quantification of the QoL burden felt by DFU 
and LU patients, which has been shown to be worse than several other chronic conditions. 
Both aetiologies of wound are much more burdensome for a patient across all recorded 
outcomes when they become severe. A wound becomes severe as it gets bigger, or as time 
passes without healing. This measurement is easy to apply and non-intrusive for a patient and 
given the differences in the EQ-5D index score measured between mild and severe wounds; 
this matrix is precise enough to highlight patients who experience worse QoL than others.  
The objectives of study 4, the chart extraction was to understand and investigate the incidence 
of and reasons behind treatment switching of a primary dressing. This study highlighted the 
widespread prevalence of treatment switching, with nearly 80% of visits resulting in a change 
of treatment. When analysing the reasons behind switches; 50% of records did not have any 
note explaining the switch; and after excluding these, records with notes but no reason for the 
switch were the largest identified sub-category. This researcher asserts that the prevalence of 
switching, and perhaps switching without clinical reasoning could be responsible for the 
reduced healing outcomes seen in patients in the real-world compared to a clinical trial setting; 
given that within a clinical trial the standard care given is truly standardised; which cannot be 
said for the sample examined in this chart extraction.  
The next chapter presents the economic evaluation of the PMM dressing; using multiple 
methods of cost-modelling and leveraging data that has been produced by the earlier studies 
in this thesis.  
 
4.8 Dissemination  
The results of these studies have been presented at conference, at The International Society 
of Pharmacoeconomics and Outcomes Research (ISPOR) in the United States, Baltimore 2018 
and at the ISPOR conference in Europe, Barcelona, 2018. The abstracts and posters are 





Chapter 5 Economic evaluation of a protease modulating matrix dressing 
versus a neutral dressing for treating DFU and LU.  
 
5.1 Introduction 
The economic modelling that is presented in this chapter is the culmination of the work 
presented so far in this thesis. The systematic reviews (study 1) presented in Chapter 2 
explored the clinical effectiveness of different protease-modulating matrix dressings (PMM), 
economic outcomes associated with topical wound care interventions, and the variance 
associated with ‘standard care’ for diabetic foot ulcers (DFU) and leg ulcers (LU). The Delphi 
methodology expert panel (study 2) discussed in Chapter 3 highlighted the views of clinicians, 
that there is a need for interventions that offer better solutions for patients, they also 
supported the use of PMM dressings in addition to standard care to improve wound healing 
outcomes. Patients themselves were consulted in chapter 4, via the patient reported outcomes 
(PRO) study (study 3), which elicited patient experiences via the use of validated tools. Chapter 
4 also investigated treatment switching via the chart extraction study (study 4); which 
examined multiple sites and care settings in the United Kingdom (UK).  
Economic models are frequently based on the results of a clinical trial; however as shown by 
the comparison of outcomes of the patients included in the chart extraction (study 4), 
outcomes that are seen in the real-world are often very different. This thesis has repeatedly 
noted that the guidance associated with the use of dressings for chronic wounds such as DFU 
and LU is sparse, with limited advice on the clinical benefits offered by dressings and a focus 
on cost-minimisation.  
This chapter presents the economic evaluation (study 5) and the economic models used to 
evaluate the clinical and cost outcomes associated with using a sucrose octasulfate dressing; 
an example of a PMM dressing. The schematic of the five studies can be seen in Figure 5.1, 





Figure 5.1. Economic evaluation within the PhD framework 
This chapter begins with a literature review of economic models examining the PMM dressing 
with proven clinical benefit to patients (sucrose octasulfate). Then an explanation of the 
methods used is provided, and the results presented followed by discussion and conclusions.  
The rationale for undertaking further cost analysis in relation to the use of PMM dressings, 
particularly the sucrose octasulfate dressing is discussed in the following section. A full cost-
utility analysis relevant to the UK is possible given the data collected in this PhD thesis. Utility 
scores calculated from EQ-5D in the PRO study, study 3, are used to value health states used 
by cost-utility modelling.  
 
5.2 Background 
5.2.1 Existing economic evaluations of PMM dressings  
Economic modelling in the field of wound care is abundant, as demonstrated by the results of 




allows the assessment of an intervention to society, considering the benefits offered and the 
costs incurred. Where budgets are finite, as in the United Kingdom (UK) National Health Service 
(NHS), economic modelling can help to guide decision making regarding the distribution of 
resources; towards a scenario where maximal health gains are achieved from a set budget. The 
research in chapter 2 examined the clinical and economic benefits of PMM dressings, and 
found that the sucrose octasulfate dressing, offered significant improvement (p < 0.05) in 
clinical and patient outcomes in patients with DFU or LU, in terms of wound area reduction or 
time to wound closure for patients (Meaume et al., 2012; Munter et al., 2017;Edmonds et al., 
2018). 
To explore the economic modelling already undertaken, specifically related to this dressing 
formulation, a scoping literature search using a systematic approach was undertaken to 
understand the economic benefits that could be gained by use of the sucrose octasulfate 
dressing. Additionally, this review included consultation with the manufacturer, given that 
sometimes economic models are commissioned but not published. Consultation with the 
manufacturer allowed the addition of unpublished economic analyses to inform this literature 
review.  
The search strategy used is included in Appendix C. Four studies were identified (see Table 5.1). 
All four studies were included; resulting in four economic modelling studies that examined the 




Table 5.1. Summary of studies in economic review of sucrose octasulfate dressing 
Study name 




Maunoury et al., 
2017 
(Unpublished) 
Maunoury et al., 
2017 
(Unpublished) 
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results.  












Proportion at 40% 
WAR by week 8 
  
Wound closure at 
20 weeks.  47.6% 
vs 29.8% for 
comparator 
WAR > 40% at 8 





responder in 8 
weeks. Greater 
cost/ patient but 
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Average gain of 
0.74 life-years 
without ulcer and 
0.18 QALYs, 
saving €34,215 
per patient  
Average gain of 
5.9 life-years 
without ulcer and 




A critical review of the included models was carried out, using a tool adapted from the 
literature, and used by the National Institute for Health and Care Excellence (NICE) when 
assessing devices in their Medical Technologies Evaluation process (MTEP) (Drummond and 



































Study design Tree Markov  Markov Markov  
Research question stated?  Yes No Yes Yes  
Economic importance of research stated?  Yes Yes Yes Yes 
Viewpoint of analysis stated and justified?  Yes Yes Yes Yes 
Rationale given for interventions?  Yes Yes Yes Yes 
Comparators clearly described?  Yes Yes Yes Yes 
Evaluation justified? Yes No Yes Yes 
Effectiveness estimates sources stated?  Yes No Yes Yes 
Design/results of effectiveness source given? Yes No Yes N/A 
Primary outcome measure clearly stated?  Yes Yes Yes Yes 
Stated method to value health states/benefits?  No No Yes Yes 
Resource quantity separate from unit cost?  Yes No Yes Yes 
Stated method for estimating quantities/costs?   No No Yes Yes 
Currency & price data recorded?  Yes No Yes Yes 
Adjustments for inflation/currency conversion?  N/A Yes Yes Yes 
Model choice and key parameters justified?  Yes No Yes Yes 
Time horizon of cost and benefits stated?  Yes Yes Yes Yes 
Discount rate stated and justified?  N/A Yes Yes Yes 
Approach to sensitivity analysis described?  Yes Yes Yes Yes 
Choice of variables for sensitivity justified?  Yes No Yes Yes 
Ranges of parameters varied stated?  Yes No Yes Yes 
Incremental analysis reported?  Yes Yes Yes Yes 
Outcomes disaggregated and aggregated?  No No Yes Yes 
Answer to the study question given?  Yes N/A Yes Yes 
Conclusions align with data?  Yes Yes Yes Yes 




Of the included economic models; the critical analysis shows that in general the reporting was 
clear and thorough; with enough detail included to replicate the models if necessary- meaning 
it is appropriate to accept the results. All the models were in favour of the sucrose octasulfate 
dressing; showing dominance, greater response rate, or a cost saving. However; none of the 
models included data from the UK and were based on data from either Germany or France. 
Models that are designed for use by NICE are more likely to be representative and 
generalisable to DFU and LU patients in the UK.  
5.2.2 Approaches to economic evaluation 
There are several different types of economic analyses that can be carried out to evaluate an 
intervention. These include; budget-impact, cost-minimisation, cost-effectiveness and cost-
utility. They all have slightly different methods and are suitable for different scenarios and are 
of benefit to different stakeholders; financial analyses that focus on the short-term impact to 
the bottom line are likely to be of more interest to planners and NHS commissioners than a 
lifetime model showing cost and clinical outcomes over the next ten or twenty years.  
Budget-impact models (BIMs) are a type of economic analysis often performed by Health 
technology assessment (HTA) bodies to understand the expense associated with implementing 
a new intervention in a defined patient population. BIMs measure financial impact usually over 
3 to 5 years, in line with forecasts made to plan resource allocation. The comparison made by 
a BIM is usually with standard care; that is- the continuation of current practices without the 
new intervention; and then the costs if the new intervention were introduced.  
In England, NICE uses BIMs alongside evaluations of cost-effectiveness and has guidelines for 
manufacturers for carrying out the analysis (NICE 2013). In early 2017, NICE announced a 
budget-impact test for new interventions that it assesses (NICE, 2017). If a drug is set to cost 
more than £20 million in any of the first three years of use then commercial discussions are 
mandatory to balance the impact of the spend on the rest of the NHS (NICE, 2017). The role of 
budget-impact analyses is increasingly recognised for reimbursement decisions, not just in 
England, but also in other countries such as Australia and France (Mauskopf et al., 2013; Ghabri 
et al., 2017).  
Methodological discussions regarding BIMs discuss to what extent disease complexity, 




Mauskopf, 2018). Complex treatment pathways can be difficult given the calculations required 
for a budget-impact analysis using templates developed by NICE (NICE, 2015). Additionally, the 
link between a long-term cost-effectiveness model and calculating short term budget-impact 
can present a challenge as it has been argued that the cost-effectiveness threshold value 
should cancel out most budgetary issues (Claxton et al., 2015). However, high cost drugs with 
a large budget-impact may be discriminated against using this method and keeping budgetary 
impact separate from cost-effectiveness modelling may be a preferred option (Ghabri and 
Mauskopf, 2018). BIMs are a simple and effective way of assessing impact on the NHS’ financial 
bottom line; but are best carried out in tandem with other analyses that allow for more in 
depth modelling of the patient pathway.  
Cost-minimisation analysis, like budget-impact analysis, focusses on the cost of treatment, and 
any associated consequences. With cost-minimisation, the patient outcomes of using the 
technologies being compared has either been proven to be, or is assumed to be, equivalent 
(Dakin & Wordsworth, 2011). The goal of this type of analysis is to identify the least costly 
treatment option to achieve the desired health outcome. This method is useful when operating 
in a climate of economic stagnation- with strained budgets for healthcare. A limitation of cost-
minimisation analysis is the assumption of equivalence; some treatments can offer patient 
benefits that are not reflected in a clinical outcome - for example less frequent dosing or easier 
administration. Differences between interventions, including patient preference, could 
possibly be overlooked if only the clinical outcome and cost is the driver for decision making. 
The inherent uncertainty of declaring interventions as the same, led to Briggs and O’Brien 
pronouncing ‘the death of cost-minimisation analysis’ in 2001 due to the rare circumstances in 
which it is appropriate (Briggs and O'Brien, 2001). A decade on from this declaration, a review 
found that cost-minimisation was still in use, and by using it instead of cost-effectiveness could 
lead to an over or under estimation of uncertainty (Dakin and Wordsworth, 2011) leading to 
less precise models to inform decision making. The move away from cost-minimisation analysis 
can be seen in the economic SLR presented in chapter 2; with only one study, the oldest, using 
this method (Apelqvist & Ragnarson-Tennvall, 1996).  
Cost-effectiveness analysis not only evaluates the cost of a proposed intervention; but also, 
the outcomes that it offers to a patient. Cost-effectiveness is a method where the cost-per-




2011). Decision makers strive for optimal resource allocation, which would be the 
maximisation of outcomes and minimisation of costs. Cost-utility modelling is a subset of cost-
effectiveness, where the outcome is communicated in quality adjusted life years (QALY), rather 
than a natural unit specific to a disease area. QALYs can be calculated using utility scores; which 
are collected using tools such as EQ-5D, as presented in study 3; and this allows for a 
comparison across disease areas using a common unit (Peters et al., 2014).  In England, NICE’s 
main driver of decision making is asserted to be cost-effectiveness; measured using an 
incremental cost-effectiveness ratio (ICER), the ratio of the difference in costs over the 
difference in quality adjusted life years expressed as the cost per QALY gained (Rawlinds and 
Culyer, 2004).  
A combined approach using a cost-effectiveness analysis and BIM would help to mitigate the 
limitations of each method. A BIM provides information on the real-world costs associated with 
adopting a new technology, which can be lacking in a cost-effectiveness analysis. However, a 
cost-effectiveness analysis provides a more precise cost-per-patient; and more detail in terms 
of individual patient journeys using health states with transition probabilities instead of whole 
population aggregated statistics.  
5.2.3 Economic evaluation in the UK 
NICE has a threshold for the ICER of an intervention; with the upper end being £20,000-30,000 
per QALY gained (NICE, 2017). This is far from a definite threshold, with interventions for 
children, disadvantaged populations and very serious diseases given more flexibility (Rawlins 
et al., 2010). Different disease areas also attract varied median ICERs, that is- the cost at which 
an ICER has 50% probability of being accepted - which could be argued to be more 
representative of the true upper boundary of the threshold (Dakin et al., 2014). This begins at 
£20,356/QALY for respiratory disease, with a maximum of £55,512/QALY for musculoskeletal 
disease- surprisingly was higher than the level for cancer, where a cost of £46,082/QALY had a 
50% probability of acceptance.  
A review of NICE decision-making showed that cost-effectiveness, when considered in isolation 
and relative to the threshold, correctly predicted decision making in 82% of cases (Dakin et al., 
2014). This implies cost-effectiveness is a key factor, if not the sole driver of decision making; 




affairs also being of importance to NICE alongside government pressures relating to decision 
making.  
A report published in 2015 by the Centre for Health Economics at the University of York 
asserted that the cost per QALY threshold set by NICE was too high. This would mean that the 
approval of new drugs relative to the £20,000-30,000 per QALY threshold would be causing an 
opportunity cost to the healthcare system. Relative to NHS expenditure, they found that just 
£13,000 of NHS spending results in one QALY added to the lives of patients (Claxton et al., 
2015). For every additional £10 million in NHS spend, a net loss of 440 QALYs would be 
incurred. The implication of this research is that spending by the NHS based on NICE 
recommendations of new interventions is not representative of value for money if judged 
against the current threshold. 
The economic modelling required for a NICE submission for Medical Devices is slightly different 
to the HTA process for pharmaceutical products. For MTEP the economic evaluation carried 
out by the manufacturer needs to not only prove cost-effectiveness but is held to a higher 
standard in that the new intervention must be dominant to standard care. Dominance is 
achieved when an intervention provides greater outcomes for a reduced cost. NICE suggests 
performing a simple analysis such as budget-impact or cost-consequence/cost-minimisation 
(NICE, 2017). The appraisal of medical devices establishes the clinical outcomes offered by a 
new intervention and then reviews the associated costs. Patient outcomes, including 
improvements in quality of life (QoL), can be hard to determine for certain devices, such as 
stents and implants. For innovations that do offer advantages to patients, these methods may 
not be extensive enough to truly demonstrate the full value of an intervention. The economic 
evaluation presented in this chapter (study 5) was carried out concurrent to a MTEP of the 
sucrose octasulfate dressing.  
5.2.4 Economic evaluation of DFU and LU 
Economic analyses of DFU and LU interventions are already explored in Chapter 2, through the 
economic SLR. This review concluded that interventions that are of a higher acquisition cost 
may in fact be cost-effective when considering improvements in patient outcomes and the 
reduction of the need for ongoing care; the cost of which is approximately £7000 per annum 




standard care; as the studies did not have an aligned treatment protocol for the patients in the 
comparator arm.  
For DFU, the costs associated with ulceration are considerable, not only in terms of cost, but 
also when considering patient QoL. A persistent complicated DFU presenting with critical 
ischaemia or infection can become life-threatening and can lead to an amputation for a patient 
to avoid sepsis or death because of their ulcer. These situations are quite extreme, but their 
prevalence is growing (Narres et al., 2017). Patients with DFU are likely to suffer from multiple 
comorbidities which could also interfere with the healing process and incur additional costs to 
the healthcare system (Iglay et al., 2016).  
LU patients are at less of a risk of amputation, with ischaemia not being such a problem. 
Patients who present with a LU have issues with their cardiovascular system which has led to 
the breakdown of the veins, usually in the lower leg. Like DFU patients, these patients probably 
have comorbidities that result in additional visits to Health Care Providers (HCPs); causing a 
financial burden to the NHS, but also a treatment burden for the patient themselves, who may 
be required to see multiple HCPs in addition to having their wound dressings changed on a 
regular basis. The PRO study (study 3) in chapter 4 indicated that patients with a LU are 
approximately 10 years older on average than a patient with a DFU. Their increased age 
impacts the healing process, and patients with LUs tend to have wounds of a long duration that 
can persist for many years (Rai, 2014). 
The current standard care protocols for DFU and LU have common components, including use 
of dressings, debridement and infection control, additionally LUs require compression and DFU 
management includes offloading. Regarding dressings, current UK guidance does not indicate 
a preferred dressing for patients with these wounds (NICE, 2016). Improved wound care 
management that results in better healing outcomes is asserted to be cost saving. Additionally, 
patients could experience a QoL benefit due to improved healing rates and reduced healing 
time. 
5.3 Study aims 




− To evaluate outcomes and costs associated with the use of PMM interventions in DFU 
and LU.  
The objectives of study 5 were: 
− To examine the economic impact of PMM dressings, namely the sucrose octasulfate 
dressing,  
− To generate evidence that could be used to support a change in clinical guidelines.  
5.4 Methods 
In accordance with the preference indicated by the NICE process and methods guides, this 
economic evaluation employs both budget-impact and cost-effectiveness models (NICE, 2013). 
Using both methods addresses the range of requirements that are needed to assess a new 
intervention- both the short-term financial impact that is better presented using a BIM, and a 
more complex cost-effectiveness model of the long-term outcomes associated with DFU and 
LU. LUs have a high recurrence rate, with the wound bed often breaking down or new wound 
sites emerging. DFUs have been associated with an increased risk of mortality for patients; 
especially with more severe wounds that have resulted in an amputation; 50% of patients do 
not survive more than 5 years after amputation because of a DFU (Weledji and Fokam, 2014). 
Due to this risk of recurrence, and the associated downward trend in patient health, DFU and 
LU can be considered as long-term problems that warrant modelling over a longer period- 
justifying the use of a cost-effectiveness model.  
BIMs have become more relevant in the persistent climate of economic austerity that is 
currently being endured by the NHS. The presence of budget cuts and a need to ensure that 
maximal outcomes are achieved with minimum budget has led to a need to understand the 
costs associated with adopting any new technology; in a short-term manner focussing on the 
bottom-line figures. The NHS needs to continue the uptake of new innovations but cannot 
justify doing so if there is a risk of sacrificing the standard level of care on offer to patients. To 
assess affordability; a BIM is a simple, succinct method of doing so, in contrast with a more 
complicated cost-effectiveness analysis.  
This section first explains the methods and data used by the BIMs built to assess the economic 




Following this; an explanation of the methods used to build the cost-effectiveness model is 
presented; again, to assess the economic impact of these technologies. The use of both 
methods should allow a multi-dimensional view; and is reflective of the process used by NICE 
in health technology assessment.  
5.4.1 Budget-impact models 
The following sections explore the methods used to create the BIMs for DFU and LU, which are 
both examples of static BIMs; where patients do not change health states and mean values are 
applied to the total population.  
BIM programming 
The BIMs for DFU and LU were created using the Microsoft Excel software, saved in a .xlsm 
format to enable macros in the document. The calculations were carried out in a sheet away 
from the main page, to enable clarity and transparency of the formulae. Macros were used to 
programme navigation of the document, and for a reset button to restore default values, 
meaning a user can customise the input values for individual scenario analysis. 
BIM time horizon 
In keeping with the budget-impact method; the models here present a 5-year view; with data 
presented for the current year, and years 1-4. A 5-year view is likely the longest time horizon 
that is feasible for a BIM; as the uncertainty around the extrapolation of data increases for 
every year into the future. Results for the cumulative budget-impact are presented at both 
year 3 and year 5; to counter the exponential uncertainty present in the model. A BIM is 
primarily a financial planning aid; and NHS financial plans and costing tools account for 5 years; 
so, the 5-year figure has been presented to provide information that is of relevance to decision 
makers.  
BIM assumptions 
The BIMs for DFU and LU make several assumptions in their calculations. Assumptions are a 
key part of economic modelling methods; due to the impossibility of forecasting accurately on 
an individual per-person basis. The models assume that all patients with a DFU and LU are 
treated the same; with the sole difference of primary treatment dressing. This assumption is 
justified as the models wish to assess the impact of the use of the PMM dressing, and not the 




entirely reflective of the way that patients flow through the system in real life; as presented in 
study 4, the chart extraction, it allows the difference detected to be attributed to the impact 
of the study dressing. Additionally the outcomes data that power the model is drawn from the 
Reality study (Münter et al., 2017), a large pooled analysis of several observational trials, the 
result of multiple care pathways aggregated.  
An assumption in the BIM is that all patients are the same and follow the same healing 
trajectory. The BIM does not distinguish between patient groups and does not allow for 
subgroup analysis as the budget-impact is calculated nationwide, including all patients 
currently diagnosed, or to be diagnosed in the time horizon, with a DFU or LU. Again; this 
assumption is justified given the data sources. The data powering the resource use and healing 
time has been aggregated from large patient groups (Munter et al., 2017; Guest et al., 2018a; 
Guest et al., 2018b). Included in these real-world evidence studies is a range of patients that 
are arguably representative of the wider patient population as they are not dictated by the 
rigorous inclusion and exclusion criteria of a randomised controlled trial (RCT).  
BIM population  
The two indications explored by this thesis are distinct and separate, needing different 
approaches in identifying patients that would be eligible for treatment with the sucrose 
octasulfate dressing. First, the method used to identify the DFU population is explained, 
followed by the method used by the LU model.  
DFU BIM population 
For the BIM focussing on DFUs a population funnel has been applied to filter down from the 
entire population of the UK to identify the patients for whom the PMM dressing would be a 
relevant intervention. This is represented in Figure 5.2 which shows the layers of filtration 
applied to the population.  
First, the total UK adult population was ascertained using figures from the Office for National 
Statistics (ONS); neither DFU nor LU are expected to be seen in children and young people and 
this assumption was validated by experts (Office for National Statistics, 2016). A multiplier to 
account for annual population growth was applied, of 0.57% per year, to ensure that the model 




The process then identified all patients in the UK who are currently diagnosed with diabetes, 
this figure was obtained from the Quality and Outcomes Framework (QOF) official statistics, 
captured by the NHS and published by NHS Digital measuring prevalence of various diseases 
including diabetes (NHS Digital, 2017). There are estimates of the number of people living with 
diabetes who remain undiagnosed; but these have not been included in the BIM due to the 
uncertainty associated with accounting for these patients. In addition to the prevalent 
population published by the QOF, this BIM also included new patients who received a diagnosis 
for diabetes during the time horizon, the incident population. A large observational study 
performed in 2012 of more than 50,000 subjects over approximately 10 years was used to 
derive the figure that was used in the model, 0.6% (Andersen, 2012). 
To calculate the number of diabetic patients who develop an ulcer annually; incidence figures 
of 5-7% were obtained from literature, and this has been applied to the figure of diabetic 
patients to estimate the number of people per year who have a DFU (Kerr, 2012).  
 
Figure 5.2. DFU BIM population funnel 
 
LU BIM population 
For the BIM that concentrated on patients with LUs, the same method was applied to identify 
the relevant patients. Figure 5.3 shows the stages that were used to filter the population.  
In the same way as the DFU BIM, the LU model used the total UK population of adults aged 18 
and over. Children were once again excluded because LUs are not seen in children in routine 
practice, and the prevalence figures used only included an adult population (Office for National 
Statistics, 2016). Again, a multiplier of 0.57% per year was applied to the total population to 
account for growth (Office for National Statistics, 2017).  
Total 
population
• United Kingdom aged 18 and over
• Including annual population growth
Diabetic 
population
• Estimated prevalence plus annual incidence
Target 
population




To identify the patients in the UK who had a LU, a study of the adult population from The Health 
Improvement Network (THIN) database was consulted (Guest et al., 2015). This study 
examined 1000 patients who had a wound in a one-year period; the study categorised LUs as 
either being of venous, arterial, mixed or unspecified aetiology.  
The focus of this thesis is on LUs, however, wounds determined as venous in origin only 
accounted for approximately a third of the LUs reported by the study. It was decided to include 
these figures in the prevalence estimate for LU as all LUs would be eligible for treatment with 
the PMM dressing. This gave an estimate of 1.5% annual prevalence among the adult UK 
population.  
 
Figure 5.3. LU BIM population funnel 
BIM treatment mix 
The treatment mix input denotes what proportion of the eligible population receives the new 
technology versus the proportion that continues with standard care alone. For both the DFU 
and LU model, it was decided to assume 0% uptake in the first year. This would then be 
indicative of the full population costs of using standard care to treat a DFU or LU.  
After discussion with the manufacturer about projected uptake, figures for years 2-5 were 
determined as shown in Table 5.3. The same proportions were used for both DFU and LU.  
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BIM effectiveness calculations 
Both the DFU and LU models rely on a mean days-to-healing calculation, as opposed to a 
proportion of wounds healed by a set time-period. Using a mean time to healing calculation 
enables the model to calculate the number of weeks that a patient is using resources from the 
NHS to manage and heal their wound. Each of the models used a different source, due to the 
availability of data. These are shown in Table 5.4.  
Table 5.4. Effectiveness data used in BIMs 
Indication Dressing 





Sucrose octasulfate dressing 
and standard care 
112 
(Edmonds et al., 
2018) 
Neutral dressing and standard 
care 
210 
(Edmonds et al., 
2018) 
Leg ulcer 
Sucrose octasulfate dressing 
and standard care 
115 (Münter et al., 2017) 
Neutral dressing and standard 
care 
135 (Münter et al., 2017) 
 
The study used to determine the effectiveness for the DFU model was the Explorer study, a 
double-blind RCT of 260 patients over 20 weeks that measured full wound closure as the 
primary endpoint (Edmonds et al., 2018). RCTs are the gold-standard of clinical evidence, at 
the top of several evidence classifications ranking the reliability of sources (Guyatt et al., 2008).  
An RCT was not available to provide data on full wound closure for LUs being treated with the 
sucrose octasulfate dressing. Due to this, a large pooled analysis of observational studies was 
used to compare the active dressing with the control of standard care (Münter et al., 2017). 




BIM resource use  
Due to the two indications, DFU and LU, having differing interventions required to treat them; 
the two models have varied resource use, in terms of the HCPs and devices used. First, the 
resource use and associated costs are shown for the DFU model and subsequently for the LU 
model.  
DFU BIM resource use 
For the BIM focussed on DFU, items that were considered fell into the broad categories of 
hospital resource use, outpatient visits, medications prescribed, and devices used. A 
retrospective cohort analysis of 130 patients in the UK with a newly diagnosed DFU was 
analysed to estimate the annual resource use of managing a DFU in the NHS (Guest et al., 
2018b). The study presented the costs over a one-year period, and to obtain a mean weekly 
cost for each item, the figures were divided by 52 to provide a figure that could be applied to 
the number of patients in the model. Using figures from a single source was deemed to provide 
internal validity, as all resource items have been measured from the same cohort of patients 
in routine practice. 
The unit costs of the items were determined from a range of sources, all specific to the NHS. 
This included the NHS schedule of reference costs 2015-16, the manual of Unit Costs of Health 
and Social Care 2016 and the British National Formulary (BNF) Drug Tariff for medications and 
devices. The items and the number of units per week calculated from the Guest (2018) paper 
are shown in Table 5.5.  
LU BIM resource use 
For the BIM focussed on LU, items that were considered fell into the same categories of 
hospital resource use, outpatient visits, medications prescribed, and devices used as in the DFU 
BIM. A retrospective cohort analysis of 505 patients in the UK with a LU was analysed to 
estimate the annual resource use of managing a LU in the NHS (Guest et al., 2018a). The study 
presented the costs over a one-year period, and to obtain a mean weekly cost for each item, 
the figures were divided by 52 to provide a figure that could be applied to the number of 
patients in the model. As per the DFU model, the Guest et al., (2018b) study provided all 




The unit costs of the items were determined from the same range of sources as the DFU BIM 
with all costs specific to the NHS. This included the NHS schedule of reference costs 2015-16, 
the manual of Unit Costs of Health and Social Care 2016 and the BNF Drug Tariff for 
medications and devices. The items and the number of units used, calculated from the Guest 




Table 5.5. DFU BIM weekly resource use and unit cost 
Item /Week Unit cost Cost source 
Hospitalisation 
Admissions 0.0050 £2330.52 National Schedule 2015/16. Weighted 
average of Diabetic lower limb complication 
codes 
Amputation 0.0042 £5507.72 National Schedule 2015/16. Weighted 
average of Amputation codes 
Outpatient visits 
GP 0.0385 £38.00 PSSRU: Unit Costs of Health & Social Care 
2017. Table 10.3b 
Hospital  0.0398 £138.00 PSSRU: Unit Costs of Health & Social Care 
2017. Chapter 7.1 
Podiatrist 0.0050 £45.00 PSSRU: Unit Costs of Health & Social Care 
2017. Chapter 13, band 6 
Practice nurse 0.1560 £50.05 National Schedule 2015/16. Weighted 
average of TVN codes 
Community nurse 1.0979 £14.65 PSSRU: Unit Costs of Health & Social Care 
2017. Chapter 10, band 6 
Medications and devices 
Antibiotics 0.1383 £1.57 BNF: Cefalexin, 1 course 28 tablets 
Analgesia 0.4398 £2.07 BNF: gastro-resistant Diclofenac Sodium, 1 
course 28 tablets 
Primary dressing 2.8458 £4.20/ 
£3.13* 
Urgo Medical dressing costs 
Secondary dressing 2.8458 £3.13 Urgo Medical dressing costs 
*Two costs available as two treatment arms in the model- either using the sucrose 
octasulfate dressing or a neutral dressing.  
Abbreviations: BNF: British National Formulary, GP: General Practitioner; PSSRU: Personal 




Table 5.6. LU BIM weekly resource use and unit cost 
Item /Week Unit cost Cost source 
Hospitalisation 
Admissions 0.0039 £452.18 National Schedule 2015/16. 
GP 0.0323 £38.00 PSSRU: Unit Costs of Health and Social Care 
2017. Table 10.3b. 
Hospital  0.0169 £138.00 PSSRU: Unit Costs of Health and Social Care 
2017. Chapter 7.1. 
Outpatient visits 
Practice nurse 0.2952 £50.05 National Schedule 2015/16. Weighted 
average of TVN codes. 
Community nurse 2.8683 £20.43 PSSRU: Unit Costs of Health and Social Care 
2017. Chapter 10, band 6. 
Medications and devices 
Antibiotics 0.1140 £1.57 BNF: Cefalexin, 1 course 28 tablets. 
Analgesia 0.1767 £2.07 BNF: gastro-resistant Diclofenac Sodium, 1 
course 28 tablets. 
Primary dressing 2.8860 £4.20/ 
£3.13* 
Urgo Medical dressing costs. 
Secondary dressing 2.8860 £3.13 Urgo Medical dressing costs. 
Compression 0.7163 £6.96 Urgo Medical. K-Four kits, 15-25cm. 
Hosiery 0.2656 £11.73 Urgo Medical. Thigh length, class 2 
compression hosiery. 
*Two costs available as two treatment arms in the model- either using the sucrose 
octasulfate dressing or a neutral dressing.  
Abbreviations: BNF: British National Formulary, GP: General Practitioner; PSSRU: Personal 




BIM data analysis 
The methods used for the budget-impact calculations were the same for both the DFU and LU 
models. Once the population funnel has been used to establish the number of patients eligible 
for treatment with the new intervention, the proportions assigned in the treatment mix are 
applied to reach a final figure for each treatment arm, namely using sucrose octasulfate and 
standard care versus just standard care alone. For years 2-5 the multiplier was applied to 
simulate population growth, using the total population figure from the previous year (Office 
for National Statistics, 2017). The calculations used are presented below and are supported by 
the International Society of Pharmacoeconomic and Outcomes Research (ISPOR). 
For DFU in year 1 
(((𝑇𝑜𝑡𝑎𝑙𝑃𝑜𝑝 × 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒) + (𝑇𝑜𝑡𝑎𝑙𝑃𝑜𝑝 × 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒))
× 𝐷𝐹𝑈 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒) × 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑚𝑖𝑥
= 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑒𝑙𝑖𝑔𝑖𝑏𝑙𝑒 𝑓𝑜𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
(ISPOR, 2017) 
 
For DFU in years 2-5 
((((𝑃𝑟𝑖𝑜𝑟𝑌𝑒𝑎𝑟𝑇𝑜𝑡𝑎𝑙𝑃𝑜𝑝 × 1.0057) × 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)
+ (𝑇𝑜𝑡𝑎𝑙𝑃𝑜𝑝 × 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒)) × 𝐷𝐹𝑈 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒) × 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑚𝑖𝑥
= 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑒𝑙𝑖𝑔𝑖𝑏𝑙𝑒 𝑓𝑜𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
(ISPOR, 2017) 
 
For LU in year 1 
(𝑇𝑜𝑡𝑎𝑙𝑃𝑜𝑝 × 𝐿𝑈𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒) × 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑚𝑖𝑥 





For LU in years 2-5 
((𝑃𝑟𝑖𝑜𝑟𝑌𝑒𝑎𝑟𝑇𝑜𝑡𝑎𝑙𝑃𝑜𝑝 × 1.0057) × 𝐿𝑈𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒) × 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑚𝑖𝑥 
= 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑒𝑙𝑖𝑔𝑖𝑏𝑙𝑒 𝑓𝑜𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
(ISPOR, 2017) 
Using the mean days until healing as ascertained through literature for both the sucrose 
octasulfate dressing and standard care, this is divided by 7 to represent the number of weeks 
taken for healing. Multiplying the healing time by the number of patients in each arm gives the 
number of weeks in treatment for each intervention over the year.  
(
𝑀𝑒𝑎𝑛 𝑑𝑎𝑦𝑠 𝑡𝑜 ℎ𝑒𝑎𝑙𝑖𝑛𝑔
7⁄ ) × 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑒𝑙𝑖𝑔𝑖𝑏𝑙𝑒 𝑓𝑜𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
= 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑤𝑒𝑒𝑘𝑠 
(ISPOR, 2017) 
Once the number of treatment weeks has been established for both arms in both the DFU and 
LU models, the cost of the resource use is calculated. For each item in the category, the unit 
cost was multiplied by the number of units used, and again multiplied by the number of 
treatment weeks when using each intervention.  
(𝑢𝑛𝑖𝑡 𝑐𝑜𝑠𝑡 × 𝑤𝑒𝑒𝑘𝑙𝑦 𝑢𝑛𝑖𝑡 𝑢𝑠𝑒) × 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑤𝑒𝑒𝑘𝑠 = 𝑎𝑛𝑛𝑢𝑎𝑙 𝑐𝑜𝑠𝑡 
(ISPOR, 2017) 
The sum of all annual costs, for both treatment arms, results in the annual budget-impact. This 
is calculated for the full 5-year time horizon.  
The results of the BIM can be expressed in various ways. The results can be presented as an 
annual figure or aggregated for the first 3 or 5 years. This study presents a cost-comparison 
result; which is the difference between the costs associated with the new intervention versus 
the costs of 100% of patients remaining on standard care for each of the 5 years. A mean cost 
per patient across the entire population eligible for treatment, regardless of the intervention 
they were assigned is also calculated.  
Further to the financial results that are presented, the health outcomes can also be calculated 




population; and again, using a comparison against a scenario where 100% of patients receive 
standard care, the number of days with open ulcer that are gained/avoided by uptake of the 
sucrose octasulfate dressing can also be calculated.  
BIM sensitivity analysis 
Sensitivity analyses were carried out to test the certainty of the results presented by the BIM. 
This consisted of pre-defined scenario analyses that differed dramatically from the base case 
to stress-test the inputs in the model.  
The variations in the inputs for the scenarios that have been tested in the DFU model in 
addition to the base case are shown in Table 5.7. These scenarios have been chosen and 
designed to test the impact of making certain parameters either more conservative or more 
optimistic for the sucrose octasulfate dressing.  
Table 5.7. DFU BIM scenarios for sensitivity analysis 
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Mean days to 
healing: sucrose 
octasulfate 
115 120 125 85 100 130 
Mean days to 
healing: standard 
care dressing 





Similarly, the scenarios that were tested in the LU model in addition to the base case are shown 
in Table 5.8. These scenarios have been chosen and designed to test the impact of making 
certain parameters either more conservative or more optimistic for the sucrose octasulfate 
dressing.  
Table 5.8. LU BIM scenarios for sensitivity analysis 
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Cost of standard 
















Mean days to 
healing: sucrose 
octasulfate 
112 120 150 90 160 100 
Mean days to 
healing: standard 
care dressing 
210 150 180 220 190 170 
 
5.4.2 Cost-effectiveness analyses 
Next in this chapter, the methods for the cost-effectiveness analyses (CEA) carried out for DFU 
and LU is explained. Both cost-utility analyses in this thesis are examples of Markov models; 
with patients moving through different health states associated with different costs and health 




nature of the condition; presenting repetitive events, such as wound recurrence and moving 
between health states such as infection or complication can be difficult using a decision tree 
model that is better when a disease has a single clear direction of travel. 
CEA programming 
The cost-utility models for DFU and LU were created using Microsoft Excel software, saved in 
a .xlsm format to enable macros in the document. The front-end of the models has a menu 
powered by the Visual Basic Application (VBA) code that joins the cover page, input pages, 
calculations pages and the presentation of results. The calculations tab includes links to the 
Markov chains that power the model to enable transparency for a user. Due to the complexity 
of the calculations, one-way deterministic and probabilistic sensitivity analyses have been 
carried out using macros programmed in the backend of the document.  
CEA Model structure  
The models are constructed using the Markov analytical framework. Markov models use 
different health states that represent the possible outcomes of an intervention when used in 
a specific indication. Health states are mutually exclusive, so a patient can only reside in one at 
a time and subjects move between health states at the end of a cycle, which is a pre-defined 
length (York Health Economics Consortium, 2019). The transition matrices provide the 
probabilities that drives the movement between health states, and these are calculated from 
relevant clinical data drawn from the clinical studies of the sucrose octasulfate dressing 
(Meaume et al., 2012; Edmonds et al., 2018). The structure, health states and transition 
probabilities were validated by clinical experts, discussed in section 5.4.3. 
DFU CEA model structure 
In the cost-utility model designed to examine the impact of the sucrose octasulfate on the DFU 
population, there are 3 core health states which are: ‘open wound’, ‘closed wound’ and 
‘complicated wound’. The model also makes a distinction for patients who have not had an 
amputation- ‘pre-amputation’, versus patients who have an amputation ‘post amputation’. 
Open wounds are defined as DFUs that have been diagnosed by a clinician; this health state 
makes no distinction between wounds of different ages or sizes, between new wounds or a 
recurrence of a previous DFU or between wounds that are following different healing 




an amputation, where the wound has been closed in the operating room by the surgeon. 
Complicated wound is a health state that represents wounds that are infected, but also those 
that have become ischaemic or gangrenous. Complicated wounds are defined as those who 
have been identified as being very unlikely to follow a normal healing trajectory. An amputation 
is often a consequence of a persistent complicated DFU, in this model amputation is not a 
health state, but has been programmed as an event, which incurs the cost of surgery, 
subsequent physiotherapy and a prosthesis, in the case of a major amputation. 
The model structure assumes that a patient starts with an open wound; and this wound can 
either close or become complicated. Complicated wounds can either heal, or result in an 
amputation event, causing a patient to move to the post-amputation block of health states. 
After amputation, patients have a closed wound (healing by primary intention, closed at the 
operating room); or their wound persists as an open wound (post-amputation) which could 
either close, or become complicated before closure. Closed health states have a risk of 
recurrence; which is higher post-amputation. In all health states, patients have a risk of death. 





Figure 5.4. DFU cost-utility model structure 
LU CEA model structure 
In the cost-utility model developed for LU patients, there health states follow a similar, but 
simplified version of the health states for DFU. This is because LUs are not as high risk for 
amputation as DFU; due to complications with diabetes, such as neuropathy or the heightened 
risk of ischaemia.  
In the model, patients were in one of the following health states: ‘open wound, ‘closed wound’ 
and ‘infected wound’. Open wound refers to any LU that has not healed, and is not infected, 
regardless of wound duration, size or other risk factors associated with healing. Closed wounds 
are those that have achieved full healing, confirmed by a clinician. Wounds that are infected 
present with symptoms such as excessive slough or exudate, itching, increased pain; these 
wounds are also not going to heal unless the infection is resolved using medications, either 
oral prescriptions or a topical application of an antimicrobial agent.  
In the model designed for this study, a patient starts with an open wound; which can either 




infected wound health state. Wounds that are infected incur higher costs to the healthcare 
system and result in lower QoL for the patient. The infection, when treated, resolves and the 
patient returns to the open wound health state. From here, a wound can then close and the 
patient has healed. LUs have a high chance of recurrence, so patients can move from the closed 
wound state back to the open wound state. In all health states, patients have a risk of death. 
The model structure is shown in Figure 5.5. 
 
Figure 5.5. LU cost-utility model structure 
CEA model features 
Both models, DFU and LU, had a base case time-horizon of 1 year. This was chosen as it best 
represents one wound episode for a patient. Another factor is that for a shorter time horizon, 
there is less of a need to extrapolate clinical trial data, which can cause inherent uncertainty in 
a model with a longer time-horizon. To allow for transparency and clarity, both excel models 
had the functionality to change the time horizon, a user could choose to see results for: 6 
months, 1 year, 2 years, 5 years and 10 years. The longer time-horizons would allow an 
observation of long-term health and cost-consequences, however, are associated with higher 
uncertainty than the base-case of 1-year.  
Discounting of future costs and outcomes was applied at 3.5% beyond the first year, in line 
with instruction in the NICE methods guide (NICE, 2013). The perspective applied to the model 




transport and productivity losses. Using the perspective of the NHS, the models only applied 
direct medical costs. The cycle length was determined to be 1 week, which is informed by 
clinical practice and validated by expert opinion. Wound status can change in a short period of 
time, so a longer cycle length would not be representative of the real-world.  
CEA assumptions 
Methods using the Markov framework necessitate the use of assumptions with regards to 
certain aspects of the patient characteristics, treatment pathway and resource use. These 
assumptions are necessary to restrict calculations to those which could have an impact on the 
outcomes. Assumptions need to be reasonable and justifiable in their use, as they apply for all 
patients included in the model. All the assumptions built into the economic models presented 
here have been validated by experts as discussed in section 5.4.3 
Both models assumed that all patients begin in the open wound health state. For the DFU 
model, there is the ability to determine the proportion of the population that has already had 
an amputation and begins in the post-amputation block.  This assumption is because patients 
with a closed wound are not treated and are not likely to be under treatment. The reality of 
the situation is that many wounds are recurrences, as shown in the PRO study (study 3) in 
Chapter 4. This assumption is unlikely to impact the results and is reasonable and justifiable.  
Another assumption applied to both the DFU and LU model is that the deceased health state 
does not incur any costs. There may be some costs billed after a patient’s death in actuality- 
but for the purposes of the model, costs are applied at the time of resource use.  
For the DFU model, there is an assumption that all patients who have an amputation were 
previously in the complicated health state and a regular open DFU does not pose a risk of 
amputation. This assumption has been validated externally by clinicians who confirmed that a 
wound would not undergo an amputation without persistent infection or critical ischaemia. 
With regards to amputation, the DFU model also assumes that an amputation can only occur 
once. In real-world practice, there is a risk of patients who have had an amputation having to 
undergo further amputations, either on the same limb or bilaterally. This assumption was 
applied as the model base case was one year, and for a patient to undergo an amputation more 




For the post-amputation health-states, the DFU model makes some assumptions around 
resource use. For patients who have undergone amputation, which is divided into either major 
or minor amputation, it was assumed that every patient would require some physiotherapy. 
Due to difficulties with mapping the level of physiotherapy required for each type of 
amputation, a uniform figure was applied to all amputations. This assumption has been 
validated by clinicians who work with patients after an amputation because of a DFU. Similarly, 
the model assumes that the provision of a prosthesis would only be available after a major 
amputation; this assumption was informed by a NICE costing report that measured resource 
use associated with DFUs (NICE, 2015).  
In some cases, it is necessary to make assumptions in the absence of data. When this is the 
case, it is preferable to make conservative assumptions that are unlikely to have a misleading 
impact when interpreting the results of the cost-utility model. In the DFU model, it was 
assumed that a closed wound would have the same estimated resource use in both the pre- 
and post-amputation blocks. This is a conservative assumption as consultation with clinicians 
implied that closed wounds post-amputation could incur higher costs. However, no data or 
literature could be found to support a differentiation; so, the assumption was to keep these 
the same.  
The LU model had less assumptions than the DFU model, in main part because it used a 
different model structure, where patients followed a simpler pathway. The assumption that all 
wounds that were infected would not move directly to healing unless the infection was 
resolved was validated by clinicians. Another assumption regarding infections that was 
validated by the consulted clinical experts was the fact that the average infection lasted 2 to 4 
weeks, so the model used a 3-week infection period as a base case.  
CEA clinical parameters and variables 
The models used data from the clinical evidence to inform the cost analysis. A core element of 
the Markov model framework is to create a transition probability matrix; a table to inform the 
model of the chance of moving to one health state from another. For the DFU model, transition 
probabilities were calculated using data from patients in the Explorer study. These patients 
also had a confirmed neuro-ischaemic DFU, and at baseline there were no statistically 




The LU model used transition probabilities calculated using data from patients in the Challenge 
study (Meaume et al., 2012). These patients also had a LU with no statistically significant 
differences between the two study arms at baseline. Prior to calculating the transition 
probability, probability and hazard rates were estimated. This was calculated as below, where 
P equals probability: 




(Briggs et al., 2006) 
The annual probability for each transition was then calculated as below, where r equals hazard 
rate, and u equals cycle length: 
𝐴𝑛𝑛𝑢𝑎𝑙 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 1 − exp(−𝑟𝑢) 
(Briggs et al., 2006) 
The weekly probability for each transition was then calculated as below: 
7 × 𝐴𝑛𝑛𝑢𝑎𝑙 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 
365.25
 
(Briggs et al., 2006) 
In both the DFU and LU model, the transition probabilities do not change over time; and are 
assumed to be representative of patients with wounds of varying duration. The studies that 
the transition probabilities were derived from included patients with wounds of varied 
duration. For a DFU, the mean duration was 7.3 months with standard deviation of 6.5 and for 
LU, a mean duration of 15.1 months with standard deviation of 8.7 (Meaume et al., 2012; 
Edmonds et al., 2018).  
The relative efficacy of each treatment arm was derived from the studies. The Explorer study 
which examined patients with a DFU measured wound healing as the primary endpoint, so no 
extrapolation calculations were necessary. Conversely, for LU, the Challenge study did not 
measure full wound healing as an endpoint of the study and measured Relative Wound Area 
Reduction (RWAR) as a surrogate endpoint for the healing rate. In the published literature 




healing at 24 weeks (Kantor and Margolis, 2000). A 2008 paper found that the majority of LUs 
exhibited surface area reduction via an exponential decay model and provided a formula to 
calculate the healing rate from the initial measured change in wound area (Cardinal et al., 
2008). This formula is as below:  
𝐻𝑒𝑎𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 (%) =  
𝐿𝑁(1 − 𝑀𝑒𝑎𝑛 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 %)
𝑊𝑒𝑒𝑘𝑠
 
(Cardinal et al., 2008) 
With regards to the patient characteristics, the Explorer study informed the DFU model about 
patient age at inclusion and amputation history (Edmonds et al., 2018). The Challenge study 
informed the LU model about patient age at inclusion (Meaume et al., 2012). Age at inclusion 
is an important parameter as it determines the rate of age-related mortality applied to the 
cohort.  
All-cause mortality among diabetic foot patients was informed by data from the Third Annual 
Report of The National Diabetes Foot Care Audit (NHS Digital, 2018). At 12 weeks, 520 patients 
were confirmed deceased from a cohort of 22,653. This data was transformed into weekly 
transition probabilities as per the above calculations. For patients with LUs, the literature does 
not show a higher mortality rate when compared with control (Nelzen et al., 1999). Considering 
this; a weekly transition for standard age-related mortality has been calculated for patients to 
move into the deceased health state (Office for National Statistics, 2018).  
The risk of recurrence was calculated for the DFU model and the LU model. The DFU model 
was informed by a prospective follow up of 73 patients over 3 years, where 42 patients 
experienced a recurrent DFU (Dubský et al., 2013). The LU model used another prospective 
follow up of patients using standard care; over 12 months, 16.1% of patients had experienced 
a recurrent ulcer (Clarke-Moloney et al., 2014).  
All variables used in the DFU and LU cost-utility models can be found in Appendix C. 
CEA Resource use 
To establish relevant resource use data for the management of DFU and LU by the NHS; a 
search of the literature was undertaken. After an appraisal of the identified studies it was found 




cost-utility modelling in the present study.  The same studies that were identified as relevant 
for the BIMs were utilised for the cost-utility analyses (Guest et al., 2018a; Guest et al., 2018b). 
Using the same sources for resource use can be argued to provide enhanced internal validity 
of the CEA and BIMs that make up this economic evaluation.  
For DFU, the retrospective real-world evidence study using the THIN database was chosen to 
estimate health resource use for healed, unhealed and amputated wounds (Guest et al., 
2018b). Not only did this study include multiple health states, but it was also published shortly 
before the development of these cost models, meaning that it is data is the most up to date. 
However, this study did not present any standard deviation of the mean values in the results, 
meaning that a generic ±30% was used in sensitivity analysis. A second source of data, NICE 
costing report for DFU provided information about NHS costs and usage assumptions for 
patients that had experienced an amputation (NICE, 2015).  
For LU, the paper that reported on 505 patients with a LU in the THIN database was used (Guest 
et al., 2018a). This paper was selected due to the provision of health state estimates, and this 
data is again the most recently published so is likely to be of most relevance to provide 
information on decision making for the NHS. For the LU paper, standard deviation of the mean 
was provided for the resource use estimates, which were used in sensitivity analysis. 
Neither of the included papers included absolute values for health resource use for infected 
wound or complicated wound health states; these were aggregated with the unhealed health 
states for both DFU and LU. To combat this, and to provide a differentiation between the 
resource use for open and complicated/infected wounds, the published values were varied 
around the mean to estimate resource use for open and complicated/infected wounds. 
Despite not revealing the values, the publications do explain that open DFUs cost 67% less than 
infected/complicated DFUs and open LUs cost 69% less than infected LUs. 
Table 5.9 shows the weekly resource use for the DFU health states and Table 5.10 for the LU 
health states. These figures have been derived by transforming the reported annual values into 
weekly values (*7/365.25).  
For DFU these figures were adjusted for the reported difference in open and 




wounds to cost 67% less. For LU the adjustment for open and infected health states was to 
multiply by 0.475 and 1.525 respectively, to allow the open wounds to cost 69% less.  
This method of variation let to certain anomalies and expert opinion questioned the use of 
antibiotics in a non-infected/complicated health state. The sensitivity analysis for these items 
included testing the use of 0 antibiotics, unless in the infected or complicated health states, to 
mitigate the uncertainty arising from this method.  
The use of secondary dressings was informed by data retrieved from the chart extraction study 
presented in chapter 4. This data showed that in open DFUs and infected DFUs 22% and 9% 
fewer secondary dressings were used than primary; and in open LUs and infected LUs 57% and 
30% fewer secondary dressings were used than primary. 
Table 5.9. DFU weekly resource use for health states 











Admissions 0.0002 0.0006 0.00 0.0144 0.0433 0.00 
GP 0.0239 0.0718 0.0294 0.0158 0.0473 0.0294 
Outpatient 0.0192 0.0577 0.0196 0.0433 0.1298 0.0196 
Podiatrist 0.0032 0.0095 0.0040 0.0017 0.0052 0.0040 
Practice Nurse 0.0998 0.2994 0.0937 0.0826 0.2478 0.0937 
Community Nurse 0.8103 2.4309 0.3789 0.5869 1.7608 0.3788 
Antibiotics 0.0795 0.2386 0.0627 0.1204 0.3612 0.0627 
Analgesia  0.3268 0.9805 0.2410 0.1324 0.3972 0.2410 
Primary dressing 2.0800 6.2400 1.0392 1.5084 4.5251 1.0392 
Secondary dressing 1.6224 5.6784 0.8106 1.1765 4.1178 0.8106 






Table 5.10. LU weekly resource use for health states 
LU weekly resource use 
(item units) 
Open Infected Closed 
Hospital admission 0.0002 0.0006 0.0002 
GP 0.0155 0.0496 0.0134 
Hospital outpatient 0.0094 0.0301 0.0025 
Practice Nurse 0.1480 0.4749 0.0709 
Community Nurse 1.4159 4.5424 0.6635 
Antibiotic prescriptions 0.0559 0.1793 0.0324 
Analgesia prescriptions 0.0876 0.2809 0.0397 
Primary dressings 1.5452 4.9570 0.5065 
Secondary dressings 0.6644 3.4699 0.2178 
Compression 0.5586 1.7919 0.3471 
Hosiery 0.2184 0.7006 0.1098 
 
CEA Unit costs 
Unit costs for resource use were collected from published data sources. Like the BIMs, the 
costs were split into: Hospital inpatient, outpatient visits, medication and devices. Additionally, 
for the DFU model. one-off costs associated with an amputation event were costed from 
published literature.  The resources, unit costs and data sources for the DFU model can be seen 
in Table 5.11 and the resources, unit costs and data sources for the LU model are shown in 









Table 5.11. DFU cost-utility model unit costs 
Item Cost Source 
Admissions £2330.52 National Schedule 2015/16.  
GP £38.00 PSSRU: Unit Costs of Health and Social Care 2017. 
Hospital  £138.00 PSSRU: Unit Costs of Health and Social Care 2017.  
Podiatrist £45.00 PSSRU: Unit Costs of Health and Social Care 2017.  
Practice nurse  £50.05 National Schedule 2015/16. 
Community nurse £20.43 PSSRU: Unit Costs of Health and Social Care 2017.  
Antibiotics £1.57 BNF: Cefalexin, 1 course 28 tablets 
Analgesia £2.07 BNF: gastro-resistant Diclofenac Sodium, 28 tablets 
SO dressing £4.28 Urgo Medical dressing costs 
Neutral Dressing £3.13 Urgo Medical dressing costs 
Orthoses £525.00 NICE costing report: diabetic foot care (August 2015) 
Minor Amputation £4440.32 National Schedule 2015/16.  
Major Amputation £9269.23 National Schedule 2015/16.  
Physiotherapy £532.80 
NICE costing report: diabetic foot care (August 2015). 
£15,230,000/28585 patients. 
Prosthesis £2876.00 
NICE costing report: diabetic foot care (August 2015). 
£16,968,000/5900 patients. 
Abbreviations: BNF: British National Formulary; PSSRU: Personal Social Services Research 










Table 5.12. LU cost-utility model unit costs 
Item Cost Source 
Admissions £452.18 National Schedule 2015/16.  
GP £38.00 PSSRU: Unit Costs of Health and Social Care 2017.  
Hospital  £138.00 PSSRU: Unit Costs of Health and Social Care 2017.  
Practice nurse (TVN) £50.05 National Schedule 2015/16.  
Community nurse £20.43 PSSRU: Unit Costs of Health and Social Care 2017. 
Antibiotics £1.57 BNF: Cefalexin, 1 course 28 tablets 
Analgesia £2.07 BNF: gastro-resistant Diclofenac Sodium, 28 tablets 
SO dressing £4.28 Urgo Medical dressing costs (UrgoStart) 
Neutral Dressing £3.13 Urgo Medical dressing costs (UrgoTul) 
Compression £6.96 Urgo Medical. K-Four kits, 15-25cm 
Hosiery £11.73 Urgo Medical. Thigh length, class 2 compression hosiery 
Abbreviations: BNF: British National Formulary; PSSRU: Personal Social Services Research 
Unit; SO: Sucrose octasulfate 
 
CEA utility scores 
To facilitate a cost-utility analysis, it is necessary to prescribe a utility score to the different 
health states in the model. The utility scores represent patient QoL. The two interventions are 
then compared not only on cost difference, but in the difference of outcomes expressed in 
quality adjusted life years. Utility scores can be derived from generic patient reported outcome 
measures; but the preference stated by NICE is to use EQ-5D (NICE, 2018). Study 3 of this 
thesis, presented in chapter 4, used EQ-5D to derive utility scores in a cross-sectional analysis 
of DFU and LU patients.  
DFU CEA utility scores 
For the DFU cost-utility model; the scores collected from the PRO study (study 3) in chapter 4 
are used as the base case for the health states. Due to the uncertainty, explained in chapter 4, 
in the closed wound group; the health states for a closed wound has been sought from 
literature (Redekop et al., 2004). The utility score given to the deceased health state is assumed 




Table 5.13. DFU health state utility scores 
Health states Utility score Source 
Open Pre-amputation 0.456 PRO study 
Complicated Pre-amputation 0.525 PRO study 
Closed Pre-amputation 0.797 (Redekop et al., 2004) 
Open Post-amputation 0.620 PRO study 
Complicated Post-amputation 0.554 PRO study 
Closed Post-amputation 0.498 (Redekop et al., 2004) 
Deceased 0.000 Assumption 
 
Additionally, in the DFU model; a disutility was applied after an amputation event to reflect the 
period after an amputation when a patient experiences pain and is possibly immobilised until 
they recover from the surgery. The disutility value, -0.28, was found in literature, and applied 
for a 4-week period after the amputation event (Clarke et al., 2002).  
LU CEA utility scores 
For the LU cost-utility model; the scores collected from the PRO study in chapter 4 are used as 
the base case for the health states. Due to the uncertainty in the results, explained in chapter 
4, the health states collected from the PRO study have been combined with existing utility 
scores sought from literature to provide a mean value (Palfreyman, 2008). The utility score 
given to the deceased health state is assumed to be 0; as per standard practice. The values 
used in the LU model are shown in Table 5.14.  
Table 5.14. LU health state utility scores 
Health states Utility scores Source 
Open wound 0.456 PRO study and (Palfreyman, 2008) 
Infected wound 0.525 PRO study and (Palfreyman, 2008) 
Closed wound 0.797 PRO study and (Palfreyman, 2008) 




CEA incremental cost-effectiveness ratios 
The results of the models will be presented using an incremental cost-effectiveness ratio (ICER) 
value. The ICER is a figure used extensively by NICE in the appraisal programmes to compare 
different interventions across disease areas. NICE has a stated willingness-to-pay threshold of 
£20,000 - £30,000 per QALY gained. For both the DFU and LU models the incremental cost-




(Briggs et al., 2006) 
CEA sensitivity analysis 
Uncertainty around assumptions and variable parameters in the models were tested by both 
one-way deterministic and probabilistic sensitivity analyses. Deterministic sensitivity analysis 
(DSA) is a method that varies a specific parameter to observe the changes on the output values 
caused by an individual factor, to see how ‘sensitive’ the model is to this parameter (York 
Health Economics Consortium, 2016). Probabilistic sensitivity analysis (PSA) is a different 
method and explores uncertainty around all parameters and the impact on the results; random 
sampling from set distributions is used in multiple runs of the model and the variance of the 
results is linked to the sensitivity of the model (York Health Economics Consortium, 2016). 
Using both methods together allows for a greater analysis of the results; DSA interrogates 
parameters individually to highlight the drivers of uncertainty, a result not produced by PSA; 
where the outcome is a distribution of outputs relative to the distribution of inputs. Arguably, 
PSA is a more real-world view; where all parameters are likely different for each patient 
presenting to the NHS.  
In this study, DSA was used first to identify key cost drivers. If a parameter caused more than 
5% variance to the base-case cost increment, it was determined to be a cost driver. Any 
parameter causing less than a 5% variance to the base case cost was excluded, and PSA was 
used to vary the remaining parameters using 1000 runs of the model. 
To perform both DSA and PSA, it is necessary to vary the parameters in the model. If the 




then this was used for the distribution. If this was not available for any variable, a 30% variance 
was applied; unless rationally another value should be used.  
To calculate the range from the standard deviation, the 68–95–99.7 rule was used; meaning 
that the range of 95% of the data was assumed to be within 2 standard deviations of the mean 
(Pukelsheim, 1994). For DSA the range was calculated, and minimum and maximum values set; 
no negative values were allowed, if the range was larger than the mean value the minimum 
was set at 0 and the maximum at the range value. For PSA, a stochastic was calculated using 
the mean and standard deviation; if this returned a negative value it was set at 0. Negative 
values were not allowed due to needing the model to be representative of real-world 
treatment; and in clinical practice it would not be possible for a patient to require a negative 
amount of resource in a week.  
The full list of ranges used to perform DSA and PSA on the DFU and LU cost-utility models are 
presented in Appendix C. The items in Table 5.15 were omitted from all sensitivity analysis as 
they were deemed to be constant; or in the case of minor amputations; this was dependent 
on the proportion of major amputations and was varied accordingly so the two values equal 
100%. Furthermore, any parameter that failed to cause more than 5% variance to the base 





Table 5.15. Items excluded from all sensitivity analysis 
Category Constant  
Hospital costs The cost of a hospital admission episode 
Outpatient costs 
The cost of a GP appointment 
The cost of a hospital outpatient appointment 
The cost of a Podiatrist appointment 
The cost of a Practice Nurse appointment 
The cost of a Community Nurse appointment 
Medication costs 
The cost of a prescription for antibiotics 
The cost of a prescription for analgesics 
The cost of a minor amputation 
The cost of a major amputation 
The cost of a course of physiotherapy 
The cost of a prosthesis 
Device costs 
The cost of a compression system 
The cost of a pair of hosiery 
The cost of a bespoke orthosis 
Dependent value The proportion of minor amputations 
 
5.4.3 Expert validation 
The cost-utility analyses presented here were validated by experts. Two external clinicians 
reviewed the model structure, the suitability of assumptions, the transition probabilities and 
the resource use levels and costs. These clinicians were involved in the expert advice panel 
using the Delphi methodology as reported in chapter 3. One was a Diabetologist who had 
extensive experience with patients with DFUs and the other a Vascular Surgeon who was an 
expert in treating LUs. In addition, two clinical experts who worked for Urgo Medical, the 
manufacturer of the sucrose octasulfate dressing were consulted, given their knowledge of the 
trials and expertise with the product and disease areas. The four clinical experts were sent a 
questionnaire to ascertain their opinions on key parameters of the model. They supported the 




regarding the resource use in different health states; however, this was addressed by 
extending sensitivity analysis to include the values suggested by the clinicians whilst retaining 
the literature values as the base case. The model structure and methods were also peer 
reviewed and validated by Health Economists; both within Manchester Met (FF & IO) and from 
an international partner (Creativ-Ceutical). Further to this, as presented in section 5.7, external 
validation from NICE and the External Assessment Centre (EAC) has been granted.  
The BIMs use lot of the same data as the cost-utility models with regards to the resource use, 
and have made some of the same assumptions, but were not individually validated by external 
clinicians due to time and resource considerations. These models were still reviewed by the 
two Urgo Medical clinical experts and by the Manchester Met Health Economics Professors (FF 
& IO).  
5.5 Results 
This economic evaluation of the sucrose octasulfate dressing consisted of using two different 
methods; budget-impact and cost-effectiveness. Both methods have been used to analyse the 
costs and consequences associated with DFUs and LUs. The different patient populations have 
been kept separate as the disease pathology, standard care, and expected outcomes differ 
drastically between the indications. The methods, parameters, inputs, and assumptions for the 
base-case analysis have been described in the previous section.  
This section presents the results of the economic models. Firstly, the results of the BIMs 
measuring the cost of introducing the sucrose octasulfate dressing into the standard of care 
for DFU and LU are explored. Following this; the results of the cost-effectiveness models for 
LU and DFU is presented.  
5.5.1 Budget-impact models 
The two BIMs allowed for an analysis of cost outcomes and health outcomes in the DFU and 
LU populations. The base-case results are presented, including the size of the eligible and 
treated populations; the cost outcomes include the total budget-impact per year and 
cumulatively at years 3 and 5; this is also presented as the per-patient cost of treatment, along 
with a cost comparison between the sucrose octasulfate dressing and a neutral alternative. 
Health outcomes are reported, which includes the number of days with ulcer, and the days 




DFU BIM population  
The mid-2016 population figure provided by the Office for National Statistics (ONS) was 
51,757,543; only including adults aged 18 and over (Office for National Statistics, 2016). The 
total population was subject to an annual growth of 0.57%, applied to the previous year total 
population (Office for National Statistics, 2017).  
The estimated prevalence of diabetes was 6.7% according to the Quality and Outcomes 
Framework (QOF) audit reported by NHS digital (NHS Digital, 2017). There is also an annual 
incidence rate of new diagnoses for diabetes, at 0.6% (Andersen, 2012). When a patient has 
diabetes, there is a 6% annual incidence of developing DFU (Kerr, 2012). Table 5.16 shows the 
results of applying the population funnel to reach the eligible DFU population for the current 
year until year 5. 




Year 2 Year 3 Year 4 Year 5 
Total population 51,767,543 51,770,494 51,773,445 51,776,396 51,779,347 
Prevalent diabetic 
population 
3,468,425 3,763,500 4,058,592 4,353,701 4,648,826 
Incident diabetic 
population 
295,075 295,092 295,109 295,125 295,142 
Total diabetic 
population 
3,763,500 4,058,592 4,353,701 4,648,826 4,943,969 
Patients who develop 
a DFU: The eligible 
population 
225,810 243,516 261,222 278,930 296,638 
 
From the eligible population, the pre-determined treatment mix was applied to obtain the 
number of patients who were treated with the sucrose octasulfate dressing and standard care, 
versus those receiving standard care alone. Table 5.17 shows the number of patients treated 








Year 2 Year 3 Year 4 Year 5 
Sucrose octasulfate and 
standard care 
0 36,527 65,306 111,572 177,983 
Standard care alone 225,810 206,88 195,917 167,358 118,655 
 
LU BIM population  
The LU model used the same total population figure as the DFU model, 51,757,543, as it also 
excluded people under the age of 18 from the model (Office for National Statistics, 2016). The 
same annual growth rate of 0.57% was applied to this model; to reflect the change in the 
national population of the UK (Office for National Statistics, 2017).  
The LU prevalence figure was derived from a whole population sample, and LUs are not only 
found in people with a specified co-morbidity, unlike DFUs that are only found in people who 
also have a diagnosis of diabetes. The estimated prevalence of leg ulceration was 1.5% of the 
adult population (Guest et al., 2015). Table 5.18 shows the results of applying the population 
funnel to reach the eligible LU population for the current year until year 5. 
Table 5.18. LU BIM eligible population 
 Current 
year 
Year 2 Year 3 Year 4 Year 5 
Total population 51,767,543 51,770,494 51,773,445 51,776,396 51,779,347 
Annual leg ulcer 
prevalence: The 
eligible population 
776,513 776,557 776,602 776,646 776,690 
 
From the eligible population, the pre-determined treatment mix was applied to obtain the 
number of patients who were treated with the sucrose octasulfate dressing and standard care, 
versus those receiving standard care alone.  Table 5.19 shows the number of patients treated 








Year 2 Year 3 Year 4 Year 5 
Sucrose octasulfate 
and standard care 
0 116,484 194,150 310,658 466,014 
Standard care 
alone 
776,513 660,074 582,451 465,988 310,676 
 
BIM cost outcomes 
The budget-impact is the total amount that hits the NHS budget for treating DFU and LU, 
respectively. The budget-impact is expressed as an annual cost; and as a cumulative amount 
at the end of years 3 and 5. In addition to budget-impact, the cost-consequence was calculated. 
This is a comparative analysis that compares the annual cost of introducing the new 
intervention with a scenario where standard care remains the same. To enable understanding, 
the cost-per-patient is also presented.  
DFU BIM cost outcomes 
The DFU BIM showed an increase in costs year-on-year until year 5. The costs of introducing 
the sucrose octasulfate dressing to the standard of care are shown in Table 5.20. The 
cumulative budget-impact at year 3 was found to be £1,177,375,87 and at year 5 was 
£2,064,669,169. The annual costs are also shown in Figure 5.6. 
Comparing the costs of introducing the sucrose octasulfate dressing with the cost of continuing 
standard care for all patients shows the cost-consequence associated with this intervention. 
The calculation uses the same treatment mix for the uptake of the new intervention.  The 
results of the cost comparison are shown in Table 5.21. The increased use of the sucrose 
octasulfate dressing was associated with cost savings when compared to the continuation of 
standard care for all patients.  
To translate the national costs represented by the budget-impact into a format more easily 
understood; the per-patient cost of treatment is also shown in Table 5.22. The figures have 
again been calculated using the same treatment mix as prescribed by the base-case. Should 




would be £1445.90, versus £1638.48 for standard care. The cost-consequence calculation 
shows that the introduction of this intervention would save up to £192.57 per patient per year.  
Table 5.20. DFU budget-impact results 
  Sucrose octasulfate 
and standard care 
Standard care Budget impact 
Current Year £0 £369,984,589 £369,984,589 
Year 2 £52,814,987 £339,145,463 £391,960,450 
Year 3 £94,425,456 £321,004,792 £415,430,249 
Year 4 £161,322,079 £274,211,863 £435,533,941 
Year 5 £257,346,017 £194,413,922 £451,759,940 
 
Table 5.21. DFU cost-consequence results 
  Budget impact Standard care Cost consequence 
Current Year £369,984,589 £369,984,589 £0 
Year 2 £391,960,450 £398,994,663 -£7,034,213 
Year 3 £415,430,249 £428,006,390 -£12,576,141 
Year 4 £435,533,941 £457,019,771 -£21,485,830 
Year 5 £451,759,940 £486,034,806 -£34,274,866 
 
Table 5.22. DFU per patient cost 
  Cost per patient 
Current Year £1,638.48 
Year 2 £1,609.59 
Year 3 £1,590.33 
Year 4 £1,561.45 





Figure 5.6. DFU budget-impact annual costs 
LU BIM cost outcomes 
The LU BIM showed a decrease in costs year-on-year until year 5. The costs of introducing the 
sucrose octasulfate dressing to the standard of care are shown in Table 5.23. The cumulative 
budget-impact at year 3 was found to be £6,767,184,844 and at year 5 was £10,382,732,268. 
The annual costs are also shown in Figure 5.7.  
Comparing the costs of introducing the sucrose octasulfate dressing with the cost of continuing 
standard care for all patients shows the cost-consequence associated with this intervention. 
The calculation uses the same treatment mix for the uptake of the new intervention.  The 
results of the cost comparison are shown in Table 5.24. The increased use of the sucrose 
octasulfate dressing was associated with cost savings when compared to the continuation of 
standard care for all patients.  
To translate the national costs represented by the budget-impact into a format more easily 
understood; the per-patient cost of treatment is also shown in Table 5.25. The figures have 








Current Year Year 2 Year 3 Year 4 Year 5





Should 100% of the population receive the sucrose octasulfate dressing, the annual cost per 
patient would be £1540.54.90, versus £3114.67 for standard care. This cost-consequence 
calculation shows that the introduction of this new intervention would save up to £1547.13 
per patient per year. 
Table 5.23. LU budget-impact results 
  Sucrose octasulfate 
and SoC 
SoC alone Budget impact 
Current Year £0 £2,418,583,307 £2,418,583,307 
Year 2 £179,447,709 £2,055,912,991 £2,235,360,700 
Year 3 £299,096,562 £1,814,144,275 £2,113,240,837 
Year 4 £478,581,777 £1,451,398,145 £1,929,979,922 
Year 5 £717,913,585 £967,653,916 £1,685,567,501 
 
Table 5.24. LU cost-consequence results 
  Budget impact Standard care Cost consequence 
Current Year £2,418,583,307 £2,418,583,307 £0 
Year 2 £2,235,360,700 £2,418,721,166 -£183,360,466 
Year 3 £2,113,240,837 £2,418,859,033 -£305,618,196 
Year 4 £1,929,979,922 £2,418,996,908 -£489,016,986 
Year 5 £1,685,567,501 £2,419,134,791 -£733,567,290 
 
Table 5.25. LU per patient cost 
  Cost per patient 
Current Year £3,114.67 
Year 2 £2,878.55 
Year 3 £2,721.14 
Year 4 £2,485.02 







Figure 5.7. LU budget-impact and cost-consequence 
BIM health outcomes 
In addition to a reduced cost to a healthcare system, it is important to calculate the patient 
impact of introducing a new intervention. The effectiveness measure that was used in the BIMs 
was the mean days to healing for the sucrose octasulfate dressing used in combination with 
standard care, and the mean days to healing recorded for standard care alone. The model 
calculated how many days that a patient has an open wound, and is therefore experiencing 
symptoms, and has calculated how many days of ulceration have been avoided by the 
introduction of the sucrose octasulfate dressing.  
DFU BIM health outcomes 
By introducing the sucrose octasulfate dressing, patients experience fewer days with an open 
DFU, because of the shorter mean time to healing. Table 5.26 shows the number of days with 
ulcer avoided by introducing the new intervention; the days with ulcer row has been calculated 
using the progressive uptake as specified in the treatment mix used in the base-case. Should 
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5,932,762 days with ulcer would have been avoided. Figure 5.8 shows the number of days with 
ulcer avoided as calculated by the DFU BIM.  
Table 5.26. DFU days with ulcer results 
Health 
Outcomes 
Current Year Year 2 Year 3 Year 4 Year 5 
Days with ulcer 30,484,353 32,144,050 33,958,866 35,424,056 36,486,488 
Days with ulcer 
avoided 
N/A                               730,547    1,306,110  2,231,437  3,559,657  
 
 
Figure 5.8. DFU days with ulcer avoided 
LU BIM health outcomes 
By introducing the sucrose octasulfate dressing, patients experience substantially fewer days 
with an open LU, because of the shorter mean time to healing. Table 5.27 shows the number 
of days with ulcer avoided by introducing the new intervention; the days with ulcer row has 
been calculated using the progressive uptake as specified in the base-case treatment mix. 


























Table 5.27. LU days with ulcer results 
Health 
Outcomes 
Current Year Year 2 Year 3 Year 4 Year 5 
Days with ulcer 163,067,760 151,661,661 144,059,610 132,651,126 117,435,559 
Days with ulcer 
avoided 
 N/A     11,415,394   19,026,741   30,444,521   45,669,384  
 
 
Figure 5.9. LU days with ulcer avoided 
Should 100% of the population receive the sucrose octasulfate dressing, then in year 5, a 
total of 76,115,640 days with ulcer would have been avoided. 
DFU BIM Sensitivity analysis 
The sensitivity analysis carried out on the DFU BIM consisted of applying a pre-defined set of 
scenarios to vary key parameters of the models. The scenarios used to test the DFU BIM are 
shown in Table 5.7 earlier in this chapter. The results for the five scenarios tested are shown. 
Table 5.28 shows the cost outcomes, the annual budget-impact, annual cost-consequence and 

























These results show the importance of the reduced mean time to healing; as in some scenarios 
where this was adjusted, the sucrose octasulfate dressing was no longer cost saving; as the 
dressing was more expensive than the comparator.  
If the price of the dressing was lowered to reflect some of the most inexpensive dressings 
available (£0.35 per dressing) then the cost benefits of the sucrose octasulfate dressing were 
lost. If the mean time to healing in the real-world was the same as in the RCT that informed 
the model, then the sucrose octasulfate dressing is still cost saving even when compared with 
the lower cost dressings. 
When testing the five scenarios the health outcomes were also measured. Table 5.29 shows 
the health outcomes, measured by the days with ulcer avoided. 
LU BIM Sensitivity analysis 
The sensitivity analysis carried out on the LU BIM consisted of applying a pre-defined set of 
scenarios to vary key parameters of the models. The scenarios used to test the LU BIM are 
shown in Table 5.8 earlier in this chapter. Table 5.30 shows the cost outcomes, the annual 
budget-impact, annual cost-consequence and the annual patient cost.  
The results show that in all scenarios, the sucrose octasulfate dressing continued to be cost 
saving. Even when the dressing was substantially more expensive than the comparator (£4.20 
vs £0.35). The cost saving is reflective of the size of the population and the much-improved 
time to healing reported in the real-world observational study when compared with standard 
care. If the mean time to healing by the sucrose octasulfate dressing only 1 day faster than 
standard care, with other parameters matching the base-case, the dressing is still cost saving 
with a lower cost per patient.  
When testing the five scenarios the health outcomes were also measured. Table 5.31 shows 
the health outcomes, measured by the days with ulcer avoided. A key factor that influences 
the number of days with ulcer avoided is the number of patients who are part of the eligible 




Table 5.28. DFU scenario analysis cost outcomes 






 Budget-impact £121,642,634 £132,538,102 £144,602,424 £155,441,320 £167,514,921 
Cost-
consequence 
£839,265 £2,262,678 £4,854,404 £6,220,165 £8,820,090 






 Budget-impact £222,890,530 £240,314,024 £257,673,831 £275,019,189 £292,285,412 
Cost-
consequence 
£0 -£53,100 -£170,885 -£304,114 -£517,474 






 Budget-impact £279,737,028 £297,673,731 £315,030,400 £324,939,293 £335,830,596 
Cost-
consequence 
-£1,853,268 -£5,995,743 -£10,719,509 -£22,892,310 -£34,083,960 






 Budget-impact £378,045,822 £403,705,925 £428,788,631 £453,293,893 £477,221,660 
Cost-
consequence 
£0 -£3,982,044 -£8,543,173 -£13,683,437 -£19,402,885 






 Budget-impact £540,518,641 £584,446,489 £628,601,636 £672,984,100 £717,593,901 
Cost-
consequence 
£0 £1,546,392 £3,317,666 £5,313,842 £7,534,940 
Cost/patient £1,436.21 £1,440.02 £1,443.83 £1,447.64 £1,451.45 
 
Table 5.29. DFU scenario analysis health outcomes 
 














 1 94,088  253,662  544,213  697,324  988,794  
2 - 121,758  391,833  697,324  1,186,552  
3 169,358  547,910  979,583  2,091,972  3,114,700  
4 -    
            
608,789  
1,306,110  2,091,972  2,966,381  





Table 5.30. LU scenario analysis cost outcomes 







£480,891,780 £471,975,401 £457,095,137 £451,157,985 £439,256,608 
Cost-
consequence 
-£5,962,187 -£14,906,317 -£29,814,333 -£35,779,239 -£47,708,372 







£2,469,053,253 £2,452,548,402 £2,419,395,126 £2,386,238,062 £2,336,428,777 
Cost-
consequence 
£0 -£16,645,587 -£49,939,607 -£83,237,423 -£133,187,468 







£1,171,331,290 £1,095,316,078 £1,019,292,198 £829,123,670 £676,980,954 
Cost-
consequence 
-£38,038,820 -£114,122,966 -£190,215,785 -£380,453,254 -£532,664,916 







£3,403,762,898 £3,348,398,855 £3,293,028,488 £3,237,651,799 £3,182,268,786 
Cost-
consequence 
£0 -£55,558,058 -£111,122,450 -£166,693,175 -£222,270,236 







£3,412,924,046 £3,349,276,766 £3,285,622,219 £3,221,960,404 £3,158,291,322 
Cost-
consequence 
£2,197.60 £2,156.49 £2,115.38 £2,074.28 £2,033.17 
Cost per patient £0 -£63,841,817 -£127,690,911 -£191,547,284 -£255,410,937 
 
Table 5.31. LU scenario analysis health outcomes 
















1 776,513  1,941,394  3,883,008  4,659,876  6,213,522  
2 -    1,553,115  4,659,610  7,766,459  12,427,043  
3 2,355,423  7,066,672  11,778,459  23,558,260  32,983,444  
4 -    3,882,787  7,766,017  11,649,689  15,533,804  





5.5.2 Cost effectiveness analysis 
The two cost-utility models allowed for a more detailed analysis of cost and health outcomes 
in the DFU and LU populations than the BIM. This is because of the inclusion of health states, 
and a treatment pathway; rather than only aggregated costs as presented by the BIMs. The 
base-case results are explored, first presenting the population characteristics and then 
showing costs per resource category and health state.  
Health outcomes are also reported, reported in variation of quality adjusted life years (QALYs) 
between the treatment groups. Additionally, the number of wounds healed are presented, and 
in the case of DFU; the number of amputation events in the treatment group using the sucrose 
octasulfate dressing and standard care versus the control group just using standard care. 
Finally, the per-patient incremental cost-effectiveness ratio (ICER), is determined.  
CEA Population 
The cost-utility models relied on the RCT data from the Explorer and Challenge clinical trials for 
DFU and LU patients respectively (Meaume et al., 2012; Edmonds et al., 2018). Therefore, the 
models are based on patient populations that matched the clinical trials. See chapter 2, section 
2.3.4 for reporting of the inclusion and exclusion criteria for these studies.  
As per the Explorer study (Edmonds et al., 2018), the patients in the DFU cost-utility analysis 
had a mean age of 65, with a sex distribution of 84% male and 16% female. The proportion 
who had previously experienced an amputation was 50%. As per the Challenge study (Meaume 
et al., 2012), the patients in the LU cost-utility analysis had a mean age of 73, with a sex 
distribution of 33% male and 67% female. 
CEA Cost outcomes 
The base case for the DFU and LU cost-utility models uses the data inputs presented earlier in 
this chapter. These values are believed to be those that are most representative of the clinical 
and resource use parameters that a patient would experience in the NHS if they were to 
present with a DFU or LU.  
Total costs are presented as a per-patient cost and extracted at the base-case time horizon of 
one year. The total costs associated with the use of the sucrose octasulfate dressing and 




Table 5.32. DFU cost-utility per-patient cost 
 
Table 5.33. LU cost-utility per-patient cost 
 
The DFU cost-utility model reported that the sucrose octasulfate dressing incurred £666.51 
less cost than the neutral dressing and the LU cost-utility model reported that the sucrose 
octasulfate dressing incurred £274.25 less cost than the neutral dressing. The costs split by 
resource use category and reported on a per patient basis are shown in Table 5.34 for DFU and 
Table 5.35 for LU, and further split by resource use item in Figure 5.10 for DFU and 5.11 for LU.  




Standard care Increment % change 
Primary 
dressing  
£390.72 £359.63 £31.09 +9% 
Inpatient  £597.61 £811.94 -£214.33 -26% 
Outpatient  £1280.27 £1564.24 -£283.97 -18% 
Medication  £37.95 £44.69 -£6.74 -15% 
Devices  £734.94 £802.96 -£68.02 -8% 
Amputation  £142.86 £267.40 -£124.54 -47% 
Total £3184.35 £3850.86 -£666.51 -17% 
 
DFU Total per patient cost (£) 
Sucrose octasulfate dressing £3184.35 
Neutral dressing  £3850.86 
LU Total per patient cost (£) 
Sucrose octasulfate dressing £1582.58 









Standard care Increment % change 
Primary dressing  £157.77 £151.94 £5.83 +4% 
Inpatient  £4.60 £4.53 £0.07 +2% 
Outpatient  £1140.25 £1370.58 -£230.33 -17% 
Medication  £8.19 £9.78 -£1.59 -16% 
Devices  £271.78 £320.00 -£48.22 -15% 
Total £1582.58 £1856.83 -£274.25 -15% 
 
 



















Figure 5.11. LU costs per resource use item
Both models found that the cost of the primary dressings was higher when using the sucrose 
octasulfate dressing; by 9% in the DFU model and 4% in the LU model. This cost is offset by the 
savings made across the other categories.  
In the DFU model, the biggest relative change was seen in the cost of amputation events, which 
was 47% less in the sucrose octasulfate group than the standard care only group. The largest 
absolute change in costs in the DFU model was seen in the outpatient category, with a saving 
of £283.97 when using the sucrose octasulfate dressing.  
In the LU model; in addition to the primary dressing, the inpatient category experienced a 
modest cost increase of £0.07 (2%). All other categories saw a cost saving when using the 
sucrose octasulfate dressing, with the greatest relative change, 17%, in the outpatient 
category, which was also the largest absolute change, at a saving of £230.33. This accounted 









LU item costs for sucrose octasulfate vs neutral dressing per patient





A summary of costs split by health state and reported on a per patient basis are shown in Table 
5.36 and Figure 5.12 for DFU. Amputation event costs are included in the table for the DFU 
model; despite these not being a health state.  
Table 5.36. DFU costs per health state 
Health state Sucrose 
octasulfate  
Standard care Increment 
% 
change 
Open pre-amputation  £464.04   £556.70  -£92.66 -17% 
Complicated pre-amputation  £433.58   £771.50  -£337.92 -44% 
Closed pre-amputation  £403.79   £206.09  £197.70 +96% 
Open post-amputation  £758.98   £834.95  -£75.97 -9% 
Complicated post-amputation  £545.13   £877.62  -£332.49 -38% 
Closed post-amputation  £435.96   £336.60  £99.36 +30% 
Amputation costs  £142.86   £267.40  -£124.54 -47% 
Total   £3184.35   £3850.86  -£666.51 -17% 
 
When costs are disaggregated in this manner, it becomes clear that more patients reside in the 
closed wound health states, as increases in cost can be seen here, +96% pre-amputation and 
+30% post amputation.  A summary of costs split by health state and reported on a per patient 
basis are shown in Table 5.37 and Figure 5.13 for LU. Consistent with the findings in the DFU 
model, more costs were incurred for the closed wound health state, an increase of 37%, for 
the sucrose octasulfate dressing. 
Table 5.37. LU costs per health state 
Health state Sucrose 
octasulfate  
Standard care Increment % change 
Open  £489.07   £1009.64  -£520.57 -52% 
Infected   £51.43   £84.02  -£32.59 -39% 
Closed   £1042.09   £763.17  £278.92 +37% 





Figure 5.12. DFU costs per health state 
 



























CUA health outcomes 
At the base-case time horizon of one year, the models calculated the cumulative number of 
QALYs attributed to each treatment arm. These are shown in Table 5.38.  
Table 5.38. QALYs gained in cost-utility models 
 Sucrose octasulfate 
dressing 
Standard care Increment 
DFU 0.682 0.665 0.017 
LU 0.726 0.658 0.069 
 
DFU CUA health outcomes 
The DFU cost-utility model calculated the number of wounds that had healed by the time 
horizon. For the sucrose octasulfate dressing, 653 wounds had healed at one year compared 
with 473 wounds healed in the standard care arm. Figures 5.14 and 5.15 show this, split by 
pre- and post-amputation.  
A cost per healed wound was calculated by the model; resulting in a cost of £4879.84 per 
healed wound using the sucrose octasulfate dressing and a cost of £8136.19 per healed wound 
using standard care alone. 
Additionally, for the DFU model, it was possible to calculate the number of amputation events 
that took place in each treatment arm. At one year, 21 amputations had taken place in the 
sucrose octasulfate treatment group, compared with 40 in the standard care group, shown in 






Figure 5.14. DFUs closed pre-amputation 
 





















































Figure 5.16. DFU model amputation events 
 



























































LU CUA health outcomes 
The LU cost-utility model calculated the number of wounds that had healed by the time 
horizon of one year. For the sucrose octasulfate dressing, 949 wounds had healed compared 
with 854 wounds healed in the standard care arm shown in Figure 5.17.  
A cost per healed wound was calculated by the model; resulting in a cost of £1666.80 per 
healed wound using the sucrose octasulfate dressing and a cost of £2174.89 per healed wound 
using standard care alone. 
CUA Incremental cost-effectiveness ratios 
For both the DFU and LU models the ICER was calculated. 








When an intervention is both more effective, and less costly than the comparator, it is declared 
to be the dominant intervention; this is also shown by the negative ICER value. When 
considering both the DFU and LU indications, the sucrose octasulfate dressing was the 
dominant intervention.  
CUA sensitivity analysis 
The sensitivity analysis to test the robustness of the results was carried out in two stages. The 
first part was the DSA, where each parameter was varied individually according to the assigned 
minimum and maximum values. After this, values that caused a ≥5% variance were deemed to 
be key driving variables, and these were taken forward to be used in the PSA. For the PSA, the 
range values and estimated standard deviation of each parameter were used for the model to 




Figure 5.18 presents the results of the DFU DSA, for variables that caused a ≥5% variance and 
Figure 5.19 presents the results of the LU DSA, for variables that caused a ≥5% variance. For 
the tabulated results of the DFU and LU DSA please see Appendix C.   
The DFU PSA, which showed that in all cases the sucrose octasulfate dressing resulted in a cost 
saving and a QALY gain. The results of the DFU PSA are shown in Table 5.39. The results of the 
LU PSA are shown in Table 5.40. Figure 5.20 presents the results of the LU PSA, which showed 
that in approximately 90% of cases the sucrose octasulfate dressing resulted in a cost saving 
and a QALY gain.  
 
Figure 5.18. DFU DSA results 
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Figure 5.19. LU DSA results 
Table 5.39. DFU PSA results 
 
Cost increment  ICER 
Minimum -£1352 -£92,789 
Median -£661 -£31,193 
Maximum -£1 -£99 
Mean -£664 -£31,713 
Standard deviation £212 £9,085 
2.50% -£1092 -£49,704 
97.50% -£262 -£15,209 
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Table 5.40. LU PSA results 
 
Cost increment ICER 
Minimum -£1857 -£36,964 
Median -£305 -£10,577 
Maximum £427 £58,872 
Mean -£335 -£10,632 
Standard deviation £302 £9184 
2.50% -£1000 -£29,202 
97.50% £150 £5225 
 
 

























Figure 5.21. LU PSA Results 
The DSA showed that when varying parameters individually the cost of the dressings was a key 
driver, as were transition probabilities for the sucrose octasulfate dressing and standard care. 
Despite these being influential factors, these could be varied within the set ranges and the 
sucrose octasulfate dressing would remain cost saving in any scenario. Scenario analysis also 
showed that if the comparator product were free (£0) the sucrose octasulfate dressing would 
remain cost saving (-£239.05) due to the increased efficacy and shorter healing time. 
The PSA varied all parameters shown to cause more than 5% variance on the cost increment 
in the DSA. For DFU the mean cost saving was £664 (range: -£1352 - -£1). When looking at the 
ICER, the sucrose octasulfate dressing is dominant, saving cost and gaining QALYs.  
The DSA showed that when varying parameters individually then resource use during the open 
health state cause the largest variance in costs. In only two scenarios does the sucrose 
octasulfate dressing incur costs- with community nurse visits set at 0, £24.59 per patient is 
incurred and with primary dressing use at maximum in the closed health state, the sucrose 
octasulfate dressing incurs £9.68 per patient cost. The sucrose octasulfate dressing remains 






















product were free (£0) the sucrose octasulfate dressing would remain cost saving (-£105.80) 
due to the increased efficacy and shorter healing time.  
The PSA varied all parameters shown to cause more than 5% variance on the cost increment 
in the DSA. For LU the mean cost saving was £340 (range: -£1723- £423). There was a broader 
range in the LU figures due to the large standard deviations of the mean resource use figures. 
When looking at the mean ICER produced, the sucrose octasulfate dressing is dominant, saving 
cost and gains QALYs. 
Key drivers of the cost results are the cost of the dressings, the transitions for healing and 
infection/complication and the resource use with regards to community nursing and hospital 




The economic evaluation in this chapter was designed to assess the cost implications of using 
the sucrose octasulfate dressing in combination with standard care, rather than using a neutral 
dressing with standard care. Two different methods of economic analyses were performed, 
budget-impact and cost-utility. The BIMs provided a population-level overview of the costs 
associated with integrating the sucrose octasulfate dressing into standard care. The BIMs were 
designed as static models; meaning that patients did not move through different health states 
or cost levels - they had a wound that healed in the period specified by the clinical data. The 
cost-utility model further analysed the consequences of using the sucrose octasulfate dressing. 
These models used health states that were representative of different stages of having a 
wound; and patients moved through these states using transition probabilities defined from 
published literature. These two models were chosen as they have different focuses; but 
together provide a clear overview of the costs and consequences of the new intervention. This 
selection is representative of the process used by NICE during HTA; and as such can be 
considered an appropriate evidence package to guide decision making.  
The results of the analysis were in clear favour of the sucrose octasulfate dressing; with the 
increase in acquisition cost being overshadowed by the savings made in other areas; driven by 




The published clinical data showed improved outcomes for patients when using the sucrose 
octasulfate dressing, which the model demonstrates (Meaume et al., 2012; Munter et al., 
2017; Edmonds et al., 2018). It is this efficacy, leading to shorter healing times, that drives the 
cost saving results. Wounds treated with the sucrose octasulfate dressing are more likely to 
heal, and thus less likely to spend time in the complicated/infected health states, where more 
resources are used. Particularly, for DFU patients, the avoidance of amputation is a driver of 
cost savings. The literature used specifies that wounds are more expensive to the healthcare 
system post-amputation (with a much higher likelihood of hospital admission) and by healing 
patients faster, some of these consequences are avoided. 
5.6.1 Findings in context 
The models agree with previous studies that were discussed in chapter 2 and in the scoping 
literature review reported at the start of this chapter in section 5.2. The models found that 
interventions that improve healing outcomes for patients result in savings to the healthcare 
system; even if the intervention is costlier that the direct comparators. The resource use data 
used here is from two studies of the THIN database published in March 2018 (Guest et al., 
2018a; Guest et al., 2018b). Using a single source of information for the resource use, across 
indications and health states, is very useful in strengthening the internal validity of the results; 
as the data has been taken from the same cohort of patients. This cohort was a sample from 
real-world practice in the NHS; and as such the resource use levels applied in the model are 
generalisable to the wider population. The DFU study informed by the THIN database reports 
a cost range of £2140 - £16,900 dependent on the wound status (Guest et al., 2018b). The 
model built for this study shows an average per patient cost of £3627.76/£4172.54 (sucrose 
octasulfate/neutral dressing) which falls within these bounds. In the model, patients move 
between the health states, incurring the relevant weekly cost. In the Guest et al., (2018b) study 
DFU patients were shown to receive compression, this was excluded from the costs used in 
this current study model as it is not recommended for the treatment of DFUs. In the paper, 
13% of costs come from amputations, which is higher than the 3-5% shown in our model. It is 
possible that the likelihood of amputation in the general population is higher than the sample 
population in the Explorer clinical trial (Edmonds et al., 2018).  
The LU article from Guest et al., (2018a), estimated the costs of treating a LU as between 




modest cost of £1579.23/£1856.56 (sucrose octasulfate/neutral dressing) despite using 
resource use values from this study published in this paper. This is likely driven by the large 
standard deviations of the resource use mean values, which were used in the base-case. When 
performing sensitivity analysis, the standard deviation was used to estimate the range of 
values, and the highest cost for neutral dressing was £3737. The healing rate applied from the 
RCT (Meaume et al., 2012) was higher than the healing rate reported in literature; and is 
perhaps reflective of the benefits of a highly protocolised treatment regimen as used in RCTs. 
There are no previous published examples of UK focussed cost-utility models for the sucrose 
octasulfate dressing; with the work presented in this chapter being the first study to assess this 
dressing using the methods prescribed by NICE (NICE, 2013).  
Further real-world data collection regarding use of the technology could provide data to show 
the effectiveness of the sucrose octasulfate dressing in patients receiving wound care outside 
of RCTs. 
5.6.2 Budget-impact models 
The BIMs found a slight cost increase in some scenarios, where the time to healing benefit was 
significantly reduced, and the least costly dressing used as part of standard care. However; 
these scenarios still resulted in fewer days with ulcer for patients. Given that clinical decision 
making is not be made on cost alone; it would be necessary to consider the improved outcomes 
for patients in any analysis.  
5.6.3 Cost-utility analyses 
The cost-utility analyses were more decisive in their results, with the sucrose octasulfate 
dressing dominating standard care, that is offering a cost saving and clinical benefits, in both 
the DFU and LU models. Extensive sensitivity analysis of the DFU model found that in all 
scenarios the sucrose octasulfate dressing remained cost saving; even in the case where the 
competitor product was provided free of charge. For the LU model, this was true in 
approximately 90% of cases, and where costs were incurred, they were still accompanied by 
health gains for patients. This is compelling evidence to support the assertion that improving 
clinical outcomes reduce cost to the healthcare system; even when the intervention being 




5.6.4 Discussion of methods 
The economic evaluation presented here was part of an evolving process, with the models 
being developed from scratch to support the needs of this research. The study initially set out 
to perform a budget-impact analysis and a cost-utility analysis, two models that incorporated 
both indications of interest, DFU and LU. Combining the two indications in one model proved 
to overcomplicate the programming, without offering any tangible benefits. The models were 
based on different data, and the indications had different resource use, and in the case of the 
cost-utility analysis, the DFU model included more health states due to the need to incorporate 
the amputation event. This led to the decision to separate the models by indication; but they 
were designed on the same frameworks and aesthetically were near identical to show that 
they were part of the same larger body of work.  
5.6.5 Additional analyses 
The individual methods; budget-impact and cost-utility, were also adapted through the process 
to provide slightly different results that would be useful for a decision maker. The BIM was 
modified to compare the cost associated with uptake of the sucrose octasulfate dressings with 
a scenario where standard care remained the same. This provided a cost-consequence analysis 
which when reported, showed that using the new intervention resulted in savings when 
compared to not using it. Cost-utility analysis traditionally only reports the ICER value, with the 
results expressed in QALYs. The cost-utility analyses presented in this chapter were 
programmed to count the number of healed wounds for DFU and LU and in the case of DFU, 
the number of amputations, in each treatment arm. This allowed for a meaningful comparison 
of health outcomes; expressed in healing and amputation rates. Using the cost data in the 
model, it was also possible to assign a cost-per event; so, a cost-effectiveness calculation was 
performed to model the cost per healed wound.  
5.6.6 Strengths and limitations 
This research has several key strengths, with one being the use of contemporary data that is 
published and peer reviewed. The double-blind clinical trials are of high quality, as discussed 
in chapter 2, and this supports the results of the models. Further to this, multiple methods 
have been used; and these all have been tested with multiple sensitivity analyses; DSA, PSA 
and scenario analysis. Expert validation has been undertaken extensively with different groups 




models have been externally reviewed and accepted by NICE and are now a part of UK clinical 
guidance (NICE 2019).  
As with all methods; the economic evaluations performed in this study to assess the sucrose 
octasulfate dressing have their limitations, and strategies to overcome these have been 
implemented.  
The static BIMs make assumptions that all patients treated cost the same per week until 
healing, with no provision to separate wounds that could cost more, such as complicated DFUs 
and infected LUs. The population funnel that identifies patients is also based on an annual 
incidence figure that covers the entire diabetic population and the model assumes that all 
these patients seek treatment from a health care professional. Another limitation that may 
reduce real-world applicability of the results is the fact that product list-prices have been used; 
which are possibly higher than the confidential net price that the NHS pays a manufacturer. 
These limitations do not nullify the results of the BIMs, as they have been developed and 
reported in line with the International Society of Pharmacoeconomics and Outcomes Research 
(ISPOR) good practice guidelines for BIMs (ISPOR Task Force Report, 2014). The taskforce 
recommended using a cost calculator approach and to use published data to inform the 
models, both principles have been followed by the DFU and LU BIMs in this chapter. 
The cost-utility models developed for this analysis are also subject to some inherent limitations 
because of employing the Markov method. Markov assigns probabilities to moving between 
the included health states, reported in a transition matrix, however, the model has no memory; 
meaning that past health states do not influence future transitions. This is potentially 
problematic when considering long lasting wounds, that are shown to be harder to heal 
(Margolis et al., 2004). Again, the model relies on list prices for resource use; which overlooks 
the impact of any patient access scheme or confidential price discount agreed between the 
manufacturer and the NHS. However, these limitations have been addressed by the design of 
the models and the fact that have been created using peer reviewed and published data. The 
patient characteristics that were programmed into the cost-utility models as reflective of the 
clinical trial populations of the Explorer and Challenge RCTs (Meaume et al., 2012; Edmonds et 
al., 2018). These trials included patients with varied wound duration, wound size and of 




Additionally, the DFU cost-utility analysis used the same weekly cost for patients with closed 
wounds both pre- and post-amputation. Discussion with clinical experts highlighted the fact 
that a closed wound post-amputation is likely to incur a higher weekly cost; however, without 
the data available, this was left at the same level. This is a conservative assumption and will 
have affected both groups in the analysis and as such does not serve to undermine the cost-
saving of the sucrose octasulfate dressing.   
The LU cost-utility analysis relies on the mean values from the Guest (2018a) paper, which 
mostly have a large standard deviation. These values were tested using the sensitivity analysis, 
where the sucrose octasulfate dressing remained cost saving in all but two scenarios. 
Both cost-utility analyses rely on RCT results to model the rate of healing, it is possible that 
real-world treatment practices deviate from these and as such, wound healing may take 
longer, but would still be expedited with use of the sucrose octasulfate dressing.  
5.6.7 Further areas for research 
Further work in this area could build on the results of the economic models presented in this 
chapter. The overall budget-impact of wounds is high, a significant area of spending for the 
NHS- and wound management should remain a priority item to ensure that patients receive 
optimal health outcomes whilst the health system manages the budget by prioritising 
interventions that can improve healing. With regards to the sucrose octasulfate dressing, 
further work could be done to assess the impact of the dressing on subgroups; such as those 
identified in chapter 4, patients with severe wounds that suffer lower quality of life because of 
their DFU or LU. Other risk factors for healing as identified in literature, such as wounds that 
are larger, long duration, or patients with comorbidities that could impact healing should be 
tested using economic modelling; to see if treating these groups with the sucrose octasulfate 
dressings result in health gains and cost savings. To achieve this; further clinical studies of 
effectiveness could be carried out, assessing the impact of the sucrose octasulfate dressing in 
real-world practice, in the NHS. A limitation of the LU model in presented in this chapter was 
the need to extrapolate the relative wound area reduction using statistical methods that 
introduce uncertainty; a further RCT of the dressing in the LU population would reduce 




The model frameworks presented in this chapter, approved by a NICE EAC, can be repurposed 
in the future as they have been extensively validated to ensure they are representative of both 
DFU and LU. Given this; further work can be done to refine populations and reduce uncertainty 
to provide more robust evidence for medical decision making that can be communicated to 
the healthcare system and to practicing clinicians.  
 
5.7 Health technology assessment 
The cost-utility models were extensively tested, and peer reviewed as part of the HTA 
assessment made of the sucrose octasulfate dressing by NICE in 2018. NICE relies on external 
academic groups to assess economic submissions made during HTA. This is partly due to the 
capacity of the NICE team, but also to utilise the world class expertise in health economics and 
modelling at academic centres in the UK. The centre that was selected to assess the cost-utility 
models was King’s Technology Evaluation Centre, (KiTEC); a collaboration between the King's 
College London School of Biomedical Engineering & Imaging Sciences, the School of Population 
Health and Environmental Sciences, and King’s Health Economics, as well as the Guy's and St 
Thomas' NHS Foundation Trust Medical Physics department. KiTEC is a specialist External 
Assessment Centre (EAC) that works on NICE’s MTEP. 
The EAC checked the electronic models for errors and ascertained that the model was valid 
and believed the model structures adequately captured the required health states to examine 
the costs and consequences of the technology and comparators for patients with DFUs and 
LUs. The EAC reported that the assumptions in the model are reasonable and valid. They 
asserted that there are cheaper neutral dressings that may be equivalent to the comparator 
used in the models; however, this was addressed by the sensitivity analysis; the EAC asserted 
that the sensitivity analyses were appropriate.  
The EAC critique of the DFU model used in this study, included some amendments to the 
resource use assigned to health states, and some unit costs - however none of the changes 
resulted in the sucrose octasulfate dressing being cost incurring. The EAC concluded that even 
with amendments, that the sucrose octasulfate dressing was dominant, saving cost and 
generating health gains. The EACs amended base case resulted in an annual cost saving of £342 




analysis the sucrose octasulfate dressing was cost saving in all analyses except for one analysis 
in which healing rates estimated from the Explorer trial (Edmonds et al., 2018) were reduced 
by 50%. In this scenario the sucrose octasulfate dressing generated a modest cost increase 
compared to standard care. 
As per the review of the DFU model, the EAC amended some resource use assumptions and 
unit costs for the LU model. There were also concerns about using the exponential 
transformation rate to convert relative wound healing rates into healing rates, but in the 
absence of full healing data for the LU population it was accepted as the best option. The key 
change made by the EAC was the inclusion of the assumption that healed ulcers had zero 
weekly resource use. The EAC concluded that even with amendments, that the sucrose 
octasulfate dressing is dominant, saving cost and generating health gains. The EACs amended 
base case resulted in an annual cost saving of £541 for LU patients; a far greater saving than 
that of the base case model presented in this chapter. This is a result of the assumption that 
healed wounds incur no costs. Additionally, the EAC found that the sucrose octasulfate 
dressing was cost saving in all sensitivity analyses. 
5.7.1 Publication of NICE guidance 
Following the peer review and analysis carried out by KiTEC, the NICE MTEP committee 
reviewed the models and supporting submission of clinical evidence supporting the adoption 
of the sucrose octasulfate dressing. A positive NICE guidance for the sucrose octasulfate 
dressing was published on the 31st January 2019 (NICE, 2019). The NICE guidance reports that: 
Evidence supports the case for adopting UrgoStart dressings to treat 
diabetic foot ulcers and Leg ulcers in the NHS, because they are associated 
with increased wound healing compared with non-interactive dressings. 
NICE (2019). Full guideline available at: 
https://www.nice.org.uk/guidance/mtg42 
This guidance should have the implication that clinicians who treat DFU and LU patients should 
now consider using the sucrose octasulfate dressing, as it has been declared as better for 




research has directly impacted treatment guidelines and serves to improve outcomes for 
patients.  
 
5.8 Chapter summary 
This chapter presents the final study (study 5) of this thesis. The BIMs and cost-utility models 
that are described and reported here draw on the learnings from the other studies that have 
been carried out as part of this thesis (see chapters 2-4).  
The economic evaluations carried out in this chapter has demonstrated that sucrose 
octasulfate dressings are proven to improve healing, but also are associated with cost savings 
to the healthcare system; even when tested with robust sensitivity analyses. This result has 
been externally validated by a NICE EAC and subsequence NICE guidance has been published 
to support the use of these dressings. The budget-impact analyses showed that by adopting 
the sucrose octasulfate dressing, the health care system can experience potentially large 
savings whilst reducing the number of days with ulcers for patients.  
The implications of this research are that patients should experience faster healing and the 
sucrose octasulfate dressing should be routinely offered to patients who present with either a 
DFU or LU. The increased wound healing rate means that less patients should experience 
infected or complicated wounds, and in the case of DFUs, amputations should be avoided.  
This new NICE guidance recommending the sucrose octasulfate dressing is currently in 
opposition to advice in the guideline for treating DFUs NICE Guidance (NG) 19, which states 
that the least costly dressing is the one that ought to be used (NICE, 2016). This was due to no 
evidence of superiority for a single dressing at the point of publication of NG19. Further work 
in this field would be to ensure that a future update of NICE NG19 includes a reference to the 
sucrose octasulfate dressing being proven to increase wound healing and has been 
recommended by NICE for use in DFU and LU patients.  
The next chapter presents the overall discussion of the thesis, to explore the outcomes relative 





5.9 Dissemination  
The results of these study have been presented at the ISPOR conference in Europe, Barcelona, 






Chapter 6 Overall Discussion 
 
6.1 Introduction 
This PhD thesis set out to evaluate the clinical and economic impact of protease-modulating 
matrix (PMM) dressings with regards to the management of diabetic foot ulcers (DFU) and leg 
ulcers (LU) in the United Kingdom (UK), with the intent of making recommendations for 
guidance.  
 
6.2 Aims and objectives 
The aim of this thesis was: 
− To evaluate the clinical and economic impact of PMM interventions in DFU and LU to 
inform the development of treatment guidelines in the United Kingdom. 
To achieve this aim the objectives of the thesis were: 
A. To evaluate current treatment guidelines.  
B. To gain consensus on guidelines, and treatment strategies for chronic wounds.  
C. To document quality of life (QoL) for DFU and LU patients 
D. To assess clinical and economic impact of PMM interventions in wound management.  
E. To assess the clinical and economic impact of the proposed recommendations.  
Five different studies that link together were carried out to address the primary aim of this 





Figure 6.1. Overall PhD study framework 
The aim and all thesis objectives have been successfully achieved, as outlined below. Further 
to this; the research that is presented here has culminated in a change of policy; in the form of 
a new clinical guideline regarding the use of the sucrose octasulfate dressing. The National 
Institute for Health and Care Excellence (NICE) has released guidance based on the body of 
evidence that was submitted as part of a medical technology evaluation process; NICE MTG42 
guidance documents (https://www.nice.org.uk/guidance/mtg42). This guidance advises the 
use of the sucrose octasulfate dressing; acknowledging that it is a cost saving intervention that 
results in improved health outcomes for patients with DFU and LU (NICE 2019).  
 
6.3 Discussion of thesis objectives 
Each of the objectives are discussed in turn, highlighting the role of each of the studies; for 
further detail on the methodologies and results please refer to the corresponding chapters for 




6.3.1 Objective A: Evaluation of current treatment guidelines 
Current treatment guidelines have been summarised in chapter 1 of this thesis; in the UK NG19 
for DFU and SIGN120 for (v)LU. These documents, however, provide very little guidance with 
regards to the use of dressings, and as such this objective was achieved by evaluating current 
practice; in the absence of explicit guidance.  
A varied approach to treatment is a key finding that recurs throughout this research.  It is 
speculated that this is a direct result of a lack of clear guidance regarding wound dressings 
dictated by a national body such as NICE. In study 1, presented in chapter 2, the clinical 
systematic literature review (SLR), no meta-analysis was possible due to the heterogeneity of 
the included studies. This not only related to diverse patient populations but also the lack of 
uniformity across the standard care arms of included studies; there was no reference arm from 
which a strong network to power a meta-analysis could be built.  
The economic SLR examined the use of standard care, and once again found that the standard 
care arms of the included studies in the economic SLR were not aligned; presenting multiple 
examples of ‘standard care’, that included a vast array of different protocols. Such 
heterogeneity is unhelpful; for clinicians and patients as there is not a consistent treatment 
protocol. Heterogeneity is also troubling for payers and industry as it makes a meta-analysis 
impossible. Meta-analysis is a key part of the NICE health technology assessment methodology 
to provide statistically robust comparisons with other interventions (NICE, 2013). Unchecked 
heterogeneity and a lack of meta-analysis introduces uncertainty that limits the extent of the 
guidance that can be published (Hakoum et al., 2017). If one assumes that payers and 
manufacturers want to encourage robust meta-analyses and minimise uncertainty; it implies 
that the reason for the divergence in standard care is due to a lack of consensus where there 
is no mandated guideline to adhere to.  
Study 4 in chapter 4 also presented evidence to confirm the suspicion that standard care is in 
fact, not standard. The real-world data, representative of multiple clinical settings, found that 
treatment switches occur in nearly 80% of visits; making the variance in treatment between 
patients, or even between visits for the same patient, very explicit. Again, this variance is 
mutually detrimental; where no stakeholder is served well. Payers end up spending more on 




on the health care providers is increased as patients’ wounds do not heal. Manufacturers do 
not benefit, given that the high rate of treatment switching contrasts with the 
recommendation that a dressing be used for a set time (usually 6-8 weeks) to replicate the 
outcomes seen in clinical trials (Urgo Medical Ltd, 2019). When a dressing is switched earlier, 
the outcomes reported in clinical trials, where strict treatment protocols have been followed 
in narrow pre-defined populations, are unlikely to be replicated; an effect that can be 
considered as a bias (Kim et al., 2018).  
The incidence of chronic wounds is increasing, further adding to the burden felt by all parties, 
requiring more effective treatment strategies (Diabetes UK, 2018; Office for National Statistics, 
2018).  
With such a variance found in treatment; both in real-world data and SLRs, should an optimal 
strategy be used, it is unlikely to be implemented uniformly throughout the UK, and will likely 
be outweighed by the volume of sub-optimal strategies still in practice. This claim is supported 
by a recent real-world evidence study, that found continued use of compression in patients 
with a DFU; despite this being contra-indicated (Guest et al., 2018). A further example is the 
£5.4 million spent on silver dressings for over 20 million patients in 2015; despite studies 
showing limited clinical benefit and a subsequent Cochrane review reporting that these 
treatments neither promote wound healing nor reduce infection (Storm-Versloot et al., 2010; 
NHS Presqipp, 2015). The result of this is resources being used sub-optimally, and the NHS 
budget being unable to maximise the health gain to the population due to clinical practice 
continuing to use out-dated practices that have limited benefits, instead of those with proven 
clinical and economic benefits.  
In accordance with current guidelines (NICE, 2016) a clinician is encouraged to use “the least 
costly” dressing, an instruction that the economic SLR has demonstrated is unlikely to result in 
cost-effective treatment pathways. Current guidance falls short of a mandated treatment 
pathway for wound care dressings; which may be negatively impacting patient outcomes, as 
evidenced by the results of the chart extraction study in chapter 4, and supported by real-
world studies in the literature, where healing outcomes also do not match randomised 




Therefore, this research does not support the continuation of current NICE (2016) and SIGN 
(2010) guidance in its current form, as the resulting variation does not offer the best value to 
patients, payers, or the healthcare system. Variations, by their nature, mean that some 
patients are not receiving optimal care, and interventions that help to improve outcomes are 
not routinely used. This lack of mandated treatment guidance regarding wound care dressings 
is theorised to have come from the lack of high quality RCTs in this area. Guidance needs to be 
evidence-based; and without evidence, the guidance cannot be confirmed to be clinically nor 
cost effective.  
6.3.2 Objective B: Consensus on guidelines and treatment strategies for chronic wounds 
The literature reviewed in the Delphi panel in chapter 2 found a lack of consensus regarding 
wound care dressings, and the uncertainty surrounding new interventions. The Delphi panel 
that was convened to address this uncertainty arrived at a consensus regarding: the role of 
matrix metalloproteinases (MMPs); the need for management plans associated with shorter 
treatment periods and fewer adverse events; and a recommendation for early investment in 
treatment to improve patient QoL and provide a reduction in long-term costs. Consensus was 
reached swiftly, with multiple statements being endorsed unanimously by the panel. The 
consensus statement explicitly stated that prolonged futile treatment is costlier. The 
independent experts also highlighted the need for a long-term view from decision makers 
when making decisions about wound care dressings.  
There are relatively few examples of Delphi panels being convened in the field of wound care 
(Serena et al., 2012; Schultz et al., 2017). Delphi studies often use a single type of expert; and 
Serena et al., (2012) is an example of this, focusing only on researchers gaining consensus 
regarding wound care research. Schultz et al., (2017) sought diversity in their panel, which 
aimed to answer a clinical question surrounding biofilms and their contribution to delayed 
healing of chronic wounds. Both studies, and the one presented in this thesis, are successful 
examples of the Delphi methodology, as all reached a consensus agreed by the experts which 
has since been published.  
Advice surrounding Delphi methodology includes a recommendation to use a group of 
homogenous experts (Atkins et al., 2005). Contrary to this proposed methodology, the study 




group of stakeholders that treat patients with wounds. It was reasoned that to include just one 
type of health care provider (HCP) would risk excluding other HCPs from the final output; if a 
group was not involved in the development, they may be hesitant to follow the 
recommendations.  
There is also the risk that if groups do not interact with those outside of their direct sphere, 
they may fail to see limitations that could be obvious to others (Karlsen et al., 2017). To avoid 
this ‘echo chamber’ effect and to produce a consensus statement meaningful to multiple 
stakeholders; a range of stakeholders were invited to participate. The Delphi methodology is 
also well suited to multi-disciplinary groups; especially when the groups involve HCPs of 
differing seniority; the anonymity afforded in the early rounds allows an equal weighting to be 
given to all opinions; without politics dictating that the group defers to the most senior person 
in the room.  
Unfortunately, expert opinion is often subject to low levels of evidence classifications, due to 
its typically uncontrolled nature, yet as shown in study 2 this can be counterbalanced using a 
Delphi methodology. The anonymous, iterative approach protects from many of the risks of a 
traditional expert panel; including the risk of undue bias or pressure from the research sponsor. 
Such is this risk, Clause 22 of the Prescription Medicines Code of Practice Authority (PMCPA) 
Code of Practice is dedicated to meetings with HCPs, with further advice published specifically 
on advisory boards (PMCPA, 2016; 2019).  This guidance does not always result in compliant 
interactions between industry and HCPs, as presented in section 3.2.5. Given the resulting poor 
reputation of the pharmaceutical and related industries, it is important to uphold scientific 
values and principles that can be offered by the Delphi methodology when compared to a 
traditional unstructured advisory board (House of Commons Health Committee, 2005; 
Goldacre, 2012; Morriss, 2019).  
Furthermore, thesis objective B “to gain consensus on guidelines and treatment strategies for 
chronic wounds” has been achieved by the publication of guidance by NICE in January 2019 
recommending the use of the sucrose octasulfate dressing. The publication of Medical 
Technologies Guidance 42 (MTG42) represents consensus between the members of the 
Medical Technologies Evaluation Process (MTEP) committee, the evidence review group, 




NICE recommendation represents the highest commendation, globally, for an intervention and 
reflects the consensus that shorter healing times lead to improved outcomes; both in terms of 
clinical healing, patient QoL and financial benefits for the health care system (All-Party 
Parliamentary Group on Global Health, 2015).  
6.3.3 Objective C: QoL in patients with DFU and LU 
Another finding that is critical to stress, is the high burden to patients that is a consequence of 
having a chronic wound. This is not a revelation by this study and has been widely reported in 
literature; with chronic wound patients reporting a ‘loss of self’, depression anxiety, and 
problems with everyday activities (Walshe, 1995; Kinmond et al., 2003; Green & Jester, 2009; 
2010). Study 3 in this thesis found that QoL was greatly impacted by having a DFU or LU, 
aligning with previous findings in literature (Jeffcote et al., 2009; Meaume et al., 2018). 
However, the research presented here has gone further and quantified the impact on QoL 
using the latest version of the EuroQol tool; the EQ-5D-5L that offers improved sensitivity to 
small changes in patient QoL (Janssen et al., 2018).  
DFU patients had a lower mean index score when compared to patients with a LU, implying 
that patients with a DFU have a worse QoL than patients with a LU. There are many potential 
reasons why DFU patients report worse QoL than LU patients, including the fact that they tend 
to be younger and may have higher expectations of their health; additionally the DFU is also 
likely to be just one of a series of co-morbidities suffered by the patient. However, further 
qualitative research to investigate the relative differences found between DFU and LU would 
be able to provide more insight. The comparison of different types of wound can be made due 
to the use of a generic tool collected in a real-world setting. The study compared the utility 
scores of these patients with other chronic diseases and found that they scored lower, 
indicative of a worse QoL, than epilepsy, heart failure, asthma and chronic obstructive 
pulmonary disorder (COPD) (Peters et al., 2014). 
QoL is not only measured using utility scores, there is also a financial impact on a patient, a 
wound has tangible costs that could include productivity costs from not being able to attend 
work. Patients may also need to purchase different clothing or shoes to accommodate the 
ulcer or pay transport costs associated with attending various appointments with HCPs based 




economic models; with Tabolli et al., (2007) asserting that carer burden is under reported for 
these patients. The pressure exerted by these costs may negatively impact a patient’s QoL.  
Despite this burden; chronic wounds and the impact they have is not very prominent in the 
media, a simple Google news search only returns 32,400 and 6,720 results for DFU and venous 
LU and 65,500 for chronic wounds; however, searching for epilepsy returns 538,000 hits, 
asthma over 6.5 million, COPD over 17 million and heart failure over 22.5 million results 
(Google, 2019). This is a demonstration of the relatively limited coverage that these wounds 
receive and could explain why the severe patient burden is not acknowledged, and despite the 
high patient burden and cost to the healthcare system; chronic wound management is not a 
clinical priority area for the National Health Service (NHS) (NHS England, 2019). Without 
prioritising chronic wound management there is a risk that the current problems could 
continue, and potentially increase as the size of the diabetic and aging population grows. 
6.3.4 Objective D: Clinical and economic impact of PMM interventions in wound management 
The clinical SLR in chapter 2 found evidence of some PMM interventions being effective versus 
control in clinical studies. This study also found that not all PMM interventions are the same, 
with the results of the included RCTs suggesting that the sucrose octasulfate dressing is 
superior to oxidized regenerated cellulose. Versus control, the sucrose octasulfate dressing 
had favourable outcomes in trials measuring full wound closure and relative wound area 
reduction (Meaume et al., 2012; Edmonds et al., 2018). The sucrose octasulfate RCTs are 
considered as high quality; they achieve a higher level of evidence by using double blinded 
methods which are typically challenging in wound care studies. This means the results should 
be considered robust and relevant to clinical practice. 
The chart extraction study, presented in chapter 4, also demonstrates the benefits offered by 
PMM dressings, by providing baseline real-world outcomes achieved by the current treatment 
practices. In this study 25% of DFUs healed within 20 weeks; this healing rate is similar to the 
control arm in the sucrose octasulfate RCT; where 30% of wounds healed when using a neutral 
dressing versus the sucrose octasulfate dressing which healed 48% of patients within 20 weeks.  
Regarding economic impact; wounds are expensive to payers; they also exert a huge pressure 
on the resources of the healthcare system. Diabetes UK estimated that in 2014–2015 around 




amputations with prescriptions for dressings accounting for £184 million of expenditure in 
2012 (Diabetes UK, 2016). This had risen by 51% since 2004, a rate much higher than inflation 
in the same period; indicative of the increasing prevalence of wounds and the growing 
economic burden (Kerr, 2017). When considering that there is an intervention (the sucrose 
octasulfate dressing) that can improve outcomes; this spend feels poorly directed, when it 
could be used to address unmet needs of patients in other disease areas.  
The chart extraction study, study 4, highlighted an infection incidence rate of nearly 20%. 
Infected wounds are more labour intensive to heal and require more frequent dressing 
changes; resulting in additional burden to the practitioners. The cost-utility analysis performed 
in study 5, showed that costs for HCP appointments, both inpatient and outpatient, accounted 
for 60% and 72% of annual costs for DFU and LU patients, respectively. This explicitly 
demonstrates that the cost of HCP time is the primary driver of costs, with wounds needing a 
high level of intervention to achieve closure; aligning with previous cost studies of chronic 
wounds; where nurse visits or inpatient stays accounted for most costs (Guest et al., 2005; 
2015). It is not the cost of devices, but the cost of HCPs that drives the expense of chronic 
wounds; and in addition to the financial cost of the time; there is a further opportunity cost for 
the other patients that an HCP could be treating if a chronic wound healed quickly with minimal 
intervention.  
6.3.5 Objective E: Clinical and economic impact of the proposed recommendations 
The results of the economic SLR in study 1 highlighted the high cost to the healthcare system 
of nearly £4,000 for a DFU and over £1,500 for a LU (Guest et al., 2012; Craig et al., 2013; Jemec 
et al., 2014). Given the high, and growing, prevalence of wounds it should not be surprising 
that wounds contribute to a significant portion of healthcare spending in the UK, an estimated 
5.5% of NHS expenditure was on wound care in 2016 (Phillips et al., 2016). This SLR also found 
that more expensive interventions are, in all included studies, cost-effective when compared 
to standard care. The sucrose octasulfate dressing, the most effective PMM intervention, was 
found to be associated with improved healing and faster onset of healing both of which 
contribute to the reduced healthcare system costs of chronic wounds.  
If a wound heals faster, the patient will be in treatment for a shorter time; leading to a 




as the evaluation performed in this study. As most costs have been shown to come from HCP 
visits, even a short reduction in healing time would offset the cost of using a more expensive 
dressing. The relative change in dressing cost may be initially large, but the absolute change is 
small when compared to the other high cost items; explaining why the sucrose octasulfate 
dressing was still cost saving in study 5 when the comparator price was set at £0.00. This is a 
powerful argument that demonstrates that making these changes is a low-risk strategy for 
payers; the sensitivity analyses performed on the cost-utility models found no scenarios where 
the sucrose octasulfate dressing is associated with a large cost increase.  
The economic modelling assigned a standard care protocol that was derived from a large-scale 
real-world study of DFU and LU patients in the UK (Guest et al., 2018a; Guest et al., 2018b). An 
assumption was made that this real-world study included patients with various versions of 
standard care, and the aggregated results were assumed generalisable to a wider population. 
The active arm was identical to the standard care arm, except for the primary dressing as per 
the clinical trial protocols and justifies the assumption that the differences found were due to 
the sucrose octasulfate dressing and not confounding factors. These assumptions were 
validated by clinical and academic experts; and by the External Assessment Centre (EAC) and 
NICE committee during the production of the subsequent MTG42 guidelines 
(https://www.nice.org.uk/guidance/mtg42).  
The budget impact models provided a population-level overview of the costs associated with 
integrating the sucrose octasulfate dressing into standard care and found that a saving was 
made for both DFU and LU populations, both in terms of costs and patient days with ulcer. 
When considering the cost-utility analyses, the results of the analysis were in clear favour of 
the sucrose octasulfate dressing; with the increase in acquisition cost being overshadowed by 
the savings made in other areas; driven primarily by the improved rate of healing reported in 
the clinical evidence. Compared to other cost studies found in literature; this result is similar; 
finding in favour of the active intervention, as per all the included studies in the economic SLR 
presented in chapter 2. This is because all the models were based on clinical studies where the 
intervention offered an improvement in healing outcomes, and thus reduced healing times in 
the model. As discussed in chapter 5, a reduction in healing time leads to a significant cost 
saving, one that can offset an increase in acquisition cost of a topical intervention or dressing. 




is based on data from randomised double blinded trials which enhances the validity of the 
results. 
The sucrose octasulfate dressing reduces the time to healing in both DFU and LU patients and 
as a result reduces the economic impact of these wounds. The economic modelling in study 5 
confirms this assertion; which has since been taken forward by NICE and included in clinical 
guidance for the UK healthcare system (https://www.nice.org.uk/guidance/mtg42).  
6.4 Strengths and limitations 
This PhD thesis has several strengths, including methodological strengths and external support 
for the conclusions drawn. Methodologically, this research used a multi-method approach, 
drawing from different data sources and using different analysis methods to paint a complete 
picture surrounding the use of PMM interventions in wound care. This picture included 
evidence from patients, clinicians, existing research and evaluation of current practice. This is 
a key strength as the evidence produced here has been subject to evaluation by The King's 
Technology Evaluation Centre (KiTEC) NICE EAC, and subsequent appraisal by the NICE 
committee. The review by the EAC and NICE has resulted in the recommendation to use the 
sucrose octasulfate dressing being accepted into mainstream guidance published by NICE. This 
is unique, as before now no dressing has been recommended for use by NICE, other than the 
generic instruction to use that with the lowest acquisition cost. 
Another strength of this research is the diverse range of stakeholders who have had input. 
Clinicians have been consulted throughout; in study 2 they were the source of the evidence 
and in study 5 their expertise was consulted to validate the assumptions and parameters used 
in the economic modelling. Clinician input is crucial as they have direct, front-line experience 
with patients, they can offer key insights that may be lacking from desk research such as the 
SLRs in chapter 2. Patients were also a crucial stakeholder, with study 3 focussed entirely on 
collecting their experience and quantifying this for use in the economic modelling study in 
chapter 5. Patients are the ultimate beneficiary of any changes to wound care strategies and 
have their own opinions and experiences with care; it is important to understand their 
perspective. The approach towards healthcare has moved away from doctor driven treatment 
mandates and towards a paradigm where patients are active participants in their care 




less involvement from the individuals. Furthermore, policy experts were consulted in study 2 
and study 5; to provide insights regarding the health system and validate assumptions 
regarding resource use and uptake. 
An important stakeholder when assessing the merits of this research is NICE; and a strength of 
this research is their validation after the endorsement by KiTEC, (external review group that 
independently assesses evidence for NICE to maintain consistent standards across the NICE 
processes and committees). NICE is a world leader in producing guidance on interventions, and 
the ratification of the economic evaluation structure and results provides strength to this 
research and enhances the validity of this thesis.  
Current literature has been extensively reported on in this thesis, with the overall PhD having 
several SLRs of the evidence. These included the clinical SLR of PMM interventions and the 
broad economic SLR in study 1; the systematic literature search in study 2 that was used to 
develop the statements tested during the Delphi panel. Further scoping literature reviews in 
study 3 and study 5 were performed using a systematic approach to retrieval of articles. 
Therefore, this study has been guided by current literature and given that the results presented 
in this thesis are concordant with the existing evidence, provides a level of external validity to 
the results.  This study does not stand alone but has made conclusions that align and build on 
the current body of evidence and further synthesizes the evidence, and collected new data, to 
update the body of knowledge with meaningful results that have had real impact on practice 
through a change in clinical guidance (NICE 2019).  
In addition to secondary research synthesising current literature, this PhD also collected 
original data from varied sources to investigate the research topic further. This included the 
opinions solicited from experts in study 2, the use of validated patient reported outcome tools 
in study 3, and the retrospective real-world data collected in study 4; both presented in chapter 
4. New data was necessary to fill the evidence gaps found through the literature searches to 
ensure the generalisability of this research to the patient population in the UK.  
The economic evaluations performed in study 5 were heavily evidence-based, synthesising the 
results of the previous studies with all assumptions being valid, justifiable, and based on the 




results of the economic evaluations can be interpreted as robust and with limited uncertainty; 
as proven by their resistance to sensitivity analysis and adoption by NICE.  
During the development of this thesis, several outputs relating to each of the individual studies 
have been produced to disseminate the knowledge gained to a broad audience. This had the 
additional advantage of subjecting the methods and results to a peer review process before 
the development of the final economic evaluation; which gives the results of the economic 
analyses even more credence. The International Society of Pharmacoeconomic and Outcomes 
Research (ISPOR) is the leading professional society for health economics and outcomes 
research (HEOR) globally; with the mission of promoting excellence to improve decision making 
for health globally (ISPOR, 2019). ISPOR hosts annual conferences that are attended by 
thousands of HEOR experts. All studies that constitute this PhD thesis have published outputs, 
see Appendix D.  
Despite the numerous strengths of this research; there are also inevitable limitations; that have 
been mitigated where possible. Studying wound care interventions is often difficult, due to the 
inherent challenges in performing a double blinded RCT. This is because the intervention is not 
just a pill or procedure; but a device that is attached to a patient by a healthcare provider. 
Dressings typically come in different packaging and experienced practitioners would be able to 
identify a type of dressing based on look and feel alone. As a result; many studies of wound 
care interventions are subject to low levels of evidence; which explains why the Cochrane 
review performed in venous LU (Westby et al., 2015) struggled to identify any superior 
dressings in line with their strict methodology that assesses study design and risk of bias. This 
has been overcome in this study, because of the level of evidence available to support the 
sucrose octasulfate dressing. The manufacturer could perform double blinded trials due to 
them offering a range of products; and were able to allocate identical dressings to the 
treatment arms, but with only one group receiving the dressing impregnated with the PMM, 
sucrose octasulfate.  
An additional limitation of this research into chronic wounds is the variability in the diagnosis 
methods for LU. There is variance within LUs, regarding what is considered a venous LU and 
what is just a LU. The studies included in this PhD programme have taken a pragmatic approach 




include those of venous, arterial, mixed, or unspecified, origin. This decision has been taken, 
not only for pragmatic purposes, but also because the treatment regimen for these variations 
of LU is similar. 
The economic evaluation presented in chapter 5 also takes the perspective favoured by the 
NICE methodology, which only includes direct medical costs (NICE, 2013). This perspective thus 
excludes costs incurred by the patient and carers; including transportation, time off work, and 
any modifications to their home or lifestyle required due to having a DFU or LU. Further, 
societal costs are excluded from this approach; which include time off work and any social care 
required by the patient. The decision was taken because of the evaluation taking place in the 
England, where the dominant HTA body, NICE, only considers direct medical costs when 
assessing the cost-effectiveness of an intervention. This standard is currently being challenged 
as part of the NICE methods and process review, which is considering the inclusion of other 
costs (NICE, 2019). The models in this thesis have been designed to accommodate the addition 
of these costs and future research can explore the extent of these costs.  
All research results are subject to levels of uncertainty; however, the uncertainty in this 
programme has been mitigated through a variety of methods. This is by performing repeated 
literature searches to support the individual studies, where appropriate. Also, the economic 
models were validated by external experts; tested using multiple sensitivity analyses; and 
further validated by the independent evidence review group in the process of developing NICE 
guidance. Finally, having a series of studies that support the primary aim of the thesis allows 
for analysis of the results as a collective; and these results all support each other; with the 
strength of the conclusions supported by each study.  
6.5 Lessons learned 
Due to the interdependence of the studies in the thesis, a few minor amendments had to be 
made to the planned study that followed. Where necessary, if the results of a previous study 
highlighted an important finding this was included in the studies going forwards. The focus 
throughout the PhD, has been on the PMM dressings; and considering the findings of the 
clinical SLR (study 1), which highlighted that not all PMM interventions are the same; the focus 
was placed on the intervention found the be the most efficacious, the sucrose octasulfate 




intervention offering maximal benefit was assessed. Additionally, in study 1, a QoL SLR was 
planned; however, the review discovered that a SLR has been carried out by Green (2009 and 
2010) which followed the same proposed design; assessing quantitative and qualitative 
evidence separately. This planned systematic review was then abbreviated and presented as a 
scoping review at the start of study 3; to contextualise the study and highlight how the original 
research carried out for this PhD added to current literature.  
The changes made throughout the process sought only to strengthen the results and enhance 
the validity of the research and to improve any recommendations that could be made using 
the body of evidence produced. The changes were minor and only served to clarify the scope, 
in the case of focussing on the sucrose octasulfate dressing, or to avoid the duplication of work 
already in existence, such as the abbreviation of the QoL SLR.  
6.6 Towards the development of guidelines 
The primary aim of this PhD thesis was to evaluate the clinical and economic impact of PMM 
interventions in DFU and LU, with the intention of developing recommendations for guidance; 
this being at the heart of the figure shown throughout this thesis (Fig 6.1). This next section 
begins with an examination of current UK guidelines for DFU and LU and their limitations. Next; 
a discussion of the recommendations made in this PhD, and how they address the limitations 
of current practice. Finally, this section discusses the future implications and next steps with 
regards to guidance for using wound dressings DFU and LU.  
6.6.1 Current guidance 
A guideline for treatment of DFU was issued by NICE in 2015, focusing on prevention and 
management, and was last updated in January 2016 (NICE, 2016). The guidance, NG19, advises 
the use of 1 or more of the following: offloading, control of ischaemia, control of infection, 
debridement and wound dressings (NICE 2016). Section 1.5.10, is the sole paragraph in this 
guideline on the use of dressings: 
When deciding about wound dressings and offloading when treating 
diabetic foot ulcers, take into account the clinical assessment of the wound 
and the person's preference, and use devices and dressings with the lowest 





This is repeated in the Scottish Intercollegiate Guidelines Network (SIGN) guideline for treating 
venous LUs; published earlier in 2010. Wound dressings are somewhat more prominent in this 
guideline; being included in the key recommendations, and having a section, 4.3, dedicated to 
them (SIGN, 2010). However; the SIGN guidance states: 
“Simple non-adherent dressings are recommended in the management of 
venous leg ulcers” 
(SIGN, 2010) 
This instruction is indicative of the budgetary pressures faced by the NHS; and shows a 
preference for the lowest cost wound care dressing as at the time of writing there was no 
robust evidence considered by NICE or SIGN to support the clinical and cost-effectiveness of a 
more expensive or advanced dressing. There is an abundance of different types of wound 
dressings used in clinical practice, as shown in the chart extraction in chapter 4. With such a 
range of products on offer, a cost-containment strategy is useful in reducing acquisition costs 
in a crowded market, as manufacturers are forced to compete on price to win NHS tenders. 
As a health technology assessment body, NICE fits the cost-effectiveness archetype, given the 
assessment methodology that calculates an incremental cost-effectiveness ratio (ICER), and 
maps this against a willingness to pay thresholds of £20,000-30,000 per QALY (McCabe et al., 
2008). Chapter 5 of this thesis explores both cost-consequence and cost-utility as relevant 
modelling methods appropriate for NICE.  
Despite this guidance appearing to be sensible and pragmatic in reducing upfront acquisition 
costs, a limitation of this instruction is that it disregards clinical benefits and the associated 
cost savings offered by efficacious interventions such as the sucrose octasulfate dressing. 
Dressings that are shown to reduce healing times can provide other savings to the health care 
system, in the form of reduced contact with health care professionals, overall lower resource 
use, and lower risk of infection and amputation due to less time with an open wound.  
The guidance to choose the dressing with the lowest acquisition cost is in opposition to usual 
NICE decision-making processes and worryingly, cost-containment could lead to products that 
offer expedited healing and improved patient outcomes being left on the shelf in favour of 
cheaper alternatives not offering any significant clinical benefit- and ultimately leading to 




unnecessary patient suffering, a detriment to society due to the significant costs and high 
resource use incurred by persistent ulceration.  
Another limitation of this strategy is that practitioners in the UK should now be used to the 
typical assessments of cost-effectiveness or cost-utility issued by NICE over the last 20 years 
that routinely recommend interventions that are higher cost; but cost-effective given their 
efficacy. The deviation from this standard procedure in guideline NG19 may lead to confusion 
about best practice. Clinicians likely understand the benefits of reducing healing times beyond 
only the clinical benefits, but also the economic benefits; and as such could use interventions 
that allow them to achieve this. Without a clear direction that needs to be universally applied; 
the variation that is seen in treatment pathways will continue and optimal outcomes will not 
be achieved.  
6.6.2 Development of guidance 
As shown by the results of these studies, the management of chronic wounds such as DFU and 
LU is a key area that could benefit from updated and refined guidance that provides explicit 
details regarding dressings. The focus of the studies presented in this thesis is specifically the 
use of PMM dressings which have not, to date, been addressed by NICE or SIGN.  
The evidence presented in this thesis, and the subsequent publication by NICE of guidance for 
use of the sucrose octasulfate dressing can be presented to clinicians to inform their decision 
making when choosing a dressing for a patient.  
The clinical SLR in chapter 2 supports the superiority of the sucrose octasulfate dressing above 
other PMM dressings; and demonstrates an improvement in wound healing, both complete 
closure rates, time to healing, and speed of onset. The patient reported outcome (PRO) study 
confirms that improved healing will result in an improved QoL for patients with DFU and LU as 
they are shown to be impacted by their wounds, with more severe wounds causing further 
suppression of QoL. This heavy burden, and the efficacy of PMM interventions was 
unanimously supported by the experts consulted in chapter 3, the Delphi study.  
The need for guidance is highlighted by the economic SLR which noted the discrepancy in 
standard care. As only 4 out of 12 included studies were performed within the last 5 years it 




finding again no universal application of standard of care when looking at wound dressings. 
This researcher speculates that this is a direct consequence of the lack of guidance, and that 
without clear direction it will only continue; meaning patient QoL is being reduced and extra 
NHS funds spent on wound care quite unnecessarily when an efficacious dressing is available.  
This thesis has proposed that patients presenting with a DFU or LU be treated with the sucrose 
octasulfate dressing as part of the main care protocol. This strategy has been tested thoroughly 
in the economic evaluations carried out in chapter 5 and found to be not only cost-effective 
but cost-saving in nearly all scenarios included in the robust sensitivity analyses. 
This thesis agrees with the published discourse asserting that a focus on healing wounds faster 
results in better economic outcomes, instead of relying on acquisition cost (Guest et al., 2015). 
However, this is in stark contrast to the published guidance, which does not recommend a 
specific dressing (SIGN, 2010; NICE 2016). It is not clear why NICE persists with this instruction 
despite the cost-effectiveness of more expensive interventions being proven. It can be 
speculated that this is because of the prior lack of submission to NICE or another body by a 
wound care dressing. 
This thesis has addressed this gap; by proving the high-quality evidence and extensive 
economic modelling using data relevant to the UK, and in a concurrent project this evidence 
has been submitted to the NICE MTEP; and guidance recommending the use of the sucrose 
octasulfate dressing, MTG42 as presented in section 5.7.1 has been approved and published 
(NICE, 2019).  
6.6.3 Beyond treatment guidance 
The NICE guideline that recommends the use of the sucrose octasulfate dressing is a key 
milestone in improving outcomes for patients with DFU and LU. This guidance provides an 
instruction to clinicians that the sucrose octasulfate dressing provides patients with improved 
outcomes and is associated with cost savings to the NHS. This is the first time in UK clinical 
practice that a single type of dressing has been recommended for use above all others. This is 




Going beyond treatment guidelines; it is important to raise awareness of MTG42 to ensure 
uptake and optimal access for patients across the UK. As NICE is recognised as a world-leading 
body it is hoped that this guideline will also enable access to patients outside of the UK.  
The implications of these findings are that there should be a shift towards using the sucrose 
octasulfate dressing, the only wound care dressing proven to be cost effective and 
recommended by NICE (NICE, 2019). However, there are potential barriers to this. The NHS in 
England is a large system with defined procurement processes, meaning a change is hard to 
implement outside of set process cycles (NHS Supply Chain, 2020). However, there is hope for 
the sucrose-octasulfate dressing to be prioritised at the next review of Advanced Wound Care 
products at the end of 2020 (NHS Supply Chain, 2020). Further to this, medical technologies 
guidance has no funding mandate, unlike guidance published for pharmaceutical products. As 
such, there is no legal obligation for commissioners to follow this guidance, which could have 
negative implications for patients, clinicians and payers if unproven dressings are used, 
perhaps due to their lower acquisition price, despite a persistent open wound being 
burdensome for all stakeholders. 
 
6.7 Chapter summary 
The five studies that constitute this research programme have each helped to shed light on 
areas where research had previously been sparse and have proceeded to fill evidence gaps 
using secondary research to interrogate the existing literature and collecting new data to 
supplement where necessary. This evidence was used to drive the development of new 
economic models for DFU and LU; using data, insights and conclusions that were generated 
from the previous studies in the thesis. The subsequent acceptance of the economic models 
by NICE and publication of MTG42 is a testament to the robust nature of this research 
programme, and the accompanying evidence generation initiatives.  
This chapter has discussed the objectives of this thesis in depth, including the strengths and 
limitations. The final chapter of this thesis includes a brief summary of the thesis, followed by 





Chapter 7 Summary, recommendations and conclusions 
7.1 Introduction 
This final part of the thesis draws on the body of evidence that has been discussed in the 
previous chapters and presents the summary, conclusions and recommendations based on the 
evidence and insights presented here in this research. Together the studies answer the primary 
research aim; to evaluate the clinical and economic impact of PMM interventions in DFU and 
LU to inform the development of treatment guidelines in the United Kingdom.  A positive 
impact would mean reduced healing times for patients, resulting in more time without an ulcer 
and more life years lived with better quality of life (QoL). Because of reduced time to healing, 
financial savings to the healthcare system would be experienced; patients would have fewer 
expensive complications and have less interaction with healthcare professionals.  
The following section presents a short summary of the thesis, considers the implications of the 
studies in relation to clinical, economic and policy themes; and then presents the contribution 
to knowledge made by the studies, individually and as a collective. 
7.2 Summary of thesis 
Below, a summary of each of the studies is presented, for further detail please see each of the 
corresponding chapters. Together, these five studies form the body of work that addresses the 
primary aim of this PhD thesis.  
Study 1 comprised of two systematic literature reviews (SLRs). The clinical SLR found evidence 
of PMM interventions being effective in improving healing outcomes when compared to 
standard care. The economic SLR found an abundance and variance of treatment options, 
presenting multiple applications of ‘standard care,’ which included a vast array of different 
protocols. The expert panel in study 2 concluded that that chronic wounds cause significantly 
reduced health and QoL for patients and this needs to be taken into consideration in patient 
care with the aim of reducing healing time, and that inhibiting MMPs plays an important role 
in wound healing. By use of the EQ-5D, study 3 mapped patient QoL against a severity ranking; 
and showed that patients with DFU or LU had a lower utility score when compared to patients 
with other chronic conditions, implying that patients with DFU or LU have a worse QoL than 
patients with epilepsy, heart failure, asthma or COPD. A retrospective chart review of 




nearly a quarter of records not providing a reason for the change. This finding reflects the 
outcome of the economic review in chapter 2; that there is no single application of standard 
care. This researcher theorised that it is the lack of explicit guidance regarding the use of 
dressings that has led to this variation in care.  
Study 5 carried out a full economic evaluation, comprising two different methods of economic 
modelling; a static budget-impact model (BIM) and Markov model cost-utility analysis (CUA). 
The budget-impact analyses showed that by introducing the sucrose octasulfate dressing, the 
health care system can experience potentially large savings whilst reducing the number of days 
with ulcers for patients. The results of the cost-utility analysis were in favour of the sucrose 
octasulfate dressing; driven by the improved rate of healing reported in the clinical evidence. 
The sucrose octasulfate dressing was proven to be a cost dominant strategy, meaning that it 
only cost-saving and resulted in health gains. This conclusion was tested extensively using 
sensitivity analysis and stood resolute in a variety of scenarios.  
7.3 Summary of strengths and limitations of the thesis 
This thesis enjoys the following strengths: 
− Thorough peer review, ISPOR, by NICE and the EAC.  
− Resulted in the publication of the first NICE clinical guideline on a specific dressing 
(https://www.nice.org.uk/guidance/mtg42). 
− Multi-method approach using primary and secondary data sources to provide a holistic 
and well-rounded thesis.  
− Diverse range of stakeholders, multi-disciplinary approach reflects the treatment of 
chronic wounds in practice.  
− Alignment with previous research providing external validity to the results. 
The following limitations have been identified and, where possible, their impact mitigated: 
− Lack of high-quality evidence in wound care; mitigated by the two double-blind RCTs 
performed on the sucrose octasulfate dressing. 
− Variability of diagnosis methods for LU; overcome by including all leg ulcers that are 




− Economic modelling takes a payer perspective, that of NICE in England, and thus 
excludes patient, carer and societal costs. This is the industry standard and what is 
required for submission into NICE technology appraisal programmes.  
7.4 Summary of implications of the thesis 
This thesis began with an assessment of the current literature and found no contemporary 
studies on QoL for patients with DFU and LU; no NHS perspective economic modelling, no 
analysis of treatment switching and no assessment of the sucrose octasulfate dressing. The 
body of knowledge that is presented in this thesis has addressed these gaps and drawn 
conclusions that have several implications for the future. The implications are presented below 
under the categories of clinical and practice, economic, and policy.   
7.4.1 Clinical and practice implications 
The research presented in this thesis has demonstrated that there is a dressing available that 
can improve clinical outcomes for patients; the sucrose octasulfate dressing (Meaume et al., 
2012; Edmonds et al., 2018). The implication of this is that, if used, wounds will be more likely 
to heal, and they will do so at a faster rate. Additionally, patients will benefit from reduced 
adverse events due to less time with an active ulcer as shown in the economic modelling 
presented in chapter 5. For DFU patients this equates to fewer amputations, which can be a 
significant and traumatic surgery; additionally, this will mitigate some of the mortality risk 
associated with DFU and amputation (Stern et al., 2017). For LU, this would mean fewer 
infections for patients and less likelihood of a wound becoming long-lasting and thus even 
more difficult to treat (Margolis et al., 2004).   
For a wound care practitioner, the findings presented here should provide evidence to support 
decision making regarding wound care dressings; as it has been shown that the sucrose 
octasulfate dressing is the cost-effective choice that offers improved healing. This should 
provide clarity where previously there has been none; being able to rely on the series of studies 
presented here using the multi-methods approach should give confidence to decision makers; 
even in opposition to current NICE guidance NG19 that instructs them to use the dressing with 




Empowering health care providers (HCPs) to make decisions that are in the best interest of 
their patients is an important implication of this research; and one that should hopefully cause 
a step-change in how patients with a DFU or LU are treated.  
7.4.2 Economic implications 
The clinical outcomes presented in this thesis have subsequent economic implications for the 
healthcare system in terms of reducing cost and facilitating efficient resource utilisation. 
Wounds accounted for approximately 5.5% of NHS expenditure in 2016 (Phillips et al., 2016), 
and this would be expected to reduce if wounds were more likely to heal, and heal faster, with 
fewer adverse events.  
The cost-utility models presented in chapter 5 showed that the highest cost category for both 
DFU and LU was outpatient treatment such as community nurses or General Practitioner (GP) 
appointments; and this research shows that this can be reduced by following the treatment 
regimen including the sucrose octasulfate dressing. In the DFU model, the biggest relative 
change was seen in the cost of amputation events, which was 47% less in the sucrose 
octasulfate group than the standard care only group. Amputation is a costly adverse event, and 
the model shows a nearly 50% drop in the number of amputations carried out in the sucrose 
octasulfate arm (40/1000 patients vs 21/1000 patients). Key drivers of the cost are the cost of 
the dressings, the transitions for healing and infection/complication and the resource use with 
regards to community nursing and hospital visits. The increased likelihood of healing drives the 
cost savings for the sucrose octasulfate dressing. 
These cost savings would enable budgets and resources to be redistributed in the healthcare 
system to ensure that the maximum health benefit is being obtained from the limited budget 
and resources available.   
7.4.3 Policy implications 
The findings of the CUA and BIMs presented here have been ratified by the NICE Medical 
Technologies Evaluation Process (MTEP) during the assessment of the sucrose octasulfate 
dressing, as discussed in chapter 5. As a result of this assessment, and as a testament to the 
robust nature of this research; NICE has subsequently published a new guideline regarding the 
sucrose octasulfate dressing. Medical Technologies Guidance 42 was published in January 2019 




people with DFU or (v)LU. This guidance is published and freely available on the NICE website 
at www.nice.org.uk/guidance/mtg42.  
The publication of guidance supporting the sucrose octasulfate dressing is encouraging, 
however uptake of medical technologies guidance is not mandatory. This is inherently biased 
against interventions that present as a device, as pharmaceutical products with the same level 
of evidence and recommendation for use by NICE have a funding mandate from the NHS; and 
should a patient be clinically indicated to receive the product, then it must be made available 
to them. However, this does not currently extend to medical devices assessed using the MTEP. 
To realise the outcomes presented in this thesis, the recommendation to use the sucrose 
octasulfate dressing should also be in receipt of a funding mandate, to prevent clinicians from 
avoiding use until later in the treatment pathway due to a bias in favour of dressings with a 
lower acquisition cost. 
Fortunately, this is currently under review and a presentation given at the NICE Annual 
Conference 2019 in Manchester has explicitly stated that a funding mandate is being 
developed for medical technologies guidance. This is to address the bias against interventions 
that are classified as a device. The policy is expected in March 2020 and active from October 
2020; it was stated that it will be both prospective and retrospective, thus applicable to the 
sucrose octasulfate dressing, however the criteria and mechanism for funding is not yet 
finalised (NICE, 2019).  
This is the first guideline of its kind; to recommend the use of one dressing above others and 
will hopefully lead to an improvement in healing outcomes for patients, which is associated 
with financial savings for the health system. This thesis has repeatedly pointed out that the use 
of the dressing with the lowest acquisition cost is not the best strategy to improve outcomes 
in the categories of clinical, economic, and QoL.  
7.5 Contribution to knowledge 
This thesis has resulted in a substantial contribution to the knowledge base in this area, 
drawing on the existing literature, generating new data, and synthesising the two in models to 
explore proposed changes to practice. This thesis has explored the use of the sucrose 
octasulfate dressing; a specific type of PMM dressing that is marketed in the UK under the 




The clinical SLR was the first to examine PMM interventions in both DFU and LU patients. 
Previously, research on dressings has been limited due to the inherent difficulty of performing 
a randomised, double-blind controlled study; and thus, has been subject to the biases of less 
robust levels of evidence. The sucrose octasulfate dressing has been tested in multiple double-
blind controlled trials and has been found to reduce healing time for patients with a DFU or 
LU. These studies have for the first time both been included in the SLR presented here; and 
due to the inclusion of this high-quality evidence; conclusions could be drawn about the 
efficacy of the sucrose octasulfate dressing, when compared to both a neutral dressing and 
other PMM interventions.  
The economic SLR has built upon previous SLRs in wound care, after the exploratory SLR 
performed prior to the Delphi panel did not find evidence of strong meta-analyses done in this 
area. The economic SLR presented in chapter 2 has explored the reasons for this evidence gap 
and has identified the lack of standardized standard care as a key driver. Now that this 
relationship has been identified; researchers designing clinical trials should be mindful of these 
results and focus on using interventions that allow a meta-analysis. The economic SLR also 
provides evidence that directly counters the assertion in current guidance that practitioners 
should use the dressing with the lowest acquisition cost; as this SLR has shown that 
interventions can be cost-effective despite having a higher acquisition cost than a comparator.  
The Delphi panel presented in chapter 3 of this thesis took a novel approach to eliciting expert 
opinion. This study mirrors the real-world treatment of chronic wounds by including a 
multidisciplinary team of wound care experts; reflecting the varied group of experts that see 
patients with DFU and LU. The modification of the method to include a literature review using 
a systematic search strategy to produce the evidence-based statements sets this study apart 
as distinct and original in its methodology. This study has applied a greater level of academic 
rigour than is typically found when eliciting expert opinion. The subsequent peer-reviewed 
publication in the Journal of Wound Care (Russell et al., 2018) will hopefully be the start of a 
paradigm shift away from the advisory-board style expert panel favoured by the 
pharmaceutical industry and towards a more systematic, repeatable style. 
The PRO study presented here was the first to use EQ-5D-5L in patients with DFU and LU 




EQ-5D-3L allows for a greater depth of analysis to accurately detect small changes in patients 
QoL. In addition to this study being the first use of EQ-5D-5L in these disease areas, it is the 
first example of reporting utility scores for patients in the UK with DFU and LU in an 
observational setting; to understand a real-life QoL score, as is experienced by patients day-to-
day and not impacted by any clinical trial protocol they could be following. This adds to the 
body of knowledge by providing utility scores that can be used in economic modelling; and can 
be assumed generalisable to the UK population.  
The chart extraction presented as part of the real-world evidence chapter (chapter 4) has 
produced new primary data, which has been analysed to produce evidence to inform decision 
making. The real-world evidence presented here is valuable in understanding current 
treatment pathways and builds upon previous work by Guest et al., (2018) that reported 
outcomes and resource use for DFU and LU. This provides additional data to understand the 
habits of practitioners; which is important when trying to evaluate treatment guidelines, or the 
lack of, and understand the attitudes towards treatment switching.  
The economic evaluation carried out for this study has contributed to knowledge by providing 
a robust analysis that presents the sucrose octasulfate dressing as cost saving to the NHS when 
used in patients with DFU and LU. The CUA and BIMs show that an improvement in healing 
time would be directly responsible for a financial saving to the healthcare system and a QoL 
gain to patients; should the sucrose octasulfate dressing be used in routine practice when a 
patient presents with a chronic wound.  
These models have been evaluated by NICE and adopted into clinical guidance, MTG42; the 
first clinical guideline of its kind, for a specific type of wound dressing, recommending its use 
to improve outcomes for patients. This is a pivotal contribution to knowledge that has tangible 
consequences in the real-world; patients should be better off, with faster healing wounds that 
cost the NHS less because of this study.  
Together these studies provide an overwhelming body of knowledge using a multi-methods 
approach. This is a unique attribute of this thesis; the synergy between 5 different 
methodologies to produce a powerful argument regarding the clinical and cost-effectiveness 





The recommendations are presented below.  
7.6.1 Healing chronic wounds early needs to be a higher priority 
Chronic wound care should be a higher priority area for the NHS. This is because of the 
substantial burden that is caused by a DFU or a LU. This burden is felt by patients, the 
healthcare system and the wider society. Ultimately, given the amount of time, money, and 
resources that is spent on managing wounds, the burden of chronic wounds is felt by other 
patients in the healthcare system, as they compete for the finite resources available from the 
NHS. The use of hospital beds when a wound has an exacerbation, or the use of an operating 
theatre when a DFU requires surgery are both examples of resource use that is incurred by 
chronic wounds, which could be avoidable if there was a priority focus on implementing the 
best strategies to improve healing outcomes for patients.  
Not only cost, but due to the limited focus on healing wounds, patient QoL is suppressed for 
longer than is necessary as they suffer with a wound for a long time; evidence also suggests 
that the longer a wound has existed, the harder it is to heal. This means that healing, and not 
just managing, a wound should be a priority upon presentation to a health care provider.  
7.6.2 The sucrose octasulfate dressing provides a solution 
The sucrose octasulfate dressing has been clinically proven to improve healing outcomes for 
patients with either a DFU or LU. This reduced time to healing has been proven in this thesis 
to reduce the costs to the healthcare system by avoiding a long continuation of treatment for 
many weeks whilst wound healing stalls because of using a standard neutral dressing. It is 
important for clinicians and commissioners to not be myopic about the acquisition cost of a 
device; the device only accounts for a small fraction of the overall cost of healing a DFU or LU.  
The use of the sucrose octasulfate dressing would also alleviate the patient burden felt because 
of chronic wounds. This is both directly; due to experiencing fewer days with a wound, but also 
indirectly through the avoidance of adverse events associated with long lasting open wounds. 
For DFU, the rapid healing offered by the sucrose octasulfate dressing leads to fewer 
amputations in the economic modelling, and less complications such as critical ischaemia or 
hospitalisation. For a LU patient, having a healed wound means there is less risk of an infection; 




exudate or smell. By controlling the number of adverse events through faster healing, the 
sucrose octasulfate dressing provides a solution to patients with chronic wounds that is non-
invasive and recognised by NICE. The recognition by NICE, a world-leading health technology 
assessment body, is important to ratify the claims made here; both by providing impartial 
external validity and instilling confidence in clinicians that the sucrose octasulfate dressing 
improves healing outcomes, and, in turn, economic outcomes.  
7.6.3 Treatment guidelines for DFU and LU require updating 
Current treatment guidelines for patients with a DFU or LU are out of date and the explicit 
recommendation in NICE NG19 to use the dressing with the lowest acquisition cost could 
potentially be causing harm to patients. This recommendation could arguably be a root cause 
of the divergence in treatment pathways seen throughout the study; coupled with the 
inconclusive Cochrane reviews on the topic of wound dressings. SIGN guidelines that instruct 
on the treatment of LU also lack specificity when discussing dressings. The lack of instruction 
has led to no single intervention being recognised as superior.  
The sucrose octasulfate dressing has received a positive recommendation from NICE in January 
2019; and the publication of this guidance has automatically rendered NG19 and SIGN 120 out 
of date. Harm to patients could consequently occur if a clinician is unaware of the new 
guidance and defers to the NG19 or SIGN guidance; subsequently using a low-cost dressing 
that does not offer the reduced time to healing and other benefits that are associated with the 
sucrose octasulfate dressing. It is the strong recommendation of this research that these 
treatment guidelines are updated to be consistent with the latest guidance supporting the use 
of the sucrose octasulfate dressing in patients with DFU and LU.  
7.6.4 Further research into the sucrose octasulfate dressing 
This thesis has presented the sucrose octasulfate dressing as a potential solution to several key 
issues facing patients with wounds and the clinicians who treat them. Namely, the QoL burden, 
the clinical difficulty of healing wounds, and the associated expense. Further research into the 
impact of these recommendations would help to substantiate claims made here; such as a 
larger real-world study to observe treatment patterns and patient outcomes. This research 
could focus on outcomes experienced by patients outside of a clinical trial setting; where much 




uncertainty surrounding the effectiveness of a new intervention should increase the uptake 
and use of the dressing. It is only with widespread use would the financial and economic 
implications of this research be fully realised. Studies to address the limitations of this thesis, 
explored in section 6.4, would help to support the evidence generated here; perhaps to include 
much larger studies to test the results of the real-world studies presented in chapter 4.  
Further economic modelling undertaken from the perspective of either the patient or society, 
would help to further understand the cost and health implications of having a wound. 
However; in the UK this type of model is perhaps surplus to requirements as the healthcare 
budget comes from the government through the NHS, and not from an individual. Therefore, 
in the UK it is direct medical costs that are of highest importance when assessing the viability 
of introducing a new intervention. Personal and societal approaches to economic evaluation 
are important to understand the full burden of disease but are inevitably more complicated, 
with a broader spectrum of costs included, outside the remit of the NHS.  
Given that one of the results of this research is the change in treatment guidance, research 
that explored the uptake of this guidance and the impact on treatment practice would be 
useful in assessing the success of this thesis in influencing treatment practice; beyond the 
development of treatment guidelines.  
7.7 Overall Conclusions 
The research that has been presented in this thesis has influenced a shift in the understanding 
and treatment paradigm for DFU and LU. The key finding of this research is that the economic 
evaluation showed the dominance of the sucrose octasulfate intervention, meaning it is both 
more effective and cost saving. Clinicians and policy makers should be aware of these findings 
to facilitate efficient resource allocation to maximise efficiencies when operating in an 
environment of budgetary pressures. Not only would these financial savings benefit the health 
care system, but these findings will also improve the health and QoL outcomes of patients with 
chronic wounds.  
More work to educate health care providers on the use of this dressing would help to improve 
uptake of the guidance that has been produced using work presented in this thesis. Gaining a 
positive NICE guidance for a product is often only the first hurdle in access; uptake and real-




that the sucrose octasulfate dressing should be used first line would help to maximise these 
outcomes as it would reduce the delay for patients receiving an efficacious treatment.  
The impact of this guidance and the body of work presented here may raise awareness of the 
impact of chronic wounds and raise their priority within the NHS; especially as evidence to 
support the sucrose octasulfate dressing as the solution to the palpable unmet need is now 
available.  
7.8 Closing statement 
This thesis has been undertaken with the intention of supporting patients with chronic wounds 
in achieving optimal outcomes to improve their QoL. By doing this, there will be an opportunity 
to redistribute funds within the NHS to spend in areas that do not yet have interventions to 
resolve the unmet need. The findings presented here should help to guide resource allocation 
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Appendix A. Study 1: Systematic literature review (Chapter 2) 
A.1.Search string used in electronic databases 
 “((Wound* AND chronic) OR (ulcer AND (pressure OR diabetic foot OR leg))) AND 
(management OR treatment OR care) AND (dressing*) AND ((resource AND (use OR 
utilisation)) OR cost) AND (quality of life OR patient outcomes OR burden OR impact) AND 
(effectiveness OR efficacy)” 
Appendix B. Study 2: Delphi methodology expert panel (Chapter 3) 
B.1. Search terms used to identify literature 
Search terms Item 
(Wound* and chronic) or (ulcer and (diabetic foot or leg)) Population 
Management or treatment or care Intervention 
Dressing* Intervention 
Resource and (use or utilisation) or cost Outcome 
Quality of life or patient outcomes or burden or impact Outcome 















B.2. Panel representation 
Name Title Place of work 
David Russell Consultant Vascular Surgeon and 
Honorary Clinical Associate 
Professor 
Leeds Teaching Hospitals NHS 
Trust 
Dr Leanne Atkin Vascular Nurse Specialist Mid Yorkshire NHS Trust 
April Betts Project Manager/PhD researcher Manchester Metropolitan 
University 








Sarah Gardner Clinical Lead, Tissue Viability Oxford Health NHS Foundation 
Trust 
Dr Julie Green Senior Lecturer in Nursing, 
Director of Postgraduate 
Programmes 
Keele University, School of 
Nursing and Midwifery 
Dr Chris Manu Consultant Diabetologist and 
Clinical Researcher in Diabetic 
Foot 
Kings College Hospital, London 
Tracey McKenzie Head of Tissue Viability Services Torbay and Southern Devon 
NHS Foundation Trust 
Helena Meally Hospital Podiatrist Leeds Teaching Hospitals NHS 
Trust 
Louise Mitchell Clinical Lead Podiatrist Birmingham Community 
HealthCare 




Visiting Professor of Health 




Andrew Sharpe Advanced Podiatrist and Lecturer 
Practitioner 
West Lancashire Community 
Service, University of 
Huddersfield 












B.3. Workbook 1 




Managing chronic wounds is an increasing burden, in 2016 the prevalence of wounds was estimated to be 
as high as 15/10,000, triple a previous estimate (1). The costs of treating chronic wounds, including 
Venous Leg Ulcers (VLU), Diabetic Foot Ulcers (DFU), and Pressure Ulcers (PU) are also increasing, with 
community prescriptions having risen 51% from £122 million to £184 million in the period between 2006 
and 2012 (2, 3).  
The field of wound management has a number of areas of uncertainty regarding emerging technologies 
and their place in the treatment pathway. This study aims to address the areas needing expert consensus.  
Following an extensive review of existing literature (for details please see 'Search Methodology' sheet), 
evidence-based statements were generated to address identified emerging concepts and areas of 
controversy; which include the following: 
• The definition of chronicity 
• The burden of illness 
• Reducing healing time 
• The role of matrix metalloproteinases (MMPs) 
• Impact of early interventions on clinical outcomes 
• The use of dressings and treatments 
Process Summary: Modified Delphi Method 
The Delphi methodology was developed by the RAND Corporation in the 1950’s and aims to arrive at an 
expert consensus using an iterative process. The method consists of a group of experts anonymously 
replying to a questionnaire; then receiving the group feedback, after which this process repeats itself (4). 
This is an accepted methodology and there are many examples available (5) (6). 
The modified process that we are using includes two rounds of anonymous voting followed by a face-to-
face meeting.  You are invited to read the list of statements on the Voting Sheet of this workbook and 
vote yes if you agree or no if you do not. If you vote no; you must fill in comments, if you vote yes; this is 
not necessary. Your comments should include your reasons for rejecting the statement, and suggestions 
of how to rephrase the statement based on your assessment of the evidence base of the references 
provided. 
After the first round of voting, all responses will be compiled and moved forwards as follows:  
1. Statements with over 80% agreement → Confirmed and removed from the second round 
2. Statements with over 80% dissent → Rejected and removed from the second round 
3. Statements that did not reach 80% agreement or dissent → Will be modified using the 
comments and included in the second round of voting.  
You will receive a summary of the group’s votes in round one, and updated workbook for the second 
round of voting. Again, you are invited to read the list of statements on the Voting Sheet of this workbook 
and vote yes if you agree or no if you do not. If you vote no; you must fill in comments, if you vote yes; 
this is not necessary.  
After the second round of voting, all responses will be compiled and moved forwards as follows: 
1. Statements with over 80% agreement → Confirmed.  
2. Statements with over 80% dissent → Rejected. 
3. Statements that did not reach 80% agreement or dissent → Will be modified using the 












B.3.3 Request for comments if voting ‘no’: 
 
B.3.4 Workbook 1 voting sheet:  
ID 
# 





A: Definition of chronicity 
1 
Wounds are deemed chronic if 
they are caused by an 
underlying aetiology or do not 
follow a standard healing 
pattern. 
176 3 





306 307 308 3 
2 
Chronic wounds have 30 times 
the level of matrix 
metalloproteinases (MMPs) 
than acute wounds. 
156 1 
    197 3 








Venous Leg Ulcers (VLU), 
Diabetic Foot Ulcer (DFU), and 
Pressure Ulcer (PU) patients 
are shown to have raised levels 
of MMPs from onset. 
233 3 





B: The burden of illness 
4 
Chronic wounds significantly 
impact quality of life because of 
the pain they cause. 
180 268 2 
    
271 272 273 3 
194 1 
274 275 1 
5 
VLU, DFU and PU are a 
significant workload burden for 
health care providers. 
91 2 















Patients with VLU, DFU and PU 
suffer significantly reduced 
quality of life across all 
dimensions, such as: pain, 
physical limitations, social 
isolation, depression/anxiety. 
114 2 
    
237 238 2 
241 266 1 




The psychological impact of 
chronic wounds is severe, 
patients report a loss of self, 
social isolation, poor self-
image, feelings of being a 
burden and hopelessness for 
the future. 
239 277 278 279 2 
    
280 281 282 2 
283 2 
284 1 
285 286 1 
8 
The focus of treatment is 
centred on the physical wound, 
patients report that this is 
insufficient, considering the 
large psychological and social 
burden. 
167 1 
    
248 289 290 3 
287 3 




(TLC-NOSF) has been shown to 
significantly reduce 
263 1 






anxiety/depression for a 
patient. 
10 
Chronic wounds cause a 
burden to both the patient and 
to the caregiver. 
243 244 2     
11 
The cost to the patient and the 
carer is often excluded or 
underestimated in cost 
effectiveness models. 
120 3 







In addition to a severe quality 
of life burden, the patient also 
faces financial costs such as 
time away from work, early 
retirement, medications, 
dressings and transport costs. 
121 3 





Wounds can take a long time to 
heal and have a high likelihood 
of recurrence, leading to a 
significant quality of life impact. 
157 1 










C: Reduce healing time 
14 
Ulcers can be slow to heal, with 
wound size and duration 
affecting healing. 
148 1 






More severe ulcers are more 
expensive. 
107 2 
    
109 2 




A large initial wound area 
reduction is indicative of 
healing by 24 weeks. 
51 1 
    62 1 
150 2 
17 
The standard follows up in 
clinical trials is 12 weeks to 
observe wound area reduction. 
164 1 
    165 1 
166 1 
D: The role of matrix metalloproteinases (MMPs) 
18 
228 3 





Inflammation is an early stage 




MMPs are a part of healthy 
healing, expressed in the 
inflammation phase during 
early wound healing. 
210 211 1 
    
220 3 
20 
When a wound moves to the 
next phase of healing, levels of 
MMPs fall. 
200 202 203 3     
21 
Excess proteases present in 
VLU, DFU and PU can impair 
wound healing by preventing 
progression to the next stage of 
healing. 
57 58 1 




The wound is stuck in the 
inflammation phase leading to 
the destruction of new tissues. 
195 3 





Elevated levels of MMPs are 
predictive of non-healing. 
156 1 
    
193 1 
204 3 







Interventions that modulate 
the wound environment may 
enhance healing. 
63 65 1 








Removing excess MMPs from a 
wound improves healing. 
53 2 
    
57 58 1 
65 1 
66 68 1 
73 1 
26 
TLC- NOSF technology inhibits 
MMPs and accelerates healing. 
54 2 
    
59 1 
74 1 
62 64 65 1 
27 
Of the 24 known MMPs, MMP-
9 has been shown to be 
detrimental to healing, killing 
growth factors. 
199 3 









A specific MMP-9 inhibitor is 
potentially more effective in 
stimulating healing. 
196 3 
    216 3 
219 3 
29 
TLC- NOSF reduces levels of 
MMP-9. 
301 3 
    
302 3 
30 
TLC-NOSF has been shown as 
superior to neutral foam 
dressings in reducing healing 
time 
62 63 64 1 
    
13 2 
E: Early interventions lead to better outcomes 
31 
VLU, DFU and PU are 
associated with increased 
morbidity and mortality. 
78 1 







Patients with VLU, DFU and PU 
are most likely to be elderly 
and frail, needing minimally 
invasive treatment options.  
168 1 








Early assessment, diagnosis and 
treatment of a VLU, DFU and 
PU can significantly improve 
quality of life. 
264 3 
34 
An adjunctive therapy to 
standard of care can promote 
faster healing. 
4  1 
    
6  3 
8  3 
43 1 
44 45 3 
235 3 
35 
Older wounds are harder and 
more expensive to heal, so 
early intervention will reduce 
healing time and cost. 
40 41 2 






Dressings that are associated 
with less resource use and 
shorter treatment periods, lead 
to fewer adverse events and 
less disease progression. 
87 2 










Early investment in treatment 
provides a reduction in long 
term costs; prolonged futile 
conservative treatment is more 
costly. 
128 129 133 2 
131 132 3 
152 1 
F: The use of dressings and treatments 
38 
Ankle-brachial pressure index 
(ABPI) measurements help to 
diagnose VLU and assess 
patient’s suitability for 
compression. 
106 2 
    




An adjunctive therapy as well 
as compression can promote 
faster healing. 
3  2 
    
4  1 
6  3 
8  3 
43 1 
44 45 3 
235 3 
40 
Hosiery has been shown as a 
cost-effective option and 
increased use is likely to result 
in substantial savings for the 
NHS. 
99 100 1     




An ideal dressing would be cost 
effective, accepted by the 
patient, easy to change, 
effectively manage exudate, 
reduce healing time, and be 


















TLC-NOSF has been shown as 
superior to Oxidized 
regenerated cellulose/collagen; 
especially in non-responsive, 
older wounds. 
60 61 69 70 1     
43 The purchase price of a 
dressing is not indicative of 
85 2 





cost-effectiveness; there is a 






Protease inhibitors have been 
shown to be a cost-effective 
option. 
82 2 
    
84 2 




Nurse visits are a key driver of 
cost; advanced dressings 
requiring fewer changes are 
therefore preferred. 
102 3 






Dressing changes can be a 
cause of pain and products and 
techniques to minimise this are 
recommended. 
140 2 






Local management of the 
wound site considered easy in 
most cases with the TLC-NOSF 
dressing. 
11 3 
    




B.4. Comments on workbook 1 
B.4.1 Comments per statement compiled from the returned workbooks.  
Please note that statements in green were confirmed as having met or exceeded the 80% 




A: Definition of chronicity   
1 
Wounds are deemed chronic if they are 
caused by an underlying aetiology or do 
not follow a standard healing pattern. 
"Wounds that do not heal in an orderly 
set of stages or in predictable amount of 
time. Some patients have underlying 
aetiologies, but wounds heal in 12 weeks 
and remain healed. Suggest including 
long duration or "recurring frequency.  
"Chronic if not following a standard 
healing pattern in a defined period but 
may be acute and heal if an underlying 
aetiology is managed e.g. offloading for 
the diabetic foot, compression for VLUs. 
Would define as chronic only if they do 
not follow a standard pattern of healing 
irrespective of the underlying aetiology." 
2 
Chronic wounds have 30 times the level of 
matrix metalloproteinases (MMPs) than 
acute wounds. 
"Chronic wounds have a significantly 
increased level of matrix 
metalloproteinases (MMPs) when 
compared to acute wounds, this may be 
up to 30 times greater. - based on this 
evidence shown, only one lower evidence 




"The statement needs rephrasing. A 
suggestion of up to 30 x … has been 
reported " 
3 
Venous Leg Ulcers (VLU), Diabetic Foot 
Ulcer (DFU), and Pressure Ulcer (PU) 
patients are shown to have raised levels 
of MMPs from onset. 
"Statement needs rephrasing. Remove 
onset or define onset further. " 
"These ulcers may show raised levels of 
MMPs at initial presentation to a 
specialist, but this may be delayed from 
onset of the ulcer. Would change to "at 
presentation to a specialist"." 
B: The burden of illness   
4 
Chronic wounds significantly impact 
quality of life because of the pain they 
cause. 
"DFU's can impact quality of life of a 
patient without causing pain." 
"Statement needs rephrasing. Chronic 
wounds is too generic, what about 
neuropathic DFU? Pain associated with 
chronic wounds significantly …. " 
"Not all chronic wounds cause pain" 
5 
VLU, DFU and PU are a significant 
workload burden for health care 
providers. 
"All areas seem to be qualified in the 
studies my concern is with the term 
'significantly' which implies clinical 
significance, is significantly required in 
the statement?" 
6 
Patients with VLU, DFU and PU suffer 
significantly reduced quality of life across 





limitations, social isolation, 
depression/anxiety. 
7 
The psychological impact of chronic 
wounds is severe, patients report a loss of 
self, social isolation, poor self-image, 
feelings of being a burden and 
hopelessness for the future. 
  
8 
The focus of treatment is centred on the 
physical wound, patients report that this 
is insufficient, considering the large 
psychological and social burden. 
"The focus of treatment is centred on the 
physical wound, this is insufficient, 
considering the large perceived and 
patient reported psychological and social 
burden"? 
"Sometimes the case but not always. 
Some patients report …" 




OligoSaccharide Factor (TLC-NOSF) has 
been shown to significantly reduce 
pain/discomfort and anxiety/depression 
for a patient. 
"For patients with chronic wounds" 
10 
Chronic wounds cause a burden to both 
the patient and to the caregiver. 
  
11 
The cost to the patient and the carer is 







In addition to a severe quality of life 
burden, the patient also faces financial 
costs such as time away from work, early 




Wounds can take a long time to heal and 
have a high likelihood of recurrence, 
leading to a significant quality of life 
impact. 
"Statement needs rephrasing. Wounds 
have significant impact on QOL due to 
the duration required for healing & high 
recurrence rates" 
"Depends on underlying cause" 
14 
Ulcers can be slow to heal, with wound 
size and duration affecting healing. 
  
15 More severe ulcers are more expensive. 
"does 'severe ulcer' need qualifying? We 
are referring to DFU and PU scores, is 
there a score for VLU or is it based on 
size?" 
"What is the definition of severe? This 
statement is too general. Costs increase 
when patients are admitted to hospital 
so may want a statement on avoiding 
complications that result in admission. 
Also the duration of the wound impacts 
on cost so this may be a more useful 
statement." 
"Needs rephrasing. Define severity in 
terms of ulcers (VLE, DFU, PU).   " 
"Done necessarily agree with this as we 




classed as 'severe' but due to poor 
management/ lack of skills these become 
expensive." 
16 
A large initial wound area reduction is 
indicative of healing by 24 weeks. 
"'large initial' needs qualifying and these 
studies only relate to VLU. "During the 
first four weeks if a greater than 20% 
reduction of wound area is seen, healing 
at 24 weeks is likely in VLU" 
"Although I agree in principle that this is 
the case, what is the definition of large?? 
Maybe statement needs to be more 
specific." 
"We would expect to see wound healing 
within a four-week period." 
17 
The standard follows up in clinical trials is 
12 weeks to observe wound area 
reduction. 
"Not all trials are designed this way" 




Inflammation is an early stage of the 
standard wound healing process. 
  
19 
MMPs are a part of healthy healing, 
expressed in the inflammation phase 
during early wound healing. 
  
20 
When a wound moves to the next phase 






Excess proteases present in VLU, DFU and 
PU can impair wound healing by 
preventing progression to the next stage 
of healing. 
"No reference to VLU, DFU or PU in 
quotations. Rephrasing of statement 
required" 
22 
The wound is stuck in the inflammation 
phase leading to the destruction of new 
tissues. 
"This does not make sense as a stand-
alone statement. Suggest when MMPs 
are elevated wounds remain stuck in 
…………." 
"Does not destruct but prohibits 
progression" 
23 




Interventions that modulate the wound 
environment may enhance healing. 
  
25 
Removing excess MMPs from a wound 
improves healing. 
"Only helpful once underlying conditions 
addressed" 
"Removing excess MMPs from a wound 
may improve healing" 
26 
TLC- NOSF technology inhibits MMPs and 
accelerates healing. 
"Does it inhibit all types of MMPs? This is 
not shown in this evidence. "TLC-NOSF 
technology can inhibit MMPs synthesis, 
facilitating faster healing" 
"reduces MMP's yes but will not always 






Of the 24 known MMPs, MMP-9 has been 
shown to be detrimental to healing, killing 
growth factors. 
"Whilst MMP-9 is significant other MMPs 
also impact on wound healing." 
28 
A specific MMP-9 inhibitor is potentially 
more effective in stimulating healing. 
"Unsure good level of evidence supports 
this" 
29 TLC- NOSF reduces levels of MMP-9. 
"In vitro TLC-NOSF has been shown to 
reduce levels of MMP-9" 
"Can we make this statement without 
level 1 evidence. Suggest some studies 
have shown …." 
"Unsure good level of evidence supports 
this" 
30 
TLC-NOSF has been shown as superior to 
neutral foam dressings in reducing healing 
time 
  
D: Early interventions lead to better outcomes   
31 
VLU, DFU and PU are associated with 
increased morbidity and mortality. 
  
32 
Patients with VLU, DFU and PU are most 
likely to be elderly and frail, needing 
minimally invasive treatment options.  
"VLU, DFU and PU is more prevalent in 
older people and the frail, minimally 
invasive treatment options may be need 
in these groups where surgery is not 
indicated." 
"Age should not be a barrier to invasive 





"Reference only to VLU in quotations 
used" 
"Do not agree with whole of statement " 
"Potentially benefiting from minimally 
invasive options. Most of these patients 
are higher risk, but not excluded from 
standard open interventions." 
33 
Early assessment, diagnosis and 
treatment of a VLU, DFU and PU can 
significantly improve quality of life. 
"Suggest early diagnosis ……. can lead to 
improved outcomes" 
"Reference only to VLU in quotations 
used" 
34 
An adjunctive therapy to standard of care 
can promote faster healing. 
"Rephrasing needed. Quotations refer to 
adjunctive therapy in relation to VLU." 
"Not in all cases" 
"Blanket statement and not necessarily 
applies to all wounds. Should be 
considered in cases where wound healing 
may be compromised but not in those 
that would heal without complications." 
35 
Older wounds are harder and more 
expensive to heal, so early intervention 
will reduce healing time and cost. 
"Suggest change to the longer the 
duration of the wound the harder it is to 
heal and the more costly. I think you 
have two separate statements here" 
"No reference to older wounds within 





Dressings that are associated with less 
resource use and shorter treatment 
periods, lead to fewer adverse events and 
less disease progression. 
"Not enough evidence relating to fewer 
adverse events or less disease 
progression from quotations. Rephrasing 
needed " 
"No dressing will prevent disease 
progression" 
"Unclear statement. Advanced dressings 
associated with increased initial resource 
but reduced overall resource because of 
early healing. " 
37 
Early investment in treatment provides a 
reduction in long term costs; prolonged 
futile conservative treatment is more 
costly. 
  
E: The use of dressings and treatments   
38 
Ankle-brachial pressure index (ABPI) 
measurements help to diagnose VLU and 
assess patient’s suitability for 
compression. 
"ABPI assesses suitability for compression 
but will not help diagnose a VLU - it only 
assesses for PAD" 
"ABPI doesn’t diagnose venous ulcers it 
assesses for suitability for compression 
by assessing arterial status. Statement 
needs rewording." 
39 
An adjunctive therapy as well as 
compression can promote faster healing. 
"adjunctive therapy needs to be 
qualified, i.e. adjunctive therapy, such as 
dressings that modulate the 
microenvironment" 




"Not in all cases. Uncomplicated ulcers 
will heal without advanced dressings. 
Adjunctive therapy is beneficial in those 
predicted as 'complicated'" 
40 
Hosiery has been shown as a cost-
effective option and increased use is likely 




An ideal dressing would be cost effective, 
accepted by the patient, easy to change, 
effectively manage exudate, reduce 
healing time, and be effective on more 
severe wounds. 
"Surely an ideal dressing would be 
effective on all wounds not just severe? " 
42 
TLC-NOSF has been shown as superior to 
Oxidized regenerated cellulose/collagen; 




The purchase price of a dressing is not 
indicative of cost-effectiveness; there is a 




Protease inhibitors have been shown to 
be a cost-effective option. 
  
45 
Nurse visits are a key driver of cost; 
advanced dressings requiring fewer 
changes are therefore preferred. 
"Statement needs rephrasing. Removal of 





Dressing changes can be a cause of pain 
and products and techniques to minimise 
this are recommended. 
  
47 
Local management of the wound site 
considered easy in most cases with the 
TLC-NOSF dressing. 
"I'm not sure what these references or 
statement are eluding to? Is it that TLC-
NOSF is less painful on dressing change? 
What is meant by local management of 
the wound site?" 
"Suggest TLC-NOSF is considered easy to 
use in clinical practice or by clinicians." 
 
B.4.2 Results of iteration 1 voting 
Statement Participant number Answers Consensus 
Level 
1 2 3 4 5 6 7 8 9 10 Yes No 
1 Y N N Y Y Y Y Y Y Y 8 2 80% 
2 N Y Y Y Y Y N Y Y Y 8 2 80% 
3 Y Y N Y Y Y N Y Y Y 8 2 80% 
4 Y Y Y Y N Y N N Y Y 7 3 70% 
5 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
6 N Y Y Y Y Y Y Y Y Y 9 1 90% 
7 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
8 N N Y Y Y Y Y N Y Y 7 3 70% 




10 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
11 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
12 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
13 Y Y Y Y Y Y N N Y Y 8 2 80% 
14 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
15 N N Y Y Y Y N Y N Y 6 4 60% 
16 N Y Y Y Y Y Y Y N N 7 3 70% 
17 Y Y Y N Y Y Y N Y Y 8 2 80% 
18 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
19 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
20 Y Y Y Y Y Y Y N Y Y 9 1 90% 
21 Y Y Y Y Y Y N Y Y Y 9 1 90% 
22 Y N Y Y Y Y Y N Y Y 8 2 80% 
23 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
24 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
25 Y Y N Y Y Y Y N Y Y 8 2 80% 
26 N Y Y Y Y Y Y N Y Y 8 2 80% 
27 Y N Y Y Y Y Y Y Y Y 9 1 90% 
28 Y Y Y Y Y Y Y N Y Y 9 1 90% 
29 N N Y Y Y Y Y N Y Y 7 3 70% 




31 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
32 N N N Y Y Y N N Y Y 5 5 50% 
33 Y N Y Y Y Y N Y Y Y 8 2 80% 
34 Y Y Y Y Y Y N N N Y 7 3 70% 
35 Y N Y Y Y Y N Y Y Y 8 2 80% 
36 Y Y N Y Y Y N N Y Y 7 3 70% 
37 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
38 Y Y Y Y Y Y Y N N Y 8 2 80% 
39 N Y Y Y Y Y Y N N Y 7 3 70% 
40 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
41 Y Y Y Y Y Y Y Y N Y 9 1 90% 
42 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
43 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
44 Y Y Y Y Y Y Y Y Y Y 10 0 100% 
45 Y Y Y Y Y Y N Y Y Y 9 1 90% 
46 Y Y Y Y Y Y Y Y Y Y 10 0 100% 






B.5. Workbook 2 
B.5.1 Voting sheet, workbook 2. 
ID 
# 





B: The burden of illness 
4 
The pain caused by chronic 
wounds significantly impacts 
quality of life. 
180 268 2 
    
271 272 273 3 
194 1 
274 275 1 
8 
The main focus of treatment on 
the physical wound, some patients 
report that this is insufficient, 
considering the large psychological 
and social burden. 
167 1 
    
248 289 290 3 
287 3 
292 293 1 
C: Reduce healing time 
15 
Larger and older ulcers are more 
expensive. 
107 2 
    
109 2 




The initial wound area reduction is 
predictive of healing by 24 weeks. 
51 1 






D: The role of matrix metalloproteinases (MMPs) 
29 
TLC- NOSF have been shown to 
reduce levels of MMP-9 in vitro.  
301 3 
    
302 3 
E: Early interventions lead to better outcomes 
32 
VLU, DFU and PU are more 
prevalent in older populations who 
would potentially benefit from 
minimally invasive treatment 
options.  
168 1 





An adjunctive therapy to standard 
of care can promote faster healing 
in wounds where healing is 
compromised. 
4  1 
    
6  3 
8  3 
43 1 
44 45 3 
235 3 
36 
Treatments associated with less 
resource use, shorter treatment 
periods and fewer adverse events 
are more cost effective.  
87 2 









F: The use of dressings and treatments 
39 
An adjunctive therapy such as a 
dressing that modulates the 
microenvironment can promote 
faster healing in complicated 
wounds. 
3  2 
    
4  1 
6  3 
8  3 
43 1 
44 45 3 
235 3 
 
B.5.2 Comments on statements from iteration 2 
Please note that statements in green were confirmed as having met or exceeded the 80% 
consensus threshold. Statements in yellow did not meet the 80% threshold 
ID # Statement Comments  
B: The burden of illness 
4 
The pain caused by 
chronic wounds 
significantly impacts 
quality of life. 
"Not all chronic wounds cause pain. DFUs or other 
chronic wounds can be present with neuropathy. In 
which case other factors will be impacting the quality 
of life" 
8 
The main focus of 
treatment on the physical 
wound, some patients 
report that this is 
insufficient, considering 
"Not sure this reads correctly as a stand-alone 
statement? "Clinician focus is on treatment of the 
wound, which is insufficient as it does not account 
for the large psychological and social burden 




the large psychological 
and social burden. 
hole in the patient, it's about the whole of the 
patient." 
"Current wording within statement does not read 
correctly.  " 
"Needs to read 'The main focus of treatment is on 
the physical wound. Some patients etc.'" 
C: Reduce healing time  
15 
Larger and older ulcers are 
more expensive. 
"The final study (126) actual contradicts this point, in 
some instances pressure ulcer prevention is more 
expensive than treatment." 
"No reference to size or age of ulceration within 
references" 
"Based on the evidence in the reference list, the 
correlation with larger ulcers isn’t clear and I would 
say that it’s not always larger ulcers that are 
expensive, I would however agree to the chronicity 
being associated with cost." 
"Does this refer to leg ulcers, pressure ulcers or 
both? Needs to be more specific." 
16 
The initial wound area 
reduction is predictive of 
healing by 24 weeks. 
"I would like to think this statement is true but there 
is only reference to VLU" 
"This is a confusing statement and I'm not sure what 
is trying to be established." 





TLC- NOSF have been 
shown to reduce levels of 
MMP-9 in vitro.  
  
E: Early interventions lead to better outcomes 
32 
VLU, DFU and PU are more 
prevalent in older 
populations who would 
potentially benefit from 
minimally invasive 
treatment options.  
"Evidence does not suggest that DFU and PU are 
more prevalent in older populations." 
"Broad statement that just because you are old you 
would benefit from minimally invasive treatment - 
treatment options are based on individual 
risk/benefit analysis - surely everyone would benefit 
from minimal invasion?" 
"I agree in principle, but the wording needs to be 
sensitive to avoid it sounding 'ageist'. Wording could 
maybe be changed to " … older populations who 
would where possible, benefit from minimally 
invasive treatment options"" 
"older population does not include frailty, there may 
be younger patients who are more frail that would 
benefit from minimally invasive treatment options 
and those who are older but not frail who should be 
considered for other treatment options" 
34 
An adjunctive therapy to 
standard of care can 
promote faster healing in 
wounds where healing is 
compromised. 
"Compression therapy is the only consistent adjunct 
therapy specified, therefore should this state 
compression therapy rather than adjunctive 
therapy?" 
"Blanket statement… doesn’t necessarily apply to all 




considered in cases where wound healing may be 
compromised"" 




with less resource use, 
shorter treatment periods 
and fewer adverse events 
are more cost effective.  
"Treatments associated with improved outcomes are 
most cost effective - even if this is means more 
resources etc " 
F: The use of dressings and treatments 
39 
An adjunctive therapy 
such as a dressing that 
modulates the 
microenvironment can 
promote faster healing in 
complicated wounds. 
"Adjunctive therapy needs to be specified and there 
does not seem to be consistent evidence to back this 
statement" 
 
B.5.3. Voting iteration 2 
Statement Participant number Answer Consensus  
1 2 3 4 5 6 7 8 9 10 Yes No 
4 Y Y N Y Y Y Y Y Y Y 9 1 90% 
8 N Y Y Y N Y Y N Y Y 7 3 70% 
15 N Y Y Y N Y N N Y Y 6 4 60% 
16 Y Y Y Y N Y Y N Y Y 8 2 80% 




32 Y Y N Y N N N Y Y Y 6 4 60% 
34 N Y Y Y Y Y N N Y Y 7 3 70% 
36 Y Y Y Y Y N Y Y Y Y 9 1 90% 
39 N Y Y Y Y Y Y Y Y Y 9 1 90% 
 
B.6 Platform for future dissemination, use cases, KPI measures and future research.
B.6.1. The panel produced the below potential platforms for dissemination: 
1. Publications 
2. Conferences 
3. Nurse forums 
4. Hospitals 
5. Patient expert groups 
6. Partnership with industry 
7. Clinical pathways 
8. Local nurse champions 
9. Academia 
10. Local TVN websites 
11. CCG platforms 
B.6.2. When asked, “How could the dissemination of this consensus document lead to not 
just creation of awareness, but particularly a change in clinical practice?” the panel provided 
the following answers: 
1. Pre-requirement for nursing standards 
2. Local guidelines 
3. Training for health care assistants 
4. Collect case studies for CCGs showing cost savings 







B.6.3 For determining the impact of this consensus statement, the panel proposed:  
1. How many times cited, impact factor of journals 
2. Audits pre and post implementation 
3. Compliance report 
4. Number of times used 
5. Awareness report 
6. A change in healing rates/times 
7. If UrgoStart gains NICE approval 
 
B.6.4 When given the opportunity to discuss future areas of research, the panel suggested:  
1. Qualitative- clinicians’ experience of using the document- did it influence their practice?  
2. Risk assessment tool- how do you identify patients who are failing to heal  
3. Clinical pathways for VLU, DFU and PU based on the document 
4. A practical tool for the Health Care Assistants delivering the wound care 
5. Look into the patient experiences and quality of life,  
6. Look at caregiver burden- the financial/emotional/social impact  
7. Develop tools to measure the impact of the guidelines 




Appendix C. Study 5: Economic evaluation (Chapter 5) 
C.1. Search strategy for targeted literature review 
A literature review was undertaken using the PICO (population, intervention, comparator, 
outcome) methodology to derive search terms, the PICO framework is a well-established tool 
for developing research questions (Huang et al., 2006). The search string was entered the 
MMU library search as follows:  
 (UrgoStart or TLC-NOSF or KSOS) AND ((Resource AND (Use OR Utilisation)) OR Cost) 
The MMU library tool searches multiple databases, including PubMed, Medline, Cochrane 
and Ovid and provides a combined overview of results that can be downloaded and extracted 
to Microsoft Excel for inclusion and exclusion decision making. The inclusion and exclusion 
criteria are shown  
Inclusion criteria 
Population Leg Ulcer or Diabetic Foot Ulcer 
Interventions UrgoStart  
Outcomes Economic outcomes, resource use, cost, ICER, cost per patient 
Study design Modelling, economic studies 
Language  English 
Search dates No restrictions 
Exclusion criteria 
Population  Paediatrics (<18), Acute wounds (including Burns, Trauma, Surgery) 
Interventions Surgical, Novel non-surgical, Infection control measures, 
Debridement, Bioengineered skin substitutes, Offloading, 
Compression 




Study design In vitro studies, review or discussion articles 
Language  Non-English Language 
Search dates N/A 
 
C.2 Summary of variables applied in the DFU cost model (Base Case) 
Variable  Value Source 
Age 65 years Explorer  
Prior Amputation 50% Explorer  
Major Amputation 24% NICE Costing Document 
Minor Amputation 76% NICE Costing Document 
Proportion with prosthesis 
after major amputation 
86% NICE Costing Document 
Neutral Dressing. Transition 
probability: open pre -> 
complicated pre 
0.018660468 Explorer (comparator arm). Of 51 patients 
with open wound& no prior amputation 
16 became infected over 20 weeks.  
Neutral Dressing. Transition 
probability: open pre -> closed 
pre 
0.016694216 Explorer (comparator arm). Of 35 patients 
with open wound& no prior amputation 
10 healed by 20 weeks. 
Neutral Dressing. Transition 
probability: open pre -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
Neutral Dressing. Transition 
probability: complicated pre -> 
closed pre 
0.003223928 Explorer (comparator arm). Of 16 patients 
with infected wound& no prior 




Neutral Dressing. Transition 
probability: complicated pre -> 
open post 
0.003354487 
National Diabetes Foot Care Audit Third 
Annual Report, 2018. 1469/17514 patient 
amputations at 6 months Neutral Dressing. Transition 
probability: complicated pre -> 
closed post 
0.003354487 
Neutral Dressing. Transition 
probability: complicated pre -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
Neutral Dressing. Transition 
probability: closed pre -> open 
pre 
0.005460204 Dubsky et al., (2012), of 73 patients, 42 
had a DFU recurrence within 3 years.  
Neutral Dressing. Transition 
probability: closed pre -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
Neutral Dressing. Transition 
probability: open post -> 
complicated post 
0.014552464 Explorer (comparator arm). Of 63 patients 
with open wound with prior amputation, 
16 became infected by 20 weeks. 
Neutral Dressing. Transition 
probability: open post -> 
closed post 
0.025581983 Explorer (comparator arm). Of 47 patients 
with open wound with prior amputation, 
19 healed by 20 weeks. 
Neutral Dressing. Transition 
probability: open post -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
Neutral Dressing. Transition 
probability: complicated post -
> closed post 
0.014290858 Explorer (comparator arm). Of 16 patients 
with infected wound with prior 




Neutral Dressing. Transition 
probability: complicated post -
> deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
Neutral Dressing. Transition 
probability: closed post -> 
open post 
0.005460204 Dubsky et al. 2012, of 73 patients, 42 had 
a DFU recurrence within 3 years. 
Neutral Dressing. Transition 
probability: closed post -> 
deceased  
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
UrgoStart. Transition 
probability: open pre -> 
complicated pre 
0.013513855 Explorer (treatment arm). Of 42 patients 
with open wound& no prior amputation 
10 became infected over 20 weeks.  
UrgoStart. Transition 
probability: open pre -> closed 
pre 
0.037200636 Explorer (treatment arm). Of 32 patients 
with open wound& no prior amputation 
17 healed by 20 weeks. 
UrgoStart. Transition 
probability: open pre -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
UrgoStart. UrgoStart. 
Transition probability: 
complicated pre -> closed pre 
0.011102724 Explorer (treatment arm). Of 10 patients 
with infected wound& no prior 
amputation 2 healed by 20 weeks. 
UrgoStart. Transition 
probability: complicated pre -> 
open post 
0.003354487 
National Diabetes Foot Care Audit Third 
Annual Report, 2018. 1469/17514 
patients’ amputations at 6 months UrgoStart. Transition 







probability: complicated pre -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
UrgoStart. Transition 
probability: closed pre -> open 
pre 
0.005460204 Dubsky et al., (2012), of 73 patients, 42 
had a DFU recurrence within 3 years.  
UrgoStart. Transition 
probability: closed pre -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
UrgoStart. Transition 
probability: open post -> 
complicated post 
0.009793975 Explorer (treatment arm). Of 84 patients 
with open wound with prior amputation, 
15 became infected by 20 weeks. 
UrgoStart. Transition 
probability: open post -> 
closed post 
0.037715221 Explorer (treatment arm). Of 69 patients 
with open wound with prior amputation, 
37 healed by 20 weeks. 
UrgoStart. Transition 
probability: open post -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
UrgoStart. Transition 
probability: complicated post -
> closed post 
0.015398578 Explorer (treatment arm). Of 15 patients 
with infected wound with prior 
amputation, 4 healed by 20 weeks. 
UrgoStart. Transition 
probability: complicated post -
> deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
UrgoStart. Transition 
probability: closed post -> 
open post 
0.005460204 Dubsky et al., (2012), of 73 patients, 42 





probability: closed post -> 
deceased 
0.001934667 National Diabetes Foot Care Audit Third 
Annual Report, 2018. 520/22653 patients 
confirmed deceased at 12 weeks. 
































Duration of amputation event 
disutility 
4 weeks Clinical experts 
 
C.3 Summary of variables applied in the LU cost model (Base Case) 
Variable  Value Source 
Age 72.6 years SD: 13 Challenge  
Duration of infection 2-4 weeks Expert opinion.  
Neutral Dressing: 
Transition probability: 
open -> infected  
0.0081884 
 
Of 94 patients, 6 became infected 
over 8 weeks. 
Neutral Dressing: 
Transition probability: 
open -> closed  
0.0474747 
 
Using method described in 
Cardinal et al., (2008) the 32% 




infected -> open  
0.3333333 1/duration of infection from 
expert opinion.  
Neutral Dressing: 
Transition probability: 
closed -> open  
0.0033382 Clarke-Moloney et al. 2012, of 100 
patients 16 had a recurrence over 
1 year. 
UrgoStart: Transition 




Of 93 patients, 7 became infected 
over 8 weeks 
UrgoStart: Transition 
probability: open -> 
closed  
0.1093336 Using method described in 




RWAR gave a weekly healing rate 
of 10.93% 
UrgoStart: Transition 
probability: infected -> 
open  
0.3333333 1/duration of infection from 
expert opinion.  
UrgoStart: Transition 




Clarke-Moloney et al., (2012), of 
100 patients 16 had a recurrence 
over 1 year. 





Palfreyman (2008). Assessing the 
impact of venous ulceration on 
quality of life. Nursing times, 
104(41), pp.34-37. 
 









If a patient has had a prior amputation from a 
previous wound 
50% 0.35 0.65 
The proportion of major amputations 0.24 0.17 0.31 
The proportion having prosthesis after major 
amputation 
86% 0.60 1.00 
The duration of amputation event disutility, in weeks 4.00 2.00 6.00 
The cost of one UrgoStart Dressing 4.28 3.00 5.56 




Hospital inpatient resource use in open pre-state 0.0002 0.0001 0.0003 
GP resource use in open pre-state 0.0239 0.0168 0.0311 
Hospital outpatient resource use in open pre-state 0.0192 0.0135 0.0250 
Podiatrist resource use in open pre-state 0.0032 0.0022 0.0041 
Practice Nurse resource use in open pre-state 0.0998 0.0699 0.1298 
Community Nurse resource use in open pre-state 0.8103 0.5672 1.0534 
Antibiotic prescription resource use in open pre-state 0.0795 0.0557 0.1034 
Analgesic prescription resource use in open pre-state 0.3268 0.2288 0.4249 
Primary dressing resource use in open pre-state 2.0800 1.4560 2.7040 
Secondary Dressing resource use in open pre-state 1.6224 1.1357 2.1091 
Bespoke orthosis resource use in open pre-state 0.0192 0.0135 0.0250 
Hospital inpatient resource use in complicated pre-
state 
0.0006 0.0004 0.0008 
GP resource use in complicated pre-state 0.0718 0.0503 0.0934 
Hospital outpatient resource use in complicated pre-
state 
0.0577 0.0404 0.0750 
Podiatrist resource use in complicated pre-state 0.0095 0.0067 0.0124 
Practice Nurse resource use in complicated pre-state 0.2994 0.2096 0.3893 
Community Nurse resource use in complicated pre-
state 
2.4309 1.7016 3.1601 
Antibiotic prescription resource use in complicated 
pre-state 




Analgesic prescription resource use in complicated 
pre-state 
0.9805 0.6863 1.2746 
Primary dressing resource use in complicated pre-
state 
6.2400 4.3680 8.1120 
Secondary Dressing resource use in complicated pre-
state 
5.6784 3.9749 7.3819 
Bespoke orthosis resource use in complicated pre-
state 
0.0192 0.0135 0.0250 
Hospital inpatient resource use in closed pre-state 0.0000 0.0000 0.0000 
GP resource use in closed pre-state 0.0294 0.0206 0.0383 
Hospital outpatient resource use in closed pre-state 0.0196 0.0137 0.0255 
Podiatrist resource use in closed pre-state 0.0040 0.0028 0.0053 
Practice Nurse resource use in closed pre-state 0.0937 0.0656 0.1218 
Community Nurse resource use in closed pre-state 0.3788 0.2652 0.4925 
Antibiotic prescription resource use in closed pre-
state 
0.0627 0.0439 0.0815 
Analgesic prescription resource use in closed pre-
state 
0.2410 0.1687 0.3133 
Primary dressing resource use in closed pre-state 1.0392 0.7275 1.3510 
Secondary Dressing resource use in closed pre-state 0.8106 0.5674 1.0538 
Bespoke orthosis resource use in closed pre-state 0.0192 0.0135 0.0250 
Hospital inpatient resource use in open post state 0.0144 0.0101 0.0188 




Hospital outpatient resource use in open post state 0.0433 0.0303 0.0563 
Podiatrist resource use in open post state 0.0017 0.0012 0.0023 
Practice Nurse resource use in open post state 0.0826 0.0578 0.1074 
Community Nurse resource use in open post state 0.5869 0.4108 0.7630 
Antibiotic prescription resource use in open post 
state 
0.1204 0.0843 0.1565 
Analgesic prescription resource use in open post 
state 
0.1324 0.0927 0.1721 
Primary dressing resource use in open post state 1.5084 1.0559 1.9609 
Secondary Dressing resource use in open post state 1.1765 0.8236 1.5295 
Bespoke orthosis resource use in open post state 0.0192 0.0135 0.0250 
Hospital inpatient resource use in complicated post 
state 
0.0433 0.0303 0.0563 
GP resource use in complicated post state 0.0473 0.0331 0.0615 
Hospital outpatient resource use in complicated post 
state 
0.1298 0.0909 0.1688 
Podiatrist resource use in complicated post state 0.0052 0.0036 0.0068 
Practice Nurse resource use in complicated post 
state 
0.2478 0.1735 0.3221 
Community Nurse resource use in complicated post 
state 
1.7608 1.2325 2.2890 
Antibiotic prescription resource use in complicated 
post state 




Analgesic prescription resource use in complicated 
post state 
0.3972 0.2780 0.5164 
Primary dressing resource use in complicated post 
state 
4.5251 3.1676 5.8826 
Secondary Dressing resource use in complicated post 
state 
4.1178 2.8825 5.3532 
Bespoke orthosis resource use in complicated post 
state 
0.0192 0.0135 0.0250 
Hospital inpatient resource use in closed post state 0.0000 0.0000 0.0000 
GP resource use in closed post state 0.0294 0.0206 0.0383 
Hospital outpatient resource use in closed post state 0.0196 0.0137 0.0255 
Podiatrist resource use in closed post state 0.0040 0.0028 0.0053 
Practice Nurse resource use in closed post state 0.0937 0.0656 0.1218 
Community Nurse resource use in closed post state 0.3788 0.2652 0.4925 
Antibiotic prescription resource use in closed post 
state 
0.0627 0.0439 0.0815 
Analgesic prescription resource use in closed post 
state 
0.2410 0.1687 0.3133 
Primary dressing resource use in closed post state 1.0392 0.7275 1.3510 
Secondary Dressing resource use in closed post state 0.8106 0.5674 1.0538 
Bespoke orthosis resource use in closed post state 0.0192 0.0135 0.0250 




Quality of life weight for complicated pre-amputation 
state 
0.5700 0.3990 0.7410 
Quality of life weight for closed pre-amputation state 0.7380 0.5166 0.9594 
Quality of life weight for open post-amputation state 0.5960 0.4172 0.7748 
Quality of life weight for complicated post-
amputation state 
0.5830 0.4081 0.7579 
Quality of life weight for closed post-amputation 
state 
0.7150 0.5005 0.9295 
Disutility associated with amputation event -0.2800 -0.1960 
-
0.3640 
Neutral Dressing. Transition probability: open pre -> 
complicated pre 
0.0187 0.0131 0.0243 
Neutral Dressing. Transition probability: open pre -> 
closed pre 
0.0167 0.0117 0.0217 
Neutral Dressing. Transition probability: open pre -> 
deceased 
0.0019 0.0014 0.0025 
Neutral Dressing. Transition probability: complicated 
pre -> closed pre 
0.0032 0.0023 0.0042 
Neutral Dressing. Transition probability: complicated 
pre -> open post 
0.0034 0.0023 0.0044 
Neutral Dressing. Transition probability: complicated 
pre -> closed post 
0.0034 0.0023 0.0044 
Neutral Dressing. Transition probability: complicated 
pre -> deceased 




Neutral Dressing. Transition probability: closed pre -> 
open pre 
0.0055 0.0038 0.0071 
Neutral Dressing. Transition probability: closed pre -> 
deceased 
0.0019 0.0014 0.0025 
Neutral Dressing. Transition probability: open post -> 
complicated post 
0.0146 0.0102 0.0189 
Neutral Dressing. Transition probability: open post -> 
closed post 
0.0256 0.0179 0.0333 
Neutral Dressing. Transition probability: open post -> 
deceased 
0.0019 0.0014 0.0025 
Neutral Dressing. Transition probability: complicated 
post -> closed post 
0.0143 0.0100 0.0186 
Neutral Dressing. Transition probability: complicated 
post -> deceased 
0.0019 0.0014 0.0025 
Neutral Dressing. Transition probability: closed post -
> open post 
0.0055 0.0038 0.0071 
Neutral Dressing. Transition probability: closed post -
> deceased 
0.0019 0.0014 0.0025 
UrgoStart Transition probability: open pre -> 
complicated pre 
0.0135 0.0095 0.0176 
UrgoStart Transition probability:  open pre -> closed 
pre 
0.0372 0.0260 0.0484 
UrgoStart Transition probability: open pre -> 
deceased 




UrgoStart Transition probability: complicated pre -> 
closed pre 
0.0111 0.0078 0.0144 
UrgoStart Transition probability: complicated pre -> 
open post 
0.0034 0.0023 0.0044 
UrgoStart Transition probability: complicated pre -> 
closed post 
0.0034 0.0023 0.0044 
UrgoStart Transition probability: complicated pre -> 
deceased 
0.0019 0.0014 0.0025 
UrgoStart Transition probability: closed pre -> open 
pre 
0.0055 0.0038 0.0071 
UrgoStart Transition probability: closed pre -> 
deceased 
0.0019 0.0014 0.0025 
UrgoStart Transition probability: open post -> 
complicated post 
0.0098 0.0069 0.0127 
UrgoStart Transition probability: open post -> closed 
post 
0.0377 0.0264 0.0490 
UrgoStart Transition probability: open post -> 
deceased 
0.0019 0.0014 0.0025 
UrgoStart Transition probability: complicated post -> 
closed post 
0.0154 0.0108 0.0200 
UrgoStart Transition probability: complicated post -> 
deceased 
0.0019 0.0014 0.0025 
UrgoStart Transition probability: closed post -> open 
post 




UrgoStart Transition probability: closed post -> 
deceased 
0.0019 0.0014 0.0025 
 








The cost of one UrgoStart Dressing 4.28 3.00 5.56 
The cost of one Neutral Dressing 3.13 2.19 4.07 
The duration of infection 3.00 2.10 3.90 
Hospital inpatient resource use in open health 
state 
0.02 0.00 0.92 
GP resource use in open health state 1.70 0.00 10.52 
Hospital outpatient resource use in open health 
state 
1.03 0.00 24.64 
Practice Nurse resource use in open health state 16.26 0.00 123.72 
Community Nurse resource use in open health 
state 
155.54 0.00 411.52 
Antibiotic prescription resource use in open 
health state 
6.14 0.00 32.68 
Analgesic prescription resource use in open 
health state 
9.62 0.00 60.60 
Primary dressing resource use in open health 
state 




Secondary Dressing resource use in open health 
state 
169.74 0.00 1339.32 
Compression system resource use in open health 
state 
61.36 0.00 230.96 
Hosiery resource use in open health state 23.99 0.00 84.80 
Hospital inpatient resource use in infected health 
state 
0.02 0.00 0.92 
GP resource use in infected health state 1.70 0.00 10.52 
Hospital outpatient resource use in infected 
health state 
1.03 0.00 24.64 
Practice Nurse resource use in infected health 
state 
16.26 0.00 123.72 
Community Nurse resource use in infected health 
state 
155.54 0.00 411.52 
Antibiotic prescription resource use in infected 
health state 
6.14 0.00 32.68 
Analgesic prescription resource use in infected 
health state 
9.62 0.00 60.60 
Primary dressing resource use in infected health 
state 
169.74 0.00 1339.32 
Secondary Dressing resource use in infected 
health state 
169.74 0.00 1339.32 
Compression system resource use in infected 
health state 
61.36 0.00 230.96 




Hospital inpatient resource use in closed health 
state 
0.01 0.00 0.68 
GP resource use in closed health state 0.70 0.00 4.36 
Hospital outpatient resource use in closed health 
state 
0.13 0.00 3.04 
Practice Nurse resource use in closed health 
state 
3.70 0.00 26.68 
Community Nurse resource use in closed health 
state 
34.62 0.00 80.52 
Antibiotic prescription resource use in closed 
health state 
1.69 0.00 9.00 
Analgesic prescription resource use in closed 
health state 
2.07 0.00 12.12 
Primary dressing resource use in closed health 
state 
26.43 0.00 208.36 
Secondary Dressing resource use in closed health 
state 
26.43 0.00 208.36 
Compression system resource use in closed 
health state 
18.11 0.00 68.16 
Hosiery resource use in closed health state 5.73 0.00 21.76 
Quality of life weight for open pre-amputation 
state 
0.52 0.36 0.68 
Quality of life weight for infected pre-amputation 
state 




Quality of life weight for closed pre-amputation 
state 
0.67 0.47 0.87 
Neutral dressing. Transition probability: open -> 
infected  
0.0082 0.0057 0.0106 
Neutral dressing. Transition probability: open -> 
closed  
0.0475 0.0332 0.0617 
Neutral dressing. Transition probability: infected -
> open 
0.3333 0.2333 0.4333 
Neutral dressing. Transition probability: closed -> 
open  
0.0033 0.0023 0.0043 
UrgoStart. Transition probability: open -> 
infected  
0.0097 0.0068 0.0126 
UrgoStart. Transition probability: open -> closed  0.1093 0.0765 0.1421 
UrgoStart. Transition probability: infected -> 
open 
0.3333 0.2333 0.4333 
UrgoStart. Transition probability: closed -> open  0.0033 0.0023 0.0043 









If a patient has had a prior amputation from a 
previous wound 
 50%  35% 65% 
The cost of one UrgoStart Dressing £4.28 £3.00 £5.56 




Community Nurse resource use in complicated 
pre-state 
2.4309 1.7016 3.1601 
Bespoke orthosis resource use in closed pre-state 0.0192 0.0135 0.0250 
Hospital inpatient resource use in complicated post 
state 
0.0433 0.0303 0.0563 
Community Nurse resource use in complicated 
post state 
1.7608 1.2325 2.2890 
Transition probability: open pre -> complicated pre 0.0187 0.0131 0.0243 
Transition probability: open pre -> closed pre 0.0109 0.0076 0.0141 
Transition probability: open pre -> deceased 0.0019 0.0014 0.0025 
Transition probability: complicated pre -> open 
post 
0.0034 0.0023 0.0044 
Transition probability: complicated pre -> closed 
post 
0.0034 0.0023 0.0044 
Transition probability: closed pre -> deceased 0.0019 0.0014 0.0025 
Transition probability: open post -> complicated 
post 
0.0146 0.0102 0.0189 
Transition probability: open post -> closed post 0.0256 0.0179 0.0333 
Transition probability: open post -> deceased 0.0019 0.0014 0.0025 
Transition probability: complicated post -> closed 
post 
0.0143 0.0100 0.0186 
UrgoStart Transition probability: open pre -> 
complicated pre 




UrgoStart Transition probability:  open pre -> 
closed pre 
0.0372 0.0260 0.0484 
UrgoStart Transition probability: open pre -> 
deceased 
0.0019 0.0014 0.0025 
UrgoStart Transition probability: complicated pre -
> closed pre 
0.0111 0.0078 0.0144 
UrgoStart Transition probability: closed pre -> 
deceased 
0.0019 0.0014 0.0025 
UrgoStart Transition probability: open post -> 
complicated post 
0.0098 0.0069 0.0127 
UrgoStart Transition probability: open post -> 
closed post 
0.0377 0.0264 0.0490 
UrgoStart Transition probability: complicated post -
> closed post 
0.0154 0.0108 0.0200 
 








The cost of one UrgoStart Dressing £4.28 £3.00 £5.56 
The cost of one Neutral Dressing £3.13 £2.19 £4.07 
Hospital inpatient resource use in open health 
state 
0.02 0.00 0.92 




Hospital outpatient resource use in open health 
state 
1.03 0.00 24.64 
Practice Nurse resource use in open health state 16.26 0.00 123.72 
Community Nurse resource use in open health 
state 
155.54 0.00 411.52 
Primary dressing resource use in open health 
state 
169.74 0.00 1339.32 
Secondary Dressing resource use in open health 
state 
169.74 0.00 1339.32 
Compression system resource use in open 
health state 
61.36 0.00 230.96 
Hosiery resource use in open health state 23.99 0.00 84.80 
Hospital outpatient resource use in infected 
health state 
1.03 0.00 24.64 
Practice Nurse resource use in infected health 
state 
16.26 0.00 123.72 
Community Nurse resource use in infected 
health state 
155.54 0.00 411.52 
Secondary Dressing resource use in infected 
health state 
169.74 0.00 1339.32 
Hospital inpatient resource use in closed health 
state 
0.01 0.00 0.68 
GP resource use in closed health state 0.70 0.00 4.36 
Hospital outpatient resource use in closed 
health state 




Practice Nurse resource use in closed health 
state 
3.70 0.00 26.68 
Community Nurse resource use in closed health 
state 
34.62 0.00 80.52 
Primary dressing resource use in closed health 
state 
26.43 0.00 208.36 
Secondary Dressing resource use in closed 
health state 
26.43 0.00 208.36 
Compression system resource use in closed 
health state 
18.11 0.00 68.16 
Hosiery resource use in closed health state 5.73 0.00 21.76 
Neutral dressing. Transition probability: open -> 
infected  
0.0082 0.0057 0.0106 
Neutral dressing. Transition probability: open -> 
closed  
0.0475 0.0332 0.0617 
Neutral dressing. Transition probability: infected 
-> open 
0.3333 0.2333 0.4333 
Neutral dressing. Transition probability: closed -
> open  
0.0033 0.0023 0.0043 
UrgoStart. Transition probability: open -> 
infected  
0.0097 0.0068 0.0126 
UrgoStart. Transition probability: open -> closed  0.1093 0.0765 0.1421 
UrgoStart. Transition probability: infected -> 
open 
0.3333 0.2333 0.4333 





C.8. Results of DFU DSA. 
Variable Min Max Variance 
Transition probability: open post -> closed 
post -£       804.39  -£       551.85  -£       252.53  
The cost of one UrgoStart Dressing -£       784.06  -£       549.68  -£       234.38  
UrgoStart Transition probability: open pre -
> complicated pre -£       782.52  -£       562.40  -£       220.12  
UrgoStart Transition probability: open post 
-> complicated post -£       771.01  -£       570.28  -£       200.72  
Transition probability: open pre -> closed 
pre -£       737.89  -£       603.56  -£       134.33  
Transition probability: complicated post -> 
closed post -£       722.97  -£       616.90  -£       106.06  
UrgoStart Transition probability: closed pre 
-> deceased -£       707.59  -£       627.42  -£         80.16  
If a patient has had a prior amputation 
from a previous wound -£       694.78  -£       639.33  -£         55.45  
UrgoStart Transition probability: open pre -
> deceased -£       691.58  -£       643.07  -£         48.50  
Transition probability: open post -> 
deceased -£       684.87  -£       649.50  -£         35.37  
Bespoke orthosis resource use in closed 




UrgoStart Transition probability: 
complicated pre -> open post -£        683.42  -£      651.27  -£         32.15  
UrgoStart Transition probability: closed 
post -> open post -£        682.11  -£       652.47  -£         29.64  
Transition probability: complicated pre -> 
closed pre -£        681.43  -£       653.03  -£         28.40  
UrgoStart Transition probability: 
complicated pre -> closed post -£        680.88  -£       653.76  -£         27.12  
Community Nurse resource use in closed 
pre-state -£        679.99  -£       654.13  -£         25.86  
Primary dressing resource use in closed 
pre-state -£        676.66  -£       657.27  -£         19.38  
Transition probability: complicated post -> 
deceased -£        676.13  -£       658.12  -£         18.01  
UrgoStart Transition probability: closed pre 
-> open pre -£        675.74  -£       658.64  -£         17.10  
Practice Nurse resource use in closed pre-
state -£        674.80  -£       659.14  -£         15.66  
Bespoke orthosis resource use in closed 
post state -£        674.79  -£       659.32  -£         15.46  
Primary dressing resource use in closed 
post state -£        674.03  -£       659.86  -£         14.17  
UrgoStart Transition probability: 




Community Nurse resource use in closed 
post state -£        672.98  -£       661.14  -£         11.84  
Hospital outpatient resource use in closed 
pre-state -£        671.57  -£       662.54  -£           9.03  
Secondary Dressing resource use in closed 
pre-state -£        671.29  -£       662.82  -£           8.47  
Transition probability: closed post -> 
deceased -£        671.15  -£       663.03  -£           8.12  
Practice Nurse resource use in closed post 
state -£        670.53  -£       663.36  -£           7.17  
Primary dressing resource use in open post 
state -£        670.32  -£       663.69  -£           6.63  
Hospital outpatient resource use in closed 
post state -£        669.12  -£       664.99  -£           4.13  
Primary dressing resource use in open pre-
state -£        669.03  -£       665.09  -£           3.94  
Secondary Dressing resource use in closed 
post state -£        669.00  -£       665.12  -£           3.88  
GP resource use in closed pre-state -£        668.83  -£       665.10  -£           3.73  
GP resource use in closed post state -£        667.80  -£       666.09  -£           1.71  
Analgesic prescription resource use in 
closed pre-state -£        667.89  -£       666.22  -£           1.67  
Analgesic prescription resource use in 
closed post state -£        667.44  -£       666.67  -£           0.77  




Antibiotic prescription resource use in 
closed pre-state -£        667.22  -£       666.89  -£           0.33  
Podiatrist resource use in closed post state -£        667.08  -£       666.80  -£           0.28  
Antibiotic prescription resource use in 
closed post state -£        667.13  -£       666.98  -£           0.15  
Podiatrist resource use in open post state -£        667.03  -£       666.98  -£           0.05  
The duration of amputation event 
disutility, in weeks -£        667.06  -£       667.06   £               -    
Hospital inpatient resource use in closed 
pre-state -£        667.06  -£       667.06   £               -    
Hospital inpatient resource use in closed 
post state -£        667.06  -£       667.06   £               -    
Quality of life weight for open pre-
amputation state -£        667.06  -£       667.06   £               -    
Quality of life weight for complicated pre-
amputation state -£        667.06  -£       667.06   £               -    
Quality of life weight for closed pre-
amputation state -£        667.06  -£       667.06   £               -    
Quality of life weight for open post-
amputation state -£        667.06  -£       667.06   £               -    
Quality of life weight for complicated post-
amputation state -£        667.06  -£       667.06   £               -    
Quality of life weight for closed post-
amputation state -£        667.06  -£       667.06   £               -    




Podiatrist resource use in open pre-state -£        666.96  -£       667.06   £           0.10  
Analgesic prescription resource use in 
open post state -£        666.96  -£       667.06   £           0.10  
Antibiotic prescription resource use in 
open pre-state -£        666.96  -£       667.15   £           0.19  
Podiatrist resource use in complicated post 
state -£        666.94  -£       667.17   £           0.23  
Antibiotic prescription resource use in 
open post state -£        666.88  -£       667.13   £           0.25  
GP resource use in open post state -£        666.83  -£       667.28   £           0.44  
Hospital inpatient resource use in open 
pre-state -£        666.75  -£       667.27   £           0.53  
Antibiotic prescription resource use in 
complicated post state -£        666.77  -£       667.34   £           0.57  
Antibiotic prescription resource use in 
complicated pre-state -£        666.74  -£       667.34   £           0.59  
Podiatrist resource use in complicated pre-
state -£        666.69  -£       667.43   £           0.74  
Analgesic prescription resource use in 
complicated post state -£        666.64  -£       667.43   £           0.79  
Analgesic prescription resource use in 
open pre-state -£        666.58  -£       667.44   £           0.86  
GP resource use in open pre-state -£        666.41  -£       667.61   £           1.19  




Hospital inpatient resource use in 
complicated pre-state -£        665.86  -£       668.16   £           2.30  
Transition probability: complicated pre -> 
deceased -£        665.79  -£       668.49   £           2.70  
Secondary Dressing resource use in open 
post state -£        665.59  -£       668.32   £           2.73  
Practice Nurse resource use in open post 
state -£        665.52  -£       668.59   £           3.06  
Analgesic prescription resource use in 
complicated pre-state -£        665.32  -£       668.79   £           3.47  
Hospital outpatient resource use in open 
pre-state -£        665.06  -£       668.96   £           3.90  
Hospital outpatient resource use in open 
post state -£        664.84  -£       669.17   £           4.33  
GP resource use in complicated pre-state -£        664.72  -£       669.39   £           4.67  
The proportion having prosthesis after 
major amputation -£        663.76  -£       668.85   £           5.09  
Primary dressing resource use in 
complicated post state -£        663.97  -£       670.14   £           6.16  
Practice Nurse resource use in open pre-
state -£        663.49  -£       670.62   £           7.13  
Secondary Dressing resource use in open 
pre-state -£        663.44  -£       670.58   £           7.14  
Bespoke orthosis resource use in open 




Community Nurse resource use in open 
post state -£        662.51  -£       671.51   £           9.00  
Bespoke orthosis resource use in 
complicated post state -£        662.01  -£       672.10   £          10.09  
UrgoStart Transition probability: closed 
post -> deceased -£        661.63  -£       672.40   £          10.77  
UrgoStart Transition probability: 
complicated post -> deceased -£        661.36  -£       672.67   £          11.31  
Transition probability: closed pre -> open 
pre -£        660.85  -£       673.05   £          12.20  
Practice Nurse resource use in complicated 
post state -£        660.86  -£       673.25   £          12.39  
Secondary Dressing resource use in 
complicated post state -£        660.61  -£       673.46   £          12.85  
Hospital outpatient resource use in 
complicated pre-state -£        660.26  -£       673.86   £          13.60  
Bespoke orthosis resource use in open pre-
state -£        659.85  -£       674.26   £          14.41  
Bespoke orthosis resource use in 
complicated pre-state -£        658.43  -£       675.68   £          17.24  
Hospital outpatient resource use in 
complicated post state -£        658.07  -£       676.00   £          17.93  
Primary dressing resource use in 
complicated pre-state -£        657.33  -£       676.75   £          19.41  




Community Nurse resource use in open 
pre-state -£        655.15  -£       678.88   £          23.73  
Hospital inpatient resource use in open 
post state -£        654.60  -£       679.42   £          24.81  
Practice Nurse resource use in complicated 
pre-state -£        654.22  -£       679.80   £          25.58  
Transition probability: closed post -> open 
post -£        652.77  -£       680.88   £          28.10  
UrgoStart Transition probability: open post 
-> deceased -£        652.63  -£       681.29   £          28.67  
Secondary Dressing resource use in 
complicated pre-state -£        651.89  -£       682.19   £          30.30  
Community Nurse resource use in 
complicated post state -£       649.05  -£       685.02   £         35.98  
Transition probability: open pre -> 
deceased -£       647.53  -£       686.80   £         39.27  
Transition probability: complicated pre -> 
closed post -£       641.05  -£       692.04   £         50.99  
UrgoStart Transition probability: 
complicated pre -> closed pre -£       639.56  -£       692.34   £         52.78  
Transition probability: complicated pre -> 
open post -£       635.53  -£       697.43   £         61.90  
UrgoStart Transition probability: 




Community Nurse resource use in 
complicated pre-state -£       624.66  -£       709.46   £         84.80  
Transition probability: closed pre -> 
deceased -£       624.55  -£       709.60   £         85.05  
Hospital inpatient resource use in 
complicated post state -£       616.64  -£       717.43   £       100.78  
UrgoStart Transition probability:  open pre 
-> closed pre -£       573.43  -£       741.38   £       167.95  
The cost of one Neutral Dressing -£       538.53  -£       795.15   £       256.62  
UrgoStart Transition probability: open post 
-> closed post -£       517.91  -£       782.74   £       264.83  
Transition probability: open post -> 
complicated post -£       514.54  -£       803.07   £       288.53  
Transition probability: open pre -> 
complicated pre -£       476.30  -£       830.60   £       354.30  
 
C.9. Results of LU DSA 
Variable Min Max Variance 































































































































































































































































Appendix D. Publications 
D.1 Econ SLR abstract. 
A Systematic Review of Economic Outcomes Associated with Use of Topical Interventions for 
Treatment of Chronic Wounds. Fatoye, F et al. Value in Health, Volume 21, S174 
OBJECTIVES: A combination of interventions may be appropriate for a patient with a chronic 
wound. However, standard care varies by aetiology, geographical location and clinician 
discipline. A systematic review was undertaken to examine the economic impact of topical 
interventions for chronic wounds and the variance associated with standard care. 
METHODS: A systematic review following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines. Searches of: Science Direct, National Institute 
for Health and Clinical Excellence Evidence search, Medline (PubMed), Centre of Reviews and 
Dissemination (University of York), Cochrane Database and discussion with experts and 
manufacturers identified the literature. Two researchers performed data extraction, with a 
third consulted where there were disagreements. Economic endpoints including: incremental 
cost-effectiveness ratio, cost-per Quality Adjusted Life Year and disease related resource use 
were extracted. A narrative synthesis of results and critical appraisal using the Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) statement were performed.  
RESULTS: 3422 records identified. After screening, 817 full text articles were judged versus 
inclusion and exclusion criteria. 15 studies were included: 6 economic analysis along clinical 
trials, and 9 modelling studies.10 studies focused on VLUs, 3 studies on DFUs and 1 on Pressure 
Ulcers and 1 on Chronic Wounds. Data tables for methods, results and appraisal using the 
CHEERS statement were completed. Quality scores ranged from 10 – 15 with a mean of 12.9.  
CONCLUSIONS: This review provides some evidence that topical interventions can offer cost-
effective solutions for treating chronic wounds compared with standard care. Current evidence 
predominantly uses the endpoint of wound area reduction; evaluations using complete wound 
closure as primary endpoint could be more useful. This review informs decision makers and 
clinicians that more expensive wound care products can be cost-effective in the management 









D.3. Clinical SLR abstract 
A Systematic Review of Clinical Efficacy Associated with use of Protease-Modulating 
Interventions with Diabetic Foot Ulcer or Venous Leg Ulcer. Yeowell, G et al. Value in Health, 
Volume 21, S163 
OBJECTIVES: Diabetic foot ulcers (DFUs) or leg ulcers (LUs) of venous, arterial or mixed origin 
can cause a considerable burden to a patient and healthcare provider, taking a long time to 
heal and requiring frequent interventions. Dressings are a mainstay of treatment with 
countless options for a Healthcare Provider. Protease-modulating matrix (PMM) interventions 
are an alternative to basic or other advanced dressings. A systematic review was undertaken 
to assess the clinical effectiveness of PMM interventions for DFUs and LUs.  
METHODS: A systematic review following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) reporting guidelines. An online database search, and 
consultation with experts and manufacturers identified the literature. Databases searched 
included: Centre Reviews and Dissemination (CRD) York Database, Cochrane Library, Medline 
(PubMed), National Institute for Health and Clinical Excellence Evidence Search, Science 
Direct/Scopus. Two researchers performed data extraction with a third consulted in case of 
any discrepancies. A narrative synthesis of results and critical appraisal of included studies was 
performed.  
RESULTS: A total of 283 records were identified by literature searching. After initial screening 
of titles and abstracts, 215 full text articles were judged against pre-defined inclusion and 
exclusion criteria. Six randomised controlled trials and 2 observational studies were included 
in the review. A total of 1310 patients were included in this study. The three VLU RCTs included 
a total of 377 patients, and the DFU studies included 933 patients. Healing was the most 
frequently reported outcome, followed by wound area reduction. A meta-analysis was not 
possible given the heterogeneity of the included studies.  
CONCLUSIONS: This review provides some evidence that PMM interventions have a clinical 
benefit on wound healing outcomes; however, there were several methodological issues with 
the studies included. New evidence shows promising results for the treatment of DFUs 










D.5. Delphi abstract 
Addressing Uncertainty in Wound Management Using A Modified Delphi Methodology. Betts, 
A et al. Value in Health, Volume 20, Issue 9, A794 
OBJECTIVES: Increasing prevalence and rising costs of Venous Leg Ulcers (VLU), Diabetic Foot 
Ulcers (DFU) and Pressure Ulcers (PU), means that a consistent level of care and understanding 
is needed to improve patient outcomes and maximise cost efficiencies. This study aimed to 
gain consensus on a set of evidence-based statements from a range of clinical experts.  
METHODS: A literature search identified 827 articles, inclusion/exclusion criteria were applied 
resulting in 145 articles providing 308 quotations in 4 categories: epidemiology, clinical 
effectiveness, quality of life, and economics. From this, 47 statements were developed. A 
modified Delphi methodology was used and a consensus threshold of 80% was set. Round I 
and II: Participants electronically examined and voted yes/no for each statement. If the 
threshold was not met, comments informed changes. Round III: A meeting to discuss all 
statements.  
RESULTS: Round I: 38/47 statements confirmed, none rejected. 9 statements modified using 
comments and resubmitted. Round II: 5/9 remaining statements confirmed, none rejected, 
leaving 4. At the meeting, all 47 were confirmed. During examination of confirmed statements, 
some modifications were made; agreed by all members of the panel. A consensus document 
is being developed using the statements.  
CONCLUSIONS AND DISCUSSION: The consensus document developed from the statements 
should help to address areas of uncertainty in the management of chronic wounds by 
Healthcare Professionals across a range of disciplines resulting in benefits for the patient and 
healthcare system. The panel enjoyed the Delphi methodology, which was an efficient way of 
arriving at consensus for a large and varied group. Using a Delphi methodology to gain 
consensus on evidence-based statements generated from a literature review is an efficient and 
















D.8. PRO abstract 
Using EQ-5D to measure quality of life in patients with diabetic foot ulcers and venous leg 
ulcers. Betts, A. et al. Value in Health, Volume 21, S241 
BACKGROUND: Quality of life (QoL) is a subjective phenomenon; meaning it is difficult to assess 
accurately. There are many instruments to measure QoL; generic tools enable comparisons 
across interventions and disease areas. The quality of life impact of Diabetic Foot Ulcer (DFU) 
and Venous Leg Ulcer (VLU) is important to consider, as these wounds can often be long lasting 
and burdensome for a patient with the need for frequent dressing changes, which can often 
be painful and cause anxiety.  
METHODS: This is a cross-sectional study to determine QoL of patients with DFU and VLU. The 
study was carried out in multiple treatment centres in the United Kingdom; Patients attending 
clinics as part of treatment were enrolled sequentially, after obtaining consent. Data was 
anonymous at collection and entered into a SPSS (version 25) database for analysis. Descriptive 
statistics of demographic characteristics performed. EQ-5D-5L index scores were calculated 
using Crosswalk analysis. Subgroup analysis took into account wound severity as judged by the 
duration of wound and the size of the wound. 
RESULTS: Ninety-four patients completed the study, 42 with a DFU and 51 with a VLU. The 
mean EQ-5D-5L index score for DFU patients was 0.55 and for VLU patients 0.64. Seventeen 
(42%) DFUs and 19 (38%) VLUs were classified as severe, these wounds had even lower index 
scores 0.47 and 0.56 for DFU and VLU respectively. 
DISCUSSION: These scores indicate that DFU and VLU patients suffer from impaired QoL, with 
wounds that are older and longer in duration having a worse impact. Interventions and 
strategies to treat chronic wounds should consider quality of life outcomes for these patients; 
especially when treating populations with more severe wounds. Interventions that reduce the 











D.10. Chart extraction abstract 
Real Life Use of Dressings in the Treatment of Leg Ulcers and Diabetic Foot Ulcers. Betts, A et 
al. Value in Health, Volume 21, S174 - S175 
OBJECTIVES: Leg ulcers (LUs) and diabetic foot ulcers (DFUs) can take a long time to heal, with 
dressings requiring frequent changes. Establishing current treatment pathways and reasoning 
for changing a care plan, will provide real life understanding regarding the use of dressings and 
areas providing opportunity to improve patient outcomes and reduce the economic burden of 
these conditions. The study aimed to establish treatment pathways, incidence of treatment 
switching, patient outcomes and resource use of patients with a LU or DFU. 
METHODS: A multi-centre, retrospective, chart examination performed in multiple care 
settings. The data extracted included wound characteristics, each visit by the patient, and every 
intervention. Reasons for a change of treatment plan, and infection and healing rates were 
captured. Reasons for changing treatment were coded and analysed.  
RESULTS: 7 UK centres provided data from 97 patients, totalling 107 wounds and 1050 visits. 
90 (9%) wounds were observed for the first time and 42 (4%) healed wounds not requiring 
dressings were observed, 189 (18%) changes used the same dressing as previously recorded. 
This left 729 (69%) instances of treatment switching. Reasons for changes to treatment plan 
were either Clinical (28%), Patient (5%), External (5%) or No reason (62%). External reasons 
included available stock and guidance from other clinicians. 
CONCLUSIONS: 69% of visits resulted in a different type of dressing being applied, with 62% of 
these changes being made without a reason. The data also suggests superior clinical outcomes 
are achieved in Randomised Clinical Trials compared to real life. Patients in RCTs receive the 
same intervention for the trial duration; yet this study finds a switch in nearly 80% of eligible 
visits. It is theorised therefore that without mandated guidance regarding dressings, current 
treatment switching practices may continue as observed, with potential adverse outcomes on 










D.12. DFU BIM abstract 
The budget impact and cost-consequence of treating diabetic foot ulcers with UrgoStart. 
Betts, A. et al. Value in Health, Volume 21, S249 
OBJECTIVES: Diabetic Foot Ulcers are a common complication of diabetes and precede more 
than 80% of amputations in this population. It is estimated that more than 5 million people in 
the United Kingdom will have diabetes by 2025; and 10% of this population is expected to have 
a DFU. Treating ulcers is expensive and investing in interventions that can improve time to 
healing could reduce current spending by the National Health Service (NHS). UrgoStart is a 
dressing shown to reduce healing time of DFUs by 20 days when compared to a neutral 
dressing in a double-blind randomised controlled trial. 
METHODS: A budget impact model (BIM) was developed from the perspective of the NHS with 
a time horizon of 5 years. The BIM identifies patients eligible for treatment with UrgoStart; and 
considers population growth and new patients diagnosed with diabetes. A 2018 retrospective 
database analysis of 130 patients examined resource utilization and costs associated with DFU; 
this was applied to the eligible population.  
RESULTS: Over the 5-year period, 1.3 million patients were eligible for treatment with 
UrgoStart. The cost of treatment per patient using UrgoStart was £1445.90 vs £1638.64 using 
a neutral dressing. The growing population and newly diagnosed diabetic patients with 
ulceration accounted for an increase of approximately £25.6 million per year. Over the 5-year 
period, using UrgoStart instead of a neutral dressing could save £251.7 million for the NHS 
whilst also avoiding 26.1 million days with ulceration for patients.  
CONCLUSIONS: Analysis showed that contrary to current National Institute of Health and Care 
Excellence (NICE) guidance; using only the “least costly” dressing for chronic wounds such as 
DFU is not an optimal treatment strategy. UrgoStart, has shown to reduce healing time, which 











D.14. LU BIM abstract 
The budget impact and cost-consequence of treating leg ulcers with UrgoStart. Betts, A. et al. 
Value in Health, Volume 21, S249 
OBJECTIVES: Leg ulcers (LU) can be a complication of vascular or arterial disease, or of mixed 
or unknown aetiology. In a study of 1000 acute and chronic wounds, LUs accounted for 33% of 
all wounds. LUs incur a considerable treatment cost; frequent contact with various health care 
providers for assessment and dressing changes is expensive to the National Health Service 
(NHS). Reducing healing time could alleviate this burden whilst improving patient outcomes. 
METHODS: A budget impact model (BIM) was developed from the perspective of the NHS with 
a time horizon of 5 years. UrgoStart is a protease-modulating dressing, and mean time to 
closure for LUs in a large pooled observational study of 6800 patients was 112.5 days, 
compared to 210 days for a population not using UrgoStart. Population data from the United 
Kingdom, including population growth, and the incidence of LU the BIM identifies patients 
eligible for treatment with UrgoStart. A 2018 retrospective database analysis of 505 patients 
informed resource utilization and costs used in the model.   
RESULTS: Over the 5-year period, 3.8 million patients were eligible for treatment with 
UrgoStart. The cost of treatment per patients using UrgoStart was £1544.23 vs £3114.67 using 
a neutral dressing. The much-improved time to healing demonstrated by UrgoStart is the driver 
of these cost savings. Using UrgoStart on all eligible LUs could save on average £1.1 billion per 
year for the NHS; and reduce the number of days with ulceration by 47%, from 815 million to 
435 million days.  
CONCLUSIONS: This analysis shows that UrgoStart should be considered as part of a preferred 
treatment strategy for LUs; there is also evidence to show better healing rates when used as a 
first line intervention. With current drives towards efficiency in the NHS, UrgoStart provides an 










D.16. DFU CUA abstract 
Cost-effectiveness and cost-utility analysis of treating diabetic foot ulcers with UrgoStart 
compared to a neutral dressing. Betts, A. et al. Value in Health, Volume 21, S260 
OBJECTIVES: Current National Institute of Health and Care Excellence (NICE) guidance does not 
indicate a preferred dressing for patients with Diabetic Foot Ulcer (DFU). UrgoStart has recently 
been shown as superior to a neutral dressing in the double blind randomised controlled 
Explorer trial. This study examined the cost-effectiveness of UrgoStart compared with a neutral 
dressing for DFU patients. 
METHODS: A Markov-model was designed with seven health states: open, closed, and 
complicated (pre and post amputation), and deceased. Complicated wounds can cause an 
amputation event, moving a patient to the post-amputation block. The model took the 
perspective of the National Health Service (NHS) in the United Kingdom, with a cohort of 1000 
patients and base-case time horizon of 1 year. The Explorer trial informed transition 
probabilities and health-state utility scores; there were no statistically significant differences 
between the characteristics of the treatment arms at baseline. Both deterministic and 
probabilistic sensitivity analyses were performed.  
RESULTS: UrgoStart was the dominant treatment strategy in terms of cost-effectiveness, with 
a cost saving of £666.51 and a 0.022 gain in quality-adjusted-life years, per patient. Using 
UrgoStart leads to more wounds healed at 52 weeks than a neutral dressing, 653 and 473 
respectively at a cost of £4879.84 per healed wound for UrgoStart compared with £8136.19 
for a neutral dressing. The use of UrgoStart also avoided 19 amputations over a year. Sensitivity 
analysis showed UrgoStart as cost saving, even when a comparator was set at £0. Across 1000 
runs of the model, UrgoStart was dominant every time.  
CONCLUSIONS: This analysis showed UrgoStart to be a cost-effective treatment option, with 
benefits to the patient and the NHS. Primary cost drivers such as community nurse visits and 
hospital admissions; can be reduced significantly with faster healing. UrgoStart should be 










D.18. LU CUA abstract 
Cost-effectiveness and cost-utility analysis of treating leg ulcers with UrgoStart compared to a 
neutral dressing. Betts, A. et al. Value in Health, Volume 21, S260 
OBJECTIVES: Leg Ulcers (LUs) cause a burden on the patient and National Health Service (NHS); 
often taking a long time to heal and requiring significant resources to achieve wound closure. 
UrgoStart has been demonstrated to improve healing outcomes for patients with LUs. This 
study examined the cost-effectiveness of UrgoStart compared with a neutral dressing for LU 
patients. 
METHODS: A Markov-model with four health states: open, infected, closed and deceased. 
Infected wounds had to become open wounds in order to close, and closed wounds had a risk 
of recurrence. The model took the perspective of the NHS in the United Kingdom, with a cohort 
of 1000 patients and base-case time horizon of 1 year. The Challenge randomised double blind 
controlled trial informed the patient characteristics and transitions. The study endpoint was 
relative wound area reduction at 8 weeks; which was used to calculate the transition 
probability of healing in the model.  Both deterministic and probabilistic sensitivity analyses 
were performed. 
RESULTS: UrgoStart was the dominant treatment strategy in terms of cost-effectiveness, with 
a cost saving of £274.25 and a 0.03 gain in quality-adjusted-life years, per patient. Community 
nurse visits were the primary cost driver; accounting for 54% and 56% of total costs in the 
treatment and comparator arm respectively. At 52 weeks 949 wounds had healed using 
UrgoStart vs 854 wounds using a neutral dressing, at a cost of £1666.80 and £2174.89 per 
healed wound respectively. Sensitivity analysis showed a cost saving for UrgoStart, even when 
a comparator was set at £0 cost; over 1000 runs of the model, UrgoStart was dominant in 
approximately 90% of cases. 
CONCLUSIONS: This analysis showed UrgoStart to be a cost-effective treatment option for 
treating LU; with benefits for the patient and the NHS. UrgoStart should be considered as a 
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